[
  {
    "title": "Here's How Much a $1000 Investment in AbbVie Made 10 Years Ago Would Be Worth Today",
    "url": "https://www.zacks.com/stock/news/2204045/heres-how-much-a-1000-investment-in-abbvie-made-10-years-ago-would-be-worth-today",
    "time_published": "20240101T133004",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default28.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.77141"
      }
    ],
    "overall_sentiment_score": 0.172591,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.693171",
        "ticker_sentiment_score": "0.288933",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.058188",
        "ticker_sentiment_score": "0.033051",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "XORTX Welcomes New Member to the Board of Directors",
    "url": "https://www.globenewswire.com/news-release/2024/01/02/2802570/0/en/XORTX-Welcomes-New-Member-to-the-Board-of-Directors.html",
    "time_published": "20240102T120000",
    "authors": [
      "XORTX Therapeutics Inc."
    ],
    "summary": "CALGARY, Alberta, Jan. 02, 2024 ( GLOBE NEWSWIRE ) -- XORTX Therapeutics Inc. ( \"XORTX\" or the \"Company\" ) ( NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU ) , a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes Mr. ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/9898c4f8-b373-438a-abfa-709c4372a061",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.165514,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PODD",
        "relevance_score": "0.052918",
        "ticker_sentiment_score": "0.052981",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.052918",
        "ticker_sentiment_score": "0.052981",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KALV",
        "relevance_score": "0.052918",
        "ticker_sentiment_score": "0.052981",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.052918",
        "ticker_sentiment_score": "0.052981",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XRTX",
        "relevance_score": "0.157827",
        "ticker_sentiment_score": "0.28239",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Could Abbott Laboratories Stock Help You Become a Millionaire?",
    "url": "https://www.fool.com/investing/2024/01/03/could-abbott-laboratories-stock-help-you-become-a/",
    "time_published": "20240103T144500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "There is a lot going the company's way, despite recent struggles.",
    "banner_image": "https://media.ycharts.com/charts/19f3a994f7203ab09064828d2a0d375f.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.2649,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.395012",
        "ticker_sentiment_score": "0.194311",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Assertio Holdings, Inc. Announces Leadership Transition",
    "url": "https://www.globenewswire.com/news-release/2024/01/03/2803350/0/en/Assertio-Holdings-Inc-Announces-Leadership-Transition.html",
    "time_published": "20240103T135900",
    "authors": [
      "Assertio Therapeutics",
      "Inc."
    ],
    "summary": "Dan Peisert Stepping Down as CEO ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/f2c70793-94c4-48b5-89e5-d0f45c87e6b1",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.242123,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ASRT",
        "relevance_score": "0.634467",
        "ticker_sentiment_score": "0.36076",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.055492",
        "ticker_sentiment_score": "0.045167",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "1 Concerning Trend for AbbVie Investors to Keep an Eye On",
    "url": "https://www.fool.com/investing/2024/01/03/1-concerning-trend-for-abbvie-investors-to-keep-an/",
    "time_published": "20240103T133000",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Is AbbVie a good stock for dividend investors to own?",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F759502%2Fabbvie-chart-showing-its-dividend-growth-rate-by-year.png&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.122768,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CERE",
        "relevance_score": "0.065866",
        "ticker_sentiment_score": "0.220688",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.678673",
        "ticker_sentiment_score": "0.139579",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.065866",
        "ticker_sentiment_score": "0.061072",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Assertio  ( ASRT )  Shares Fall as Dan Peisert Steps Down as CEO",
    "url": "https://www.zacks.com/stock/news/2205675/assertio-asrt-shares-fall-as-dan-peisert-steps-down-as-ceo",
    "time_published": "20240104T144600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Assertio (ASRT) appoints Heather Mason as its interim CEO as its current CEO, Dan Peisert, steps down from his role. Shares of the company fall on the same.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/2297.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.972193"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": -0.011988,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SPPI",
        "relevance_score": "0.077845",
        "ticker_sentiment_score": "-0.080017",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.077845",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PBYI",
        "relevance_score": "0.374875",
        "ticker_sentiment_score": "0.168052",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DVAX",
        "relevance_score": "0.442339",
        "ticker_sentiment_score": "0.242451",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ASRT",
        "relevance_score": "0.565644",
        "ticker_sentiment_score": "-0.048003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRDA",
        "relevance_score": "0.442339",
        "ticker_sentiment_score": "0.06778",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AQST",
        "relevance_score": "0.077845",
        "ticker_sentiment_score": "0.108469",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Ozempic and other weight-loss drugs' popularity set these stocks up for big gains",
    "url": "https://www.marketwatch.com/story/ozempic-and-other-weight-loss-drugs-popularity-set-these-stocks-up-for-big-gains-fa2a3f33",
    "time_published": "20240104T121000",
    "authors": [
      "Michael Brush"
    ],
    "summary": "Gut-punch to medical technology and processed-food stocks is temporary.",
    "banner_image": "https://images.mktw.net/im-806705/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": -0.053067,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SMPL",
        "relevance_score": "0.089019",
        "ticker_sentiment_score": "0.03816",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDLZ",
        "relevance_score": "0.1185",
        "ticker_sentiment_score": "-0.034339",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZBH",
        "relevance_score": "0.1185",
        "ticker_sentiment_score": "-0.020159",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.089019",
        "ticker_sentiment_score": "0.002098",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.1185",
        "ticker_sentiment_score": "0.085125",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "POST",
        "relevance_score": "0.059415",
        "ticker_sentiment_score": "0.052029",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KLG",
        "relevance_score": "0.059415",
        "ticker_sentiment_score": "0.052029",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PODD",
        "relevance_score": "0.176933",
        "ticker_sentiment_score": "0.02006",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTZ",
        "relevance_score": "0.176933",
        "ticker_sentiment_score": "-0.043394",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.147818",
        "ticker_sentiment_score": "-0.009016",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRBR",
        "relevance_score": "0.059415",
        "ticker_sentiment_score": "0.070995",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HSY",
        "relevance_score": "0.059415",
        "ticker_sentiment_score": "-0.201029",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "3 Dividend Growers Suited for Income Investors",
    "url": "https://www.zacks.com/commentary/2207189/3-dividend-growers-suited-for-income-investors",
    "time_published": "20240108T220200",
    "authors": [
      "Derek Lewis"
    ],
    "summary": "A company's ability to consistently pay and increase dividend payouts reflects a stable and healthy financial position. Who doesn't enjoy payday?",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/22364.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.496858,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.351558",
        "ticker_sentiment_score": "0.295021",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.534294",
        "ticker_sentiment_score": "0.520288",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Here's Why Investors Should Retain Abbott  ( ABT )  Stock Now",
    "url": "https://www.zacks.com/stock/news/2207160/heres-why-investors-should-retain-abbott-abt-stock-now",
    "time_published": "20240108T174100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Investors are optimistic about Abbott (ABT) led by solid prospects in the Diagnostic business and raised guidance.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/41/899.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.96136"
      }
    ],
    "overall_sentiment_score": 0.200688,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HQY",
        "relevance_score": "0.195419",
        "ticker_sentiment_score": "0.043526",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.098456",
        "ticker_sentiment_score": "0.099177",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ITGR",
        "relevance_score": "0.195419",
        "ticker_sentiment_score": "0.127566",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DVA",
        "relevance_score": "0.147216",
        "ticker_sentiment_score": "0.117948",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:EUR",
        "relevance_score": "0.049322",
        "ticker_sentiment_score": "0.053915",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Wearable Technology Market Gains Ground, 3 Stocks in Focus",
    "url": "https://www.zacks.com/stock/news/2206848/wearable-technology-market-gains-ground-3-stocks-in-focus",
    "time_published": "20240108T134500",
    "authors": [
      "Moumi Mondal"
    ],
    "summary": "In the wearable medical devices industry, investors can keep a keen eye on stocks such as ABT, MDT and DXCM.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/18/20877.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.344721,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GLDAF",
        "relevance_score": "0.043264",
        "ticker_sentiment_score": "0.201312",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.2138",
        "ticker_sentiment_score": "0.303235",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.295867",
        "ticker_sentiment_score": "0.377378",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.374624",
        "ticker_sentiment_score": "0.423993",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "3 Simple Tricks That Every Investor Should Use  ( but Most Don't ) ",
    "url": "https://www.fool.com/investing/2024/01/09/3-simple-tricks-that-every-investor-should-use-but/",
    "time_published": "20240109T151500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Having a few tricks up your sleeve can increase your returns over time.",
    "banner_image": "https://media.ycharts.com/charts/48e06246cfdd0fa2187cc0683cfa221e.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.233827,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.170576",
        "ticker_sentiment_score": "-0.026863",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.128363",
        "ticker_sentiment_score": "0.032509",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.085782",
        "ticker_sentiment_score": "0.123385",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.170576",
        "ticker_sentiment_score": "-0.026863",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Influenza Diagnostics Market Expected to Exceed USD 2.0 billion by 2031, at a CAGR 5.6%| Analysis by Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36575512/influenza-diagnostics-market-expected-to-exceed-usd-2-0-billion-by-2031-at-a-cagr-5-6-analysis-by-",
    "time_published": "20240110T134049",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Jan. 10, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global influenza diagnostics market is estimated to flourish at a CAGR of 5.6% from 2023 to 2031.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.401521,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.032781",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HOLX",
        "relevance_score": "0.032781",
        "ticker_sentiment_score": "0.315643",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.065506",
        "ticker_sentiment_score": "0.237603",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.032781",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.065506",
        "ticker_sentiment_score": "0.183436",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DSRLF",
        "relevance_score": "0.032781",
        "ticker_sentiment_score": "0.406633",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BIO",
        "relevance_score": "0.032781",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.098121",
        "ticker_sentiment_score": "0.081729",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QDEL",
        "relevance_score": "0.032781",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Top Dividend Stocks to Buy in 2024 and Hold Forever",
    "url": "https://www.fool.com/investing/2024/01/10/2-top-dividend-stocks-to-buy-in-2024-and-hold/",
    "time_published": "20240110T124500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "It's hard to beat these companies' track records.",
    "banner_image": "https://media.ycharts.com/charts/361971a021d466f2989532d51c543986.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.226369,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.055621",
        "ticker_sentiment_score": "-0.019994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.055621",
        "ticker_sentiment_score": "0.036001",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.469935",
        "ticker_sentiment_score": "0.262389",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.055621",
        "ticker_sentiment_score": "-0.019994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "V",
        "relevance_score": "0.423251",
        "ticker_sentiment_score": "0.177242",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Biliary Stent Market to Cross USD 666.5 million at a CAGR of 5.2 % by 2031: Transparency Market Research Report",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36571195/biliary-stent-market-to-cross-usd-666-5-million-at-a-cagr-of-5-2-by-2031-transparency-market-resea",
    "time_published": "20240110T074412",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Jan. 10, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. -The global biliary stent market is estimated to flourish at a CAGR of 5.2% from 2023 to 2031.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.335284,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.036146",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MMSI",
        "relevance_score": "0.036146",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.036146",
        "ticker_sentiment_score": "0.086974",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.179254",
        "ticker_sentiment_score": "0.216235",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.036146",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.036146",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.072217",
        "ticker_sentiment_score": "0.148109",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OCPNF",
        "relevance_score": "0.108141",
        "ticker_sentiment_score": "0.111489",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.108141",
        "ticker_sentiment_score": "0.085311",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "$100 Invested In Abbott Laboratories 10 Years Ago Would Be Worth This Much Today - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/news/24/01/36596051/100-invested-in-abbott-laboratories-10-years-ago-would-be-worth-this-much-today",
    "time_published": "20240111T153038",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Abbott Laboratories ABT has outperformed the market over the past 10 years by 1.21% on an annualized basis producing an average annual return of 11.09%. Currently, Abbott Laboratories has a market capitalization of $196.70 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.160819,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.980595",
        "ticker_sentiment_score": "0.386944",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "2 Ultrareliable Dividend Stocks to Buy in 2024 and Hold for at Least a Decade",
    "url": "https://www.fool.com/investing/2024/01/11/2-ultra-reliable-dividend-stocks-to-buy-in-2024-an/",
    "time_published": "20240111T103900",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Strong advantages over the competition could allow these businesses to keep raising their dividend payouts for at least another 10 years.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F760816%2Fcouple-at-home-with-device-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.205181,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MDT",
        "relevance_score": "0.402941",
        "ticker_sentiment_score": "0.333402",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.308246",
        "ticker_sentiment_score": "0.206293",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.052685",
        "ticker_sentiment_score": "0.124609",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stocks Generating Improved Relative Strength: Abbott Laboratories",
    "url": "https://www.investors.com/ibd-data-stories/stocks-generating-improved-relative-strength-abbott-laboratories/",
    "time_published": "20240111T080000",
    "authors": [
      "Investor's Business Daily",
      "INVESTOR'S BUSINESS DAILY"
    ],
    "summary": "The Relative Strength ( RS ) Rating for Abbott Laboratories ( ABT ) headed into a new percentile Thursday, as it got a lift from 68 to 77. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.429025,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.76191",
        "ticker_sentiment_score": "0.589428",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.21517",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Uber, Abbott Laboratories, Vertex Pharmaceuticals And More On CNBC's 'Final Trades' - Abbott Laboratories  ( NYSE:ABT ) , Uber Technologies  ( NYSE:UBER ) ",
    "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/01/36606668/uber-abbott-laboratories-vertex-pharmaceuticals-and-more-on-cnbcs-final-trades",
    "time_published": "20240112T135103",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Halftime Report Final Trades,\" Joshua Brown of Ritholtz Wealth Management said Uber Technologies, Inc. UBER shares hit an all-time high on Thursday above the Feb. 2021 high. He remains long on the stock and still loves it.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/12/uber_-logo.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      }
    ],
    "overall_sentiment_score": 0.29394,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.436009",
        "ticker_sentiment_score": "0.618511",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.558244",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.152499",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.558244",
        "ticker_sentiment_score": "0.571354",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Extracorporeal Membrane Oxygenation Machines Market size to grow by 640.24 million by 2027 with a CAGR of 10.05 ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/extracorporeal-membrane-oxygenation-machines-market-size-to-grow-by-640-24-million-by-2027-with-a-cagr-of-10-05-between-2022---2027--technavio-302033129.html",
    "time_published": "20240112T031500",
    "authors": [],
    "summary": "Extracorporeal Membrane Oxygenation Machines Market size to grow by 640.24 million by 2027 with a CAGR of 10.05 ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.247318,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CTSO",
        "relevance_score": "0.048621",
        "ticker_sentiment_score": "0.128956",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.048621",
        "ticker_sentiment_score": "0.128956",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FSNUF",
        "relevance_score": "0.048621",
        "ticker_sentiment_score": "0.128956",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LIVN",
        "relevance_score": "0.048621",
        "ticker_sentiment_score": "0.128956",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRUMF",
        "relevance_score": "0.048621",
        "ticker_sentiment_score": "0.128956",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GNGBY",
        "relevance_score": "0.048621",
        "ticker_sentiment_score": "0.128956",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.048621",
        "ticker_sentiment_score": "0.128956",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FMS",
        "relevance_score": "0.048621",
        "ticker_sentiment_score": "0.128956",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MCRPF",
        "relevance_score": "0.048621",
        "ticker_sentiment_score": "0.128956",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Top Analyst Reports for AMD, Abbott Laboratories & QUALCOMM",
    "url": "https://www.zacks.com/research-daily/2210113/top-analyst-reports-for-amd-abbott-laboratories-qualcomm",
    "time_published": "20240115T174100",
    "authors": [
      "Sheraz Mian"
    ],
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including Advanced Micro Devices, Inc. (AMD), Abbott Laboratories (ABT) and QUALCOMM Incorporated (QCOM).",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default273.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.208688,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "QCOM",
        "relevance_score": "0.097457",
        "ticker_sentiment_score": "0.215286",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.097457",
        "ticker_sentiment_score": "0.113169",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharmaceutical Chemicals Market Size Is Expected To Grow At A CAGR Of More Than 7% Through 2024-2028 As Per The Business Research Company's Pharmaceutical Chemicals Global Market Report 2024",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36631583/pharmaceutical-chemicals-market-size-is-expected-to-grow-at-a-cagr-of-more-than-7-through-2024-202",
    "time_published": "20240115T163000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LONDON, Jan. 15, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's pharmaceutical chemicals global market report 2024, the pharmaceutical chemicals market has exhibited robust growth, escalating from $129.54 billion in 2023 to an estimated $138.71 billion in 2024, boasting a ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.30942,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.059341",
        "ticker_sentiment_score": "0.130056",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Global Sulfatases Market Forecasts to 2028, with Competitor Analysis for Bayer, BASF, Yara, Compass Minerals, Sumitomo Chemicals, UPL, Israel Chemical Company, Novozymes & Syngenta Crop Protection",
    "url": "https://www.prnewswire.com/news-releases/global-sulfatases-market-forecasts-to-2028-with-competitor-analysis-for-bayer-basf-yara-compass-minerals-sumitomo-chemicals-upl-israel-chemical-company-novozymes--syngenta-crop-protection-302034516.html",
    "time_published": "20240115T111500",
    "authors": [
      "Research and Markets"
    ],
    "summary": "Global Sulfatases Market Forecasts to 2028, with Competitor Analysis for Bayer, BASF, Yara, Compass Minerals ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.211127,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.05749",
        "ticker_sentiment_score": "0.121006",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMP",
        "relevance_score": "0.05749",
        "ticker_sentiment_score": "0.121006",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Prenatal Vitamin Supplements Market to grow by USD 237.81 million from 2022 to 2027; North America to account for ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/prenatal-vitamin-supplements-market-to-grow-by-usd-237-81-million-from-2022-to-2027-north-america-to-account-for-51-of-market-growth--technavio-302034169.html",
    "time_published": "20240115T063500",
    "authors": [],
    "summary": "Prenatal Vitamin Supplements Market to grow by USD 237.81 million from 2022 to 2027. North America to account for ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.299152,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.055492",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.110717",
        "ticker_sentiment_score": "0.031681",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KIKOF",
        "relevance_score": "0.055492",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.055492",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TXMD",
        "relevance_score": "0.055492",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLX",
        "relevance_score": "0.055492",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NSRGF",
        "relevance_score": "0.055492",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What's in Store for Abbott Laboratories  ( ABT )  in Q4 Earnings?",
    "url": "https://www.zacks.com/stock/news/2210532/whats-in-store-for-abbott-laboratories-abt-in-q4-earnings",
    "time_published": "20240116T115800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Abbott Laboratories' (ABT) fourth-quarter 2023 results are likely to reflect solid base business momentum.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.259701,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MMSI",
        "relevance_score": "0.109455",
        "ticker_sentiment_score": "0.050113",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.145583",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ACAD",
        "relevance_score": "0.109455",
        "ticker_sentiment_score": "0.147863",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Advanced Micro Devices, Abbott Laboratories, Qualcomm, Morgan Stanley and Intuitive Surgical",
    "url": "https://www.zacks.com/stock/news/2210521/the-zacks-analyst-blog-highlights-advanced-micro-devices-abbott-laboratories-qualcomm-morgan-stanley-and-intuitive-surgical",
    "time_published": "20240116T113600",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Advanced Micro Devices, Abbott Laboratories, Qualcomm, Morgan Stanley and Intuitive Surgical are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/0d/701.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.177829,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMD",
        "relevance_score": "0.341857",
        "ticker_sentiment_score": "0.202679",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.276648",
        "ticker_sentiment_score": "0.110714",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.140485",
        "ticker_sentiment_score": "0.040143",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QCOM",
        "relevance_score": "0.276648",
        "ticker_sentiment_score": "0.161938",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.140485",
        "ticker_sentiment_score": "0.040143",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Better Growth Stock: Abbott vs. AbbVie",
    "url": "https://www.fool.com/investing/2024/01/16/better-growth-stock-abbott-vs-abbvie/",
    "time_published": "20240116T100000",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "These healthcare giants also offer investors the promise of increasing passive income.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F761326%2Fgettyimages-two-researchers-work-in-a-lab.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999355"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.334975,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.511864",
        "ticker_sentiment_score": "0.515043",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.100308",
        "ticker_sentiment_score": "0.243918",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Abbott's  ( ABT )  Innovations Aid, Macroeconomic Issues Stay",
    "url": "https://www.zacks.com/stock/news/2211543/abbotts-abt-innovations-aid-macroeconomic-issues-stay",
    "time_published": "20240117T160100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Abbott (ABT) is successfully continuing the rollout of Alinity, the company's fully integrated and automated molecular diagnostics analyzer.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.972193"
      }
    ],
    "overall_sentiment_score": 0.140348,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "HQY",
        "relevance_score": "0.140076",
        "ticker_sentiment_score": "0.05471",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.140076",
        "ticker_sentiment_score": "0.037643",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HAE",
        "relevance_score": "0.18602",
        "ticker_sentiment_score": "0.049643",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DVA",
        "relevance_score": "0.140076",
        "ticker_sentiment_score": "0.05471",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:EUR",
        "relevance_score": "0.046907",
        "ticker_sentiment_score": "0.059823",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Continuous Glucose Monitoring Systems Market to Hit US$20.5 Billion by 2030 | Updated Insights Report by Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36683594/continuous-glucose-monitoring-systems-market-to-hit-us-20-5-billion-by-2030-updated-insights-repor",
    "time_published": "20240118T183000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 19, 2024 ( GLOBE NEWSWIRE ) -- Continuous glucose monitoring ( CGM ) systems have brought significant advancements to the field of diabetes management by providing real-time data on blood glucose levels.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.388487,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MOOIF",
        "relevance_score": "0.01706",
        "ticker_sentiment_score": "0.199568",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.034112",
        "ticker_sentiment_score": "0.242427",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.034112",
        "ticker_sentiment_score": "0.242427",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.034112",
        "ticker_sentiment_score": "0.198683",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "$100 Invested In This Stock 10 Years Ago Would Be Worth $300 Today - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/insights/news/24/01/36700971/100-invested-in-this-stock-10-years-ago-would-be-worth-300-today",
    "time_published": "20240119T200027",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Abbott Laboratories ABT has outperformed the market over the past 10 years by 1.65% on an annualized basis producing an average annual return of 11.83%. Currently, Abbott Laboratories has a market capitalization of $197.62 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_4.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.160819,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.980595",
        "ticker_sentiment_score": "0.386944",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Global Transdermal Skin Patches Market Forecast Report, 2024-2030: A $9.9B Projected Industry, Dominated by Teva Pharma, 3M Company, Nitto Denko Corporation, and Johnson & Johnson",
    "url": "https://www.prnewswire.com/news-releases/global-transdermal-skin-patches-market-forecast-report-2024-2030-a-9-9b-projected-industry-dominated-by-teva-pharma-3m-company-nitto-denko-corporation-and-johnson--johnson-302039341.html",
    "time_published": "20240119T171500",
    "authors": [
      "Research and Markets"
    ],
    "summary": "Global Transdermal Skin Patches Market Forecast Report, 2024-2030: A $9.9B Projected Industry, Dominated by Teva ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.292081,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NDEKF",
        "relevance_score": "0.031738",
        "ticker_sentiment_score": "0.121467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDRFF",
        "relevance_score": "0.031738",
        "ticker_sentiment_score": "0.121467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.031738",
        "ticker_sentiment_score": "0.121467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.063425",
        "ticker_sentiment_score": "0.143639",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VTRS",
        "relevance_score": "0.031738",
        "ticker_sentiment_score": "0.121467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LYPHF",
        "relevance_score": "0.031738",
        "ticker_sentiment_score": "0.121467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.031738",
        "ticker_sentiment_score": "0.121467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.031738",
        "ticker_sentiment_score": "0.121467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MMM",
        "relevance_score": "0.063425",
        "ticker_sentiment_score": "0.126538",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "ABT: Analyzing 2024 Gain Potential in 3 Medical Stocks",
    "url": "https://stocknews.com/news/abt-a-vmd-analyzing-2024-gain-potential-in-3-medical-stocks/",
    "time_published": "20240119T162709",
    "authors": [
      "StockNews.com Staff"
    ],
    "summary": "The medical industry is navigating an exciting landscape marked by unprecedented demographic shifts, widespread technological advancement, surging medical expenses, and escalating risk of chronic diseases. This dynamic landscape presents a spectrum of opportunities for the companies operating ...",
    "banner_image": "https://stocknews.com/wp-content/uploads/2023/06/Anushka-Mukherjee_Headshot-2.jpg",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "stocknews.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999998"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.241034,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "A",
        "relevance_score": "0.027413",
        "ticker_sentiment_score": "0.138612",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.190096",
        "ticker_sentiment_score": "0.215581",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VMD",
        "relevance_score": "0.163354",
        "ticker_sentiment_score": "0.153473",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.027413",
        "ticker_sentiment_score": "0.237198",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.027413",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Hepatitis C Virus Testing Market Poised to Expand at a 5.8% CAGR, Surpassing US$1,185.2 Million by 2030 | Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36691001/hepatitis-c-virus-testing-market-poised-to-expand-at-a-5-8-cagr-surpassing-us-1-185-2-million-by-2",
    "time_published": "20240119T083000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 19, 2024 ( GLOBE NEWSWIRE ) -- Market Overview: The Hepatitis C Virus ( HCV ) Testing Market is a dynamic and evolving sector within the healthcare industry, driven by the persistent threat posed by the Hepatitis C Virus.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.33534,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HOLX",
        "relevance_score": "0.025775",
        "ticker_sentiment_score": "0.244618",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.038655",
        "ticker_sentiment_score": "0.080127",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OSUR",
        "relevance_score": "0.012889",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.012889",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.012889",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIO",
        "relevance_score": "0.025775",
        "ticker_sentiment_score": "0.116589",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QGEN",
        "relevance_score": "0.025775",
        "ticker_sentiment_score": "0.151882",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "My 5 Top Dividend Stocks to Buy Hand Over Fist in 2024",
    "url": "https://www.fool.com/investing/2024/01/21/my-5-top-dividend-stocks-to-buy-in-2024/",
    "time_published": "20240121T111700",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "These stocks may help you win in 2024 -- no matter what the market does.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F761894%2Fgettyimages-1172040755.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999365"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.983783"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.344613,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "0.17327",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.078099",
        "ticker_sentiment_score": "0.311035",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.116914",
        "ticker_sentiment_score": "0.107532",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.226339",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.078099",
        "ticker_sentiment_score": "0.188048",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Rehabilitation Equipment Global Market to Showcase Growth at a CAGR of ~5% by 2028, Examines DelveInsight",
    "url": "https://www.prnewswire.com/news-releases/rehabilitation-equipment-global-market-to-showcase-growth-at-a-cagr-of-5-by-2028-examines-delveinsight-302040512.html",
    "time_published": "20240122T223100",
    "authors": [
      "DelveInsight Business Research",
      "LLP"
    ],
    "summary": "The increasing demand for rehabilitation equipment is driven by several factors, including a growing number of accidents, injuries, and falls.",
    "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.218223,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MFCSF",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "0.089754",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVRO",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "0.026075",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZBH",
        "relevance_score": "0.079921",
        "ticker_sentiment_score": "-0.002038",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EKSO",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "0.098104",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OFIX",
        "relevance_score": "0.05333",
        "ticker_sentiment_score": "0.003986",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RWLK",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "0.098104",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GMED",
        "relevance_score": "0.05333",
        "ticker_sentiment_score": "0.003986",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.05333",
        "ticker_sentiment_score": "0.004985",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.079921",
        "ticker_sentiment_score": "-0.002038",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ATEC",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "-0.011827",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SRGAQ",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "-0.011827",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANIK",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "0.020645",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "0.026075",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DNPUF",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "0.098104",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSUMF",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "0.098104",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRUMF",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "0.020645",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IART",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "-0.023117",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVCRQ",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "0.098104",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DYNT",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "0.098104",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MAAL",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "0.098104",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.079921",
        "ticker_sentiment_score": "0.011181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BVS",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "0.020645",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMAX",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "0.098104",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.02668",
        "ticker_sentiment_score": "0.020645",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Brain Implants Market Set for Remarkable Growth: Projected to Reach $8.77 Billion by 2028 As Per The Business Research Company's Brain Implants Global Market Report 2024",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36719319/brain-implants-market-set-for-remarkable-growth-projected-to-reach-8-77-billion-by-2028-as-per-the",
    "time_published": "20240122T163000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LONDON, Jan. 22, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Brain Implants Global Market Report 2024, the global brain implants market has been experiencing rapid growth in recent years and is poised for significant expansion in the coming years.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.28117,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.054236",
        "ticker_sentiment_score": "0.121772",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.054236",
        "ticker_sentiment_score": "0.121772",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.054236",
        "ticker_sentiment_score": "0.121772",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LIVN",
        "relevance_score": "0.054236",
        "ticker_sentiment_score": "0.121772",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What's in Store for Zimmer Biomet  ( ZBH )  in Q4 Earnings?",
    "url": "https://www.zacks.com/stock/news/2213563/whats-in-store-for-zimmer-biomet-zbh-in-q4-earnings",
    "time_published": "20240122T154200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Zimmer Biomet (ZBH) is expected to have gained from the uptake of Persona OsseoTi Keel Tibia for Cementless Knee Replacement in the fourth quarter.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/69/45495.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.197633,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RXST",
        "relevance_score": "0.131884",
        "ticker_sentiment_score": "0.057745",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZBH",
        "relevance_score": "0.381625",
        "ticker_sentiment_score": "0.217763",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.175221",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SRPT",
        "relevance_score": "0.131884",
        "ticker_sentiment_score": "0.094494",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Buy Abbott Laboratories  ( ABT )  Ahead of Earnings?",
    "url": "https://www.zacks.com/stock/news/2213332/should-you-buy-abbott-laboratories-abt-ahead-of-earnings",
    "time_published": "20240122T133000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Abbott Laboratories (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.99237"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.461499,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.900719",
        "ticker_sentiment_score": "0.599723",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "CVS Health  ( CVS )  to Report Q4 Earnings: What's in the Cards?",
    "url": "https://www.zacks.com/stock/news/2213329/cvs-health-cvs-to-report-q4-earnings-whats-in-the-cards",
    "time_published": "20240122T132400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "CVS Health's (CVS) fourth-quarter 2023 results are likely to reflect the strength of the Pharmacy & Consumer Wellness and Health Services segments.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      }
    ],
    "overall_sentiment_score": 0.287182,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CVS",
        "relevance_score": "0.661118",
        "ticker_sentiment_score": "0.544724",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "RXST",
        "relevance_score": "0.12003",
        "ticker_sentiment_score": "0.012615",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.159569",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SRPT",
        "relevance_score": "0.12003",
        "ticker_sentiment_score": "0.087079",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Renal function test market forecasting a US$1.6 billion illumination by 2030, with Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36711091/renal-function-test-market-forecasting-a-us-1-6-billion-illumination-by-2030-with-persistence-mark",
    "time_published": "20240122T070000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 22, 2024 ( GLOBE NEWSWIRE ) -- Renal Function Test Market: A Comprehensive Analysis Renal Function Tests are a series of diagnostic tests used to assess the functioning of the kidneys.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.374337,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BAX",
        "relevance_score": "0.014497",
        "ticker_sentiment_score": "0.207185",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.014497",
        "ticker_sentiment_score": "0.207185",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Arterial Device-Focused Inari Medical Likely Acquisition Target, Shares Are Attractively Valued: Analyst - Inari Medical  ( NASDAQ:NARI ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36745475/arterial-device-focused-inari-medical-likely-acquisition-target-shares-are-attracti",
    "time_published": "20240123T195652",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Needham initiated coverage on Inari Medical Inc NARI, noting it as a leader in the very large and underpenetrated market for venous thrombectomy. Inari Medical projects an annual patient population of 280,000 with pulmonary embolism ( PE ) in the U.S., equating to a total available market ( TAM ) ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/NARI.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Mergers",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.231817,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRUMF",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TFX",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NARI",
        "relevance_score": "0.776097",
        "ticker_sentiment_score": "0.535824",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Protein Supplement Market Set for Robust Growth: Projected 8.7% CAGR, Reaching US$113.1 Billion by 2030, Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36742343/protein-supplement-market-set-for-robust-growth-projected-8-7-cagr-reaching-us-113-1-billion-by-20",
    "time_published": "20240123T170000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 23, 2024 ( GLOBE NEWSWIRE ) -- Protein supplements play a crucial role in the health and fitness industry, aiding individuals in meeting their nutritional requirements.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.463391,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HESG",
        "relevance_score": "0.042159",
        "ticker_sentiment_score": "0.088752",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.042159",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HLF",
        "relevance_score": "0.042159",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GLAPF",
        "relevance_score": "0.042159",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cough Suppressant Market to Hit US$ 39,216.3 Million by 2030 | Updated Insights Report by Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36734013/cough-suppressant-market-to-hit-us-39-216-3-million-by-2030-updated-insights-report-by-persistence",
    "time_published": "20240123T120000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 23, 2024 ( GLOBE NEWSWIRE ) -- Cough suppressants, also known as antitussives, are pharmaceutical substances engineered to alleviate cough symptoms.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.291889,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HLCO",
        "relevance_score": "0.020848",
        "ticker_sentiment_score": "0.009603",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.041682",
        "ticker_sentiment_score": "0.183297",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.062488",
        "ticker_sentiment_score": "0.179295",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Expectorant Drugs Market Poised to Reach US$22.9 Billion by 2030 with a Steady 4.5% CAGR | Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36732382/expectorant-drugs-market-poised-to-reach-us-22-9-billion-by-2030-with-a-steady-4-5-cagr-persistenc",
    "time_published": "20240123T093000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 23, 2024 ( GLOBE NEWSWIRE ) -- Market Size & Overview: The global expectorant drugs market is projected to grow at a robust CAGR of 4.5%, surging from US$16.8 billion in 2023 to reach US$22.9 billion by the conclusion of 2030.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.714479"
      }
    ],
    "overall_sentiment_score": 0.399092,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MFCSF",
        "relevance_score": "0.015226",
        "ticker_sentiment_score": "0.124442",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.015226",
        "ticker_sentiment_score": "0.306033",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.015226",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.015226",
        "ticker_sentiment_score": "0.119248",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.015226",
        "ticker_sentiment_score": "0.066705",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "S&P 500 ends with record high for 2nd session in row",
    "url": "https://www.moneycontrol.com/news/business/markets/sp-500-ends-with-record-high-for-2nd-session-in-row-12105241.html",
    "time_published": "20240123T010143",
    "authors": [],
    "summary": "Friday's finish confirmed that the SP 500 has been in a bull market since it closed at its low on Oct. 12, 2022, according to one commonly used measure.",
    "banner_image": "https://images.moneycontrol.com/static-mcnews/2020/08/wall-street-1.jpg?impolicy=website&width=168&height=118",
    "source": "Money Control",
    "category_within_source": "Markets",
    "source_domain": "www.moneycontrol.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.14298,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "0.11768",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "0.21237",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "0.04322",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADM",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "0.010699",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LPLA",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "0.063858",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Top Stocks to Watch as Earnings Approach",
    "url": "https://www.zacks.com/stock/news/2213851/top-stocks-to-watch-as-earnings-approach",
    "time_published": "20240123T002800",
    "authors": [
      "Shaun Pruitt"
    ],
    "summary": "Several expansive companies are expected to post stellar quarterly growth when they report Q4 results on Wednesday, January 24.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b6/2622.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.917436"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.374667,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PGR",
        "relevance_score": "0.412861",
        "ticker_sentiment_score": "0.50517",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.213988",
        "ticker_sentiment_score": "0.219314",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IBM",
        "relevance_score": "0.316168",
        "ticker_sentiment_score": "0.296084",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "URI",
        "relevance_score": "0.658003",
        "ticker_sentiment_score": "0.471236",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Leaders from Amazon, Hitachi America, Abbott Laboratories, Lendlease and More to Speak at Questex's Sensors Converge 2024",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36765327/leaders-from-amazon-hitachi-america-abbott-laboratories-lendlease-and-more-to-speak-at-questexs-se",
    "time_published": "20240124T190000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, Jan. 24, 2024 ( GLOBE NEWSWIRE ) -- Questex's Fierce Technology Group today announces leaders from Amazon, Hitachi America, Abbott Laboratories, Lendlease and more will speak at Sensors Converge 2024. The event will offer over 80 sessions over three days.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.218075,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLESY",
        "relevance_score": "0.12645",
        "ticker_sentiment_score": "-0.005833",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.063425",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.12645",
        "ticker_sentiment_score": "-0.005835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TXN",
        "relevance_score": "0.063425",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HTHIF",
        "relevance_score": "0.12645",
        "ticker_sentiment_score": "-0.005836",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NXPI",
        "relevance_score": "0.063425",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Is Abbott Stock Trading Lower Today? - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/news/earnings/24/01/36763629/abbott-laboratories-surpasses-q4-sales-expectations-despite-dip-in-covid-19-testing-demand",
    "time_published": "20240124T173429",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Abbott Laboratories ABT posted higher sales of $10.24 billion in the fourth quarter, despite continued soft demand for the company's Covid-19 testing equipment, beating the consensus of $10.18 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/abbott-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.294221,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TNDM",
        "relevance_score": "0.212115",
        "ticker_sentiment_score": "0.140682",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.313484",
        "ticker_sentiment_score": "-0.060395",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Abbott's  ( ABT )  Q4 Earnings Match Estimates, Margins Rise",
    "url": "https://www.zacks.com/stock/news/2215090/abbotts-abt-q4-earnings-match-estimates-margins-rise",
    "time_published": "20240124T154800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Abbott (ABT) delivers better-than-expected revenues and in-line earnings for the fourth quarter of 2023.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b1/44137.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.28585,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HAE",
        "relevance_score": "0.154951",
        "ticker_sentiment_score": "0.158055",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SGRY",
        "relevance_score": "0.154951",
        "ticker_sentiment_score": "0.135945",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.154951",
        "ticker_sentiment_score": "0.155454",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Health Care Bellwether Skids On Light Earnings Outlook",
    "url": "https://www.investors.com/news/technology/abt-stock-abbott-laboratories-earnings-q3-2023/",
    "time_published": "20240124T135400",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "ABT Stock Skids On Light Earnings Outlook Despite Quarterly Sales Beat Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/02/Stock-abbott-06-company.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      }
    ],
    "overall_sentiment_score": 0.317476,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "INBX",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.21355",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.722944",
        "ticker_sentiment_score": "0.311271",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.21355",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Abbott Labs' fourth-quarter sales top estimates amid strong medical-device demand",
    "url": "https://www.marketwatch.com/story/abbott-labs-fourth-quarter-sales-top-estimates-amid-strong-medical-device-demand-4d68669e",
    "time_published": "20240124T125700",
    "authors": [
      "Eleanor Laise"
    ],
    "summary": "Abbott Laboratories on Wednesday reported fourth-quarter sales that topped expectations amid strength in its medical-device and nutrition segments.",
    "banner_image": "https://images.mktw.net/im-549400/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.162117,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.148273",
        "ticker_sentiment_score": "0.197008",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TNDM",
        "relevance_score": "0.148273",
        "ticker_sentiment_score": "0.111972",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.148273",
        "ticker_sentiment_score": "0.006598",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nasdaq, S&P 500 Futures Jump As Wall Street Eagerly Awaits Tesla's Q4 Earnings: Analyst Says Rally Broadening But Favors These Stocks - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/01/36755805/nasdaq-s-p-500-futures-jump-as-wall-street-eagerly-awaits-teslas-q4-earnings-analyst-says-rally-bro",
    "time_published": "20240124T124145",
    "authors": [
      "Shanthi Rexaline"
    ],
    "summary": "U.S. stock futures indicate a positive opening on Wednesday, buoyed by strong earnings reports from Netflix, Inc. NFLX and semiconductor equipment maker ASML Holding N.V. ASML. Investors are eagerly awaiting Tesla, Inc.'s TSLA fourth-quarter results, which are expected to take center stage.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Wall-Street-US-Stocks.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.967645"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.928139"
      }
    ],
    "overall_sentiment_score": 0.181687,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.172919",
        "ticker_sentiment_score": "0.108241",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMB",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "-0.100818",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TXN",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "-0.139714",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.220007",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MMM",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "-0.100818",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ASML",
        "relevance_score": "0.172919",
        "ticker_sentiment_score": "0.185069",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "0.175759",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "T",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BACHY",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.123025",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FCX",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GD",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "-0.139714",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WT",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.206003",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FOREX:EUR",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.175",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "S&P 500 futures point to fresh record on Netflix results, bond market calm",
    "url": "https://www.marketwatch.com/story/s-p-500-futures-point-to-fresh-record-on-netflix-results-bond-market-calm-bc2b7035",
    "time_published": "20240124T102500",
    "authors": [
      "Jamie Chisholm"
    ],
    "summary": "Futures showed the S&P 500 on course for another record as a batch of well-received earnings, calmer bond markets and a monetary boost in China lifted risk appetite.",
    "banner_image": "https://images.mktw.net/im-560005/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      }
    ],
    "overall_sentiment_score": 0.203871,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.421485",
        "ticker_sentiment_score": "0.283587",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWQGF",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "0.26708",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LRCX",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FCX",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HRGLF",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "-0.063804",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Investor Optimism Improves Following Earnings Reports; S&P 500 Reaches Another High - Abbott Laboratories  ( NYSE:ABT ) , IBM  ( NYSE:IBM ) ",
    "url": "https://www.benzinga.com/news/earnings/24/01/36752497/investor-optimism-improves-following-earnings-reports-s-p-500-reaches-another-high",
    "time_published": "20240124T084959",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "The CNN Money Fear and Greed index showed a further increase in overall market sentiment, while the index remained in the \"Greed\" zone on Tuesday. U.S. stocks closed mixed on Tuesday, with the Dow Jones index snapping a three-day winning streak. However, the S&P 500 hit a new all-time closing ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/24/image18.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": -0.053398,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "T",
        "relevance_score": "0.116914",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "0.525561",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "IBM",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "0.525561",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "WBD",
        "relevance_score": "0.116914",
        "ticker_sentiment_score": "-0.206002",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "MMM",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "0.525561",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Netflix, Tesla And 3 Stocks To Watch Heading Into Wednesday - Netflix  ( NASDAQ:NFLX ) , Tesla  ( NASDAQ:TSLA ) ",
    "url": "https://www.benzinga.com/news/earnings/24/01/36752351/netflix-tesla-and-3-stocks-to-watch-heading-into-wednesday",
    "time_published": "20240124T073640",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "With U.S. stock futures trading higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects AT&T Inc. T to report quarterly earnings at 56 cents per share on revenue of $31.48 billion before the opening bell.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/24/netflix_-_logo.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.928769"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.285702,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.524949",
        "ticker_sentiment_score": "0.503736",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.366061",
        "ticker_sentiment_score": "0.3313",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.524949",
        "ticker_sentiment_score": "0.337724",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "T",
        "relevance_score": "0.366061",
        "ticker_sentiment_score": "0.312897",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.524949",
        "ticker_sentiment_score": "0.665478",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "World's Smallest Brain Stimulation Device For Movement Disorder: FDA Approved Abbott's Liberta RC DBS system - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/news/large-cap/24/01/36789135/worlds-smallest-brain-stimulation-device-for-movement-disorder-fda-approved-abbotts-liberta-rc-dbs",
    "time_published": "20240125T201959",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Abbott Laboratories ABT received FDA approval to launch the Liberta RC DBS system, the world's smallest rechargeable deep brain stimulation ( DBS ) device with remote programming, to treat people living with movement disorders.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Micro-Chip-And-Human-Brain---Neuron-Tech.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.225792,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.334762",
        "ticker_sentiment_score": "0.34956",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 No-Brainer Dividend Stocks to Buy for the New Year",
    "url": "https://www.fool.com/investing/2024/01/25/no-brainer-dividend-stocks-to-buy-for-the-new-year/",
    "time_published": "20240125T102000",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "These companies have fantastic track records of maintaining and raising their payouts.",
    "banner_image": "https://g.foolcdn.com/editorial/images/762006/getty-happy-couple-reassured-relief-relieved.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998356"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.997902"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.232466,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DMPZF",
        "relevance_score": "0.046724",
        "ticker_sentiment_score": "0.079439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.046724",
        "ticker_sentiment_score": "0.170453",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.093289",
        "ticker_sentiment_score": "0.076148",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.046724",
        "ticker_sentiment_score": "0.071917",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DPZ",
        "relevance_score": "0.093289",
        "ticker_sentiment_score": "0.084436",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Looking Into Abbott Laboratories's Recent Short Interest - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/01/36806138/looking-into-abbott-laboratoriess-recent-short-interest",
    "time_published": "20240126T174520",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Abbott Laboratories's ABT short percent of float has fallen 11.59% since its last report. The company recently reported that it has 10.55 million shares sold short, which is 0.61% of all regular shares that are available for trading.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.239316,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.221819",
        "ticker_sentiment_score": "0.083071",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stocks Rally Amid Big Earnings, Economic Data: Weekly Review",
    "url": "https://www.investors.com/news/stock-market-continues-to-rally-asml-netflix-tesla-intel-are-big-earnings-movers-weekly-review/",
    "time_published": "20240126T172900",
    "authors": [
      "IBD STAFF",
      "Investor's Business Daily"
    ],
    "summary": "Stock Market Continues To Rally. ASML, Netflix, Tesla, Intel Are Big Earnings Movers: Weekly Review Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2023/06/Stock-teslafrontnose-01-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.928139"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999897"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.08166,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "PCAR",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "0.013004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "-0.067699",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.100308",
        "ticker_sentiment_score": "0.023613",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEX",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "0.143388",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.060287",
        "ticker_sentiment_score": "0.075292",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.020113",
        "ticker_sentiment_score": "0.035033",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TXN",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "-0.107406",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "URI",
        "relevance_score": "0.12023",
        "ticker_sentiment_score": "0.159096",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TXT",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "0.202956",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "0.074287",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.080323",
        "ticker_sentiment_score": "-0.014907",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNP",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "-0.224991",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "V",
        "relevance_score": "0.080323",
        "ticker_sentiment_score": "-0.021101",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LRCX",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "-0.107406",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SAVE",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "-0.13454",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GD",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "0.202956",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GE",
        "relevance_score": "0.100308",
        "ticker_sentiment_score": "0.035632",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NSC",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "-0.224991",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "KLAC",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "-0.107406",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.12023",
        "ticker_sentiment_score": "0.084831",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HUM",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "0.124534",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOC",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "0.202956",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BAH",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "0.202956",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAL",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "-0.067699",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMUS",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "0.036945",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LMT",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "0.202956",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.100308",
        "ticker_sentiment_score": "-0.038213",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "0.143388",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOW",
        "relevance_score": "0.020113",
        "ticker_sentiment_score": "0.105654",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.060287",
        "ticker_sentiment_score": "0.118296",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.100308",
        "ticker_sentiment_score": "0.036031",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FCX",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "-0.163211",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "BRO",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "0.078443",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAL",
        "relevance_score": "0.060287",
        "ticker_sentiment_score": "0.024078",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "-0.067699",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CNI",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "-0.224991",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Thyroid Function Test Market Expansion at 4.2% CAGR to US$ 2.5 Billion, Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36796407/thyroid-function-test-market-expansion-at-4-2-cagr-to-us-2-5-billion-persistence-market-research",
    "time_published": "20240126T083519",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 26, 2024 ( GLOBE NEWSWIRE ) -- Thyroid Function Tests ( TFTs ) serve as diagnostic tools to assess the health and functionality of the thyroid gland, a crucial regulator of metabolism through hormone production.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.360656,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HCSG",
        "relevance_score": "0.026562",
        "ticker_sentiment_score": "0.139962",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.053094",
        "ticker_sentiment_score": "0.321943",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DHR",
        "relevance_score": "0.026562",
        "ticker_sentiment_score": "0.328355",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Monthly Meeting Q&A with Jim Cramer: Everything from health care to industrials to portfolio management",
    "url": "https://www.cnbc.com/2024/01/28/monthly-meeting-qa-with-jim-cramer-everything-from-health-care-to-industrials.html",
    "time_published": "20240128T180102",
    "authors": [
      "Paulina Likos"
    ],
    "summary": "During the January Monthly Meeting, we took questions directly from Investing Club members.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107200470-1677528554271-NUP_200782_00237.jpg?v=1697057003&w=600&h=300&vtcrop=y",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.682689"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.928139"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.07939,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BABA",
        "relevance_score": "0.019086",
        "ticker_sentiment_score": "0.029932",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DKNG",
        "relevance_score": "0.076236",
        "ticker_sentiment_score": "0.033849",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.038162",
        "ticker_sentiment_score": "0.032468",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.076236",
        "ticker_sentiment_score": "0.033849",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIDU",
        "relevance_score": "0.019086",
        "ticker_sentiment_score": "0.029932",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WYNN",
        "relevance_score": "0.038162",
        "ticker_sentiment_score": "0.032468",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.038162",
        "ticker_sentiment_score": "0.032468",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.057215",
        "ticker_sentiment_score": "0.033046",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.019086",
        "ticker_sentiment_score": "0.029932",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.189076",
        "ticker_sentiment_score": "0.051361",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.057215",
        "ticker_sentiment_score": "0.033046",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ETN",
        "relevance_score": "0.076236",
        "ticker_sentiment_score": "0.033849",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTRA",
        "relevance_score": "0.057215",
        "ticker_sentiment_score": "0.033046",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PANW",
        "relevance_score": "0.038162",
        "ticker_sentiment_score": "0.032468",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "We're calling up a health care stock from our Bullpen watch list, starting a new position",
    "url": "https://www.cnbc.com/2024/01/29/were-calling-up-a-health-care-stock-from-our-bullpen-watch-list-starting-a-new-position.html",
    "time_published": "20240129T140341",
    "authors": [
      "Jim Cramer"
    ],
    "summary": "Now that expectations have cooled down, we think this pullback is one worth buying.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107250871-1685970222341-gettyimages-1258453480-Port_Trade_Growth_In_Lianyungang.jpeg?v=1698261998&w=600&h=300&vtcrop=y",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.96136"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.905476"
      }
    ],
    "overall_sentiment_score": 0.209243,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.074809",
        "ticker_sentiment_score": "0.090625",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.037446",
        "ticker_sentiment_score": "0.087033",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.221819",
        "ticker_sentiment_score": "0.153796",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares U.S. Medical Devices ETF  ( IHI ) ?",
    "url": "https://www.zacks.com/stock/news/2216843/should-you-invest-in-the-ishares-us-medical-devices-etf-ihi",
    "time_published": "20240129T112006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for IHI ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default131.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.219004,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.064973",
        "ticker_sentiment_score": "0.031018",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SEM",
        "relevance_score": "0.129516",
        "ticker_sentiment_score": "0.026807",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.129516",
        "ticker_sentiment_score": "0.070142",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.129516",
        "ticker_sentiment_score": "0.070142",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.129516",
        "ticker_sentiment_score": "0.070142",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Looking At Abbott Laboratories's Recent Unusual Options Activity - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/insights/options/24/01/36850241/looking-at-abbott-laboratoriess-recent-unusual-options-activity",
    "time_published": "20240130T170124",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bearish stance on Abbott Laboratories ABT. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.152244,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.723234",
        "ticker_sentiment_score": "0.244043",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.072217",
        "ticker_sentiment_score": "-0.022472",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.072217",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Meal Replacement Market Size Is Expected To Reach $25.7 Billion By 2028 At A CAGR Of More Than 8% As Per The Business Research Company's Meal Replacement Global Market Report 2024",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36849479/the-meal-replacement-market-size-is-expected-to-reach-25-7-billion-by-2028-at-a-cagr-of-more-than-",
    "time_published": "20240130T163000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LONDON, Jan. 30, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Meal Replacement Global Market Report 2024, the meal replacement market has exhibited robust growth, escalating from $17.27 billion in 2023 to $18.54 billion in 2024, marking a Compound Annual Growth Rate ( CAGR ) ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.372931,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NSRGF",
        "relevance_score": "0.058759",
        "ticker_sentiment_score": "0.334217",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.058759",
        "ticker_sentiment_score": "0.334217",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UL",
        "relevance_score": "0.058759",
        "ticker_sentiment_score": "0.334217",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Vestaron announces CEO transition, appoints Juan Estupinan as Interim CEO",
    "url": "https://www.benzinga.com/pressreleases/24/02/g36884636/vestaron-announces-ceo-transition-appoints-juan-estupinan-as-interim-ceo",
    "time_published": "20240201T120000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Durham, North Carolina, Feb. 01, 2024 ( GLOBE NEWSWIRE ) -- The Board of Directors of Vestaron Corporation, a leading provider of innovative peptide insecticide solutions, announced today that Anna Rath has left her position as Chief Executive Officer and as a member of the Board of Directors of ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.463238,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.067158",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Neuromodulation Market Worth $11.0 Billion | MarketsandMarkets\u2122.",
    "url": "https://www.prnewswire.com/news-releases/neuromodulation-market-worth-11-0-billion--marketsandmarkets-302051831.html",
    "time_published": "20240202T153000",
    "authors": [
      "MarketsandMarkets"
    ],
    "summary": "CHICAGO, Feb. 2, 2024 /PRNewswire/ -- Neuromodulation Market in terms of revenue was estimated to be worth $6.2 billion in 2023 and is poised to reach $11.0 billion by 2028, growing at a CAGR of 12.0% from 2023 to 2028 according to a new report by MarketsandMarkets\u2122.",
    "banner_image": "https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.289712,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NPCE",
        "relevance_score": "0.040416",
        "ticker_sentiment_score": "0.097628",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.040416",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.040416",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.080728",
        "ticker_sentiment_score": "0.093635",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.040416",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Could Abbott Labs Be the Next Big Winner in the Billion-Dollar Weight Loss Market?",
    "url": "https://www.fool.com/investing/2024/02/02/could-abbott-be-big-winner-weight-loss-market/",
    "time_published": "20240202T100300",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Abbott Labs is using its well-established strengths to make gains in the weight loss market.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F763499%2Fgettyimages-1139704348.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.057745,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.056407",
        "ticker_sentiment_score": "0.22549",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.112532",
        "ticker_sentiment_score": "0.083808",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.112532",
        "ticker_sentiment_score": "0.101063",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Abbott Laboratories Stock a Buy Now?",
    "url": "https://www.fool.com/investing/2024/02/03/is-abbott-laboratories-stock-a-buy-now/",
    "time_published": "20240203T124500",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Can Abbott Laboratories be a reliable income stock to hang on to now?",
    "banner_image": "https://media.ycharts.com/charts/08055129e638269990fb8cb2b3960bb5.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.928769"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.338982,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.145145",
        "ticker_sentiment_score": "0.318979",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Healthcare Dividend Kings to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/02/04/2-healthcare-dividend-kings-to-buy-and-hold-foreve/",
    "time_published": "20240204T132000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "It's going to take a lot to interrupt these companies' streaks.",
    "banner_image": "https://g.foolcdn.com/editorial/images/762995/physicians-in-an-operating-room.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.905476"
      }
    ],
    "overall_sentiment_score": 0.189542,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.154455",
        "ticker_sentiment_score": "0.085755",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.254573",
        "ticker_sentiment_score": "-0.096638",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Stocks to Buy Near Their 52-Week Highs",
    "url": "https://www.fool.com/investing/2024/02/05/2-stocks-to-buy-near-their-52-week-highs/",
    "time_published": "20240205T144500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "It's not too late to invest in these stocks.",
    "banner_image": "https://g.foolcdn.com/editorial/images/763705/person-sitting-at-a-desk-looking-at-two-monitors.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.314276,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.331765",
        "ticker_sentiment_score": "0.348557",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.331765",
        "ticker_sentiment_score": "0.189439",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Embolization Coil Market to grow by USD 481.9 million from 2022 to 2027, Abbott Laboratories and Achieva Medical ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/embolization-coil-market-to-grow-by-usd-481-9-million-from-2022-to-2027---abbott-laboratories-and-achieva-medical-are-among-the-key-companies--technavio-302053633.html",
    "time_published": "20240206T223600",
    "authors": [],
    "summary": "Embolization Coil Market to grow by USD 481.9 million from 2022 to 2027, Abbott Laboratories and Achieva Medical ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.127694,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MMSI",
        "relevance_score": "0.073321",
        "ticker_sentiment_score": "0.04126",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.146025",
        "ticker_sentiment_score": "0.04477",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.073321",
        "ticker_sentiment_score": "0.04126",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.146025",
        "ticker_sentiment_score": "0.063505",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRUMF",
        "relevance_score": "0.073321",
        "ticker_sentiment_score": "0.04126",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.073321",
        "ticker_sentiment_score": "0.04126",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PEN",
        "relevance_score": "0.073321",
        "ticker_sentiment_score": "0.04126",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.073321",
        "ticker_sentiment_score": "0.04126",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KANKF",
        "relevance_score": "0.073321",
        "ticker_sentiment_score": "0.04126",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.073321",
        "ticker_sentiment_score": "0.04126",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MCRPF",
        "relevance_score": "0.073321",
        "ticker_sentiment_score": "0.04126",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer - Corvus Pharma  ( NASDAQ:CRVS ) ",
    "url": "https://www.benzinga.com/pressreleases/24/02/g36965884/corvus-pharmaceuticals-appoints-jeffrey-arcara-as-chief-business-officer",
    "time_published": "20240206T210500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "BURLINGAME, Calif., Feb. 06, 2024 ( GLOBE NEWSWIRE ) -- Corvus Pharmaceuticals, Inc. CRVS, a clinical-stage biopharmaceutical company, today announced the appointment of Jeffrey Arcara as Chief Business Officer.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.165162,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.077094",
        "ticker_sentiment_score": "-0.001014",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRVS",
        "relevance_score": "0.371523",
        "ticker_sentiment_score": "0.00527",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "We're making a small stock sale to add to our newest position in the portfolio",
    "url": "https://www.cnbc.com/2024/02/06/were-making-a-small-trade-to-add-to-our-newest-portfolio-position.html",
    "time_published": "20240206T180949",
    "authors": [
      "Jeff Marks"
    ],
    "summary": "We are reallocating capital from one high-quality stock to another that may be more underappreciated.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107253593-1686246163158-gettyimages-1255499822-PGONCHAR_4177.jpeg?v=1706725359&w=600&h=300&vtcrop=y",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.905476"
      }
    ],
    "overall_sentiment_score": 0.420975,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.273807",
        "ticker_sentiment_score": "0.369886",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.440549",
        "ticker_sentiment_score": "0.503051",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Abbott Laboratories Stock Getting Closer To Key Technical Benchmark",
    "url": "https://www.investors.com/news/abbott-laboratories-getting-closer-to-key-technical-benchmark/",
    "time_published": "20240207T161100",
    "authors": [
      "GLENN LARKIN",
      "INVESTOR'S BUSINESS DAILY",
      "Investor's Business Daily"
    ],
    "summary": "In a welcome move, Abbott Laboratories ( ABT ) saw its Relative Strength Rating improve from 67 to 73 on Wednesday. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/05/IRU4.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.371044,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.250386",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.661658",
        "ticker_sentiment_score": "0.346743",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Want to Get Richer? Here Are the 3 Best Stocks to Buy Now and Hold Forever",
    "url": "https://www.fool.com/investing/2024/02/07/get-rich-best-stocks-buy-now-hold-forever/",
    "time_published": "20240207T101700",
    "authors": [
      "Justin Pope"
    ],
    "summary": "Healthcare is an excellent place to find some tried and true wealth compounders.",
    "banner_image": "https://g.foolcdn.com/editorial/images/763634/group-of-happy-people.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.290408,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.274628",
        "ticker_sentiment_score": "0.254041",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.274628",
        "ticker_sentiment_score": "0.256984",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.111747",
        "ticker_sentiment_score": "0.101814",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Abbott Laboratories Getting Closer To Key Technical Benchmark",
    "url": "https://www.investors.com/ibd-data-stories/abbott-laboratories-getting-closer-to-key-technical-benchmark/",
    "time_published": "20240207T080000",
    "authors": [
      "INVESTOR'S BUSINESS DAILY",
      "Investor's Business Daily"
    ],
    "summary": "In a welcome move, Abbott Laboratories ( ABT ) saw its Relative Strength Rating improve from 67 to 73 on Wednesday. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.362319,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.29234",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.739411",
        "ticker_sentiment_score": "0.422149",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Wearable Medical Devices Market to grow by USD 15.54 billion from 2022 to 2027; Market is fragmented due to the ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/wearable-medical-devices-market-to-grow-by-usd-15-54-billion-from-2022-to-2027-market-is-fragmented-due-to-the-presence-of-prominent-companies-like-abbott-laboratories-alphabet-inc-apple-inc-and-many-more---technavio-302057089.html",
    "time_published": "20240208T223600",
    "authors": [],
    "summary": "Wearable Medical Devices Market to grow by USD 15.54 billion from 2022 to 2027. Market is fragmented due to the ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.220358,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DFKCY",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "0.009265",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "0.009265",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "0.009265",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "0.009265",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "0.009265",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PHG",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "0.009265",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSNLF",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "0.009265",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OMRNF",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "0.009265",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "0.009265",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BTCY",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "0.009265",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "0.009265",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "0.009265",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GE",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "0.009265",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This Is What Whales Are Betting On Abbott Laboratories - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/insights/options/24/02/37012682/this-is-what-whales-are-betting-on-abbott-laboratories",
    "time_published": "20240208T163206",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bullish stance on Abbott Laboratories ABT. We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.153858,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.782863",
        "ticker_sentiment_score": "0.335841",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.075635",
        "ticker_sentiment_score": "-0.107127",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.075635",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Prediction: 2 Stocks That Could Trounce the Market",
    "url": "https://www.fool.com/investing/2024/02/08/prediction-2-stocks-that-could-trounce-the-market/",
    "time_published": "20240208T150000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "They have done it before.",
    "banner_image": "https://media.ycharts.com/charts/e15bf0846b51c8b52cdc3347650dbbd0.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.714479"
      }
    ],
    "overall_sentiment_score": 0.205126,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DXCM",
        "relevance_score": "0.450768",
        "ticker_sentiment_score": "0.24971",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.413878",
        "ticker_sentiment_score": "0.269869",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.043421",
        "ticker_sentiment_score": "0.051208",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Insulet's  ( PODD )  Omnipod 5 Gets CE Mark for Added Compatibility",
    "url": "https://www.zacks.com/stock/news/2223400/insulets-podd-omnipod-5-gets-ce-mark-for-added-compatibility",
    "time_published": "20240208T145200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Insulet's (PODD) tubeless automated insulin delivery system's CE mark approval with multiple CGM sensor brands is likely to serve a wider patient pool.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.286704,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MMSI",
        "relevance_score": "0.147818",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PODD",
        "relevance_score": "0.598255",
        "ticker_sentiment_score": "0.310315",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.147818",
        "ticker_sentiment_score": "0.103064",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DVA",
        "relevance_score": "0.220141",
        "ticker_sentiment_score": "0.161435",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.147444",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Medical Device Technologies Market is Anticipated to Reach USD 662.7 billion by 2028: Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37004095/medical-device-technologies-market-is-anticipated-to-reach-usd-662-7-billion-by-2028-transparency-",
    "time_published": "20240208T120000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Feb. 08, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global medical device technologies market is estimated to flourish at a CAGR of 4.3% from 2021 to 2028.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.423859,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.031612",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.063174",
        "ticker_sentiment_score": "0.107762",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.031612",
        "ticker_sentiment_score": "0.12322",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.063174",
        "ticker_sentiment_score": "0.317822",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "OCPNF",
        "relevance_score": "0.031612",
        "ticker_sentiment_score": "0.148981",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WLDS",
        "relevance_score": "0.031612",
        "ticker_sentiment_score": "0.145032",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.094638",
        "ticker_sentiment_score": "0.1079",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.031612",
        "ticker_sentiment_score": "0.221755",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNN",
        "relevance_score": "0.031612",
        "ticker_sentiment_score": "0.333601",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.063174",
        "ticker_sentiment_score": "0.193004",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.031612",
        "ticker_sentiment_score": "0.333601",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TRUMF",
        "relevance_score": "0.031612",
        "ticker_sentiment_score": "0.148981",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAX",
        "relevance_score": "0.031612",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.063174",
        "ticker_sentiment_score": "0.193004",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Pain Management Devices Market Projected to Attain a Valuation of USD 7.1 billion by 2028, Exhibiting a CAGR of 6.4%: Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37032016/pain-management-devices-market-projected-to-attain-a-valuation-of-usd-7-1-billion-by-2028-exhibiti",
    "time_published": "20240209T124500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Feb. 09, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global pain management devices market is estimated to flourish at a CAGR of 6.4% from 2021 to 2028.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.180755,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.032513",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVRO",
        "relevance_score": "0.032513",
        "ticker_sentiment_score": "0.217442",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.064973",
        "ticker_sentiment_score": "0.077484",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.064973",
        "ticker_sentiment_score": "-0.009135",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAX",
        "relevance_score": "0.032513",
        "ticker_sentiment_score": "-0.190734",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.129516",
        "ticker_sentiment_score": "0.122344",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WLDS",
        "relevance_score": "0.032513",
        "ticker_sentiment_score": "0.202453",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.097325",
        "ticker_sentiment_score": "0.036503",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.032513",
        "ticker_sentiment_score": "-0.008874",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Molecular Cytogenetics Market is Expected to Reach $4.9 Billion | MarketsandMarkets\u2122",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37031674/molecular-cytogenetics-market-is-expected-to-reach-4-9-billion-marketsandmarkets",
    "time_published": "20240209T123000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Chicago, Feb. 09, 2024 ( GLOBE NEWSWIRE ) -- Molecular Cytogenetics market in terms of revenue was estimated to be worth $3.1 billion in 2023 and is poised to reach $4.9 billion by 2028, growing at a CAGR of 9.9% from 2023 to 2028 according to a latest report published by MarketsandMarkets\u2122.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.142737,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "A",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.048006",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TECH",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.048006",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.048006",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OCX",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.048006",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ILMN",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.048006",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.048006",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIO",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.048006",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DHR",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.048006",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "These 2 Stocks Are Trying to Ride the Ozempic Bandwagon: Are They Buys?",
    "url": "https://www.fool.com/investing/2024/02/09/these-2-stocks-are-trying-to-ride-the-ozempic-band/",
    "time_published": "20240209T114500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "There's room for multiple winners in the fast-growing weight-loss market.",
    "banner_image": "https://media.ycharts.com/charts/9a7dfc4b05a8112da29aeee9f1a537f2.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.109291,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "REGN",
        "relevance_score": "0.104455",
        "ticker_sentiment_score": "-0.018962",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.05234",
        "ticker_sentiment_score": "-0.112999",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.156123",
        "ticker_sentiment_score": "0.142628",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Abbott Laboratories Is the Latest Company to Get Involved in the Weight Loss Market. Here's How.",
    "url": "https://www.fool.com/investing/2024/02/11/abbott-laboratories-is-the-latest-company-to-get-i/",
    "time_published": "20240211T180600",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Abbott Labs has an impressive portfolio of nutrition drinks, and its latest addition could help it profit from a new market: people taking prescribed weight loss drugs.",
    "banner_image": "https://g.foolcdn.com/editorial/images/764003/digital-health-wellness-exercise-nutrition-track-data-doctor.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.189493,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HIMS",
        "relevance_score": "0.064623",
        "ticker_sentiment_score": "-0.053033",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.128822",
        "ticker_sentiment_score": "0.135657",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.128822",
        "ticker_sentiment_score": "0.147552",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "These 17 Words From AbbVie's CEO Explain Why the Stock Is Still a Buy",
    "url": "https://www.fool.com/investing/2024/02/11/these-17-words-from-abbvies-ceo-explain-why-the-st/",
    "time_published": "20240211T132500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The drugmaker is handling its biggest obstacle yet relatively well.",
    "banner_image": "https://g.foolcdn.com/editorial/images/764237/physician-talking-to-patient.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.264273,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.624973",
        "ticker_sentiment_score": "0.346092",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.064276",
        "ticker_sentiment_score": "0.183306",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "FDA Advisors Set To Discuss Abbott's TriClip For Heart Valve Disorder As Questions On Pivotal Trial Loom - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/markets/equities/24/02/37071771/fda-advisors-set-to-discuss-abbotts-triclip-for-heart-valve-disorder-as-questions-on-pivotal-tri",
    "time_published": "20240212T160006",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Tuesday, February 13, 2024, the FDA's Circulatory System Devices Panel of the Medical Devices Advisory Committee will meet regarding the premarket approval application ( PMA ) for Abbott Laboratories ABT TriClip G4 System.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/ABT.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.253503,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EW",
        "relevance_score": "0.3007",
        "ticker_sentiment_score": "0.015851",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.3007",
        "ticker_sentiment_score": "0.22342",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Intrathecal Pumps Market Anticipated to Touch USD 405.6 million, Projected a CAGR of 4.5% by 2031: Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37070871/intrathecal-pumps-market-anticipated-to-touch-usd-405-6-million-projected-a-cagr-of-4-5-by-2031-tr",
    "time_published": "20240212T152500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Feb. 12, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global intrathecal pumps market is estimated to flourish at a CAGR of 4.5% from 2022 to 2031.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.380917,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.03478",
        "ticker_sentiment_score": "0.05005",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.03478",
        "ticker_sentiment_score": "0.080115",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GAHC",
        "relevance_score": "0.03478",
        "ticker_sentiment_score": "0.127966",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRUMF",
        "relevance_score": "0.03478",
        "ticker_sentiment_score": "0.22692",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TFX",
        "relevance_score": "0.03478",
        "ticker_sentiment_score": "0.211061",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "0.266909",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.104078",
        "ticker_sentiment_score": "0.079878",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.03478",
        "ticker_sentiment_score": "0.17536",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Novo Nordisk's Magic Run Continues Even With Increasing Competition",
    "url": "https://www.fool.com/investing/2024/02/12/novo-nordisks-magic-run-continues-even-with/",
    "time_published": "20240212T141500",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Novo Nordisk's Q4 earnings were rock solid as momentum in the diabetes and obesity markets continued to fuel growth.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F764199%2Fblood-pressure-doctor-senior-citizen-1.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.32476,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.039023",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.439786",
        "ticker_sentiment_score": "0.530137",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.039023",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PMNT",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.305091",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Global Generic Drugs Market Size is Estimated to Reach USD 546.03 Billion by 2031, Growing at a CAGR of 4.1%: Straits Research",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37064298/global-generic-drugs-market-size-is-estimated-to-reach-usd-546-03-billion-by-2031-growing-at-a-cag",
    "time_published": "20240212T114500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, United States, Feb. 12, 2024 ( GLOBE NEWSWIRE ) -- Generic medications are bioequivalent to name-brand medications, meaning they have the same active components and therapeutic results. Similarities exist in the dosages, risks, consequences, side effects, strengths, intended purposes, ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.057295,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.029728",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.029728",
        "ticker_sentiment_score": "-0.045086",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VTRS",
        "relevance_score": "0.059415",
        "ticker_sentiment_score": "-0.023004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAX",
        "relevance_score": "0.029728",
        "ticker_sentiment_score": "-0.045086",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANIP",
        "relevance_score": "0.029728",
        "ticker_sentiment_score": "0.125607",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.029728",
        "ticker_sentiment_score": "-0.045086",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.029728",
        "ticker_sentiment_score": "-0.045086",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.029728",
        "ticker_sentiment_score": "-0.045086",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.029728",
        "ticker_sentiment_score": "-0.045086",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.029728",
        "ticker_sentiment_score": "-0.045086",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cardiology's Quantum Leap: FDA's Advisory Panel Gives Thumbs Up To Abbott's Minimally Invasive Heart Valve Repair Device - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/news/large-cap/24/02/37133493/cardiologys-quantum-leap-fdas-advisory-panel-gives-thumbs-up-to-abbotts-minimally-invasive-heart-v",
    "time_published": "20240214T174737",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Tuesday, the FDA's Circulatory System Devices Panel of the Medical Devices Advisory Committee for the FDA confirmed 13 to 1, with 0 abstention, that the benefits of Abbott Laboratories ABT TriClip transcatheter edge-to-edge repair ( TEER ) system outweighed the risks to treat tricuspid ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Abott-TriClip.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.316844,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.31482",
        "ticker_sentiment_score": "0.182764",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Abbott Laboratories says FDA independent panel votes to approve heart device",
    "url": "https://www.marketwatch.com/story/abbott-laboratories-says-fda-independent-panel-votes-to-approve-heart-device-c796f12f",
    "time_published": "20240214T010600",
    "authors": [
      "Sabela Ojea"
    ],
    "summary": "Abbott Laboratories said that a Food and Drug Administration panel voted in favor of the safety profile of its heart device TriClip.",
    "banner_image": "https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.421357,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.760593",
        "ticker_sentiment_score": "0.870838",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Novo Nordisk Has More Than Ozempic. One of Its Other Treatments Grew 393% Last Year.",
    "url": "https://www.fool.com/investing/2024/02/18/novo-nordisk-has-more-than-ozempic-one-of-its/",
    "time_published": "20240218T143000",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "It may be best known for its diabetes treatment, Ozempic, but Novo Nordisk has a host of other blockbuster drugs, too.",
    "banner_image": "https://media.ycharts.com/charts/1ed14a2a1bf47b44b31b4ba079332fb3.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.217474,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.044304",
        "ticker_sentiment_score": "0.050831",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.044304",
        "ticker_sentiment_score": "0.050831",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.088472",
        "ticker_sentiment_score": "0.096448",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.595343",
        "ticker_sentiment_score": "0.362101",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.044304",
        "ticker_sentiment_score": "0.050831",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Smartest Dividend Stocks to Buy With $400 Right Now",
    "url": "https://www.fool.com/investing/2024/02/18/smartest-dividend-stocks-to-buy-with-400-dollars/",
    "time_published": "20240218T115800",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "These stocks reward you during any market environment.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F765475%2Fgettyimages-1357572936.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.997874"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.352988,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KO",
        "relevance_score": "0.313104",
        "ticker_sentiment_score": "0.25878",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.226583",
        "ticker_sentiment_score": "0.349582",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.091684",
        "ticker_sentiment_score": "0.143841",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Peering Into Abbott Laboratories's Recent Short Interest - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/02/37219467/peering-into-abbott-laboratoriess-recent-short-interest",
    "time_published": "20240220T183024",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Abbott Laboratories's ABT short percent of float has risen 21.31% since its last report. The company recently reported that it has 12.70 million shares sold short, which is 0.74% of all regular shares that are available for trading.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.267332,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.221819",
        "ticker_sentiment_score": "0.155473",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie taps longtime executive Robert Michael as new CEO, succeeding Richard Gonzalez",
    "url": "https://www.cnbc.com/2024/02/20/abbvie-taps-robert-michael-as-ceo-succeeding-richard-gonzalez.html",
    "time_published": "20240220T150658",
    "authors": [
      "Annika Kim Constantino"
    ],
    "summary": "Michael, who is AbbVie's chief operating officer, will become the company's second-ever CEO since the company spun out from Abbott Laboratories in 2013.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/106886633-16216093432021-05-21t145854z_868084266_rc29kn9d8g4p_rtrmadp_0_abbvie-usa.jpeg?v=1701366953&w=1920&h=1080",
    "source": "CNBC",
    "category_within_source": "Business",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.22236,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.105604",
        "ticker_sentiment_score": "0.288188",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.105604",
        "ticker_sentiment_score": "-0.072674",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.493128",
        "ticker_sentiment_score": "0.116578",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.054327",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Invesco Pharmaceuticals ETF  ( PJP )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2228267/is-invesco-pharmaceuticals-etf-pjp-a-strong-etf-right-now",
    "time_published": "20240220T112006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default91.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      }
    ],
    "overall_sentiment_score": 0.267515,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.1172",
        "ticker_sentiment_score": "0.061498",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.1172",
        "ticker_sentiment_score": "0.061498",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.231884",
        "ticker_sentiment_score": "0.267105",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.1172",
        "ticker_sentiment_score": "0.061498",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Announces Appointment of New CEO Robert Michael",
    "url": "https://www.zacks.com/stock/news/2229455/abbvie-abbv-announces-appointment-of-new-ceo-robert-michael",
    "time_published": "20240221T154300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Robert Michael is set to succeed Richard A. Gonzalez as AbbVie's (ABBV) CEO, effective Jul 1, 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/db/3038.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.857896"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.219621,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ACIU",
        "relevance_score": "0.343755",
        "ticker_sentiment_score": "0.168325",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.210579",
        "ticker_sentiment_score": "0.172638",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.714592",
        "ticker_sentiment_score": "0.343678",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.070935",
        "ticker_sentiment_score": "0.065297",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PBYI",
        "relevance_score": "0.406745",
        "ticker_sentiment_score": "0.231943",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Abbott Laboratories Stock Gets A Healthy Technical Rating Upgrade",
    "url": "https://www.investors.com/news/abbott-laboratories-stock-gets-a-healthy-technical-rating-upgrade/",
    "time_published": "20240221T080000",
    "authors": [
      "INVESTOR'S BUSINESS DAILY",
      "Investor's Business Daily",
      "JULIE MAK"
    ],
    "summary": "In a welcome move, Abbott Laboratories ( ABT ) stock saw its Relative Strength Rating improve from 67 to 73 on Wednesday. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/05/IRU77.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.448462,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.268294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.769861",
        "ticker_sentiment_score": "0.685395",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "A pacemaker for the brain helped a woman with crippling depression. It may soon offer hope to others",
    "url": "https://apnews.com/article/treatmentresistant-depression-dbs-deep-brain-stimulation-26383d6e5f9eb797485b7bc277cac59c",
    "time_published": "20240221T051100",
    "authors": [
      "LAURA UNGAR"
    ],
    "summary": "NEW YORK ( AP ) - Emily Hollenbeck lived with a deep, she likened to a black hole, where gravity felt so strong and her limbs so heavy she could barely move. She knew the illness could kill her. Both of her parents had taken their lives.",
    "banner_image": "https://dims.apnews.com/dims4/default/1c9aa92/2147483647/strip/true/crop/8640x5755+0+2/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F59%2F91%2F5e3552a559504aefb798116aec1a%2Feee06aea5e9e475a95918bbc6c79f83a",
    "source": "Associated Press",
    "category_within_source": "Markets",
    "source_domain": "apnews.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": -0.031381,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "HHH",
        "relevance_score": "0.025901",
        "ticker_sentiment_score": "0.154859",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.025901",
        "ticker_sentiment_score": "-0.053951",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Neuromodulation Market is Expected to Reach $11.0 Billion | MarketsandMarkets\u2122",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37257909/neuromodulation-market-is-expected-to-reach-11-0-billion-marketsandmarkets",
    "time_published": "20240222T123000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Chicago, Feb. 22, 2024 ( GLOBE NEWSWIRE ) -- Neuromodulation market in terms of revenue was estimated to be worth $6.2 billion in 2023 and is poised to reach $11.0 billion by 2028, growing at a CAGR of 12.0% from 2023 to 2028 according to a latest report published by MarketsandMarkets\u2122.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.069129,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NPCE",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ECOR",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVRO",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STIM",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HSDT",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Abbott Laboratories Options Trading: A Deep Dive into Market Sentiment - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/insights/options/24/02/37289903/abbott-laboratories-options-trading-a-deep-dive-into-market-sentiment",
    "time_published": "20240223T174542",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bearish stance on Abbott Laboratories ABT. We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.101014,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.712905",
        "ticker_sentiment_score": "0.196319",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.077094",
        "ticker_sentiment_score": "-0.022692",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.077094",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Abbott  ( ABT )  Up 5.8% Since Last Earnings Report: Can It Continue?",
    "url": "https://www.zacks.com/stock/news/2231121/abbott-abt-up-58-since-last-earnings-report-can-it-continue",
    "time_published": "20240223T163024",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default23.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999476"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.267177,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.046273",
        "ticker_sentiment_score": "0.156347",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: Pfizer's Velsipity Receives EU Nod, ABBV Gets New CEO & More",
    "url": "https://www.zacks.com/stock/news/2230738/pharma-stock-roundup-pfizers-velsipity-receives-eu-nod-abbv-gets-new-ceo-more",
    "time_published": "20240223T133700",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "European Commission approves Pfizer's (PFE) Velsipity ulcerative colitis (UC) pill. AbbVie (ABBV) appoints Robert A. Michael as the new CEO.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.239347,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SKXJF",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.121196",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.426225",
        "ticker_sentiment_score": "0.156384",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.061419",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.121196",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.245339",
        "ticker_sentiment_score": "0.18671",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.099476",
        "ticker_sentiment_score": "0.027784",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Microsoft, Amazon.com, Berkshire Hathaway, Abbott and BlackRock",
    "url": "https://www.zacks.com/stock/news/2230634/the-zacks-analyst-blog-highlights-microsoft-amazoncom-berkshire-hathaway-abbott-and-blackrock",
    "time_published": "20240223T100500",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Microsoft, Amazon.com, Berkshire Hathaway, Abbott and BlackRock are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fd/423.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.27794,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.146025",
        "ticker_sentiment_score": "0.041029",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.217508",
        "ticker_sentiment_score": "0.054341",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.146025",
        "ticker_sentiment_score": "0.041029",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.146025",
        "ticker_sentiment_score": "0.08165",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.146025",
        "ticker_sentiment_score": "0.041029",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's Why You Should Buy Edward Lifesciences  ( EW )  Stock Now",
    "url": "https://www.zacks.com/stock/news/2231893/heres-why-you-should-buy-edward-lifesciences-ew-stock-now",
    "time_published": "20240226T165400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Investors are optimistic about Edward Lifesciences' (EW) progress with the Structural Heart business and strong TAVR potential.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/41/899.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999336"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.271747,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EW",
        "relevance_score": "0.249361",
        "ticker_sentiment_score": "0.27727",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.050679",
        "ticker_sentiment_score": "0.146323",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.200688",
        "ticker_sentiment_score": "0.036188",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.050679",
        "ticker_sentiment_score": "0.146323",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COR",
        "relevance_score": "0.200688",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.200688",
        "ticker_sentiment_score": "0.147212",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.050679",
        "ticker_sentiment_score": "0.146323",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Could Abbott Laboratories Stock Help You Become a Millionaire?",
    "url": "https://www.fool.com/investing/2024/02/26/could-abbott-laboratories-stock-help-you-become-a/",
    "time_published": "20240226T121000",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "Abbott's earnings have soared over the past decade.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F766713%2Fgettyimages-1188369583.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.334408,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.111488",
        "ticker_sentiment_score": "0.295686",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Global Nanomedicine Market Report 2023-2028: United States Emerges as a Key Player",
    "url": "https://www.prnewswire.com/news-releases/global-nanomedicine-market-report-2023-2028-united-states-emerges-as-a-key-player-302070908.html",
    "time_published": "20240226T114500",
    "authors": [
      "Research and Markets"
    ],
    "summary": "DUBLIN, Feb. 26, 2024 /PRNewswire/ -- The \"Nanomedicine Market - Forecasts from 2023 to 2028\" report has been added to ResearchAndMarkets.com's offering. The medical application of nanotechnology is the focus of the interdisciplinary field of nanomedicine.",
    "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.234378,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.088147",
        "ticker_sentiment_score": "0.109752",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.044141",
        "ticker_sentiment_score": "0.104084",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.044141",
        "ticker_sentiment_score": "0.104084",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.044141",
        "ticker_sentiment_score": "0.104084",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Magnificent Dividend Growth Stocks to Buy Now and Hold for at Least a Decade",
    "url": "https://www.fool.com/investing/2024/02/27/3-magnificent-dividend-growth-stocks-to-buy-now-ho/",
    "time_published": "20240227T104500",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "These stocks don't offer the highest yields, but their payouts are growing fast.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F766804%2Fsmart-investor-looking-for-stocks-to-buy-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.988915"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.360043,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "UNH",
        "relevance_score": "0.222327",
        "ticker_sentiment_score": "0.402348",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.222327",
        "ticker_sentiment_score": "0.237543",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.112269",
        "ticker_sentiment_score": "-0.038443",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Traumatic Brain Injury Market Analysis 2024-2028: Projected Growth Rate, Key Trends And Opportunities As Per The Business Research Company's Traumatic Brain Injury Global Market Report 2024",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37398971/traumatic-brain-injury-market-analysis-2024-2028-projected-growth-rate-key-trends-and-opportunitie",
    "time_published": "20240229T163000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LONDON, Feb. 29, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Traumatic Brain Injury Global Market Report 2024, the traumatic brain injury market has experienced substantial growth, surging from $2.48 billion in 2023 to $2.72 billion in 2024, demonstrating a noteworthy ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.078315,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.046273",
        "ticker_sentiment_score": "-0.069218",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Better Dividend Growth Stock: AbbVie or Amgen?",
    "url": "https://www.fool.com/investing/2024/02/29/better-dividend-growth-stock-abbvie-or-amgen/",
    "time_published": "20240229T144500",
    "authors": [
      "George Budwell"
    ],
    "summary": "A strong case can be made for owning both of these dividend growth stocks. But one of them is the better buy.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F767246%2Fdividend-concept.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999967"
      }
    ],
    "overall_sentiment_score": 0.382731,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.457794",
        "ticker_sentiment_score": "0.560592",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.364529",
        "ticker_sentiment_score": "0.401299",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.053992",
        "ticker_sentiment_score": "0.167789",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is AbbVie Stock a Buy Now?",
    "url": "https://www.fool.com/investing/2024/02/29/is-abbvie-stock-a-buy-now/",
    "time_published": "20240229T130000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "Some would say the growth story is over, but that view might be a bit myopic.",
    "banner_image": "https://media.ycharts.com/charts/c8545d39ac9bed18f1107ca089cc2cdd.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.241716,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.668128",
        "ticker_sentiment_score": "0.340936",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.128478",
        "ticker_sentiment_score": "0.155288",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "$100 Invested In Abbott Laboratories 10 Years Ago Would Be Worth This Much Today - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/insights/news/24/03/37425286/100-invested-in-abbott-laboratories-10-years-ago-would-be-worth-this-much-today",
    "time_published": "20240301T163050",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Abbott Laboratories ABT has outperformed the market over the past 10 years by 1.07% on an annualized basis producing an average annual return of 11.57%. Currently, Abbott Laboratories has a market capitalization of $206.49 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_3.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.160819,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.980595",
        "ticker_sentiment_score": "0.386944",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Ozempic Won't Sink This Medical Device Stock's Prospects -- Quite the Opposite",
    "url": "https://www.fool.com/investing/2024/03/03/ozempic-wont-sink-this-medical-device-stock/",
    "time_published": "20240303T144500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "There is a world of opportunities ahead for this healthcare giant.",
    "banner_image": "https://g.foolcdn.com/editorial/images/767012/diabetes-patient-adjusting-device.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.172452,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DXCM",
        "relevance_score": "0.16317",
        "ticker_sentiment_score": "0.224353",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.054732",
        "ticker_sentiment_score": "0.11313",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.369163",
        "ticker_sentiment_score": "0.335658",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Global Meal Replacement Products Market Size is Projected to Reach USD 24.29 billion by 2030, Growing at a CAGR of 8.26%: Straits Research",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37458008/global-meal-replacement-products-market-size-is-projected-to-reach-usd-24-29-billion-by-2030-growi",
    "time_published": "20240304T144500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, United States, March 04, 2024 ( GLOBE NEWSWIRE ) -- A pre-packaged, calorie-restricted food item known as a meal replacement product serves as a stand-in for a whole-food meal. The most popular forms of meal replacement items on the market include ready-to-eat foods, shakes, bars, and ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.238913,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SMPL",
        "relevance_score": "0.03448",
        "ticker_sentiment_score": "0.097015",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.03448",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.03448",
        "ticker_sentiment_score": "0.097015",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HLF",
        "relevance_score": "0.03448",
        "ticker_sentiment_score": "0.097015",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KHC",
        "relevance_score": "0.03448",
        "ticker_sentiment_score": "0.097015",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GLAPF",
        "relevance_score": "0.068896",
        "ticker_sentiment_score": "0.138575",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NSRGF",
        "relevance_score": "0.03448",
        "ticker_sentiment_score": "0.097015",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Sell Alert: John A. McCoy Jr. Cashes Out $55K In Abbott Laboratories Stock - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/insights/news/24/03/37484838/sell-alert-john-a-mccoy-jr-cashes-out-55k-in-abbott-laboratories-stock",
    "time_published": "20240305T150225",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Revealing a significant insider sell on March 5, John A. McCoy Jr., Vice President at Abbott Laboratories ABT, as per the latest SEC filing. What Happened: Jr. opted to sell 472 shares of Abbott Laboratories, according to a Form 4 filing with the U.S. Securities and Exchange Commission on Tuesday.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/insider_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.993856"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      }
    ],
    "overall_sentiment_score": 0.170725,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.298749",
        "ticker_sentiment_score": "0.205092",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Executive Vice President Of Abbott Laboratories Sold $94K In Stock - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/insights/news/24/03/37484835/executive-vice-president-of-abbott-laboratories-sold-94k-in-stock",
    "time_published": "20240305T150220",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Revealing a significant insider sell on March 5, Louis H Morrone, Executive Vice President at Abbott Laboratories ABT, as per the latest SEC filing. What Happened: A Form 4 filing with the U.S.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/insider_image_2.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.996718"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.995077"
      }
    ],
    "overall_sentiment_score": 0.229009,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.241085",
        "ticker_sentiment_score": "0.32591",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Massive Insider Trade At Abbott Laboratories - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/insights/news/24/03/37484832/massive-insider-trade-at-abbott-laboratories",
    "time_published": "20240305T150215",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Making a noteworthy insider sell on March 5, Mary K Moreland, Executive Vice President at Abbott Laboratories ABT, is reported in the latest SEC filing. What Happened: Moreland's decision to sell 676 shares of Abbott Laboratories was revealed in a Form 4 filing with the U.S.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/insider_image_2.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.998663"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.989041"
      }
    ],
    "overall_sentiment_score": 0.184182,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.30021",
        "ticker_sentiment_score": "0.231125",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "FDA Approval For DexCom's Stelo Opens Continuous Glucose Monitoring To Masses, Analyst Expects Competitive Pricing Against Abbott's - DexCom  ( NASDAQ:DXCM ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37522301/fda-approval-for-dexcoms-stelo-opens-continuous-glucose-monitoring-to-masses-analys",
    "time_published": "20240306T214839",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Tuesday, the FDA approved DexCom Inc's DXCM Stelo Glucose Biosensor System as the first over-the-counter ( OTC ) continuous glucose monitor ( CGM ) . The Dexcom Stelo Glucose Biosensor System is an integrated CGM ( iCGM ) intended for anyone 18 years and older who does not use insulin.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Dexcom-Stelo-Company_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.714479"
      }
    ],
    "overall_sentiment_score": 0.244421,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DXCM",
        "relevance_score": "0.68039",
        "ticker_sentiment_score": "0.439166",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.223866",
        "ticker_sentiment_score": "0.096152",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Dexcom Pops As It Enters A New CGM Market: Non-Diabetics",
    "url": "https://www.investors.com/news/technology/dexcom-stock-continuous-glucose-monitor-stelo/",
    "time_published": "20240306T152500",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Dexcom Stock Pops After FDA Clears Its New Continuous Glucose Monitor Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2023/03/Stock-dexcom-one-04-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.94762"
      }
    ],
    "overall_sentiment_score": 0.250101,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.107736",
        "ticker_sentiment_score": "0.2163",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.107736",
        "ticker_sentiment_score": "0.176098",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.457794",
        "ticker_sentiment_score": "0.179837",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.107736",
        "ticker_sentiment_score": "0.2163",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Abbott  ( ABT )  to Reduce Childhood Malnutrition With New Pact",
    "url": "https://www.zacks.com/stock/news/2237550/abbott-abt-to-reduce-childhood-malnutrition-with-new-pact",
    "time_published": "20240307T172700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Abbott's (ABT) latest partnership supports its sustainability goal of transforming care for malnutrition and improving the lives of 3 billion people per year by the decade's end.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/41/899.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.988787"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.196342,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HESG",
        "relevance_score": "0.091684",
        "ticker_sentiment_score": "0.059189",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.137148",
        "ticker_sentiment_score": "0.072207",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.182162",
        "ticker_sentiment_score": "0.137045",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.182162",
        "ticker_sentiment_score": "0.032166",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COR",
        "relevance_score": "0.182162",
        "ticker_sentiment_score": "0.033038",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Abbott Laboratories a Top Dividend Growth Stock to Buy Now?",
    "url": "https://www.fool.com/investing/2024/03/07/is-abbott-laboratories-a-top-dividend-growth-stock/",
    "time_published": "20240307T100000",
    "authors": [
      "George Budwell"
    ],
    "summary": "Abbott Laboratories has been growing its dividend at a blistering pace. Is its stock a buy?",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F768237%2Fai-healthcare.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.346224,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.275867",
        "ticker_sentiment_score": "0.261974",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Biomarkers Market to Reach USD 125.6 billion by 2031, Projected a CAGR of 10.4%: Report Analysis by Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37527945/biomarkers-market-to-reach-usd-125-6-billion-by-2031-projected-a-cagr-of-10-4-report-analysis-by-t",
    "time_published": "20240307T073100",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, March 07, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global biomarkers market is estimated to flourish at a CAGR of 10.4% from 2023 to 2031.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.327327,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BMXMF",
        "relevance_score": "0.032961",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "A",
        "relevance_score": "0.032961",
        "ticker_sentiment_score": "0.231614",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.032961",
        "ticker_sentiment_score": "0.052468",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.032961",
        "ticker_sentiment_score": "0.231614",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.032961",
        "ticker_sentiment_score": "0.196953",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.032961",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.032961",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIO",
        "relevance_score": "0.098659",
        "ticker_sentiment_score": "0.188286",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "QGEN",
        "relevance_score": "0.065866",
        "ticker_sentiment_score": "0.163382",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.098659",
        "ticker_sentiment_score": "0.099932",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QTRX",
        "relevance_score": "0.032961",
        "ticker_sentiment_score": "0.186094",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "$100 Invested In Abbott Laboratories 10 Years Ago Would Be Worth This Much Today - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/insights/news/24/03/37568459/100-invested-in-abbott-laboratories-10-years-ago-would-be-worth-this-much-today",
    "time_published": "20240308T210026",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Abbott Laboratories ABT has outperformed the market over the past 10 years by 1.21% on an annualized basis producing an average annual return of 11.92%. Currently, Abbott Laboratories has a market capitalization of $209.96 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.160819,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.980595",
        "ticker_sentiment_score": "0.386944",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Signos uses a glucose monitor patch and AI to help you eat healthier. Here's what it's like",
    "url": "https://www.cnbc.com/2024/03/09/signos-review-i-learned-how-eating-and-exercise-impact-my-blood-sugar.html",
    "time_published": "20240309T150001",
    "authors": [
      "Ashley Capoot"
    ],
    "summary": "Signos uses continuous glucose monitors, or CGMs, and an artificial intelligence-powered app to help people better understand their metabolisms.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107384875-1709916022085-img_3015.jpg?v=1709916106&w=1920&h=1080",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.115986,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DXCM",
        "relevance_score": "0.077094",
        "ticker_sentiment_score": "-0.016192",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.015442",
        "ticker_sentiment_score": "0.044344",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Pharmaceutical Stocks to Buy Hand Over Fist in March",
    "url": "https://www.fool.com/investing/2024/03/11/3-pharmaceutical-stocks-to-buy-hand-over-fist-in/",
    "time_published": "20240311T132800",
    "authors": [
      "Justin Pope"
    ],
    "summary": "There are some great companies at attractive prices in the lucrative pharmaceutical space.",
    "banner_image": "https://g.foolcdn.com/editorial/images/767295/drug-development-pharmaceutical-pharma-research-researchers-doctors-1.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.967645"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.234754,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.219809",
        "ticker_sentiment_score": "0.063941",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.055621",
        "ticker_sentiment_score": "0.035129",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DNA",
        "relevance_score": "0.272788",
        "ticker_sentiment_score": "0.151968",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.219809",
        "ticker_sentiment_score": "0.196",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Dividend Kings of Healthcare Stocks to Buy Hand Over Fist in March",
    "url": "https://www.fool.com/investing/2024/03/11/dividend-kings-healthcare-stocks-to-buy-in-march/",
    "time_published": "20240311T093500",
    "authors": [
      "Justin Pope"
    ],
    "summary": "These are some of the best-performing stocks in what's arguably society's most important industry.",
    "banner_image": "https://g.foolcdn.com/editorial/images/767296/jnj.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.319223,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.051886",
        "ticker_sentiment_score": "0.015964",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.103554",
        "ticker_sentiment_score": "0.184254",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.20537",
        "ticker_sentiment_score": "0.211033",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.255106",
        "ticker_sentiment_score": "0.149871",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bio-Rad  ( BIO )  Suffers due to BioPharma Softness, Stiff Competition",
    "url": "https://www.zacks.com/stock/news/2239177/bio-rad-bio-suffers-due-to-biopharma-softness-stiff-competition",
    "time_published": "20240312T122700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Bio-Rad's (BIO) margin performance gets affected by the inflationary trend of elevated raw material costs, increased logistics costs and higher employee-related expenses.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.997335"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.140344,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.044634",
        "ticker_sentiment_score": "0.063671",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.17715",
        "ticker_sentiment_score": "0.094646",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.067141",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COR",
        "relevance_score": "0.17715",
        "ticker_sentiment_score": "0.030972",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.044634",
        "ticker_sentiment_score": "0.063671",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSRLF",
        "relevance_score": "0.044634",
        "ticker_sentiment_score": "0.063671",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIO",
        "relevance_score": "0.17715",
        "ticker_sentiment_score": "0.104173",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.17715",
        "ticker_sentiment_score": "0.16695",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Japan In-Vitro Diagnostics Market Analysis Report 2024-2030: Strategic Partnerships Drive Innovations, Tumor Marker Testing Gains Momentum",
    "url": "https://www.prnewswire.com/news-releases/japan-in-vitro-diagnostics-market-analysis-report-2024-2030-strategic-partnerships-drive-innovations-tumor-marker-testing-gains-momentum-302085636.html",
    "time_published": "20240312T023000",
    "authors": [
      "Research and Markets"
    ],
    "summary": "Japan In-Vitro Diagnostics Market Analysis Report 2024-2030: Strategic Partnerships Drive Innovations, Tumor Marker ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.204707,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BMXMF",
        "relevance_score": "0.258351",
        "ticker_sentiment_score": "0.226323",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ONTTF",
        "relevance_score": "0.05257",
        "ticker_sentiment_score": "0.117906",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.05257",
        "ticker_sentiment_score": "0.117906",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSMXF",
        "relevance_score": "0.258351",
        "ticker_sentiment_score": "0.226323",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DHR",
        "relevance_score": "0.05257",
        "ticker_sentiment_score": "0.117906",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.05257",
        "ticker_sentiment_score": "0.117906",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Medical Devices ETF Hits 52-Week High: Stocks to Watch",
    "url": "https://www.zacks.com/commentary/2240185/medical-devices-etf-hits-52-week-high-stocks-to-watch",
    "time_published": "20240313T163800",
    "authors": [
      "Bryan Hayes"
    ],
    "summary": "Historically viewed as a defensive area, health care also boasts many growth aspects and benefits from advances in technology.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b8/1573.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.904684"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.967645"
      }
    ],
    "overall_sentiment_score": 0.341039,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DXCM",
        "relevance_score": "0.306198",
        "ticker_sentiment_score": "0.121662",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EW",
        "relevance_score": "0.306198",
        "ticker_sentiment_score": "0.243875",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.247208",
        "ticker_sentiment_score": "0.366443",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "IBD Stock Of The Day Lingers In Buy Zone As Diabetes Play Eyes Obesity",
    "url": "https://www.investors.com/research/ibd-stock-of-the-day/dexcom-stock-buy-zone-diabetes-obesity-continuous-glucose-monitors/",
    "time_published": "20240313T160442",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Dexcom ( DXCM ) is Wednesday's IBD Stock Of The Day. Dexcom stock is lingering in a buy zone, bolstered by U.S. clearance of a new body-worn glucose monitor. The company developed Stelo, its newest continuous glucose monitor, for the roughly 25 million people in the U.S. with type 2 diabetes ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/03/SOTD-3-13-24DXCM.png",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.996023"
      }
    ],
    "overall_sentiment_score": 0.138038,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.053149",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.10132",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.10132",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.057767",
        "ticker_sentiment_score": "-0.23901",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.531326",
        "ticker_sentiment_score": "0.152339",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.053149",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Global In Vitro Toxicology Testing Market Size is projected to reach USD 28.19 billion by 2031, growing at a CAGR of 10.8%: Straits Research",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37656766/global-in-vitro-toxicology-testing-market-size-is-projected-to-reach-usd-28-19-billion-by-2031-gro",
    "time_published": "20240313T123000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, United States, March 13, 2024 ( GLOBE NEWSWIRE ) -- In Vitro toxicology testing is used to determine the toxicity of a substance on non-living cells or tissues. It is a crucial component of preclinical safety evaluation in the pharmaceutical, chemical, and regulatory industries.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.152705,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "A",
        "relevance_score": "0.03319",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.03319",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.03319",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.03319",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.03319",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIO",
        "relevance_score": "0.03319",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRL",
        "relevance_score": "0.03319",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LH",
        "relevance_score": "0.03319",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ERFSF",
        "relevance_score": "0.03319",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DHR",
        "relevance_score": "0.03319",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Roche  ( RHHBY )  Launches AI-Based Predictive CGM Accu-Chek",
    "url": "https://www.zacks.com/stock/news/2239783/roche-rhhby-launches-ai-based-predictive-cgm-accu-chek",
    "time_published": "20240313T115600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Roche (RHHBY) is likely to enter the growing diabetes market with its AI-enabled predictive glucose monitoring system that may revolutionize diabetes management.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b8/1573.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.333849,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DXCM",
        "relevance_score": "0.312423",
        "ticker_sentiment_score": "0.239508",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.252332",
        "ticker_sentiment_score": "0.355314",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.127795",
        "ticker_sentiment_score": "0.123507",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Zacks Investment Ideas feature highlights: Tenet Healthcare and HCA Healthcare",
    "url": "https://www.zacks.com/stock/news/2240735/zacks-investment-ideas-feature-highlights-tenet-healthcare-and-hca-healthcare",
    "time_published": "20240314T130200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Tenet Healthcare and HCA Healthcare are part of the Zacks Investment Ideas article.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.904684"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.995973"
      }
    ],
    "overall_sentiment_score": 0.33877,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DXCM",
        "relevance_score": "0.334008",
        "ticker_sentiment_score": "0.097794",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EW",
        "relevance_score": "0.334008",
        "ticker_sentiment_score": "0.193772",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.280938",
        "ticker_sentiment_score": "0.295843",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Attention Reckitt Benckiser Group investors: Portnoy Law Firm Announces Investigation into Reckitt Benckiser Group PLC Following $60 Million Baby Formula Verdict and Subsequent Stock Plummet - Reckitt Benckiser Group  ( OTC:RBGLY ) ",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37759198/attention-reckitt-benckiser-group-investors-portnoy-law-firm-announces-investigation-into-reckitt-",
    "time_published": "20240315T201101",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 15, 2024 ( GLOBE NEWSWIRE ) -- The Portnoy Law Firm advises Reckitt Benckiser Group PLC ( \"Reckitt\" or the \"Company\" ) RBGLY investors that the law firm has initiated an investigation on ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.014814,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "-0.074147",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RBGPF",
        "relevance_score": "0.268786",
        "ticker_sentiment_score": "-0.075876",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What's Going On With Abbott Laboratories Stock On Friday? - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/news/large-cap/24/03/37755685/whats-going-on-with-abbott-laboratories-stock-on-friday",
    "time_published": "20240315T174845",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "An Illinois jury has issued a verdict compelling Reckitt Benckiser Group Plc's RBGLY RBGPF Mead Johnson to pay $60 million to the mother of a premature infant who tragically succumbed to necrotizing enterocolitis ( NEC ) after being fed the company's Enfamil baby formula.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Port-Charlotte--Florida---February-15--2.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.051073,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.333257",
        "ticker_sentiment_score": "0.205394",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RBGPF",
        "relevance_score": "0.22595",
        "ticker_sentiment_score": "-0.060798",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Abbott's Formula Selloff Could Be A Buying Opportunity, Says Analyst",
    "url": "https://www.investors.com/news/technology/abbott-stock-infant-formula-similac-lawsuits/",
    "time_published": "20240315T163313",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Abbott Stock Dives As Fellow Formula Maker Fined $60 Million Following Infant Death Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2019/10/stock-Abbott-05-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      }
    ],
    "overall_sentiment_score": -0.096686,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.166169",
        "ticker_sentiment_score": "-0.029786",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.083541",
        "ticker_sentiment_score": "-0.026914",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.166169",
        "ticker_sentiment_score": "-0.06886",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.166169",
        "ticker_sentiment_score": "-0.06886",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RBGPF",
        "relevance_score": "0.246999",
        "ticker_sentiment_score": "-0.305291",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Here's why we're buying more of this healthcare stock after its Friday sell-off",
    "url": "https://www.cnbc.com/2024/03/15/why-were-buying-more-of-this-healthcare-stock-after-friday-sell-off.html",
    "time_published": "20240315T145017",
    "authors": [
      "Zev Fima"
    ],
    "summary": "When news breaks and hits the stock price - but likely not the earnings number - you're getting an actual discount.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107281361-1691075973723-gettyimages-1229154325-Rafael_Henrique-17102020-1485.jpeg?v=1709224685&w=600&h=300&vtcrop=y",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.905476"
      }
    ],
    "overall_sentiment_score": 0.268191,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "0.272254",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Lutikizumab Clinical Trials Approved Bispecific Antibodies Market Insight",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37768775/lutikizumab-clinical-trials-approved-bispecific-antibodies-market-insight",
    "time_published": "20240317T170809",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Delhi, March 17, 2024 ( GLOBE NEWSWIRE ) -- Global Bispecific Antibody Market Opportunity Insight 2029 Report Highlights: Global Market Forecast Till 2029: > USD 36 Billion Insight On Bispecific Antibodies In Clinical Trials: > 600 Bispecific Antibodies",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.14381,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.185781",
        "ticker_sentiment_score": "0.120262",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.185781",
        "ticker_sentiment_score": "0.043688",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Jim Cramer: It's not too late to buy this portfolio health-care stock after Friday's selloff",
    "url": "https://www.cnbc.com/2024/03/18/jim-cramer-its-not-too-late-to-buy-abbott-stock-after-friday-selloff.html",
    "time_published": "20240318T155552",
    "authors": [
      "Morgan Chittum"
    ],
    "summary": "The Investing Club holds its \"Morning Meeting\" every weekday at 10:20 a.m. ET.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107248804-1685557819267-gettyimages-1494887228-dsc_6170_tmhhfzze.jpeg?v=1710774347&w=600&h=300&vtcrop=y",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.169597,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.082111",
        "ticker_sentiment_score": "0.073757",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.24289",
        "ticker_sentiment_score": "0.133805",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.163354",
        "ticker_sentiment_score": "0.099411",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.163354",
        "ticker_sentiment_score": "0.099411",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.163354",
        "ticker_sentiment_score": "0.099411",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RBGPF",
        "relevance_score": "0.082111",
        "ticker_sentiment_score": "0.073757",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "India Baby Care Products Market size to grow by USD 15.69 billion from 2022 to 2027, Market is fragmented due to the ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/india-baby-care-products-market-size-to-grow-by-usd-15-69-billion-from-2022-to-2027--market-is-fragmented-due-to-the-presence-of-prominent-companies-like-abbott-laboratories-artsana-spa-bio-veda-action-research-co-and-many-mor-302090314.html",
    "time_published": "20240318T011200",
    "authors": [],
    "summary": "India Baby Care Products Market size to grow by USD 15.69 billion from 2022 to 2027, Market is fragmented due to the ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.260822,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KMB",
        "relevance_score": "0.033751",
        "ticker_sentiment_score": "0.064873",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MHCRF",
        "relevance_score": "0.033751",
        "ticker_sentiment_score": "0.064873",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.033751",
        "ticker_sentiment_score": "0.064873",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PIGEF",
        "relevance_score": "0.033751",
        "ticker_sentiment_score": "0.064873",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.033751",
        "ticker_sentiment_score": "0.064873",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.033751",
        "ticker_sentiment_score": "0.064873",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UL",
        "relevance_score": "0.033751",
        "ticker_sentiment_score": "0.064873",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PHG",
        "relevance_score": "0.033751",
        "ticker_sentiment_score": "0.064873",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's Why Investors Should Retain Abbott  ( ABT )  Stock Now",
    "url": "https://www.zacks.com/stock/news/2243034/heres-why-investors-should-retain-abbott-abt-stock-now",
    "time_published": "20240319T174000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Investors are optimistic about Abbott (ABT), led by solid prospects in the Diagnostic business and robust adoption of FreeStyle Libre.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.972193"
      }
    ],
    "overall_sentiment_score": 0.275075,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.099683",
        "ticker_sentiment_score": "0.186131",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.149038",
        "ticker_sentiment_score": "0.059211",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.149038",
        "ticker_sentiment_score": "0.092145",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DVA",
        "relevance_score": "0.197816",
        "ticker_sentiment_score": "0.121069",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:EUR",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "We're looking to buy more of this health care stock after an overblown selloff",
    "url": "https://www.cnbc.com/2024/03/19/were-looking-to-buy-more-of-this-health-care-stock-after-a-big-selloff.html",
    "time_published": "20240319T154340",
    "authors": [
      "Morgan Chittum"
    ],
    "summary": "The Investing Club holds its \"Morning Meeting\" every weekday at 10:20 a.m. ET.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107389439-17108587581710858755-33780250380-1080pnbcnews.jpg?v=1710858758&w=600&h=300&vtcrop=y",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.98396"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.031392,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.252114",
        "ticker_sentiment_score": "0.025426",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.169676",
        "ticker_sentiment_score": "0.018764",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBUX",
        "relevance_score": "0.252114",
        "ticker_sentiment_score": "0.025426",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RBGPF",
        "relevance_score": "0.085324",
        "ticker_sentiment_score": "0.013629",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cardiovascular Implants Market Poised For Strong Growth, Reaching $34.5 Billion In 2028: Latest Report Unveils Insights As Per The Business Research Company's Cardiovascular Implants Global Market Report 2024",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37826136/cardiovascular-implants-market-poised-for-strong-growth-reaching-34-5-billion-in-2028-latest-repor",
    "time_published": "20240319T154000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LONDON, March 19, 2024 ( GLOBE NEWSWIRE ) -- The global cardiovascular implants market is experiencing robust growth, as highlighted in the newest report \"Cardiovascular Implants Market Global Report 2024\", by The Business Research Company.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.353544,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MDT",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.348987",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.348987",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.106778",
        "ticker_sentiment_score": "0.321013",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "What the Options Market Tells Us About Abbott Laboratories - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/insights/options/24/03/37823679/what-the-options-market-tells-us-about-abbott-laboratories",
    "time_published": "20240319T141622",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bearish move on Abbott Laboratories. Our analysis of options history for Abbott Laboratories ABT revealed 19 unusual trades. Delving into the details, we found 5% of traders were bullish, while 94% showed bearish tendencies.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.158439,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.620415",
        "ticker_sentiment_score": "-0.017946",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Diabetes Monitoring Apps Don't Deliver Meaningful Benefits, Report Says",
    "url": "https://www.forbes.com/sites/brucejapsen/2024/03/21/report-questions-value-of-diabetes-monitoring-apps/",
    "time_published": "20240321T150000",
    "authors": [
      "Bruce Japsen"
    ],
    "summary": "Digital diabetes management tools \"fail to deliver meaningful benefits to patients\" while at the same time increasing the cost of healthcare to consumers, health insurers and taxpayers, a new report finds.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65fb261cf7042485436c59aa/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.245252,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DRIO",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.023977",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.023977",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TDOC",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.029054",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "We're buying more of this health-care company amid an overdone sell-off",
    "url": "https://www.cnbc.com/2024/03/21/were-buying-more-of-this-health-care-company-amid-an-overdone-sell-off.html",
    "time_published": "20240321T130905",
    "authors": [
      "Jeff Marks"
    ],
    "summary": "The company has lost billions in market capitalization over the past few trading sessions.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107357257-1704980167454-gettyimages-1923334243-em025859_2024011024645207.jpeg?v=1711024629&w=1920&h=1080",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.905476"
      }
    ],
    "overall_sentiment_score": 0.075114,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "EVR",
        "relevance_score": "0.054607",
        "ticker_sentiment_score": "0.080992",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.268",
        "ticker_sentiment_score": "0.27434",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.054607",
        "ticker_sentiment_score": "0.080992",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RBGPF",
        "relevance_score": "0.054607",
        "ticker_sentiment_score": "-0.06",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/pharmaceuticals-market-in-germany-size-is-set-to-grow-by-usd-21-44-bn-from-2023-2027--abbott-laboratories-abbvie-inc--amgen-inc-and-more-to-emerge-as-some-of-the-key-vendors--technavio-302096253.html",
    "time_published": "20240322T161800",
    "authors": [],
    "summary": "Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.244345,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BAYZF",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLCO",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "-0.020684",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FSNUF",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Point of Care Diagnostics Market is Expected to Reach $77.8 billion | MarketsandMarkets\u2122",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37889705/point-of-care-diagnostics-market-is-expected-to-reach-77-8-billion-marketsandmarkets",
    "time_published": "20240322T123000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Chicago, March 22, 2024 ( GLOBE NEWSWIRE ) -- Point of Care Diagnostics market in terms of revenue was estimated to be worth $49.7 billion in 2023 and is poised to reach $77.8 billion by 2028, growing at a CAGR of 9.4% from 2023 to 2028 according to a latest report published by ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.285736,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BMXMF",
        "relevance_score": "0.037622",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRIB",
        "relevance_score": "0.037622",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.037622",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EKDHF",
        "relevance_score": "0.037622",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.037622",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.037622",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DHR",
        "relevance_score": "0.037622",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QDEL",
        "relevance_score": "0.037622",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Want Decades of Passive Income? 2 Stocks to Buy Now.",
    "url": "https://www.fool.com/investing/2024/03/22/want-decades-of-passive-income-2-stocks-to-buy-now/",
    "time_published": "20240322T082500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "There aren't many guarantees in the equity market, but the dividend payouts of Johnson & Johnson and Abbott Laboratories may be as close as it gets to a sure thing.",
    "banner_image": "https://media.ycharts.com/charts/f446e49093d77d67a17c38a637be54f2.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.26315,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ISRG",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.188654",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.448316",
        "ticker_sentiment_score": "0.330782",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.448316",
        "ticker_sentiment_score": "0.347852",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Tricares Announces the Appointment of Ahmed Elmouelhi as President & Chief Executive Officer",
    "url": "https://markets.businessinsider.com/news/stocks/tricares-announces-the-appointment-of-ahmed-elmouelhi-as-president-chief-executive-officer-1033191681",
    "time_published": "20240325T060000",
    "authors": [
      "markets.businessinsider.com"
    ],
    "summary": "Paris, France and Munich, Germany, March 25, 2024 - TRiCares SAS ( \"TRiCares\" ) a privately held pioneer in the field of minimally invasive treatment of tricuspid regurgitation, today is pleased to announce the appointment of Ahmed Elmouelhi as President & Chief Executive Officer ( CEO ) .",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/b7926093-fc48-4e23-bec8-3dc7cbed4110/image2.jpeg",
    "source": "Business Insider",
    "category_within_source": "RSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.325206,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MDT",
        "relevance_score": "0.053992",
        "ticker_sentiment_score": "0.127",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ATRC",
        "relevance_score": "0.053992",
        "ticker_sentiment_score": "0.127",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.053992",
        "ticker_sentiment_score": "0.127",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Verano Holdings CIO To Share Insights Into Florida's Cannabis Boom At Benzinga Conference",
    "url": "https://markets.businessinsider.com/news/stocks/verano-holdings-cio-to-share-insights-into-florida-s-cannabis-boom-at-benzinga-conference-1033191268",
    "time_published": "20240325T005523",
    "authors": [
      "Nicol&#225;s Jose Rodriguez"
    ],
    "summary": "Amidst the buzz of potential recreational legalization and federal cannabis rescheduling, comprehending cannabis stock dynamics is vital for investors. Florida's burgeoning market offers a unique chance for those poised to seize emerging opportunities.",
    "banner_image": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2024/03/22/dalle_2024-03-22_17.55.09_-_.jpg",
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.98396"
      }
    ],
    "overall_sentiment_score": 0.357556,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.090134",
        "ticker_sentiment_score": "0.114106",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CEJOF",
        "relevance_score": "0.090134",
        "ticker_sentiment_score": "0.114106",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Verano Holdings CIO To Share Insights Into Florida's Cannabis Boom At Conference - Verano Holdings  ( OTC:VRNOF ) ",
    "url": "https://www.benzinga.com/markets/cannabis/24/03/37901231/verano-holdings-cio-to-share-insights-into-floridas-cannabis-boom-at-benzinga-conference",
    "time_published": "20240325T003301",
    "authors": [
      "Nicol\u00e1s Jose Rodriguez"
    ],
    "summary": "Amidst the buzz of potential recreational legalization and federal cannabis rescheduling, comprehending cannabis stock dynamics is vital for investors. Florida's burgeoning market offers a unique chance for those poised to seize emerging opportunities. At Verano Holdings Inc.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/03/22/dalle_2024-03-22_17.55.09_-_.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.992549"
      }
    ],
    "overall_sentiment_score": 0.362342,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.083251",
        "ticker_sentiment_score": "0.112514",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CEJOF",
        "relevance_score": "0.083251",
        "ticker_sentiment_score": "0.112514",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Abbott Laboratories  ( ABT )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2245920/abbott-laboratories-abt-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20240326T130009",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Zacks.com users have recently been watching Abbott Laboratories (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default203.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.212924,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.475838",
        "ticker_sentiment_score": "0.096839",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Abbott's  ( ABT )  Assert-IQ Cardiac Monitor Receives CE Mark",
    "url": "https://www.zacks.com/stock/news/2246922/abbotts-abt-assert-iq-cardiac-monitor-receives-ce-mark",
    "time_published": "20240327T162500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Abbott's (ABT) Assert-IQ ICM enables regular monitoring for abnormal heart rhythms, as well as technologies to improve data management and workflow.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.988787"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.237289,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.093836",
        "ticker_sentiment_score": "-0.067865",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.186378",
        "ticker_sentiment_score": "0.13933",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.186378",
        "ticker_sentiment_score": "0.032712",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COR",
        "relevance_score": "0.186378",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Performance Comparison: Abbott Laboratories And Competitors In Health Care Equipment & Supplies Industry - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/insights/news/24/03/37961350/performance-comparison-abbott-laboratories-and-competitors-in-health-care-equipment-amp-supplies-in",
    "time_published": "20240327T150022",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In the ever-changing and fiercely competitive business landscape, conducting thorough company analysis is crucial for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Abbott Laboratories ABT and its primary competitors in the ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.2412,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.38489",
        "ticker_sentiment_score": "0.243522",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "How Is The Market Feeling About Abbott Laboratories? - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/03/37991355/how-is-the-market-feeling-about-abbott-laboratories",
    "time_published": "20240328T180023",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Abbott Laboratories's ABT short percent of float has risen 12.16% since its last report. The company recently reported that it has 14.29 million shares sold short, which is 0.83% of all regular shares that are available for trading.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.287757,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.148634",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Reliable Dividend Growth Stocks With Yields Above 3% That You Can Buy Now and Hold for at Least a Decade",
    "url": "https://www.fool.com/investing/2024/03/30/3-reliable-dividend-growth-stocks-with-yields-abov/",
    "time_published": "20240330T091900",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "These advantaged businesses have what it takes to keep raising their payouts.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F770568%2Fgroup-of-investors-looking-at-charts.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.967321"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      }
    ],
    "overall_sentiment_score": 0.238472,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.146916",
        "ticker_sentiment_score": "-0.045412",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.049221",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.098255",
        "ticker_sentiment_score": "0.049573",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.049221",
        "ticker_sentiment_score": "0.133067",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.098255",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Elanco Appoints Two Animal Health Industry Executives, Kathy Turner and Craig Wallace, to its Board of Directors - Elanco Animal Health  ( NYSE:ELAN ) ",
    "url": "https://www.benzinga.com/pressreleases/24/04/n38018168/elanco-appoints-two-animal-health-industry-executives-kathy-turner-and-craig-wallace-to-its-board-",
    "time_published": "20240401T103000",
    "authors": [
      "PRNewswire"
    ],
    "summary": "New Directors Join the Board's Renamed Finance, Strategy and Oversight Committee GREENFIELD, Ind., April 1, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated ELAN today announced that it has appointed two new independent directors, Kathy Turner and Craig Wallace, to its Board of Directors ( ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.217498,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IDXX",
        "relevance_score": "0.051886",
        "ticker_sentiment_score": "0.065606",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CEVA",
        "relevance_score": "0.051886",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.051886",
        "ticker_sentiment_score": "0.065606",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ELAN",
        "relevance_score": "0.129237",
        "ticker_sentiment_score": "0.268143",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TRUP",
        "relevance_score": "0.051886",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Elanco Appoints Two Animal Health Industry Executives, Kathy Turner and Craig Wallace, to its Board of Directors",
    "url": "https://www.prnewswire.com/news-releases/elanco-appoints-two-animal-health-industry-executives-kathy-turner-and-craig-wallace-to-its-board-of-directors-302104172.html",
    "time_published": "20240401T103000",
    "authors": [
      "Elanco Animal Health"
    ],
    "summary": "New Directors Join the Board's Renamed Finance, Strategy and Oversight Committee",
    "banner_image": "https://mma.prnewswire.com/media/2309278/Elanco_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.199018,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IDXX",
        "relevance_score": "0.051003",
        "ticker_sentiment_score": "0.065521",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CEVA",
        "relevance_score": "0.051003",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.051003",
        "ticker_sentiment_score": "0.065521",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ELAN",
        "relevance_score": "0.226536",
        "ticker_sentiment_score": "0.315243",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TRUP",
        "relevance_score": "0.051003",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the Invesco Pharmaceuticals ETF  ( PJP ) ?",
    "url": "https://www.zacks.com/stock/news/2248126/should-you-invest-in-the-invesco-pharmaceuticals-etf-pjp",
    "time_published": "20240401T102005",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default354.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.193607,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.131643",
        "ticker_sentiment_score": "0.070705",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.131643",
        "ticker_sentiment_score": "0.070705",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.259727",
        "ticker_sentiment_score": "0.149109",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.131643",
        "ticker_sentiment_score": "0.070705",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Meet The \"Magnificent Seven\" of Healthcare Stocks",
    "url": "https://www.fool.com/investing/2024/04/01/meet-the-magnificent-seven-of-healthcare-stocks/",
    "time_published": "20240401T083000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The tech sector doesn't have a monopoly on magnificent corporations.",
    "banner_image": "https://g.foolcdn.com/editorial/images/770839/person-sitting-and-working-at-a-desk.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.24052,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.042048",
        "ticker_sentiment_score": "0.180009",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.125679",
        "ticker_sentiment_score": "0.255601",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HCA",
        "relevance_score": "0.248259",
        "ticker_sentiment_score": "0.115038",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.207928",
        "ticker_sentiment_score": "0.28535",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.167032",
        "ticker_sentiment_score": "0.306284",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.167032",
        "ticker_sentiment_score": "0.286408",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.207928",
        "ticker_sentiment_score": "0.134207",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.207928",
        "ticker_sentiment_score": "0.100054",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "FDA Approves Abbott's Heart Valve Repair Device For Patients At Risk Of Complications/Death During Open-Heart Surgeries - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/markets/equities/24/04/38053214/fda-approves-abbotts-heart-valve-repair-device-for-patients-at-risk-of-complicationsdeath-during",
    "time_published": "20240402T170012",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Tuesday, the FDA approved Abbott Laboratories' ABT first-of-its-kind TriClip transcatheter edge-to-edge repair ( TEER ) system that's specifically designed to treat tricuspid regurgitation ( TR ) , or a leaky tricuspid valve.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Monitoring-Of-Patients-Heart-In-Intensiv.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.244161,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.28008",
        "ticker_sentiment_score": "0.190289",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Abbott's  ( ABT )  i-STAT TBI Cartridge Receives FDA Approval",
    "url": "https://www.zacks.com/stock/news/2249322/abbotts-abt-i-stat-tbi-cartridge-receives-fda-approval",
    "time_published": "20240402T151800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Abbott's (ABT) i-STAT Alinity instrument uses whole blood to help assess patients with a suspected mild traumatic brain injury or concussion.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/41/899.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.988787"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.13359,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.096283",
        "ticker_sentiment_score": "-0.100976",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.14195",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.033337",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COR",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Electroceuticals/Bioelectric Medicine Market is Expected to Reach $33.6 billion | MarketsandMarkets\u2122",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38045112/electroceuticalsbioelectric-medicine-market-is-expected-to-reach-33-6-billion-marketsandmarkets",
    "time_published": "20240402T123000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Chicago, April 02, 2024 ( GLOBE NEWSWIRE ) -- Electroceuticals/Bioelectric Medicine market in terms of revenue was estimated to be worth $23.9 billion in 2024 and is poised to reach $33.6 billion by 2029, growing at a CAGR of 7.0% from 2024 to 2029 according to a latest report published by ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.221399,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NPCE",
        "relevance_score": "0.04406",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ECOR",
        "relevance_score": "0.04406",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVRO",
        "relevance_score": "0.04406",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.04406",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STIM",
        "relevance_score": "0.04406",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.04406",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CHEOF",
        "relevance_score": "0.04406",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LIVN",
        "relevance_score": "0.04406",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.04406",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MCRPF",
        "relevance_score": "0.04406",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXNX",
        "relevance_score": "0.04406",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Transformative Growth Expected In The Global Medical Equipment Market: Market Size To Reach $1,077 Billion By 2028 As Per The Business Research Company's Medical Equipment Global Market Report 2024",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38072444/transformative-growth-expected-in-the-global-medical-equipment-market-market-size-to-reach-1-077-b",
    "time_published": "20240403T153000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LONDON, April 03, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Medical Equipment Global Market Report 2024, the medical equipment market has witnessed robust growth in recent years, with the market size expected to reach $775.42 billion in 2024, reflecting a compound annual ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.338179,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GEHC",
        "relevance_score": "0.05133",
        "ticker_sentiment_score": "0.299729",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.05133",
        "ticker_sentiment_score": "0.126428",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.05133",
        "ticker_sentiment_score": "0.126428",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.05133",
        "ticker_sentiment_score": "0.126428",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares U.S. Medical Devices ETF  ( IHI ) ?",
    "url": "https://www.zacks.com/stock/news/2249507/should-you-invest-in-the-ishares-us-medical-devices-etf-ihi",
    "time_published": "20240403T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for IHI ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default211.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.216422,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.064449",
        "ticker_sentiment_score": "0.031013",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SEM",
        "relevance_score": "0.128478",
        "ticker_sentiment_score": "0.026704",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.128478",
        "ticker_sentiment_score": "0.069872",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.128478",
        "ticker_sentiment_score": "0.069872",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.128478",
        "ticker_sentiment_score": "0.069872",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Your Smartphone The Future Of Heart Disease Detection? This Finnish Startup Thinks So",
    "url": "https://www.benzinga.com/news/24/04/38085175/is-your-smartphone-the-future-of-heart-disease-detection-this-finnish-startup-thinks-so",
    "time_published": "20240404T084743",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "CardioSignal, a Finnish startup, has developed a system that uses smartphone motion sensors to detect heart disease. This innovation is a significant breakthrough in the health tech industry.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Monitoring-Of-Patients-Heart-In-Intensiv_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.385272,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SSNLF",
        "relevance_score": "0.086245",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.086245",
        "ticker_sentiment_score": "0.208412",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Top Analyst Reports for T-Mobile US, Abbott Laboratories & Palo Alto Networks",
    "url": "https://www.zacks.com/research-daily/2251046/top-analyst-reports-for-t-mobile-us-abbott-laboratories-palo-alto-networks",
    "time_published": "20240405T205500",
    "authors": [
      "Sheraz Mian"
    ],
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), Abbott Laboratories (ABT) and Palo Alto Networks, Inc. (PANW).",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default182.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.353542,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TMUS",
        "relevance_score": "0.084423",
        "ticker_sentiment_score": "0.258565",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.084423",
        "ticker_sentiment_score": "0.393699",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PANW",
        "relevance_score": "0.084423",
        "ticker_sentiment_score": "0.069222",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Abbott  ( ABT )  Receives FDA's Approval for the TriClip TEER System",
    "url": "https://www.zacks.com/stock/news/2251212/abbott-abt-receives-fdas-approval-for-the-triclip-teer-system",
    "time_published": "20240405T135200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Abbott (ABT) receives FDA nod for TriClip, a first-of-its-kind device to repair a leaky tricuspid heart valve.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e0/1871.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.972193"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.224271,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.084572",
        "ticker_sentiment_score": "0.096913",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.126561",
        "ticker_sentiment_score": "0.049657",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.126561",
        "ticker_sentiment_score": "0.049657",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DVA",
        "relevance_score": "0.168197",
        "ticker_sentiment_score": "0.039405",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Abbott  ( ABT )  Faces Low Testing Demand, Currency Headwinds",
    "url": "https://www.zacks.com/stock/news/2251992/abbott-abt-faces-low-testing-demand-currency-headwinds",
    "time_published": "20240408T141000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Abbott's (ABT) core laboratory diagnostics business is gaining strength on the continued success of the Alinity suite of diagnostics instruments, along with a broad test menu offering.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.972193"
      }
    ],
    "overall_sentiment_score": 0.167989,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.151539",
        "ticker_sentiment_score": "0.012465",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.151539",
        "ticker_sentiment_score": "0.054698",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.151539",
        "ticker_sentiment_score": "0.054698",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DVA",
        "relevance_score": "0.201105",
        "ticker_sentiment_score": "0.044891",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:EUR",
        "relevance_score": "0.050786",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights T-Mobile US, Abbott Laboratories, Palo Alto Networks, Enterprise Products Partners and The PNC Financial Services",
    "url": "https://www.zacks.com/stock/news/2251993/the-zacks-analyst-blog-highlights-t-mobile-us-abbott-laboratories-palo-alto-networks-enterprise-products-partners-and-the-pnc-financial-services",
    "time_published": "20240408T131300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "T-Mobile US, Abbott Laboratories, Palo Alto Networks, Enterprise Products Partners and The PNC Financial Services are part of the Zacks top Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e3/536.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.294667,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TMUS",
        "relevance_score": "0.243498",
        "ticker_sentiment_score": "0.147942",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.243498",
        "ticker_sentiment_score": "0.24056",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PNC",
        "relevance_score": "0.123209",
        "ticker_sentiment_score": "0.034191",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PANW",
        "relevance_score": "0.243498",
        "ticker_sentiment_score": "0.07784",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Jim Cramer Was Upset At This Hostile Takeover, But 'They Fixed The Situation. Stock's Been A Horse' - Abbott Laboratories  ( NYSE:ABT ) , Emerson Electric  ( NYSE:EMR ) ",
    "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/04/38155367/jim-cramer-was-upset-at-this-hostile-takeover-but-they-fixed-the-situation-stocks-been-a",
    "time_published": "20240409T131029",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Mad Money Lightning Round,\" Jim Cramer said he prefers Abbott Laboratories ABT over Penumbra, Inc. PEN. \"I still fear it after the environmental damage. I am concerned that you can't really put a price on it,\" Cramer said when asked about Hawaiian Electric Industries, Inc.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/09/shutterstock_2246181693.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.083032,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "EE",
        "relevance_score": "0.205807",
        "ticker_sentiment_score": "-0.019508",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HAWEL",
        "relevance_score": "0.205807",
        "ticker_sentiment_score": "0.012065",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.205807",
        "ticker_sentiment_score": "-0.106949",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBSW",
        "relevance_score": "0.304428",
        "ticker_sentiment_score": "0.120339",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "F",
        "relevance_score": "0.205807",
        "ticker_sentiment_score": "-0.09122",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GM",
        "relevance_score": "0.205807",
        "ticker_sentiment_score": "-0.09122",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PEN",
        "relevance_score": "0.304428",
        "ticker_sentiment_score": "-0.154852",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.304428",
        "ticker_sentiment_score": "0.466411",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "EMR",
        "relevance_score": "0.304428",
        "ticker_sentiment_score": "-0.207998",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "HE",
        "relevance_score": "0.103778",
        "ticker_sentiment_score": "-0.092462",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.",
    "url": "https://www.fool.com/investing/2024/04/09/forget-viking-therapeutics-heres-1-weight-loss-sto/",
    "time_published": "20240409T104500",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "Viking Therapeutics has garnered a lot of attention following a successful clinical trial for its obesity care drug. But another development-stage biotech may have a superior candidate.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F771899%2Fgettyimages-1429005115.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.212999,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALT",
        "relevance_score": "0.594257",
        "ticker_sentiment_score": "0.31462",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.110209",
        "ticker_sentiment_score": "0.254587",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.055236",
        "ticker_sentiment_score": "0.099032",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.218325",
        "ticker_sentiment_score": "0.06582",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.055236",
        "ticker_sentiment_score": "-0.047873",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade",
    "url": "https://www.fool.com/investing/2024/04/09/3-dividend-growth-stocks-with-yields-above-3-that/",
    "time_published": "20240409T082100",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Income-seeking investors can look forward to steady payout raises from these pharma stocks.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F772112%2Finvestor-stock-charts-laptop-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.207428,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.055751",
        "ticker_sentiment_score": "0.057886",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.166169",
        "ticker_sentiment_score": "0.083778",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.055751",
        "ticker_sentiment_score": "-0.058885",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.055751",
        "ticker_sentiment_score": "0.027025",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.220308",
        "ticker_sentiment_score": "0.217001",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.166169",
        "ticker_sentiment_score": "0.06886",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Abbott Laboratories Unusual Options Activity - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/insights/options/24/04/38209309/abbott-laboratories-unusual-options-activity",
    "time_published": "20240411T183113",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bullish stance on Abbott Laboratories. Looking at options history for Abbott Laboratories ABT we detected 8 trades. If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.209188,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EVR",
        "relevance_score": "0.092213",
        "ticker_sentiment_score": "0.119894",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.582526",
        "ticker_sentiment_score": "0.25019",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.092213",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Medtronic's  ( MDT )  Sphere-360 PFA Study Outcome Favorable",
    "url": "https://www.zacks.com/stock/news/2253903/medtronics-mdt-sphere-360-pfa-study-outcome-favorable",
    "time_published": "20240411T133100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Medtronic's (MDT) Sphere-360 catheter is designed to simplify the atrial fibrillation process while increasing efficiency and giving long-lasting lesions.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.231256,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GEHC",
        "relevance_score": "0.102013",
        "ticker_sentiment_score": "0.127329",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.102013",
        "ticker_sentiment_score": "0.127329",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.152499",
        "ticker_sentiment_score": "0.198608",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.152499",
        "ticker_sentiment_score": "0.039459",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Got $200? 2 Healthcare Stocks to Buy and Hold Forever.",
    "url": "https://www.fool.com/investing/2024/04/11/got-200-2-healthcare-stocks-to-buy-and-hold/",
    "time_published": "20240411T101500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "These companies provide stability, reliability, and passive income.",
    "banner_image": "https://media.ycharts.com/charts/82310276ba6dc41056260e1c00a407ca.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.327868,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MDT",
        "relevance_score": "0.410697",
        "ticker_sentiment_score": "0.393096",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.30021",
        "ticker_sentiment_score": "0.179566",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "What's in Store for Abbott Laboratories  ( ABT )  in Q1 Earnings?",
    "url": "https://www.zacks.com/stock/news/2254571/whats-in-store-for-abbott-laboratories-abt-in-q1-earnings",
    "time_published": "20240412T135100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Abbott (ABT) is likely to have progressed with its initiative to commercialize several biosimilars in emerging markets.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.234768,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EW",
        "relevance_score": "0.148502",
        "ticker_sentiment_score": "0.104611",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.148502",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.148502",
        "ticker_sentiment_score": "0.008976",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HITI",
        "relevance_score": "0.148502",
        "ticker_sentiment_score": "0.047734",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Jim Cramer Calls Cummins 'Terrific,' Recommends Selling This Chinese Auto Manufacturer - Abbott Laboratories  ( NYSE:ABT ) , Cummins  ( NYSE:CMI ) ",
    "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/04/38216143/jim-cramer-calls-cummins-terrific-recommends-selling-this-chinese-auto-manufacturer",
    "time_published": "20240412T124301",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Mad Money Lightning Round,\" Jim Cramer said he likes New Fortress Energy Inc. NFE, but \"right now Wes Edens [co-founder of Fortress Investment Group and founder of New Fortress Energy] is kind of just hurt by the president.\"",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/12/cummins-logo-signage-social.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.261859,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.321673",
        "ticker_sentiment_score": "0.207805",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NFE",
        "relevance_score": "0.510588",
        "ticker_sentiment_score": "-0.026784",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PNC",
        "relevance_score": "0.419733",
        "ticker_sentiment_score": "-0.011724",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NIO",
        "relevance_score": "0.419733",
        "ticker_sentiment_score": "-0.091001",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMI",
        "relevance_score": "0.419733",
        "ticker_sentiment_score": "0.707746",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.217834",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "STD Testing Market Projected to Reach $14.11 billion by 2030 - Exclusive Report by 360iResearch",
    "url": "https://www.prnewswire.com/news-releases/std-testing-market-projected-to-reach-14-11-billion-by-2030---exclusive-report-by-360iresearch-302114358.html",
    "time_published": "20240413T033300",
    "authors": [
      "360iResearch"
    ],
    "summary": "PUNE, India, April 12, 2024 /PRNewswire/ -- The report titled \"STD Testing Market by Type ( Blood Tests, Lumbar Puncture, Swab Tests ) , Product Type ( Instruments, Reagents & Kits ) , Test Settings, Indication, End-user - Global Forecast 2024-2030\" is now available on 360iResearch.com's ...",
    "banner_image": "https://mma.prnewswire.com/media/2359256/360iResearch_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.376763,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TRMNF",
        "relevance_score": "0.038843",
        "ticker_sentiment_score": "0.170574",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HOLX",
        "relevance_score": "0.038843",
        "ticker_sentiment_score": "0.104464",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.038843",
        "ticker_sentiment_score": "0.104464",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SEMHF",
        "relevance_score": "0.038843",
        "ticker_sentiment_score": "0.104464",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.038843",
        "ticker_sentiment_score": "0.104464",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Buy Rated Stocks to Consider as Earnings Approach",
    "url": "https://www.zacks.com/commentary/2254910/3-buy-rated-stocks-to-consider-as-earnings-approach",
    "time_published": "20240413T005700",
    "authors": [
      "Shaun Pruitt"
    ],
    "summary": "Several top-rated Zacks stocks are standing out before their first-quarter earnings report next week and here are three to consider.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default94.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.998311"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.242905,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IBKR",
        "relevance_score": "0.411848",
        "ticker_sentiment_score": "0.265562",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.33514",
        "ticker_sentiment_score": "0.295935",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ASML",
        "relevance_score": "0.484191",
        "ticker_sentiment_score": "0.369789",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Americans are savings less these days. Here's why and what that means | Business",
    "url": "https://www.cnn.com/2024/04/14/economy/stocks-week-ahead-americans-savings-less-economy-spending/index.html",
    "time_published": "20240414T113000",
    "authors": [
      "Bryan Mena"
    ],
    "summary": "Americans are saving less these days. Here's why and what that means ...",
    "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/gettyimages-1387286445.jpg?c=16x9&q=w_800,c_fill",
    "source": "CNN",
    "category_within_source": "Markets",
    "source_domain": "www.cnn.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.079323,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALK",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "-0.034531",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "-0.034531",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "-0.055057",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTRS",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "-0.055057",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "-0.055057",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "-0.055057",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "-0.055057",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BK",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "-0.055057",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "-0.079111",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "-0.055057",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSM",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "-0.034531",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XINXF",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.107016",
        "ticker_sentiment_score": "-0.024274",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BX",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "-0.034531",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EFX",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MCO",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "-0.086648",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBD",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "0.217581",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SCHW",
        "relevance_score": "0.035768",
        "ticker_sentiment_score": "-0.079111",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is AbbVie a Millionaire Maker?",
    "url": "https://www.fool.com/investing/2024/04/14/is-abbvie-a-millionaire-maker/",
    "time_published": "20240414T052300",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Everything is going according to plan, and more growth is on the way.",
    "banner_image": "https://g.foolcdn.com/editorial/images/771959/two-investors-consider-a-stock-with-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.324719,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.38588",
        "ticker_sentiment_score": "0.414875",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.050254",
        "ticker_sentiment_score": "0.174265",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Page 40320 of",
    "url": "https://www.financialexpress.com/about-news/page/40320/",
    "time_published": "20240415T081446",
    "authors": [],
    "summary": "Ambuja Realty Group has entered into the education sector, taking over Institute of Technology and Marine Engineering, although it would\u2026 Most human resource managers try to serenade the 18-25 year olds, the Generation Y, by either money or promise of\u2026",
    "banner_image": "https://www.financialexpress.com/wp-content/themes/ie-network-theme/assets/src/img/default-img-fe.jpg",
    "source": "The Financial Express",
    "category_within_source": "n/a",
    "source_domain": "www.financialexpress.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": -0.086064,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.179788",
        "ticker_sentiment_score": "0.303128",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRYPTO:NANO",
        "relevance_score": "0.179788",
        "ticker_sentiment_score": "-0.125738",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Is UNH Stock Soaring After Earnings?",
    "url": "https://www.kiplinger.com/investing/stocks/why-is-unh-stock-soaring-after-earnings",
    "time_published": "20240416T153055",
    "authors": [
      "Joey Solitro"
    ],
    "summary": "UnitedHealth Group ( UNH ) stock is soaring over 5% in Tuesday's session after the company beat both earnings and revenue estimates for its fiscal 2024 first quarter. UNH stock can certainly use the boost considering it was down 15% for the year-to-date heading into today's trading.",
    "banner_image": "https://cdn.mos.cms.futurecdn.net/hwgJ7osrMtUWhk5koeVme7-320-80.png",
    "source": "Kiplinger",
    "category_within_source": "n/a",
    "source_domain": "www.kiplinger.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.99992"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.360075,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PLD",
        "relevance_score": "0.195814",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRV",
        "relevance_score": "0.195814",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.195814",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IBKR",
        "relevance_score": "0.195814",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.195814",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.543004",
        "ticker_sentiment_score": "0.372026",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Bio-Rad  ( BIO )  Hurt by Softness in BioPharma and Competition",
    "url": "https://www.zacks.com/stock/news/2256187/bio-rad-bio-hurt-by-softness-in-biopharma-and-competition",
    "time_published": "20240416T145600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Bio-Rad's (BIO) margin performance bears the brunt of elevated raw material costs, increased logistics costs and higher employee-related expenses.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c2/53795.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.993781"
      }
    ],
    "overall_sentiment_score": 0.130647,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.045482",
        "ticker_sentiment_score": "0.065784",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.224487",
        "ticker_sentiment_score": "0.034281",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.090816",
        "ticker_sentiment_score": "0.06947",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.045482",
        "ticker_sentiment_score": "0.065784",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSRLF",
        "relevance_score": "0.045482",
        "ticker_sentiment_score": "0.065784",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIO",
        "relevance_score": "0.135857",
        "ticker_sentiment_score": "-0.069883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.135857",
        "ticker_sentiment_score": "0.051422",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DVA",
        "relevance_score": "0.18046",
        "ticker_sentiment_score": "0.041398",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Daily: Samsung Overtakes Apple As iPhone Shipments Slump",
    "url": "https://www.forbes.com/sites/daniellechemtob/2024/04/16/forbes-daily-samsung-overtakes-apple-as-iphone-shipments-slump/",
    "time_published": "20240416T121004",
    "authors": [
      "Danielle Chemtob"
    ],
    "summary": "Forbes Daily: Samsung overtakes Apple in smartphone shipments Forbes ...",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/661e6a34d66b63cd31d40669/0x0.jpg?format=jpg&crop=2284,1284,x0,y44,safe&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.069949,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.023102",
        "ticker_sentiment_score": "0.094402",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSNLF",
        "relevance_score": "0.023102",
        "ticker_sentiment_score": "-0.084059",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.023102",
        "ticker_sentiment_score": "0.094402",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.023102",
        "ticker_sentiment_score": "0.106542",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.023102",
        "ticker_sentiment_score": "-0.003907",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.023102",
        "ticker_sentiment_score": "-0.077911",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DJT",
        "relevance_score": "0.023102",
        "ticker_sentiment_score": "0.072974",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Inside The Collapse Of A Former Billionaire's Foundation For Low-Income Students",
    "url": "https://www.forbes.com/sites/giacomotognini/2024/04/16/inside-the-collapse-of-a-former-billionaires-foundation-for-low-income-students/",
    "time_published": "20240416T103000",
    "authors": [
      "Giacomo Tognini"
    ],
    "summary": "Healthcare Investor Shuts Down Scholarship Program Forbes ...",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/661d8cbaf5f4c0c35485b8cb/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.090607,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BDSX",
        "relevance_score": "0.022284",
        "ticker_sentiment_score": "-0.001791",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.011143",
        "ticker_sentiment_score": "0.078331",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SLNO",
        "relevance_score": "0.022284",
        "ticker_sentiment_score": "0.050415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXDX",
        "relevance_score": "0.077881",
        "ticker_sentiment_score": "0.053955",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QDEL",
        "relevance_score": "0.055673",
        "ticker_sentiment_score": "-0.001001",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Heart pumps tied to 14 deaths, hundreds of injuries are being recalled",
    "url": "https://www.foxbusiness.com/lifestyle/heart-pumps-tied-14-deaths-injuries-being-recalled",
    "time_published": "20240417T152600",
    "authors": [
      "Daniella Genovese"
    ],
    "summary": "Nearly 14,000 heart pumps tied to hundreds of injuries and more than a dozen deaths are being recalled, according to federal health officials.",
    "banner_image": "https://cf-images.us-east-1.prod.boltdns.net/v1/static/854081161001/52fd3ea9-8f05-451e-a69d-df2025d33919/ea2d2479-5dfb-4404-90af-4e1adf516753/1280x720/match/image.jpg",
    "source": "Fox Business News",
    "category_within_source": "n/a",
    "source_domain": "www.foxbusiness.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.049121,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.105141",
        "ticker_sentiment_score": "-0.201491",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Q1 Earnings Review",
    "url": "https://www.zacks.com/stock/news/2257009/q1-earnings-review",
    "time_published": "20240417T150400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Pre-market futures are up slightly at this hour. Markets look to rebound off a three-day losing streak on the S&P 500 and Nasdaq. the blue-chip Dow outperformed the field yesterday, closing +0.17%. Major indices are all lower over the past month, from -1.7% ( tech-heavy Nasdaq ) to -2.9% ( ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/db/2802.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.976671"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.096465,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LVS",
        "relevance_score": "0.165598",
        "ticker_sentiment_score": "0.026869",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.165598",
        "ticker_sentiment_score": "0.026869",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSX",
        "relevance_score": "0.165598",
        "ticker_sentiment_score": "0.026869",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.165598",
        "ticker_sentiment_score": "0.143135",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.165598",
        "ticker_sentiment_score": "0.026869",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SLG",
        "relevance_score": "0.165598",
        "ticker_sentiment_score": "0.026869",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Markets Try to Shake Off April Blues",
    "url": "https://www.zacks.com/stock/news/2256979/markets-try-to-shake-off-april-blues",
    "time_published": "20240417T143200",
    "authors": [
      "Mark Vickery"
    ],
    "summary": "Late March highs -- including all-time S&P levels -- have given way to profit-taking and existential concerns.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/17/1181.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.986413"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.091707,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LVS",
        "relevance_score": "0.160099",
        "ticker_sentiment_score": "0.026278",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.160099",
        "ticker_sentiment_score": "0.026278",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSX",
        "relevance_score": "0.160099",
        "ticker_sentiment_score": "0.026278",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.160099",
        "ticker_sentiment_score": "0.140005",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.160099",
        "ticker_sentiment_score": "0.026278",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SLG",
        "relevance_score": "0.160099",
        "ticker_sentiment_score": "0.026278",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Blood Collection Market size worth $ 14.76 Billion, Globally, by 2031 at 5.10% CAGR - Report By Verified Market Research\u00ae",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38294071/blood-collection-market-size-worth-14-76-billion-globally-by-2031-at-5-10-cagr-report-by-verified-",
    "time_published": "20240417T143000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Jersey City, New Jersey, April 17, 2024 ( GLOBE NEWSWIRE ) -- The Global Blood Collection Market is projected to grow at a CAGR of 5.10% from 2024 to 2031, according to a new report published by Verified Market Research\u00ae.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.284943,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.033144",
        "ticker_sentiment_score": "0.098403",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRUMF",
        "relevance_score": "0.033144",
        "ticker_sentiment_score": "0.098403",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.033144",
        "ticker_sentiment_score": "0.098403",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RSSS",
        "relevance_score": "0.033144",
        "ticker_sentiment_score": "0.171113",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.033144",
        "ticker_sentiment_score": "0.098403",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SEMHF",
        "relevance_score": "0.033144",
        "ticker_sentiment_score": "0.098403",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.033144",
        "ticker_sentiment_score": "0.098403",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DHR",
        "relevance_score": "0.033144",
        "ticker_sentiment_score": "0.098403",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Abbott  ( ABT )  Q1 Earnings Beat Estimates, Margins Contract",
    "url": "https://www.zacks.com/stock/news/2256957/abbott-abt-q1-earnings-beat-estimates-margins-contract",
    "time_published": "20240417T141300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Abbott (ABT) delivers double-digit organic sales growth in its underlying base business in the first quarter of 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.221765,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "INSP",
        "relevance_score": "0.141726",
        "ticker_sentiment_score": "0.034626",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PODD",
        "relevance_score": "0.141726",
        "ticker_sentiment_score": "0.032987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.141726",
        "ticker_sentiment_score": "0.095681",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXAS",
        "relevance_score": "0.141726",
        "ticker_sentiment_score": "0.032981",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Dow Surges 200 Points; Abbott Laboratories Posts Upbeat Earnings - Abbott Laboratories  ( NYSE:ABT ) , Edible Garden AG  ( NASDAQ:EDBL ) ",
    "url": "https://www.benzinga.com/news/earnings/24/04/38293458/dow-surges-200-points-abbott-laboratories-posts-upbeat-earnings",
    "time_published": "20240417T140753",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "U.S. stocks traded higher this morning, with the Dow Jones index gaining around 200 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.55% to 38,006.47 while the NASDAQ rose 0.24% to 15,903.38. The S&P 500 also rose, gaining, 0.40% to 5,071.74.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/17/image38.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.904684"
      }
    ],
    "overall_sentiment_score": 0.212521,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SBFM",
        "relevance_score": "0.167904",
        "ticker_sentiment_score": "0.293909",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EDBL",
        "relevance_score": "0.167904",
        "ticker_sentiment_score": "0.291227",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VIAO",
        "relevance_score": "0.167904",
        "ticker_sentiment_score": "0.35634",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.167904",
        "ticker_sentiment_score": "0.446615",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "INVO",
        "relevance_score": "0.167904",
        "ticker_sentiment_score": "0.289886",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IZM",
        "relevance_score": "0.167904",
        "ticker_sentiment_score": "0.362906",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "We're buying a health-care stock that should be higher after reporting a strong quarter",
    "url": "https://www.cnbc.com/2024/04/17/were-buying-a-health-care-stock-that-should-be-higher-after-reporting-a-strong-quarter.html",
    "time_published": "20240417T124634",
    "authors": [
      "Jeff Marks"
    ],
    "summary": "It's the third time in recent weeks that we've added to our position in the medical device maker.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107380826-1709261160392-gettyimages-146355972-e592be27-397e-433b-ae59-1c3cc44b6a8f.jpeg?v=1713281268&w=600&h=300&vtcrop=y",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.972756"
      }
    ],
    "overall_sentiment_score": 0.27593,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.295867",
        "ticker_sentiment_score": "0.254712",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Abbott Labs Q1 Revenue Jumps On Strong Medical Devices Sales, Company Boosts Annual Guidance - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/news/earnings/24/04/38290833/abbott-labs-q1-revenue-jumps-on-strong-medical-devices-sales-company-boosts-annual-guidance",
    "time_published": "20240417T124216",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Wednesday, Abbott Laboratories ABT reported first-quarter sales of $9.96 billion, up 10.8% on an organic basis for the underlying base business, beating the consensus of $9.88 billion. Reported sales increased by 2.2%, which includes the anticipated decline in COVID-19 testing-related revenue ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/17/abbott-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.258151,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.431065",
        "ticker_sentiment_score": "-0.04899",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Abbott Labs Jumps, Retreats On Q1 Beat, Shy Guidance",
    "url": "https://www.investors.com/news/technology/abbott-stock-abbott-laboratories-q1-2024-earnings/",
    "time_published": "20240417T115200",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Abbott stock see-sawed early Wednesday after the giant health care company reported adjusted income of 98 cents a share on $10 billion in first-quarter sales. The Street projected earnings of 95 cents a share and $9.88 billion in sales, according to FactSet.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2019/10/stock-Abbott-05-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.334599,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DXCM",
        "relevance_score": "0.205807",
        "ticker_sentiment_score": "0.373057",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.398148",
        "ticker_sentiment_score": "0.350658",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "S&P 500, Nasdaq Futures Point To Higher Open Today: What's Going On? - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/04/38288246/wall-street-poised-to-rebound-from-slump-as-earnings-optimism-grows-analyst-eyes-this-s-p-500-level",
    "time_published": "20240417T110902",
    "authors": [
      "Shanthi Rexaline"
    ],
    "summary": "U.S. stocks are priming for a firmer start on Wednesday, potentially striving to inflect higher from the weakness seen so far in April. As some bullish market watchers pointed out there could be an inflection from the second half of April, with earnings potentially serving as an upside catalyst.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/17/nyse-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.02176,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AA",
        "relevance_score": "0.120733",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DFS",
        "relevance_score": "0.120733",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.120733",
        "ticker_sentiment_score": "-0.142125",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.120733",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LVS",
        "relevance_score": "0.120733",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSX",
        "relevance_score": "0.120733",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRV",
        "relevance_score": "0.120733",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FHN",
        "relevance_score": "0.120733",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.120733",
        "ticker_sentiment_score": "-0.142274",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.120733",
        "ticker_sentiment_score": "-0.18681",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Investor Optimism Decreases; Dow Ends 6-Session Losing Streak - Abbott Laboratories  ( NYSE:ABT ) , Bank of America  ( NYSE:BAC ) ",
    "url": "https://www.benzinga.com/news/earnings/24/04/38284995/investor-optimism-decreases-dow-ends-6-session-losing-streak",
    "time_published": "20240417T060633",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "The CNN Money Fear and Greed index showed a decline in the overall market sentiment, with the index remaining in the \"Fear\" zone on Tuesday. U.S. stocks closed mixed on Tuesday amid increased geopolitical concerns. The Dow Jones index, meanwhile, snapped its six-session losing streak.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/17/image27.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": -0.207898,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "WBD",
        "relevance_score": "0.116348",
        "ticker_sentiment_score": "-0.386828",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "TRV",
        "relevance_score": "0.230235",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.230235",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.230235",
        "ticker_sentiment_score": "0.357554",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.230235",
        "ticker_sentiment_score": "0.357554",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Abbott Laboratories, U.S. Bancorp And 3 Stocks To Watch Heading Into Wednesday - Abbott Laboratories  ( NYSE:ABT ) , U.S. Bancorp  ( NYSE:USB ) ",
    "url": "https://www.benzinga.com/news/earnings/24/04/38284954/abbott-laboratories-u-s-bancorp-and-3-stocks-to-watch-heading-into-wednesday",
    "time_published": "20240417T060622",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "With U.S. stock futures trading higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Abbott Laboratories ABT to report quarterly earnings at 95 cents per share on revenue of $9.88 billion before the opening bell, according to ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/17/abbott_laboratories_-_logo.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.183452,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TRV",
        "relevance_score": "0.29234",
        "ticker_sentiment_score": "0.404164",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.29234",
        "ticker_sentiment_score": "0.420657",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ITCI",
        "relevance_score": "0.426225",
        "ticker_sentiment_score": "-0.090258",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OTRK",
        "relevance_score": "0.426225",
        "ticker_sentiment_score": "-0.149526",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Global Radioimmunoassay Market to Grow at a Minimal CAGR of ~3% by 2030 | DelveInsight",
    "url": "https://www.prnewswire.com/news-releases/global-radioimmunoassay-market-to-grow-at-a-minimal-cagr-of-3-by-2030--delveinsight-302119197.html",
    "time_published": "20240418T213100",
    "authors": [
      "DelveInsight Business Research",
      "LLP"
    ],
    "summary": "The increasing need for radioimmunoassay is mainly driven by the rising occurrence of cancer, infectious diseases, and various other health conditions, along with a growing number of epidemics and pandemics and increasing health awareness.",
    "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.146788,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BMXMF",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "A",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CNTG",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXAS",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EKTAY",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.082191",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SKXJF",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.173153",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.056741",
        "ticker_sentiment_score": "-0.035994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.173153",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.056741",
        "ticker_sentiment_score": "-0.035994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.056741",
        "ticker_sentiment_score": "-0.035994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DHR",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "0.060148",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TCRT",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "0.02269",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QGEN",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.056741",
        "ticker_sentiment_score": "-0.035994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLDX",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "0.02269",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BGNE",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "0.02269",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSMXF",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "0.02269",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ILMN",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALPMF",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "0.02269",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIO",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.056741",
        "ticker_sentiment_score": "-0.035994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.056741",
        "ticker_sentiment_score": "-0.035994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HOLX",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.056741",
        "ticker_sentiment_score": "-0.035994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARAY",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.082191",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MYGN",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.056741",
        "ticker_sentiment_score": "-0.035994",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Behind the Scenes of Abbott Laboratories's Latest Options Trends - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/insights/options/24/04/38321000/behind-the-scenes-of-abbott-laboratoriess-latest-options-trends",
    "time_published": "20240418T173158",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with significant funds have taken a bearish position in Abbott Laboratories ABT, a development that retail traders should be aware of. This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.194383,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EVR",
        "relevance_score": "0.080458",
        "ticker_sentiment_score": "0.127304",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.636698",
        "ticker_sentiment_score": "0.243372",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.080458",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stock Market Shows Bearish Action: Weekly Review",
    "url": "https://www.investors.com/news/stock-market-taiwan-semiconductor-asml-netflix-united-airlines-weekly-review/",
    "time_published": "20240419T165100",
    "authors": [
      "IBD STAFF",
      "Investor's Business Daily"
    ],
    "summary": "Stock Market Sells Off. Taiwan Semi, ASML, Netflix, Tesla In Focus: Weekly Review Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/10/Stock-NYSEbuilding-09-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.041784,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "-0.148103",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.098862",
        "ticker_sentiment_score": "-0.034689",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IBKR",
        "relevance_score": "0.098862",
        "ticker_sentiment_score": "0.102009",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.108439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.108439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.049526",
        "ticker_sentiment_score": "0.071953",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SLB",
        "relevance_score": "0.123399",
        "ticker_sentiment_score": "0.018007",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BK",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.108439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.049526",
        "ticker_sentiment_score": "0.105983",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.108869",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSM",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.004134",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KBH",
        "relevance_score": "0.049526",
        "ticker_sentiment_score": "0.102972",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.049526",
        "ticker_sentiment_score": "0.071953",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ITCI",
        "relevance_score": "0.049526",
        "ticker_sentiment_score": "-0.127853",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "-0.076438",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.049526",
        "ticker_sentiment_score": "0.107278",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.101928",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.049526",
        "ticker_sentiment_score": "0.012",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SCHW",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.095435",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.088742",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.0156",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Dexcom In Buy Zone After Launch Of Prescription-Free Diabetes Monitor; Earnings Due Next Week",
    "url": "https://www.investors.com/stock-lists/sector-leaders/dexcom-stock-dxcm-diabetes-insulin/",
    "time_published": "20240419T123000",
    "authors": [
      "Investor's Business Daily",
      "VIDYA RAMAKRISHNAN"
    ],
    "summary": "Dexcom Stock Is In Buy Zone Ahead Of Earnings Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/02/stock-Dexcom-02-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938238"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.955357"
      }
    ],
    "overall_sentiment_score": 0.327633,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.184598",
        "ticker_sentiment_score": "0.135154",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.440549",
        "ticker_sentiment_score": "0.428074",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.184598",
        "ticker_sentiment_score": "0.135154",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What's in Store for These 4 Medical Products Stocks in Q1 Earnings?",
    "url": "https://www.zacks.com/stock/news/2260506/whats-in-store-for-these-4-medical-products-stocks-in-q1-earnings",
    "time_published": "20240423T153600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Medical Products companies' quarterly results are likely to reflect a year-over-year decline in earnings. Let's see how BSX, TMO, ALGN and ICLR fare this time.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/59/54380.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.231672,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ICLR",
        "relevance_score": "0.119532",
        "ticker_sentiment_score": "0.031496",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.029989",
        "ticker_sentiment_score": "-0.078017",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.207571",
        "ticker_sentiment_score": "0.351416",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.1491",
        "ticker_sentiment_score": "0.126458",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBA",
        "relevance_score": "0.029989",
        "ticker_sentiment_score": "-0.078017",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NEOG",
        "relevance_score": "0.029989",
        "ticker_sentiment_score": "-0.078017",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALGN",
        "relevance_score": "0.178459",
        "ticker_sentiment_score": "0.19765",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PXXXF",
        "relevance_score": "0.029989",
        "ticker_sentiment_score": "0.338579",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here's a rapid-fire update on all 33 portfolio stocks including our tech giants reporting this week",
    "url": "https://www.cnbc.com/2024/04/24/jim-cramers-rapid-fire-update-on-all-33-investing-club-stocks.html",
    "time_published": "20240424T195309",
    "authors": [
      "Kevin Stankiewicz",
      "Morgan Chittum"
    ],
    "summary": "During the Investing Club's Monthly Meeting on Wednesday, Jim Cramer offered his updated thinking on the stocks in the portfolio.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107381791-1709565572170-gettyimages-2050810312-AFP_34KQ4DT.jpeg?v=1713980195&w=1920&h=1080",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999974"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.147834,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DD",
        "relevance_score": "0.014239",
        "ticker_sentiment_score": "0.054481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VMW",
        "relevance_score": "0.014239",
        "ticker_sentiment_score": "0.054481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INFA",
        "relevance_score": "0.028473",
        "ticker_sentiment_score": "0.058975",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.014239",
        "ticker_sentiment_score": "0.054481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "F",
        "relevance_score": "0.014239",
        "ticker_sentiment_score": "0.054481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FL",
        "relevance_score": "0.042698",
        "ticker_sentiment_score": "0.061498",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.014239",
        "ticker_sentiment_score": "0.054481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WYNN",
        "relevance_score": "0.014239",
        "ticker_sentiment_score": "0.054481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.014239",
        "ticker_sentiment_score": "0.054481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.05691",
        "ticker_sentiment_score": "0.062053",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.042698",
        "ticker_sentiment_score": "0.061498",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.014239",
        "ticker_sentiment_score": "0.054481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.042698",
        "ticker_sentiment_score": "0.061498",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BBY",
        "relevance_score": "0.042698",
        "ticker_sentiment_score": "0.061498",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STZ",
        "relevance_score": "0.014239",
        "ticker_sentiment_score": "0.054481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PANW",
        "relevance_score": "0.014239",
        "ticker_sentiment_score": "0.054481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.042698",
        "ticker_sentiment_score": "0.061498",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.028473",
        "ticker_sentiment_score": "0.058975",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.028473",
        "ticker_sentiment_score": "0.058975",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRWD",
        "relevance_score": "0.014239",
        "ticker_sentiment_score": "0.054481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TJX",
        "relevance_score": "0.028473",
        "ticker_sentiment_score": "0.058975",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GM",
        "relevance_score": "0.042698",
        "ticker_sentiment_score": "0.061498",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HON",
        "relevance_score": "0.014239",
        "ticker_sentiment_score": "0.054481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.028473",
        "ticker_sentiment_score": "0.058975",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWK",
        "relevance_score": "0.014239",
        "ticker_sentiment_score": "0.054481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.014239",
        "ticker_sentiment_score": "0.054481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTRA",
        "relevance_score": "0.014239",
        "ticker_sentiment_score": "0.054481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.014239",
        "ticker_sentiment_score": "0.054481",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Diamond Hill Mutual Funds for Higher Returns",
    "url": "https://www.zacks.com/stock/news/2261957/3-diamond-hill-mutual-funds-for-higher-returns",
    "time_published": "20240425T122100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Invests in Diamond Hill mutual funds like DHLSX, DHLTX and DHLAX for diversified investment opportunities across various asset classes.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ad/591.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999701"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.288551,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.065327",
        "ticker_sentiment_score": "0.050043",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.065327",
        "ticker_sentiment_score": "0.050043",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.065327",
        "ticker_sentiment_score": "0.050043",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RRR",
        "relevance_score": "0.065327",
        "ticker_sentiment_score": "0.045037",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COP",
        "relevance_score": "0.065327",
        "ticker_sentiment_score": "0.050043",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WCC",
        "relevance_score": "0.065327",
        "ticker_sentiment_score": "0.045037",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AIG",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.05856",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Dividend Stocks to Buy and Hold for the Next Decade",
    "url": "https://www.fool.com/investing/2024/04/27/3-dividend-stocks-to-buy-and-hold-for-the-next-dec/",
    "time_published": "20240427T111500",
    "authors": [
      "Keith Speights",
      "and Prosper Junior Bakiny",
      "David Jagielski"
    ],
    "summary": "You'll get dividends and more with these great stocks.",
    "banner_image": "https://g.foolcdn.com/editorial/images/774374/light-bulbs-with-dollar-sign-person-looking-up.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998962"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.94762"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.273184,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.396888",
        "ticker_sentiment_score": "0.293766",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.360171",
        "ticker_sentiment_score": "0.156442",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.041466",
        "ticker_sentiment_score": "0.176676",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FCAP",
        "relevance_score": "0.041466",
        "ticker_sentiment_score": "0.086608",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.284106",
        "ticker_sentiment_score": "0.173062",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Beaten-Down Dividend Stocks to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/04/28/2-beaten-down-dividend-stocks-to-buy-and-hold-fore/",
    "time_published": "20240428T114500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "These companies aren't in danger of becoming has-beens.",
    "banner_image": "https://media.ycharts.com/charts/ff86d4effb822b188bf8b9f6bfe360a3.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.972756"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.277201,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AAPL",
        "relevance_score": "0.478332",
        "ticker_sentiment_score": "0.331114",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.399911",
        "ticker_sentiment_score": "0.321287",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Better Dividend Stock: AbbVie or Johnson & Johnson?",
    "url": "https://www.fool.com/investing/2024/04/28/better-dividend-stock-abbvie-or-johnson-johnson/",
    "time_published": "20240428T082000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "One thing is for sure: Dividend seekers can't go wrong with either.",
    "banner_image": "https://media.ycharts.com/charts/606ca6d7bad2ded63e4e23f32d1c43b2.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.918141"
      }
    ],
    "overall_sentiment_score": 0.215112,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.596349",
        "ticker_sentiment_score": "0.286691",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.051221",
        "ticker_sentiment_score": "0.025897",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.479385",
        "ticker_sentiment_score": "0.29997",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "What the Options Market Tells Us About Abbott Laboratories - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/insights/options/24/05/38566419/what-the-options-market-tells-us-about-abbott-laboratories",
    "time_published": "20240501T204605",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bullish approach towards Abbott Laboratories ABT, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.207571,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EVR",
        "relevance_score": "0.074926",
        "ticker_sentiment_score": "0.116146",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.653008",
        "ticker_sentiment_score": "0.324403",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.074926",
        "ticker_sentiment_score": "-0.117159",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.074926",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Molecular Biology Enzymes And Kits And Reagents Market Surges to USD 69.4 Billion by 2031, Propelled by 17.35% CAGR - Verified Market Research\u00ae",
    "url": "https://www.benzinga.com/pressreleases/24/05/g38585243/molecular-biology-enzymes-and-kits-and-reagents-market-surges-to-usd-69-4-billion-by-2031-propelle",
    "time_published": "20240502T140000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Lewes, Delaware, May 02, 2024 ( GLOBE NEWSWIRE ) -- The Global Molecular Biology Enzymes And Kits And Reagents Market is projected to grow at a CAGR of 17.35% from 2024 to 2031, according to a new report published by Verified Market Research\u00ae.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.296724,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "A",
        "relevance_score": "0.044634",
        "ticker_sentiment_score": "0.058747",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRMNF",
        "relevance_score": "0.022326",
        "ticker_sentiment_score": "0.071137",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.022326",
        "ticker_sentiment_score": "0.066499",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ILMN",
        "relevance_score": "0.022326",
        "ticker_sentiment_score": "0.066499",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RSSS",
        "relevance_score": "0.022326",
        "ticker_sentiment_score": "0.164373",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.044634",
        "ticker_sentiment_score": "0.058747",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIO",
        "relevance_score": "0.044634",
        "ticker_sentiment_score": "0.058747",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QGEN",
        "relevance_score": "0.022326",
        "ticker_sentiment_score": "0.066499",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "How Is The Market Feeling About Abbott Laboratories? - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/05/38613561/how-is-the-market-feeling-about-abbott-laboratories",
    "time_published": "20240503T131513",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Abbott Laboratories's ABT short percent of float has fallen 7.69% since its last report. The company recently reported that it has 14.48 million shares sold short, which is 0.84% of all regular shares that are available for trading.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.262256,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.079385",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Reasons to Buy AbbVie Stock on the Dip",
    "url": "https://www.fool.com/investing/2024/05/05/3-reasons-to-buy-abbvie-stock-on-the-dip/",
    "time_published": "20240505T174400",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "A little patience with the drugmaker should pay off.",
    "banner_image": "https://g.foolcdn.com/editorial/images/774891/patient-taking-medicine.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.905476"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.168056,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.542261",
        "ticker_sentiment_score": "0.293827",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.059194",
        "ticker_sentiment_score": "0.143438",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Patient Monitoring Devices Market is Expected to Reach $71.1 billion | MarketsandMarkets\u2122",
    "url": "https://www.benzinga.com/pressreleases/24/05/g38640933/patient-monitoring-devices-market-is-expected-to-reach-71-1-billion-marketsandmarkets",
    "time_published": "20240506T123000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Chicago, May 06, 2024 ( GLOBE NEWSWIRE ) -- Patient Monitoring Devices market in terms of revenue was estimated to be worth $48.5 billion in 2024 and is poised to reach $71.1 billion by 2029, growing at a CAGR of 8.0% from 2024 to 2029 according to a latest report published by MarketsandMarkets\u2122.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.387942,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "OMRNF",
        "relevance_score": "0.034381",
        "ticker_sentiment_score": "-0.027212",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EW",
        "relevance_score": "0.034381",
        "ticker_sentiment_score": "-0.027212",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NHNKF",
        "relevance_score": "0.034381",
        "ticker_sentiment_score": "-0.027212",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.034381",
        "ticker_sentiment_score": "-0.027212",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGWPF",
        "relevance_score": "0.034381",
        "ticker_sentiment_score": "-0.027212",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAX",
        "relevance_score": "0.034381",
        "ticker_sentiment_score": "-0.027212",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GNGBY",
        "relevance_score": "0.034381",
        "ticker_sentiment_score": "-0.027212",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.034381",
        "ticker_sentiment_score": "-0.027212",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "BioPorto A/S Appoints President and CEO of BioPorto Inc.",
    "url": "https://www.globenewswire.com/news-release/2024/05/07/2876582/0/en/BioPorto-A-S-Appoints-President-and-CEO-of-BioPorto-Inc.html",
    "time_published": "20240507T111000",
    "authors": [
      "BioPorto A/S"
    ],
    "summary": "May 7, 2024News release ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/b9686d8c-3706-4a6c-b22a-ae722c122c21",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.260449,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.045054",
        "ticker_sentiment_score": "0.079326",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.089965",
        "ticker_sentiment_score": "0.083897",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Tesla, Johnson & Johnson, Netflix, Abbott and ConocoPhillips",
    "url": "https://www.zacks.com/stock/news/2270202/the-zacks-analyst-blog-highlights-tesla-johnson-johnson-netflix-abbott-and-conocophillips",
    "time_published": "20240508T101800",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Tesla, Johnson & Johnson, Netflix, Abbott and ConocoPhillips are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/04/590.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.285535,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.355588",
        "ticker_sentiment_score": "0.190577",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.146469",
        "ticker_sentiment_score": "0.037354",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.218161",
        "ticker_sentiment_score": "0.049508",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COP",
        "relevance_score": "0.146469",
        "ticker_sentiment_score": "0.037354",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.288044",
        "ticker_sentiment_score": "0.050653",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's why we scooped up additional shares of these 2 lagging health-care stocks",
    "url": "https://www.cnbc.com/2024/05/09/why-jim-cramer-bought-more-shares-of-these-2-lagging-health-care-stocks.html",
    "time_published": "20240509T155434",
    "authors": [
      "Morgan Chittum"
    ],
    "summary": "The Investing Club holds its \"Morning Meeting\" every weekday at 10:20 a.m. ET.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107372340-1707755955868-gettyimages-1665282931-porzycki-armphoto230914_npsnU.jpeg?v=1707756116&w=600&h=300&vtcrop=y",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      }
    ],
    "overall_sentiment_score": 0.201412,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.188193",
        "ticker_sentiment_score": "0.130721",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amazon, Abbott Laboratories And 2 Other Stocks Insiders Are Selling - Amazon.com  ( NASDAQ:AMZN ) ",
    "url": "https://www.benzinga.com/news/24/05/38730179/amazon-abbott-laboratories-and-2-other-stocks-insiders-are-selling",
    "time_published": "20240509T123558",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "The Nasdaq 100 closed slightly lower on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/09/amazon-fans-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.14526,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DTST",
        "relevance_score": "0.085936",
        "ticker_sentiment_score": "0.02927",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.334008",
        "ticker_sentiment_score": "0.111122",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZM",
        "relevance_score": "0.410505",
        "ticker_sentiment_score": "0.197013",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.253866",
        "ticker_sentiment_score": "0.271349",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "STX",
        "relevance_score": "0.253866",
        "ticker_sentiment_score": "0.113431",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What the Options Market Tells Us About Abbott Laboratories - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/insights/options/24/05/38770599/what-the-options-market-tells-us-about-abbott-laboratories",
    "time_published": "20240510T201821",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bullish stance on Abbott Laboratories. Looking at options history for Abbott Laboratories ABT we detected 9 trades. If we consider the specifics of each trade, it is accurate to state that 33% of the investors opened trades with bullish ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.195945,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.679118",
        "ticker_sentiment_score": "0.297704",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "-0.109385",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Rock-Solid Dividend Stocks That Are Ideal for Retirees",
    "url": "https://www.fool.com/investing/2024/05/10/3-rock-solid-dividend-stocks-ideal-for-retirees/",
    "time_published": "20240510T133000",
    "authors": [
      "David Jagielski"
    ],
    "summary": "These are low-risk stocks with high yields.",
    "banner_image": "https://g.foolcdn.com/editorial/images/775891/couple-using-a-computer.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.254137,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CERE",
        "relevance_score": "0.05654",
        "ticker_sentiment_score": "-0.03902",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.329551",
        "ticker_sentiment_score": "0.133645",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.05654",
        "ticker_sentiment_score": "0.124934",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "T",
        "relevance_score": "0.277118",
        "ticker_sentiment_score": "0.102301",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.16849",
        "ticker_sentiment_score": "0.05271",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Q&A: This New CEO Has Big Ideas For A Small Biotech",
    "url": "https://www.investors.com/news/technology/catalyst-pharmaceuticals-biotech-stock-richard-daly-qa/",
    "time_published": "20240510T133000",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Catalyst Pharmaceuticals CEO Richard Daly: Big Plans For The Small Biotech Stock Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/05/TECH1_daly_051024.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.337516,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.046363",
        "ticker_sentiment_score": "0.244453",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CPRX",
        "relevance_score": "0.069495",
        "ticker_sentiment_score": "0.088537",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "0.279129",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.023191",
        "ticker_sentiment_score": "0.223411",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.069495",
        "ticker_sentiment_score": "0.236529",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.046363",
        "ticker_sentiment_score": "0.067621",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Senhwa Biosciences Announces Jason Huang, MD as New Chief Medical Officer",
    "url": "https://www.prnewswire.com/news-releases/senhwa-biosciences-announces-jason-huang-md-as-new-chief-medical-officer-302143219.html",
    "time_published": "20240513T110000",
    "authors": [
      "Inc.",
      "Senhwa Biosciences"
    ],
    "summary": "NEW TAIPEI CITY, May 13, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. ( TPEx: 6492 ) , announced the appointment of Jason Huang, M.D., former Regional Therapeutic Area Expert ( RTAE ) , Janssen, a subsidiary of Johnson and Johnson, as the company's chief medical officer.",
    "banner_image": "https://mma.prnewswire.com/media/1933477/Senhwa_Logo_Logo_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.285702,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.175549",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Looking At Abbott Laboratories's Recent Unusual Options Activity - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/insights/options/24/05/38824758/looking-at-abbott-laboratoriess-recent-unusual-options-activity",
    "time_published": "20240514T174557",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on Abbott Laboratories. Looking at options history for Abbott Laboratories ABT we detected 11 trades. If we consider the specifics of each trade, it is accurate to state that 27% of the investors opened trades with ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.189679,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.6809",
        "ticker_sentiment_score": "0.130784",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.088147",
        "ticker_sentiment_score": "-0.10946",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "5 Best Dividend Stocks To Help Hedge Inflation",
    "url": "https://www.forbes.com/sites/investor-hub/article/best-dividend-stocks-to-hedge-inflation/",
    "time_published": "20240514T114547",
    "authors": [
      "CFP(R)",
      "Jason Kirsch"
    ],
    "summary": "As inflation seems to be sticking around with rates above 3%, investors seek refuge in assets that can offer stability and growth. Dividend stocks, known for their consistent payouts and potential for capital appreciation, emerge as a compelling option in turbulent economic times.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/66427a30deb5a930366dabcb/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.998626"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.494702,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.131427",
        "ticker_sentiment_score": "0.282941",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PLD",
        "relevance_score": "0.144432",
        "ticker_sentiment_score": "0.251166",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DSGR",
        "relevance_score": "0.013202",
        "ticker_sentiment_score": "0.25193",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.013202",
        "ticker_sentiment_score": "0.064791",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.092213",
        "ticker_sentiment_score": "0.276817",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Massive Insider Trade At Abbott Laboratories - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/insights/news/24/05/38847898/massive-insider-trade-at-abbott-laboratories",
    "time_published": "20240515T150238",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Revealing a significant insider sell on May 14, Robert E. Funck Jr., Executive Vice President at Abbott Laboratories ABT, as per the latest SEC filing. What Happened: Jr.'s recent move involves selling 10,097 shares of Abbott Laboratories. This information is documented in a Form 4 filing with ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/insider_image_2.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.996718"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      }
    ],
    "overall_sentiment_score": 0.219457,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.341699",
        "ticker_sentiment_score": "0.452044",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Sepsis Diagnostics Market Surges to USD 891.05 Million by 2031, Propelled by 7% CAGR - Verified Market Research\u00ae",
    "url": "https://www.benzinga.com/pressreleases/24/05/g38873988/sepsis-diagnostics-market-surges-to-usd-891-05-million-by-2031-propelled-by-7-cagr-verified-market",
    "time_published": "20240516T140000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Lewes, Delaware, May 16, 2024 ( GLOBE NEWSWIRE ) -- The Global Sepsis Diagnostics Market is projected to grow at a CAGR of 7% from 2024 to 2031, according to a new report published by Verified Market Research\u00ae.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.205421,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BMXMF",
        "relevance_score": "0.02683",
        "ticker_sentiment_score": "0.111529",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.02683",
        "ticker_sentiment_score": "0.111529",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.02683",
        "ticker_sentiment_score": "0.111529",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RSSS",
        "relevance_score": "0.02683",
        "ticker_sentiment_score": "0.167516",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.02683",
        "ticker_sentiment_score": "0.111529",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TTOO",
        "relevance_score": "0.02683",
        "ticker_sentiment_score": "0.111529",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "These Dividend Stocks Are an Investor's Best Friend",
    "url": "https://www.fool.com/investing/2024/05/16/these-dividend-stocks-are-an-investors-best-friend/",
    "time_published": "20240516T120000",
    "authors": [
      "George Budwell"
    ],
    "summary": "These two healthcare stocks are well-known for their top-tier dividend programs.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F777461%2Fdividends.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      }
    ],
    "overall_sentiment_score": 0.427908,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MDT",
        "relevance_score": "0.310843",
        "ticker_sentiment_score": "0.411438",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.18967",
        "ticker_sentiment_score": "0.209958",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "CVRx Announces Key Senior Leadership Team Hires",
    "url": "https://www.globenewswire.com/news-release/2024/05/16/2883291/0/en/CVRx-Announces-Key-Senior-Leadership-Team-Hires.html",
    "time_published": "20240516T113000",
    "authors": [
      "CVRx",
      "Inc."
    ],
    "summary": "MINNEAPOLIS, May 16, 2024 ( GLOBE NEWSWIRE ) -- CVRx, Inc. ( NASDAQ: CVRX ) ( \"CVRx\" ) , a commercial-stage medical device company, today announced three additions to its senior leadership team. Philip B. Adamson, MD, MSc, FACC, FESC, FRCP ( Ed ) has been appointed as Chief Medical Officer, ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/04c4feba-7841-4ac8-8ca5-6c03be383a0e",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.241974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MDT",
        "relevance_score": "0.051003",
        "ticker_sentiment_score": "0.055976",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVRX",
        "relevance_score": "0.477606",
        "ticker_sentiment_score": "0.309363",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.051003",
        "ticker_sentiment_score": "0.086006",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's Why You Should Hold on to Abbott  ( ABT )  Stock for Now",
    "url": "https://www.zacks.com/stock/news/2276548/heres-why-you-should-hold-on-to-abbott-abt-stock-for-now",
    "time_published": "20240521T132900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Abbott's (ABT) share recovery in the Nutrition business buoys optimism.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.997845"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.258615,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MEDP",
        "relevance_score": "0.141935",
        "ticker_sentiment_score": "0.083425",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.106699",
        "ticker_sentiment_score": "0.295713",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.141935",
        "ticker_sentiment_score": "0.079153",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HITI",
        "relevance_score": "0.106699",
        "ticker_sentiment_score": "0.059447",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:EUR",
        "relevance_score": "0.035661",
        "ticker_sentiment_score": "0.014626",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Jim Cramer Calls This Healthcare Stock A 'Worthy Spec,' Recommends Avoiding Canada Goose - Canada Goose Hldgs  ( NYSE:GOOS ) ",
    "url": "https://www.benzinga.com/news/24/05/38939482/jim-cramer-calls-this-healthcare-stock-a-worthy-spec-recommends-avoiding-canada-goose",
    "time_published": "20240521T124412",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Mad Money Lightning Round,\" Jim Cramer recommended buying Dutch Bros Inc. BROS. On May 7, Dutch Bros posted better-than-expected first-quarter financial results and raised its full-year revenue guidance. \"The outlook is fabulous.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/21/Shanghai-china-sep-9th-2023-Canada-Goose.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.904684"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.157627,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MGTX",
        "relevance_score": "0.398148",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.398148",
        "ticker_sentiment_score": "0.022322",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BROS",
        "relevance_score": "0.398148",
        "ticker_sentiment_score": "0.585463",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NTNX",
        "relevance_score": "0.304428",
        "ticker_sentiment_score": "-0.007153",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOS",
        "relevance_score": "0.398148",
        "ticker_sentiment_score": "0.235115",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: UnitedHealth, Danaher, Abbott and Ark Restaurants",
    "url": "https://www.zacks.com/stock/news/2276402/the-zacks-analyst-blog-highlights-stocks-recently-featured-in-the-blog-include-unitedhealth-danaher-abbott-and-ark-restaurants",
    "time_published": "20240521T105900",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "UnitedHealth, Danaher, Abbott and Ark Restaurants are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.217868,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.162073",
        "ticker_sentiment_score": "0.054406",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARKR",
        "relevance_score": "0.266828",
        "ticker_sentiment_score": "0.113503",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.162073",
        "ticker_sentiment_score": "0.054406",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DHR",
        "relevance_score": "0.266828",
        "ticker_sentiment_score": "0.130703",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Citi elevates GE Healthcare to a top pick. Here's why we're not buying more shares just yet",
    "url": "https://www.cnbc.com/2024/05/22/citi-names-ge-healthcare-a-top-pick-jim-cramers-thoughts-on-the-call.html",
    "time_published": "20240522T154045",
    "authors": [
      "Morgan Chittum"
    ],
    "summary": "The Investing Club holds its \"Morning Meeting\" every weekday at 10:20 a.m. ET.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107417472-1716238810469-gettyimages-2153880447-dsc05750_une9fz1g.jpeg?v=1716238843&w=600&h=300&vtcrop=y",
    "source": "CNBC",
    "category_within_source": "Earnings",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.195086,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.254751",
        "ticker_sentiment_score": "0.159742",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.171485",
        "ticker_sentiment_score": "0.118183",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.171485",
        "ticker_sentiment_score": "0.118183",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TJX",
        "relevance_score": "0.254751",
        "ticker_sentiment_score": "0.159742",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer - Cogent Biosciences  ( NASDAQ:COGT ) ",
    "url": "https://www.benzinga.com/pressreleases/24/05/g38995156/cogent-biosciences-appoints-cole-pinnow-as-chief-commercial-officer",
    "time_published": "20240523T210500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 ( GLOBE NEWSWIRE ) -- Cogent Biosciences, Inc. COGT, a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Cole Pinnow as Chief Commercial Officer.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.997405"
      }
    ],
    "overall_sentiment_score": 0.268344,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "COGT",
        "relevance_score": "0.274834",
        "ticker_sentiment_score": "0.157429",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.139534",
        "ticker_sentiment_score": "0.029139",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.046724",
        "ticker_sentiment_score": "0.022939",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer",
    "url": "https://www.globenewswire.com/news-release/2024/05/23/2887700/0/en/Cogent-Biosciences-Appoints-Cole-Pinnow-as-Chief-Commercial-Officer.html",
    "time_published": "20240523T210500",
    "authors": [
      "Inc.",
      "Cogent Biosciences"
    ],
    "summary": "WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 ( GLOBE NEWSWIRE ) -- Cogent Biosciences, Inc. ( Nasdaq: COGT ) , a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Cole Pinnow as Chief Commercial Officer.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/2b8cbfab-a4de-4e17-bdd6-7ef597a95d2e",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.992549"
      }
    ],
    "overall_sentiment_score": 0.181146,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "COGT",
        "relevance_score": "0.137083",
        "ticker_sentiment_score": "0.099114",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.103035",
        "ticker_sentiment_score": "0.025341",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.03443",
        "ticker_sentiment_score": "0.022348",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's Why You Should Retain Edward Lifesciences  ( EW )  for Now",
    "url": "https://www.zacks.com/stock/news/2278839/heres-why-you-should-retain-edward-lifesciences-ew-for-now",
    "time_published": "20240524T145700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Investors are optimistic about Edward Lifesciences (EW), led by the strong performance of its SAPIEN 3 Ultra RESILIA platform and strong solvency.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/41/899.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999483"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.744043"
      }
    ],
    "overall_sentiment_score": 0.241167,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MEDP",
        "relevance_score": "0.199859",
        "ticker_sentiment_score": "0.065974",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EHC",
        "relevance_score": "0.199859",
        "ticker_sentiment_score": "0.112734",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EW",
        "relevance_score": "0.387374",
        "ticker_sentiment_score": "0.358704",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.050465",
        "ticker_sentiment_score": "0.146287",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.050465",
        "ticker_sentiment_score": "0.146287",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RMD",
        "relevance_score": "0.199859",
        "ticker_sentiment_score": "0.077141",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.050465",
        "ticker_sentiment_score": "0.146287",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Home Healthcare Market size is set to grow by USD 312.33 million from 2023-2027, Quality of home healthcare ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/home-healthcare-market-size-is-set-to-grow-by-usd-312-33-million-from-2023-2027--quality-of-home-healthcare-increasing-patient-satisfaction-boost-the-market-technavio-302155780.html",
    "time_published": "20240527T210000",
    "authors": [],
    "summary": "Home Healthcare Market size is set to grow by USD 312.33 million from 2023-2027, Quality of home healthcare ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.297595,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "OMRNF",
        "relevance_score": "0.038345",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.038345",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FSNUF",
        "relevance_score": "0.038345",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.038345",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.038345",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.038345",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RMD",
        "relevance_score": "0.038345",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAX",
        "relevance_score": "0.038345",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVCRQ",
        "relevance_score": "0.038345",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.038345",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.114682",
        "ticker_sentiment_score": "0.232694",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Global Immunoassay Market to Witness Growth at a CAGR of ~8% by 2030 | DelveInsight",
    "url": "https://www.prnewswire.com/news-releases/global-immunoassay-market-to-witness-growth-at-a-cagr-of-8-by-2030--delveinsight-302155907.html",
    "time_published": "20240527T140100",
    "authors": [
      "DelveInsight Business Research",
      "LLP"
    ],
    "summary": "The surge in the immunoassay market is mainly from the rising occurrence of persistent conditions like cancer and lifestyle-related ailments such as diabetes mellitus. Notably, the uptick in different types of cancer, including breast and prostate cancer, plays a pivotal role in driving market ...",
    "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.195097,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BMXMF",
        "relevance_score": "0.023981",
        "ticker_sentiment_score": "0.022058",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "A",
        "relevance_score": "0.023981",
        "ticker_sentiment_score": "0.022058",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSMXF",
        "relevance_score": "0.04794",
        "ticker_sentiment_score": "0.068239",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PHCCF",
        "relevance_score": "0.023981",
        "ticker_sentiment_score": "0.015846",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIO",
        "relevance_score": "0.023981",
        "ticker_sentiment_score": "0.022058",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LAB",
        "relevance_score": "0.023981",
        "ticker_sentiment_score": "0.022058",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DHR",
        "relevance_score": "0.04794",
        "ticker_sentiment_score": "0.073213",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HOLX",
        "relevance_score": "0.023981",
        "ticker_sentiment_score": "0.022058",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.023981",
        "ticker_sentiment_score": "0.076847",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.04794",
        "ticker_sentiment_score": "0.023626",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSRLF",
        "relevance_score": "0.04794",
        "ticker_sentiment_score": "0.019682",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRFS",
        "relevance_score": "0.023981",
        "ticker_sentiment_score": "0.022058",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QGEN",
        "relevance_score": "0.023981",
        "ticker_sentiment_score": "0.022058",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SZIHF",
        "relevance_score": "0.04794",
        "ticker_sentiment_score": "0.017711",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Apple and Nvidia fight Wednesday's stock market decline. Here is what's supporting them",
    "url": "https://www.cnbc.com/2024/05/29/apple-nvidia-fight-wednesday-stock-market-decline-what-is-supporting-them.html",
    "time_published": "20240529T155952",
    "authors": [
      "Morgan Chittum"
    ],
    "summary": "The Investing Club holds its \"Morning Meeting\" every weekday at 10:20 a.m. ET.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/102963707-GettyImages-468159964.jpg?v=1716996029&w=600&h=300&vtcrop=y",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990893"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.099035,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.38588",
        "ticker_sentiment_score": "0.111216",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.294682",
        "ticker_sentiment_score": "0.090894",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.199037",
        "ticker_sentiment_score": "0.066724",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTRA",
        "relevance_score": "0.199037",
        "ticker_sentiment_score": "0.066724",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "We're adding to our geopolitical hedge and a struggling health-care stock",
    "url": "https://www.cnbc.com/2024/05/29/were-adding-to-our-geopolitical-hedge-and-a-struggling-health-care-stock.html",
    "time_published": "20240529T133450",
    "authors": [
      "Jeff Marks"
    ],
    "summary": "We're adding to our lone oil stock and an out-of-favor medical-technology company.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107394152-1711627809352-gettyimages-2118602274-01-bb2_1227-_05c3dsrv.jpeg?v=1716987437&w=1920&h=1080",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.905476"
      }
    ],
    "overall_sentiment_score": 0.363646,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.251247",
        "ticker_sentiment_score": "0.29865",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MRO",
        "relevance_score": "0.085022",
        "ticker_sentiment_score": "0.16501",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "COP",
        "relevance_score": "0.085022",
        "ticker_sentiment_score": "0.16501",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CTRA",
        "relevance_score": "0.330654",
        "ticker_sentiment_score": "0.364603",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Zacks Initiates Coverage of NVE Corp With Neutral Recommendation",
    "url": "https://www.zacks.com/stock/news/2280418/zacks-initiates-coverage-of-nve-corp-with-neutral-recommendation",
    "time_published": "20240529T113400",
    "authors": [
      "Urbashi Dutta"
    ],
    "summary": "Discover why Zacks rates NVE Corp (NVEC) as \"Neutral,\" being the first on Wall Street to initiate coverage on the stock. Explore how NVE Corp's growth prospects in the semiconductor industry remain promising, with strong dividend yield and solid cash position amid labor market challenges.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/49/2653.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.303108,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVEC",
        "relevance_score": "0.628066",
        "ticker_sentiment_score": "0.464785",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.071145",
        "ticker_sentiment_score": "0.086604",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Berkshire Hathaway, Chipotle, More NYSE Stocks Hit With Trading Halts Triggered By Technical Issues - Abbott Laboratories  ( NYSE:ABT ) , Ault Disruptive Tech  ( AMEX:ADRT ) ",
    "url": "https://www.benzinga.com/markets/equities/24/06/39138985/berkshire-hathaway-chipotle-more-nyse-stocks-hit-with-trading-halts-triggered-by-technical-issue",
    "time_published": "20240603T143746",
    "authors": [
      "Piero Cingari"
    ],
    "summary": "Multiple stocks on the New York Stock Exchange experienced sudden trading halts after 9:40 a.m. ET Monday due to technical issues. The unexpected pauses in trading were triggered by a technical issue categorized under the \"Limit Up/Limit Down\" code, which is typically used to curb excessive ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/03/NYSE.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999767"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": -0.182235,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "GOLD",
        "relevance_score": "0.277433",
        "ticker_sentiment_score": "-0.279667",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.277433",
        "ticker_sentiment_score": "-0.279667",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "DXYZ",
        "relevance_score": "0.277433",
        "ticker_sentiment_score": "-0.279667",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.277433",
        "ticker_sentiment_score": "-0.268877",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NMG",
        "relevance_score": "0.277433",
        "ticker_sentiment_score": "-0.279667",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "SMR",
        "relevance_score": "0.277433",
        "ticker_sentiment_score": "-0.279667",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.405651",
        "ticker_sentiment_score": "-0.047001",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bull Market Buys: 2 Growth Stocks to Own for the Long Haul",
    "url": "https://www.fool.com/investing/2024/06/03/bull-market-buys-2-growth-stocks-to-own-for-the/",
    "time_published": "20240603T114500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "Innovation is paying off for both of these medical device specialists.",
    "banner_image": "https://g.foolcdn.com/editorial/images/778453/physicians-in-an-operating-room.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.149762,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MFCSF",
        "relevance_score": "0.05339",
        "ticker_sentiment_score": "0.009998",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.05339",
        "ticker_sentiment_score": "0.082705",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.407844",
        "ticker_sentiment_score": "0.128562",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.360752",
        "ticker_sentiment_score": "0.195038",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares U.S. Medical Devices ETF  ( IHI ) ?",
    "url": "https://www.zacks.com/stock/news/2282436/should-you-invest-in-the-ishares-us-medical-devices-etf-ihi",
    "time_published": "20240603T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for IHI ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default277.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.245387,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.064276",
        "ticker_sentiment_score": "0.031012",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SEM",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "0.02667",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "0.069783",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "0.069783",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "0.069783",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amarin Board of Directors Announces CEO Transition",
    "url": "https://www.globenewswire.com/news-release/2024/06/04/2892939/18362/en/Amarin-Board-of-Directors-Announces-CEO-Transition.html",
    "time_published": "20240604T113000",
    "authors": [
      "Amarin Corporation plc"
    ],
    "summary": "-- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/00eeab93-e634-4279-86b3-7973c2a21623",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.857896"
      }
    ],
    "overall_sentiment_score": 0.115734,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMRN",
        "relevance_score": "0.686097",
        "ticker_sentiment_score": "0.175368",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.042271",
        "ticker_sentiment_score": "0.0139",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Antibiotics Market size is set to grow by USD 16.63 billion from 2024-2028, Rising prevalence of infectious diseases ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/antibiotics-market-size-is-set-to-grow-by-usd-16-63-billion-from-2024-2028--rising-prevalence-of-infectious-diseases-boost-the-market-technavio-302166383.html",
    "time_published": "20240607T211500",
    "authors": [],
    "summary": "Antibiotics Market size is set to grow by USD 16.63 billion from 2024-2028, Rising prevalence of infectious diseases ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.069745,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.01328",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APNHF",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.01328",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.01328",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MAYNF",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.01328",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.01328",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALPMF",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.01328",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.01328",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.01328",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.01328",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.01328",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.01328",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Class Action Against Abbott's Glucerna Products Proceeds in Federal Court - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/general/biotech/24/06/39233852/class-action-against-abbotts-glucerna-products-proceeds-in-federal-court",
    "time_published": "20240607T181749",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "A California federal judge has reportedly allowed litigation to proceed against Abbott Laboratories ABT regarding its Glucerna shakes and nutritional powders. The lawsuit claims these products, marketed as suitable for people with diabetes, contain harmful ingredients. U.S. District Judge P.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/07/abbott-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.004838,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.281153",
        "ticker_sentiment_score": "0.02091",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "DNA Sequencing Market size is set to grow by USD 17.34 billion from 2024-2028, Growing adoption of ngs to boost the ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/dna-sequencing-market-size-is-set-to-grow-by-usd-17-34-billion-from-2024-2028--growing-adoption-of-ngs-to-boost-the-market-growth-technavio-302165939.html",
    "time_published": "20240607T180000",
    "authors": [],
    "summary": "DNA Sequencing Market size is set to grow by USD 17.34 billion from 2024-2028, Growing adoption of ngs to boost the ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.2875,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "A",
        "relevance_score": "0.028833",
        "ticker_sentiment_score": "0.02218",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TXG",
        "relevance_score": "0.028833",
        "ticker_sentiment_score": "0.02218",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ILMN",
        "relevance_score": "0.028833",
        "ticker_sentiment_score": "0.02218",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIO",
        "relevance_score": "0.028833",
        "ticker_sentiment_score": "0.02218",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DHR",
        "relevance_score": "0.028833",
        "ticker_sentiment_score": "0.02218",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.028833",
        "ticker_sentiment_score": "0.02218",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PACB",
        "relevance_score": "0.028833",
        "ticker_sentiment_score": "0.02218",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.028833",
        "ticker_sentiment_score": "0.02218",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.028833",
        "ticker_sentiment_score": "0.02218",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZTA",
        "relevance_score": "0.028833",
        "ticker_sentiment_score": "0.02218",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OUSZF",
        "relevance_score": "0.028833",
        "ticker_sentiment_score": "-0.027248",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QGEN",
        "relevance_score": "0.028833",
        "ticker_sentiment_score": "0.02218",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ERFSF",
        "relevance_score": "0.028833",
        "ticker_sentiment_score": "0.02218",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Abbott Wins FDA Approval For Two Over-The-Counter Diabetes Trackers",
    "url": "https://www.forbes.com/sites/brucejapsen/2024/06/10/abbott-wins-fda-approval-for-two-over-the-counter-diabetes-trackers/",
    "time_published": "20240610T162109",
    "authors": [
      "Bruce Japsen"
    ],
    "summary": "Abbott Laboratories Monday said the U.S. Food and Drug Administration has cleared for sale two new over-the-counter continuous glucose monitoring systems, devices that could bring more access to millions of people with diabetes.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6525ab3937f6fb687889a34b/0x0.jpg?format=jpg&crop=2498,1406,x0,y125,safe&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.193842,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.060848",
        "ticker_sentiment_score": "0.043",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Abbott Laboratories's Options: A Look at What the Big Money is Thinking - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/insights/options/24/06/39254044/abbott-laboratoriess-options-a-look-at-what-the-big-money-is-thinking",
    "time_published": "20240610T154600",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bullish approach towards Abbott Laboratories ABT, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.212351,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.07887",
        "ticker_sentiment_score": "-0.112709",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.627119",
        "ticker_sentiment_score": "0.354346",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.07887",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "FDA approves two new Abbott over-the-counter continuous glucose monitors",
    "url": "https://www.cnbc.com/2024/06/10/abbott-fda-approval-libre-rio-lingo-cgm-diabetes.html",
    "time_published": "20240610T133103",
    "authors": [
      "Ashley Capoot"
    ],
    "summary": "Abbott has FDA clearance for two new over-the-counter continuous glucose monitoring systems ...",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/106998194-1641558949731-gettyimages-1363222030-em018417_20220106104408207.jpeg?v=1718021922&w=1920&h=1080",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.221106,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DXCM",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "0.167062",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "0.137587",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Abbott Snags U.S. Clearance To Enter The Obesity Arena",
    "url": "https://www.investors.com/news/technology/abbott-stock-continuous-glucose-monitor-obesity/",
    "time_published": "20240610T120000",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Abbott Laboratories ( ABT ) gained U.S. clearance Monday for a pair of new continuous glucose monitors. The news could push Abbott stock closer to a breakout. The Food and Drug Administration signed off on Lingo and Libre Rio - vastly expanding Abbott's market in the U.S.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/02/Stock-abbott-06-company.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.172692,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MRNA",
        "relevance_score": "0.076847",
        "ticker_sentiment_score": "0.223415",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.041407",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.136172",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Magnificent Dividend Growth Stocks to Buy Now",
    "url": "https://www.fool.com/investing/2024/06/11/2-magnificent-dividend-growth-stocks-to-buy-now/",
    "time_published": "20240611T134500",
    "authors": [
      "George Budwell"
    ],
    "summary": "These two dividend growth stocks are potent capital appreciation vehicles.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F780175%2Fgetty-dividend-stocks-growing-money-income-cash.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      }
    ],
    "overall_sentiment_score": 0.487967,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TGT",
        "relevance_score": "0.536866",
        "ticker_sentiment_score": "0.637757",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.129516",
        "ticker_sentiment_score": "0.38089",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "InnovationRx: Tarsus Pharmaceuticals Takes Aim At Disease-Causing Bugs",
    "url": "https://www.forbes.com/sites/alexknapp/2024/06/12/innovationrx-tarsus-pharmaceuticals-takes-aim-at-disease-causing-bugs/",
    "time_published": "20240612T223347",
    "authors": [
      "Alex Knapp"
    ],
    "summary": "InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here. round 25 million Americans are affected by the eye disease Demodex blepharitis, which is caused by small mites that make their way into the eyelid.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/666a1df6f0243545f49d23a5/0x0.jpg?format=jpg&crop=2830,1465,x120,y45,safe&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.00971,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "TARS",
        "relevance_score": "0.034984",
        "ticker_sentiment_score": "-0.124735",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.034984",
        "ticker_sentiment_score": "0.092372",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.0699",
        "ticker_sentiment_score": "0.014426",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.034984",
        "ticker_sentiment_score": "0.037431",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Healthcare Stocks to Buy Hand Over Fist in June",
    "url": "https://www.fool.com/investing/2024/06/12/2-healthcare-stocks-to-buy-hand-over-fist-in-june/",
    "time_published": "20240612T114500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "They both have pretty impressive pasts, and their prospects look just as bright.",
    "banner_image": "https://media.ycharts.com/charts/19bc1a080c6f69546fc44ee4ad147602.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.341233,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.217346",
        "ticker_sentiment_score": "0.360761",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.217346",
        "ticker_sentiment_score": "0.338294",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Dividend Stocks That Could Pay You for Life",
    "url": "https://www.fool.com/investing/2024/06/16/2-dividend-stocks-that-could-pay-you-for-life/",
    "time_published": "20240616T123000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "There are other reasons to love these businesses, too.",
    "banner_image": "https://media.ycharts.com/charts/3bd652ae2c5fb62c2ed8b70314e36548.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.270085,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "V",
        "relevance_score": "0.411176",
        "ticker_sentiment_score": "0.365463",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.500753",
        "ticker_sentiment_score": "0.307669",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.107495",
        "ticker_sentiment_score": "0.135056",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Diamond Hill Mutual Funds for Consistent Returns",
    "url": "https://www.zacks.com/stock/news/2289577/3-diamond-hill-mutual-funds-for-consistent-returns",
    "time_published": "20240618T105700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Invests in Diamond Hill mutual funds such as DHLTX, DHLSX and DHLAX for disciplined investment strategies.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d9/554.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999897"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.360987,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "0.050095",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "0.050095",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "0.050095",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RRR",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "0.045083",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COP",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "0.050095",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WCC",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "0.045083",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AIG",
        "relevance_score": "0.13459",
        "ticker_sentiment_score": "0.059538",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.",
    "url": "https://www.fool.com/investing/2024/06/20/want-decades-of-passive-income-2-stocks-to-buy-now/",
    "time_published": "20240620T091500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "These healthcare players offer you dividends and a strong earnings picture.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F780947%2Fgettyimages-1188369583.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.917436"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99793"
      }
    ],
    "overall_sentiment_score": 0.380048,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.109206",
        "ticker_sentiment_score": "0.073797",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.109206",
        "ticker_sentiment_score": "0.164285",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Dry Eye Syndrome Drugs Market size is set to grow by USD 2.13 billion from 2024-2028, Growing geriatric population ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/dry-eye-syndrome-drugs-market-size-is-set-to-grow-by-usd-2-13-billion-from-2024-2028--growing-geriatric-population-boost-the-market-technavio-302178705.html",
    "time_published": "20240621T215500",
    "authors": [],
    "summary": "Dry Eye Syndrome Drugs Market size is set to grow by USD 2.13 billion from 2024-2028, Growing geriatric population ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.145318,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.03458",
        "ticker_sentiment_score": "0.021037",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNPHF",
        "relevance_score": "0.03458",
        "ticker_sentiment_score": "0.021037",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.03458",
        "ticker_sentiment_score": "0.021037",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VTRS",
        "relevance_score": "0.03458",
        "ticker_sentiment_score": "0.021037",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.03458",
        "ticker_sentiment_score": "0.021037",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.03458",
        "ticker_sentiment_score": "0.021037",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHC",
        "relevance_score": "0.03458",
        "ticker_sentiment_score": "0.021037",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Hospital Infection Therapeutics Market size is set to grow by USD 3.46 billion from 2024-2028, Increase in incidence ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/hospital-infection-therapeutics-market-size-is-set-to-grow-by-usd-3-46-billion-from-2024-2028--increase-in-incidence-and-prevalence-of-respiratory-disorders-boost-the-market-technavio-302177964.html",
    "time_published": "20240621T210500",
    "authors": [],
    "summary": "Hospital Infection Therapeutics Market size is set to grow by USD 3.46 billion from 2024-2028, Increase in incidence ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.097863,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BAYZF",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VTRS",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ACHL",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPRO",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Abbott Laboratories, BP, Gilead Sciences, Smith-Midland and Crimson Wine",
    "url": "https://www.zacks.com/stock/news/2292126/the-zacks-analyst-blog-highlights-abbott-laboratories-bp-gilead-sciences-smith-midland-and-crimson-wine",
    "time_published": "20240624T133600",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Abbott Laboratories, BP, Gilead Sciences, Smith-Midland and Crimson Wine are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ee/431.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.30321,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PRBZF",
        "relevance_score": "0.040348",
        "ticker_sentiment_score": "0.11887",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.120632",
        "ticker_sentiment_score": "0.046343",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.120632",
        "ticker_sentiment_score": "0.046343",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMID",
        "relevance_score": "0.120632",
        "ticker_sentiment_score": "0.046343",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.120632",
        "ticker_sentiment_score": "0.062462",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "If You Invested $1000 in AbbVie a Decade Ago, This is How Much It'd Be Worth Now",
    "url": "https://www.zacks.com/stock/news/2291993/if-you-invested-1000-in-abbvie-a-decade-ago-this-is-how-much-itd-be-worth-now",
    "time_published": "20240624T123002",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default164.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.858979"
      }
    ],
    "overall_sentiment_score": 0.180042,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.720339",
        "ticker_sentiment_score": "0.308289",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.05387",
        "ticker_sentiment_score": "-0.025004",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cardiac Marker Testing Market Surges to USD 8.69 Billion by 2031, Propelled by 8.8% CAGR - Verified Market Research\u00ae",
    "url": "https://www.benzinga.com/pressreleases/24/06/g39481612/cardiac-marker-testing-market-surges-to-usd-8-69-billion-by-2031-propelled-by-8-8-cagr-verified-ma",
    "time_published": "20240625T141500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Lewes, Delaware, June 25, 2024 ( GLOBE NEWSWIRE ) -- The Global Cardiac Marker Testing Market is projected to grow at a CAGR of 8.8% from 2024 to 2031, according to a new report published by Verified Market Research\u00ae.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.220659,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BMXMF",
        "relevance_score": "0.027042",
        "ticker_sentiment_score": "0.023253",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRIB",
        "relevance_score": "0.027042",
        "ticker_sentiment_score": "0.023253",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.027042",
        "ticker_sentiment_score": "0.023253",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EKDHF",
        "relevance_score": "0.027042",
        "ticker_sentiment_score": "0.023253",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RSSS",
        "relevance_score": "0.027042",
        "ticker_sentiment_score": "0.167652",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.027042",
        "ticker_sentiment_score": "0.023253",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSRLF",
        "relevance_score": "0.027042",
        "ticker_sentiment_score": "0.023253",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SEMHF",
        "relevance_score": "0.027042",
        "ticker_sentiment_score": "0.023253",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SZIHF",
        "relevance_score": "0.027042",
        "ticker_sentiment_score": "0.023253",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PHG",
        "relevance_score": "0.027042",
        "ticker_sentiment_score": "0.023253",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DHR",
        "relevance_score": "0.027042",
        "ticker_sentiment_score": "0.023253",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Market Whales and Their Recent Bets on ABT Options - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/insights/options/24/06/39534916/market-whales-and-their-recent-bets-on-abt-options",
    "time_published": "20240627T193306",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bullish move on Abbott Laboratories. Our analysis of options history for Abbott Laboratories ABT revealed 8 unusual trades. Delving into the details, we found 50% of traders were bullish, while 37% showed bearish tendencies.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.145936,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.093289",
        "ticker_sentiment_score": "-0.116002",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.651499",
        "ticker_sentiment_score": "0.217529",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Laboratory Information Management System (LIMS) Market size is set to grow by USD 1.62 billion from 2024-2028 ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/laboratory-information-management-system-lims-market-size-is-set-to-grow-by-usd-1-62-billion-from-2024-2028--increase-in-recent-developments-in-lims-to-boost-the-market-growth-technavio-302185306.html",
    "time_published": "20240628T211100",
    "authors": [],
    "summary": "Laboratory Information Management System ( LIMS ) Market size is set to grow by USD 1.62 billion from 2024-2028 ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.353411,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DTST",
        "relevance_score": "0.03473",
        "ticker_sentiment_score": "0.172407",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.03473",
        "ticker_sentiment_score": "0.096832",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTTHF",
        "relevance_score": "0.03473",
        "ticker_sentiment_score": "0.147604",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ILMN",
        "relevance_score": "0.03473",
        "ticker_sentiment_score": "0.096832",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SHMZF",
        "relevance_score": "0.03473",
        "ticker_sentiment_score": "0.096832",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.069394",
        "ticker_sentiment_score": "0.133849",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 High-Yielding Healthcare Stocks to Buy With $1,000 in July",
    "url": "https://www.fool.com/investing/2024/07/01/3-high-yielding-healthcare-stocks-to-buy-with-1000/",
    "time_published": "20240701T144800",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "These reliable dividend payers are no-brainer buys right now.",
    "banner_image": "https://g.foolcdn.com/editorial/images/782176/individual-investors-at-home-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999365"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.225924,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.388018",
        "ticker_sentiment_score": "0.244885",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "0.399523",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.057767",
        "ticker_sentiment_score": "0.10097",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "DexCom, Abbott to Launch First FDA Cleared OTC CGMs - Abbott Laboratories  ( NYSE:ABT ) , DaVita  ( NYSE:DVA ) ",
    "url": "https://www.benzinga.com/news/earnings/24/07/39649922/dexcom-abbott-to-launch-first-fda-cleared-otc-cgms",
    "time_published": "20240705T185811",
    "authors": [
      "Zacks"
    ],
    "summary": "DexCom Inc. DXCM and Abbott Laboratories ABT are likely to launch their first over-the-counter ( OTC ) continuous glucose monitors ( CGMs ) in the coming months of 2024.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/05/louis-reed-pwckf7l4-no-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.96136"
      }
    ],
    "overall_sentiment_score": 0.269527,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.065685",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DVA",
        "relevance_score": "0.098389",
        "ticker_sentiment_score": "0.084566",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.349665",
        "ticker_sentiment_score": "0.254546",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ECL",
        "relevance_score": "0.098389",
        "ticker_sentiment_score": "0.085628",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Hims & Hers  ( HIMS )  Gains 37.7% in Three Months: What's Next?",
    "url": "https://www.zacks.com/stock/news/2297363/hims-hers-hims-gains-377-in-three-months-whats-next",
    "time_published": "20240705T160400",
    "authors": [
      "Debanjana Dey"
    ],
    "summary": "Hims & Hers (HIMS) is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.393462,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HIMS",
        "relevance_score": "0.325924",
        "ticker_sentiment_score": "0.311663",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.111488",
        "ticker_sentiment_score": "0.099374",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TDOC",
        "relevance_score": "0.111488",
        "ticker_sentiment_score": "0.099374",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "DexCom  ( DXCM ) , Abbott to Launch First FDA Cleared OTC CGMs",
    "url": "https://www.zacks.com/stock/news/2297344/dexcom-dxcm-abbott-to-launch-first-fda-cleared-otc-cgms",
    "time_published": "20240705T155400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Dexcom (DXCM) and Abbott are set to launch their first FDA-approved over-the-counter CGMs, Stelo and Lingo & Libre Rio, respectively, in the United States this summer.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b8/1573.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.928139"
      }
    ],
    "overall_sentiment_score": 0.260446,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.066047",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DVA",
        "relevance_score": "0.09893",
        "ticker_sentiment_score": "0.096392",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.351467",
        "ticker_sentiment_score": "0.250791",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ECL",
        "relevance_score": "0.09893",
        "ticker_sentiment_score": "0.076187",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Similac Baby Formula Maker Abbott And Reckitt Face Hundreds Of Baby Formula Lawsuits - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/news/large-cap/24/07/39673676/similac-baby-formula-maker-abbott-and-reckitt-face-hundreds-of-baby-formula-lawsuits",
    "time_published": "20240708T183901",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Abbott Laboratories ABT is set to face trial on Monday over allegations that its formula for preterm infants used in neonatal intensive care units causes a potentially deadly bowel disease known as necrotizing enterocolitis ( NEC ) . This is the second trial out of hundreds of similar ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/08/Similac.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.226478,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.295867",
        "ticker_sentiment_score": "-0.024613",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RBGPF",
        "relevance_score": "0.199859",
        "ticker_sentiment_score": "-0.074046",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Looking Into Abbott Laboratories's Recent Short Interest - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/07/39716022/looking-into-abbott-laboratoriess-recent-short-interest",
    "time_published": "20240710T181513",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Abbott Laboratories's ABT short percent of float has fallen 20.24% since its last report. The company recently reported that it has 11.62 million shares sold short, which is 0.67% of all regular shares that are available for trading.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.262256,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.079385",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Molecular Diagnostics Market to Reach USD 37.00 Billion by 2031 | SkyQuest",
    "url": "https://www.benzinga.com/pressreleases/24/07/g39708532/molecular-diagnostics-market-to-reach-usd-37-00-billion-by-2031-skyquest",
    "time_published": "20240710T130000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Westford, USA, July 10, 2024 ( GLOBE NEWSWIRE ) -- SkyQuest projects that the Global Molecular Diagnostics Market will attain a value of USD 37.00 Billion by 2031, with a CAGR of 11.4% during the forecast period ( 2024-2031 ) .",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.251137,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BMXMF",
        "relevance_score": "0.03878",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "A",
        "relevance_score": "0.03878",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HOLX",
        "relevance_score": "0.03878",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.03878",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ILMN",
        "relevance_score": "0.03878",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.03878",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.03878",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRFS",
        "relevance_score": "0.03878",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QGEN",
        "relevance_score": "0.03878",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's How Abbott  ( ABT )  is Placed Ahead of Q2 Earnings Release",
    "url": "https://www.zacks.com/stock/news/2300076/heres-how-abbott-abt-is-placed-ahead-of-q2-earnings-release",
    "time_published": "20240711T142800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Abbott Laboratories' (ABT) second-quarter 2024 results are likely to reflect broad-based strength across several businesses and solid progress in the pipeline.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/91/54133.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.273834,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ENOV",
        "relevance_score": "0.065061",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.12969",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.097457",
        "ticker_sentiment_score": "-0.001059",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCA",
        "relevance_score": "0.097457",
        "ticker_sentiment_score": "0.033653",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Baby Food and Infant Formula Market size is set to grow by USD 39.99 billion from 2024-2028, New product launches boost the market, Technavio - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/baby-food-and-infant-formula-market-size-is-set-to-grow-by-usd-39-99-billion-from-2024-2028--new-product-launches-boost-the-market-technavio-302195127.html",
    "time_published": "20240712T212500",
    "authors": [],
    "summary": "Baby Food and Infant Formula Market size is set to grow by USD 39.99 billion from 2024-2028, New product launches boost the market, Technavio PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.188625,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.033144",
        "ticker_sentiment_score": "0.075806",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CPB",
        "relevance_score": "0.033144",
        "ticker_sentiment_score": "0.075806",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AUDYF",
        "relevance_score": "0.033144",
        "ticker_sentiment_score": "0.075806",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KHC",
        "relevance_score": "0.033144",
        "ticker_sentiment_score": "0.075806",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PZCUY",
        "relevance_score": "0.033144",
        "ticker_sentiment_score": "0.075806",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NSRGF",
        "relevance_score": "0.033144",
        "ticker_sentiment_score": "0.075806",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RBGPF",
        "relevance_score": "0.033144",
        "ticker_sentiment_score": "0.075806",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Vegan Food Market to Excel USD 40.53 Billion by 2031 | SkyQuest",
    "url": "https://www.benzinga.com/pressreleases/24/07/g39748127/vegan-food-market-to-excel-usd-40-53-billion-by-2031-skyquest",
    "time_published": "20240712T123355",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Westford, USA, July 12, 2024 ( GLOBE NEWSWIRE ) -- Global Vegan Food Market size was valued at around USD 16.5 Billion in 2022 and is poised to grow from USD Billion 18.23 in 2023 to USD 40.53 Billion by 2031, at a CAGR of 10.5% over the forecast period ( 2024-2031 ) .",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.313946,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CAG",
        "relevance_score": "0.050254",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GIS",
        "relevance_score": "0.050254",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BC",
        "relevance_score": "0.050254",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PEP",
        "relevance_score": "0.050254",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.050254",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.050254",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Healthcare Stocks to Buy at a Discount",
    "url": "https://www.fool.com/investing/2024/07/14/2-healthcare-stocks-to-buy-at-a-discount/",
    "time_published": "20240714T140000",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "Beaten-down stocks can sometimes present an opportunity.",
    "banner_image": "https://g.foolcdn.com/editorial/images/783034/investing-woman-wall-street-suit-stocks-finance.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.98396"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.658903"
      }
    ],
    "overall_sentiment_score": 0.260259,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.038969",
        "ticker_sentiment_score": "0.119066",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.038969",
        "ticker_sentiment_score": "0.178542",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TDOC",
        "relevance_score": "0.077845",
        "ticker_sentiment_score": "0.101704",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.038969",
        "ticker_sentiment_score": "0.119066",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.267664",
        "ticker_sentiment_score": "0.23861",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "These kinds of businesses are driving a surge in US corporate bankruptcies | Business",
    "url": "https://www.cnn.com/2024/07/14/business/stocks-week-ahead-businesses-failing-bankruptcies/index.html",
    "time_published": "20240714T113000",
    "authors": [
      "Bryan Mena"
    ],
    "summary": "These kinds of businesses are driving a surge in US corporate bankruptcies ...",
    "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/gettyimages-1360507858-copy.jpg?c=16x9&q=w_800,c_fill",
    "source": "CNN",
    "category_within_source": "Economy",
    "source_domain": "www.cnn.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.972193"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.049798,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "-0.051234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "-0.051234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LVS",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "-0.051234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FITB",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STT",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.066358",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BX",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.066358",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EFX",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "-0.051234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBD",
        "relevance_score": "0.126784",
        "ticker_sentiment_score": "0.051963",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.063594",
        "ticker_sentiment_score": "-0.115298",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INFY",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.066358",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.066358",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTRS",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "-0.051234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMI",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "-0.051234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOK",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.066358",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAL",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.066358",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AN",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SCHW",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MAN",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.066358",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTAS",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.066358",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "These kinds of businesses are driving a surge in US corporate bankruptcies | Business",
    "url": "https://amp.cnn.com/cnn/2024/07/14/business/stocks-week-ahead-businesses-failing-bankruptcies",
    "time_published": "20240714T113000",
    "authors": [
      "Bryan Mena"
    ],
    "summary": "These kinds of businesses are driving a surge in US corporate bankruptcies ...",
    "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/gettyimages-1360507858-copy.jpg?c=16x9&q=w_800,c_fill",
    "source": "CNN",
    "category_within_source": "Markets",
    "source_domain": "amp.cnn.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.972193"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.049798,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "-0.051234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "-0.051234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LVS",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "-0.051234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FITB",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STT",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.066358",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BX",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.066358",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EFX",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "-0.051234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBD",
        "relevance_score": "0.126784",
        "ticker_sentiment_score": "0.051963",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.063594",
        "ticker_sentiment_score": "-0.115298",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INFY",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.066358",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.066358",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTRS",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "-0.051234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMI",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "-0.051234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOK",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.066358",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAL",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.066358",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AN",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SCHW",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MAN",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.066358",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTAS",
        "relevance_score": "0.031822",
        "ticker_sentiment_score": "0.066358",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 High-Yield Dividend Stocks That Still Look Like Bargains",
    "url": "https://www.fool.com/investing/2024/07/14/3-high-yield-dividend-stocks-that-still-look-like/",
    "time_published": "20240714T082700",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "The prices of these reliable dividend payers haven't kept pace with the frothy stock market.",
    "banner_image": "https://g.foolcdn.com/editorial/images/783254/a-person-sitting-at-their-home-office-desk-using-a-laptop-computer-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.989041"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.208126,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ADC",
        "relevance_score": "0.27838",
        "ticker_sentiment_score": "0.266088",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CURN",
        "relevance_score": "0.056808",
        "ticker_sentiment_score": "-0.012004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.382088",
        "ticker_sentiment_score": "0.3892",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.056808",
        "ticker_sentiment_score": "0.098933",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.169279",
        "ticker_sentiment_score": "0.298133",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Netflix, Goldman Sachs, J&J, ASML Lead Q2 Reports This Week As Analysts See Earnings Growth Accelerating To Fastest In Over 2 Years - SPDR S&P 500  ( ARCA:SPY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/07/39766859/netflix-goldman-sachs-j-j-asml-lead-q2-reports-this-week-as-analysts-see-earnings-growth-accelerati",
    "time_published": "20240715T091317",
    "authors": [
      "Shanthi Rexaline"
    ],
    "summary": "The second-quarter reporting season got off to a rocky start with investors reacting to some big bank earnings. Nevertheless, optimism over a healthy earnings season continues to abound. The Week That Was: Shares of high-profile big banks including JPMorgan Chase & Co. JPM, Citigroup Inc.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/15/earnings.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999813"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.22049,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AA",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALK",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.249464",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "-0.210285",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMI",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SLB",
        "relevance_score": "0.061631",
        "ticker_sentiment_score": "-0.192121",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "DAL",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.089961",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ASML",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DPZ",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SLG",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DFS",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DMPZF",
        "relevance_score": "0.061631",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HAL",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "-0.220592",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.18343",
        "ticker_sentiment_score": "-0.265821",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "-0.220592",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "TRV",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "-0.220592",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STLD",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cardiac Troponin Market Size to be Worth USD 11.5 billion by 2034, Growing at CAGR of 8.9% | Exclusive Report by Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/07/g39791778/cardiac-troponin-market-size-to-be-worth-usd-11-5-billion-by-2034-growing-at-cagr-of-8-9-exclusive",
    "time_published": "20240716T124000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Transparency Market Research Inc. - , July 16, 2024 ( GLOBE NEWSWIRE ) -- The global cardiac troponin market ( Markt f\u00fcr kardiales Troponin ) stood at US$ 4.5 billion in 2023, and the global market is projected to reach US$ 11.5 billion in 2034.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.26065,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.035555",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.106384",
        "ticker_sentiment_score": "0.067411",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.035555",
        "ticker_sentiment_score": "0.299995",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Pre Q3 Earnings: Is Hologic  ( HOLX )  Stock a Portfolio Must-Have?",
    "url": "https://www.zacks.com/stock/news/2303276/pre-q3-earnings-is-hologic-holx-stock-a-portfolio-must-have",
    "time_published": "20240717T131000",
    "authors": [
      "Moumi Mondal"
    ],
    "summary": "Hologic (HOLX) benefits from its unique set of businesses, each underpinned by its durable growth drivers. The impressive YTD price rally, earnings prowess and attractive valuation make the stock a top investment pick.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/12/13457.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.980509"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.429434,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HOLX",
        "relevance_score": "0.350564",
        "ticker_sentiment_score": "0.552948",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "QGEN",
        "relevance_score": "0.120431",
        "ticker_sentiment_score": "0.283946",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.120431",
        "ticker_sentiment_score": "0.283946",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.04028",
        "ticker_sentiment_score": "0.016971",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Are Abbott Laboratories Shares Trading Lower? - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/news/24/07/39846741/why-are-abbott-laboratories-shares-trading-lower",
    "time_published": "20240718T185118",
    "authors": [
      "Vaishali Prayag"
    ],
    "summary": "Shares of Abbott Laboratories ABT are trading lower on Thursday following the company's second-quarter 2024 financial results. What's Going On: Abbott reported second-quarter sales of $10.377 billion, slightly beating the $10.371 billion estimate. EPS came in at $1.14, surpassing analyst ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/18/Photo-by-solarseven-on-Shutterstock.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.272131,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.558244",
        "ticker_sentiment_score": "0.384685",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Nasdaq Down Over 100 Points; Abbott Laboratories Earnings Beat Views - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/news/earnings/24/07/39846457/nasdaq-down-over-100-points-abbott-laboratories-earnings-beat-views",
    "time_published": "20240718T183140",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Thursday. The Dow traded down 1.08% to 40,752.05 while the NASDAQ fell 0.80% to 17,853.34. The S&P 500 also fell, dropping, 0.75% to 5,546.48. Energy shares jumped by 1.1% on Thursday.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/18/Crude-oil-4-logo.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.928769"
      }
    ],
    "overall_sentiment_score": 0.079768,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AGEN",
        "relevance_score": "0.121959",
        "ticker_sentiment_score": "0.112059",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LESL",
        "relevance_score": "0.121959",
        "ticker_sentiment_score": "0.019092",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.061159",
        "ticker_sentiment_score": "-0.143033",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.121959",
        "ticker_sentiment_score": "0.327852",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "COMM",
        "relevance_score": "0.182047",
        "ticker_sentiment_score": "0.165862",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CHUY",
        "relevance_score": "0.121959",
        "ticker_sentiment_score": "0.272802",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.061159",
        "ticker_sentiment_score": "-0.068001",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APH",
        "relevance_score": "0.061159",
        "ticker_sentiment_score": "0.115015",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CURV",
        "relevance_score": "0.121959",
        "ticker_sentiment_score": "-0.077378",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DRI",
        "relevance_score": "0.061159",
        "ticker_sentiment_score": "0.23819",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EA",
        "relevance_score": "0.061159",
        "ticker_sentiment_score": "-0.143033",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday? - Alcoa  ( NYSE:AA ) ",
    "url": "https://www.benzinga.com/markets/cryptocurrency/24/07/39845998/vix-stages-double-digit-spike-as-risk-off-takes-over-chipmakers-fail-to-rebound-weight-los",
    "time_published": "20240718T180528",
    "authors": [
      "Piero Cingari"
    ],
    "summary": "It's another risk-off day on Wall Street, with all major U.S. indices trading in the red. The CBOE Volatility Index ( VIX ) , often referred to as the market's fear gauge, spiked over 10%, reaching levels last seen in late April.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/18/Bull-and-bear-stock-market-index.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": -0.061521,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AA",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALK",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "-0.079457",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMI",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.175433",
        "ticker_sentiment_score": "-0.06853",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.058903",
        "ticker_sentiment_score": "0.018315",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.059696",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DPZ",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SLG",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSM",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "-0.241445",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "DMPZF",
        "relevance_score": "0.058903",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BX",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.175433",
        "ticker_sentiment_score": "-0.06853",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTAS",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VIRT",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.040451",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "-0.446115",
        "ticker_sentiment_label": "Bearish"
      }
    ]
  },
  {
    "title": "Abbott  ( ABT )  Q2 Earnings Surpass Estimates, Margins Expand",
    "url": "https://www.zacks.com/stock/news/2304588/abbott-abt-q2-earnings-surpass-estimates-margins-expand",
    "time_published": "20240718T143200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Abbott (ABT) delivers a strong underlying base business performance in the second quarter of 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/85/66981.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.269866,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PODD",
        "relevance_score": "0.149192",
        "ticker_sentiment_score": "0.035238",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.149192",
        "ticker_sentiment_score": "0.102358",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GMED",
        "relevance_score": "0.185876",
        "ticker_sentiment_score": "0.071584",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HAE",
        "relevance_score": "0.149192",
        "ticker_sentiment_score": "0.06811",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Healthcare Stocks For Your Mid-July 2024 Watchlist",
    "url": "https://stockmarket.com/featured/2-healthcare-stocks-for-your-mid-july-2024-watchlist-2024-07-18",
    "time_published": "20240718T133821",
    "authors": [
      "Josh Dylan"
    ],
    "summary": "The stock market is a place where investors buy and sell shares of publicly traded companies. It offers opportunities for individuals and institutions to invest in various sectors of the economy. The market's performance is influenced by economic conditions, company earnings, and global events.",
    "banner_image": "https://u3j7m9h7.rocketcdn.me/wp-content/uploads/2020/08/ABT-stock.jpg",
    "source": "StockMarket.com",
    "category_within_source": "n/a",
    "source_domain": "stockmarket.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.998645"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999975"
      }
    ],
    "overall_sentiment_score": 0.226047,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HCSG",
        "relevance_score": "0.073773",
        "ticker_sentiment_score": "0.082986",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.288893",
        "ticker_sentiment_score": "0.311273",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.356609",
        "ticker_sentiment_score": "0.25405",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Digital PCR Market: $10.0B to $14.8B Growth Forecast  ( 2024-2029 )  | MarketsandMarkets\u2122",
    "url": "https://www.benzinga.com/pressreleases/24/07/g39836891/digital-pcr-market-10-0b-to-14-8b-growth-forecast-2024-2029-marketsandmarkets",
    "time_published": "20240718T123000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Chicago, July 18, 2024 ( GLOBE NEWSWIRE ) -- The \"Digital PCR Market Size, Share & Trends by Offering ( Product ( Reagents & Consumables, Instrument ) , Software, Services ) , Application ( Clinical ( infectious, Oncology ) , Research, Forensic, Environmental ) - Global Forecast to 2029\" report ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.245629,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BMXMF",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.046874",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ENZ",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.046874",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "A",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.046874",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.046874",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.046874",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.064362",
        "ticker_sentiment_score": "0.089099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIO",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.046874",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QGEN",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.046874",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LAB",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.046874",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DHR",
        "relevance_score": "0.064362",
        "ticker_sentiment_score": "0.115153",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QDEL",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.046874",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nasdaq, S&P 500 Futures Rebound Thursday: What's Going On - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/07/39835373/wall-street-gearing-up-for-tech-led-rebound-ahead-of-netflix-earnings-economist-expects-soft-landin",
    "time_published": "20240718T113456",
    "authors": [
      "Shanthi Rexaline"
    ],
    "summary": "Beaten-down stocks could make a comeback on Thursday, with Taiwan Semiconductor Manufacturing Company Ltd.'s TSM strong quarterly report lifting sentiment toward tech stocks. The major U.S. index futures were mixed ahead of the trading session.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/18/wall-street-artificial-ai.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99676"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.0,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AA",
        "relevance_score": "0.096866",
        "ticker_sentiment_score": "-0.014137",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALK",
        "relevance_score": "0.096866",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.096866",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMI",
        "relevance_score": "0.096866",
        "ticker_sentiment_score": "-0.014137",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.048523",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.096866",
        "ticker_sentiment_score": "0.053672",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.096866",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOK",
        "relevance_score": "0.096866",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.048523",
        "ticker_sentiment_score": "0.153904",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DPZ",
        "relevance_score": "0.096866",
        "ticker_sentiment_score": "-0.39969",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "SLG",
        "relevance_score": "0.096866",
        "ticker_sentiment_score": "-0.014137",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSM",
        "relevance_score": "0.096866",
        "ticker_sentiment_score": "0.097983",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DMPZF",
        "relevance_score": "0.048523",
        "ticker_sentiment_score": "-0.375517",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.096866",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.096866",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.096866",
        "ticker_sentiment_score": "-0.073158",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Dividend Stocks to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/07/18/2-dividend-stocks-to-buy-and-hold-forever/",
    "time_published": "20240718T100100",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "These stocks don't appeal only to dividend seekers.",
    "banner_image": "https://media.ycharts.com/charts/3b4d5c477812803f75516e8f312c00b2.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.433261,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.543004",
        "ticker_sentiment_score": "0.529633",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.464633",
        "ticker_sentiment_score": "0.545317",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Nasdaq Sees Worst Session Since 2022 As Chip Stocks Tumble After Trump's Taiwan Remarks and Biden's Potential Restrictions - Netflix  ( NASDAQ:NFLX ) ",
    "url": "https://www.benzinga.com/news/earnings/24/07/39831773/nasdaq-sees-worst-session-since-2022-as-chip-stocks-tumble-after-trumps-taiwan-remarks-and-bidens-p",
    "time_published": "20240718T072749",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "The CNN Money Fear and Greed index showed a decline in the overall market sentiment, with the index moving to the \"Neutral\" zone on Wednesday. U.S. stocks closed mixed on Wednesday, with the Nasdaq Composite recording its worst session since Dec. 2022.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/18/Semiconductor-Shutterstock.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": -0.08678,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.197413",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBD",
        "relevance_score": "0.099476",
        "ticker_sentiment_score": "-0.307907",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "SYF",
        "relevance_score": "0.197413",
        "ticker_sentiment_score": "0.247269",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FIVE",
        "relevance_score": "0.197413",
        "ticker_sentiment_score": "0.247269",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.197413",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSM",
        "relevance_score": "0.197413",
        "ticker_sentiment_score": "-0.157012",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "D.R. Horton, Netflix And 3 Stocks To Watch Heading Into Thursday - D.R. Horton  ( NYSE:DHI ) ",
    "url": "https://www.benzinga.com/news/earnings/24/07/39831466/d-r-horton-netflix-and-3-stocks-to-watch-heading-into-thursday",
    "time_published": "20240718T070512",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "With U.S. stock futures trading higher this morning on Thursday, some of the stocks that may grab investor focus today are as follows: Wall Street expects D.R. Horton, Inc. DHI to report quarterly earnings at $3.77 per share on revenue of $9.77 billion before the opening bell, according to data ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/18/DR-Horton.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.997335"
      }
    ],
    "overall_sentiment_score": 0.339832,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.43852",
        "ticker_sentiment_score": "0.372902",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.301315",
        "ticker_sentiment_score": "0.247786",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.301315",
        "ticker_sentiment_score": "0.250759",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSM",
        "relevance_score": "0.43852",
        "ticker_sentiment_score": "0.670141",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Abbott Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/news/earnings/24/07/39831467/abbott-gears-up-for-q2-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-a",
    "time_published": "20240718T070512",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Abbott Laboratories ABT is scheduled to release its financial results for the second quarter, before the opening bell on Thursday, July 18. Analysts expect the North Chicago, Illinois-based company to report quarterly earnings at $1.10 per share, up from $1.08 per share in the year-ago period.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/18/untitled.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.119396,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.24289",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "-0.15245",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "-0.082227",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "-0.073049",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Gastroparesis Treatment Market Size Estimated to Rise at a CAGR of 4.6%, Projected to Reach US$ 10.3 Billion by 2034: Transparency Market Research Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/07/g39862578/gastroparesis-treatment-market-size-estimated-to-rise-at-a-cagr-of-4-6-projected-to-reach-us-10-3-",
    "time_published": "20240719T153426",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Transparency Market Research, Inc. , July 19, 2024 ( GLOBE NEWSWIRE ) -- The global gastroparesis treatment market ( \uc704\ub9c8\ube44 \uce58\ub8cc \uc2dc\uc7a5 ) stood at US$ 6.3 billion in 2023, and the global market is projected to reach US$ 10.3 billion in 2034.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.165074,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.035138",
        "ticker_sentiment_score": "0.051084",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.035138",
        "ticker_sentiment_score": "0.139175",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.035138",
        "ticker_sentiment_score": "0.083455",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.035138",
        "ticker_sentiment_score": "-0.234127",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ETER",
        "relevance_score": "0.035138",
        "ticker_sentiment_score": "0.139175",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.105141",
        "ticker_sentiment_score": "0.06817",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.035138",
        "ticker_sentiment_score": "-0.234127",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Abbott Labs Makes Marketing Push For New Glucose Monitors, Targets Health-Conscious Consumers - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/39861919/abbott-labs-makes-marketing-push-for-new-glucose-monitors-targets-health-conscious-consumers",
    "time_published": "20240719T151041",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Abbott Laboratories ABT CEO Robert Ford said the company will use a mix of TV advertisements and guerilla marketing to promote the U.S. launch of Lingo, its glucose monitoring device. This device targets consumers without diabetes, aiming to personalize health data and enhance understanding of ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/19/abbott-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.308181,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MDT",
        "relevance_score": "0.194242",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.194242",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.287762",
        "ticker_sentiment_score": "0.117819",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Dow Plunges Over 500 Points Following Unexpected Surge In US Jobless Claims - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/news/earnings/24/07/39853970/dow-plunges-over-500-points-following-unexpected-surge-in-us-jobless-claims",
    "time_published": "20240719T064810",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "The CNN Money Fear and Greed index showed a decline in the overall market sentiment, while the index moved to the \"Neutral\" zone on Thursday. U.S. stocks closed lower on Thursday, with the Dow Jones index falling more than 500 points during the session.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/19/Stocks-Photo-by-Phongphan-on-Shutterstoc.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": -0.201381,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "SLB",
        "relevance_score": "0.120431",
        "ticker_sentiment_score": "-0.135115",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBD",
        "relevance_score": "0.120431",
        "ticker_sentiment_score": "-0.328443",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.238133",
        "ticker_sentiment_score": "-0.210339",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "SSTK",
        "relevance_score": "0.120431",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HAL",
        "relevance_score": "0.238133",
        "ticker_sentiment_score": "-0.210339",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.238133",
        "ticker_sentiment_score": "0.331738",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "10 Best Dividend Growth Stocks to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/07/21/10-best-dividend-growth-stocks-to-buy-and-hold-for/",
    "time_published": "20240721T143000",
    "authors": [
      "George Budwell"
    ],
    "summary": "Discover 10 dividend growth powerhouses that could turbocharge your portfolio's long-term performance.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F784033%2Fdividend-bank-roll.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.803643"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.414524,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TGT",
        "relevance_score": "0.142847",
        "ticker_sentiment_score": "0.313895",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.095517",
        "ticker_sentiment_score": "0.088064",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NDSN",
        "relevance_score": "0.142847",
        "ticker_sentiment_score": "0.248651",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "V",
        "relevance_score": "0.142847",
        "ticker_sentiment_score": "0.31512",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PH",
        "relevance_score": "0.095517",
        "ticker_sentiment_score": "0.288706",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NKE",
        "relevance_score": "0.095517",
        "ticker_sentiment_score": "0.264207",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.095517",
        "ticker_sentiment_score": "0.175948",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.142847",
        "ticker_sentiment_score": "0.103087",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.142847",
        "ticker_sentiment_score": "0.189064",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?",
    "url": "https://www.fool.com/investing/2024/07/22/abbvie-could-soar-24-according-to-a-wall-street-an/",
    "time_published": "20240722T144100",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "The big pharma company's top drug is losing ground, but its dividend keeps rising.",
    "banner_image": "https://media.ycharts.com/charts/3dfbc2d588b6bc329a81fadb412211f4.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.103354,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CVS",
        "relevance_score": "0.052801",
        "ticker_sentiment_score": "0.003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.052801",
        "ticker_sentiment_score": "0.063998",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BGNE",
        "relevance_score": "0.052801",
        "ticker_sentiment_score": "-0.048034",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.052801",
        "ticker_sentiment_score": "-0.048034",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.357049",
        "ticker_sentiment_score": "0.193114",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.052801",
        "ticker_sentiment_score": "0.003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RVNC",
        "relevance_score": "0.052801",
        "ticker_sentiment_score": "-0.058001",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Quest Diagnostics  ( DGX )  Tops Q2 Earnings, Raises 2024 Outlook",
    "url": "https://www.zacks.com/stock/news/2306998/quest-diagnostics-dgx-tops-q2-earnings-raises-2024-outlook",
    "time_published": "20240723T140500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Quest Diagnostics (DGX) delivers impressive base business growth in the second quarter of 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/80/66138.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.24009,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "III",
        "relevance_score": "0.049526",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.147818",
        "ticker_sentiment_score": "0.050118",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.465478",
        "ticker_sentiment_score": "0.576238",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "HAE",
        "relevance_score": "0.196212",
        "ticker_sentiment_score": "0.083694",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.147818",
        "ticker_sentiment_score": "0.075299",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Top Analyst Reports for SAP, Abbott Laboratories & Citigroup",
    "url": "https://www.zacks.com/research-daily/2307996/top-analyst-reports-for-sap-abbott-laboratories-citigroup",
    "time_published": "20240724T161400",
    "authors": [
      "Sheraz Mian"
    ],
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including SAP SE (SAP), Abbott Laboratories (ABT) and Citigroup Inc. (C), as well as two micro-cap stocks Team, Inc. (TISI) and Vaso Corporation (VASO).",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default250.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.316384,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TISI",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "0.25078",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.062761",
        "ticker_sentiment_score": "0.040361",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Behind the Scenes of Abbott Laboratories's Latest Options Trends - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/insights/options/24/07/39967810/behind-the-scenes-of-abbott-laboratoriess-latest-options-trends",
    "time_published": "20240725T184702",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bullish stance on Abbott Laboratories. Looking at options history for Abbott Laboratories ABT we detected 8 trades. If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1721933219_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.222887,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EVR",
        "relevance_score": "0.09402",
        "ticker_sentiment_score": "0.210194",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.655281",
        "ticker_sentiment_score": "0.28532",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights SAP, Abbott Laboratories, Citigroup, Team and Vaso",
    "url": "https://www.zacks.com/stock/news/2309168/the-zacks-analyst-blog-highlights-sap-abbott-laboratories-citigroup-team-and-vaso",
    "time_published": "20240725T135300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "SAP, Abbott Laboratories, Citigroup, Team and Vaso are part of the Zacks top Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/33/496.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.291697,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.171181",
        "ticker_sentiment_score": "0.055949",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.171181",
        "ticker_sentiment_score": "0.110416",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SAP",
        "relevance_score": "0.171181",
        "ticker_sentiment_score": "0.01834",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TISI",
        "relevance_score": "0.254307",
        "ticker_sentiment_score": "0.179541",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Align Technology  ( ALGN )  Beats on Q2 Earnings, Lowers '24 Sales View",
    "url": "https://www.zacks.com/stock/news/2309130/align-technology-algn-beats-on-q2-earnings-lowers-24-sales-view",
    "time_published": "20240725T132300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Align Technology's (ALGN) records second-quarter 2024 revenue growth across all regions. This was mostly due to a robust performance by the Imaging Systems & CAD/CAM Services business segment.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/95/59803.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.714479"
      }
    ],
    "overall_sentiment_score": 0.112745,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.119631",
        "ticker_sentiment_score": "0.045052",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALGN",
        "relevance_score": "0.45283",
        "ticker_sentiment_score": "0.278004",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HAE",
        "relevance_score": "0.159043",
        "ticker_sentiment_score": "0.072176",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.198059",
        "ticker_sentiment_score": "0.073536",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Edwards Lifesciences  ( EW )  Q2 Earnings Meet Mark, Margins Crash",
    "url": "https://www.zacks.com/stock/news/2308693/edwards-lifesciences-ew-q2-earnings-meet-mark-margins-crash",
    "time_published": "20240725T130200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Edwards Lifesciences (EW) reports strong contributions from the TMTT product group in the second quarter of 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/63046.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999997"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.208082,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EW",
        "relevance_score": "0.285942",
        "ticker_sentiment_score": "0.224531",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.109289",
        "ticker_sentiment_score": "0.043536",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.109289",
        "ticker_sentiment_score": "0.050087",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.109289",
        "ticker_sentiment_score": "0.065393",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Chemed  ( CHE )  Q2 Earnings Miss Estimates, Margins Expand",
    "url": "https://www.zacks.com/stock/news/2308654/chemed-che-q2-earnings-miss-estimates-margins-expand",
    "time_published": "20240725T124900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Chemed's (CHE) VITAS segment delivers impressive revenue growth and margin expansion in the second quarter of 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/69315.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.106087,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CHE",
        "relevance_score": "0.468807",
        "ticker_sentiment_score": "0.303396",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.135602",
        "ticker_sentiment_score": "0.047776",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.135602",
        "ticker_sentiment_score": "0.054969",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.224072",
        "ticker_sentiment_score": "0.081006",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 High-Yielding Dividend Stocks That Can Help Bankroll Your Retirement Years",
    "url": "https://www.fool.com/investing/2024/07/25/3-high-yielding-dividend-stocks-that-can-help-bank/",
    "time_published": "20240725T110000",
    "authors": [
      "David Jagielski"
    ],
    "summary": "These stocks provide good yields and they don't come with much risk.",
    "banner_image": "https://g.foolcdn.com/editorial/images/784054/elderly-person-holding-money.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998356"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.369701,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HD",
        "relevance_score": "0.245339",
        "ticker_sentiment_score": "0.413776",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.124164",
        "ticker_sentiment_score": "0.264488",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Abbott Laboratories's Options Frenzy: What You Need to Know - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/insights/options/24/07/39993991/abbott-laboratoriess-options-frenzy-what-you-need-to-know",
    "time_published": "20240726T201547",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bearish stance on Abbott Laboratories ABT. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1722024944_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.200748,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EVR",
        "relevance_score": "0.081001",
        "ticker_sentiment_score": "0.12742",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.584103",
        "ticker_sentiment_score": "0.254749",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Integer Holdings  ( ITGR )  Q2 Earnings Top Estimates, Margins Up",
    "url": "https://www.zacks.com/stock/news/2310286/integer-holdings-itgr-q2-earnings-top-estimates-margins-up",
    "time_published": "20240726T165400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Integer Holdings' (ITGR) second-quarter results reflect robust Medical Sales, along with strength in all the product lines.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/49902.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999819"
      }
    ],
    "overall_sentiment_score": 0.138446,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.156461",
        "ticker_sentiment_score": "0.022464",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ITGR",
        "relevance_score": "0.510302",
        "ticker_sentiment_score": "0.210259",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.156461",
        "ticker_sentiment_score": "0.022464",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Peering Into Abbott Laboratories's Recent Short Interest - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/07/39986383/peering-into-abbott-laboratoriess-recent-short-interest",
    "time_published": "20240726T144524",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Abbott Laboratories's ABT short percent of float has fallen 17.33% since its last report. The company recently reported that it has 10.75 million shares sold short, which is 0.62% of all regular shares that are available for trading.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1722005121_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.262256,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.079385",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "ICON  ( ICLR )  Q2 Earnings Surpass Estimates, Margins Expand",
    "url": "https://www.zacks.com/stock/news/2310091/icon-iclr-q2-earnings-surpass-estimates-margins-expand",
    "time_published": "20240726T130900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "ICON's (ICLR) second-quarter 2024 results reflect efficient service delivery and strong cost control.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/47/64950.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999974"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.163325,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ICLR",
        "relevance_score": "0.244723",
        "ticker_sentiment_score": "0.105121",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.184834",
        "ticker_sentiment_score": "0.097579",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HAE",
        "relevance_score": "0.244723",
        "ticker_sentiment_score": "0.077916",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.303175",
        "ticker_sentiment_score": "0.135724",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Amedisys  ( AMED )  Q2 Earnings Top Estimates, Gross Margin Down",
    "url": "https://www.zacks.com/stock/news/2309700/amedisys-amed-q2-earnings-top-estimates-gross-margin-down",
    "time_published": "20240726T115300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amedisys (AMED) delivers year-over-year growth in all three of its segmental revenues in the second quarter of 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/95/59803.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.213154,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.139534",
        "ticker_sentiment_score": "0.048508",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.139534",
        "ticker_sentiment_score": "0.055812",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMED",
        "relevance_score": "0.480769",
        "ticker_sentiment_score": "0.449157",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.230454",
        "ticker_sentiment_score": "0.082855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.139534",
        "ticker_sentiment_score": "0.345981",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Better Buy: Abbott Laboratories vs. Intuitive Surgical",
    "url": "https://www.fool.com/investing/2024/07/26/better-buy-abbott-laboratories-vs-intuitive-surgic/",
    "time_published": "20240726T092700",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "The medical technology business has been good for both companies, but which is right for your portfolio?",
    "banner_image": "https://g.foolcdn.com/editorial/images/784235/investor-calculator-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.207029,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.268",
        "ticker_sentiment_score": "0.309649",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.054607",
        "ticker_sentiment_score": "0.049981",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.368383",
        "ticker_sentiment_score": "0.271892",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.054607",
        "ticker_sentiment_score": "0.049981",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Abbott, Integra LifeSciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Pearson  ( NYSE:PSO ) ",
    "url": "https://www.benzinga.com/news/24/07/40009533/abbott-integra-lifesciences-and-other-big-stocks-moving-lower-in-mondays-pre-market-session",
    "time_published": "20240729T122400",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "U.S. stock futures were higher this morning, with the Dow futures gaining around 150 points on Monday. Shares of Abbott Laboratories ABT fell in today's pre-market trading after the company was ordered to pay $495 million in damages in its baby formula case.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/29/movers-image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": -0.071322,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "PDD",
        "relevance_score": "0.277433",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.277433",
        "ticker_sentiment_score": "-0.343019",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "GPRK",
        "relevance_score": "0.405651",
        "ticker_sentiment_score": "-0.322771",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ICL",
        "relevance_score": "0.405651",
        "ticker_sentiment_score": "-0.07281",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IOVA",
        "relevance_score": "0.277433",
        "ticker_sentiment_score": "-0.133591",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IMMP",
        "relevance_score": "0.405651",
        "ticker_sentiment_score": "-0.023426",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IART",
        "relevance_score": "0.277433",
        "ticker_sentiment_score": "-0.146374",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EZPW",
        "relevance_score": "0.277433",
        "ticker_sentiment_score": "-0.133591",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NAMS",
        "relevance_score": "0.277433",
        "ticker_sentiment_score": "-0.363985",
        "ticker_sentiment_label": "Bearish"
      }
    ]
  },
  {
    "title": "Nasdaq, S&P 500 To Start New Week In The Green: What's Driving Sentiment - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/07/40008162/us-stocks-look-to-extend-gains-ahead-of-key-tech-earnings-fomc-meeting-analyst-says-this-could-serv",
    "time_published": "20240729T114326",
    "authors": [
      "Shanthi Rexaline"
    ],
    "summary": "Index futures trading indicates cautious optimism as traders anticipate a busy week, with a slew of earnings reports, the two-day Federal Open Market Committee meeting starting Tuesday, and Friday's non-farm payrolls report.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/29/Icahn-Enterprises-L-P.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.986714"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      }
    ],
    "overall_sentiment_score": 0.076552,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.085173",
        "ticker_sentiment_score": "-0.020376",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.042647",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.085173",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LSCC",
        "relevance_score": "0.085173",
        "ticker_sentiment_score": "0.097466",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.042647",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RMBS",
        "relevance_score": "0.085173",
        "ticker_sentiment_score": "0.097466",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SANM",
        "relevance_score": "0.085173",
        "ticker_sentiment_score": "0.097466",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.042647",
        "ticker_sentiment_score": "0.211069",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FFIV",
        "relevance_score": "0.085173",
        "ticker_sentiment_score": "0.097466",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.085173",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MCD",
        "relevance_score": "0.085173",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.085173",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.085173",
        "ticker_sentiment_score": "-0.306488",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.085173",
        "ticker_sentiment_score": "-0.020376",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TLRY",
        "relevance_score": "0.085173",
        "ticker_sentiment_score": "0.097466",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LPLA",
        "relevance_score": "0.042647",
        "ticker_sentiment_score": "0.095623",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.127456",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ON",
        "relevance_score": "0.042647",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.085173",
        "ticker_sentiment_score": "-0.182795",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Abbott Laboratories Tumble Nearly 8% In Pre-Market After US Jury Charges $495M Penalty For Disease Causing Baby Formula - Abbott Laboratories  ( NYSE:ABT ) , Reckitt Benckiser Group  ( OTC:RBGLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/40006590/abbott-laboratories-tumble-nearly-8-in-pre-market-after-us-jury-charges-495m-penalty-for-disease-",
    "time_published": "20240729T103046",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "In a significant blow, Abbott Laboratories ABT saw its shares nosedive following a U.S. jury's ruling that found Abbott's formula was responsible for a girl developing a severe bowel disease, leading to a hefty $495 million penalty.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/29/abbott-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": -0.113315,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.371523",
        "ticker_sentiment_score": "-0.060196",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RBGPF",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "-0.01988",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Beaten-Down Dexcom Stock a Buy on the Dip?",
    "url": "https://www.fool.com/investing/2024/07/29/is-beaten-down-dexcom-stock-a-buy-on-the-dip/",
    "time_published": "20240729T095400",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "The market may have overreacted to a disappointing earnings report.",
    "banner_image": "https://g.foolcdn.com/editorial/images/784935/investor-thinking-about-stock-charts-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.990893"
      }
    ],
    "overall_sentiment_score": 0.031669,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "COST",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.142001",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.552966",
        "ticker_sentiment_score": "-0.048077",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.109956",
        "ticker_sentiment_score": "-0.036252",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Pitney Bowes Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket - Pitney Bowes  ( NYSE:PBI ) ",
    "url": "https://www.benzinga.com/news/24/07/40005612/why-pitney-bowes-shares-are-trading-higher-by-over-12-here-are-20-stocks-moving-premarket",
    "time_published": "20240729T092634",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Shares of Pitney Bowes Inc. PBI shares rose sharply in today's pre-market trading following a report indicating that the company has sold a part of its e-commerce business to Stord. Pitney Bowes shares jumped 12.5% to $7.58 in pre-market trading. Here are some other stocks moving in pre-market ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/29/movers-image.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.167147,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CERO",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "0.133618",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BFI",
        "relevance_score": "0.206392",
        "ticker_sentiment_score": "0.359973",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "TIVC",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "0.4676",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "LGVN",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "0.206754",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "-0.122943",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RNAZ",
        "relevance_score": "0.206392",
        "ticker_sentiment_score": "0.253925",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TGOPF",
        "relevance_score": "0.069495",
        "ticker_sentiment_score": "0.16182",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VTVT",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "-0.024929",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "YIBO",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "-0.135926",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NUZE",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "-0.214077",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "PBI",
        "relevance_score": "0.206392",
        "ticker_sentiment_score": "0.181544",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AVXL",
        "relevance_score": "0.206392",
        "ticker_sentiment_score": "-0.017104",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CGTX",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "0.190882",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GVH",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "-0.175764",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "TGL",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "-0.080912",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LUXH",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "0.137382",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PHIO",
        "relevance_score": "0.206392",
        "ticker_sentiment_score": "-0.392891",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "EZPW",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "0.238465",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "INVO",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "-0.057457",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Integra's  ( IART )  Q2 Earnings and Revenues Top, Margins Down",
    "url": "https://www.zacks.com/stock/news/2312264/integras-iart-q2-earnings-and-revenues-top-margins-down",
    "time_published": "20240730T164900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Integra's (IART) second-quarter 2024 results reflect strong demand for its diverse portfolio of leading brands and the continued successful market adoption of CereLink.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default144.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.191094,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IART",
        "relevance_score": "0.206862",
        "ticker_sentiment_score": "0.156992",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.125025",
        "ticker_sentiment_score": "0.075924",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.125025",
        "ticker_sentiment_score": "0.051685",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.206862",
        "ticker_sentiment_score": "0.101462",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Philips  ( PHG )  Q2 Earnings Rise, Revenues Fall Year Over Year",
    "url": "https://www.zacks.com/stock/news/2312228/philips-phg-q2-earnings-rise-revenues-fall-year-over-year",
    "time_published": "20240730T161200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Philips' (PHG) second-quarter results benefit from strong momentum across the Diagnosis & Treatment, Connected Care and Personal Health businesses.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/34/973.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.904684"
      }
    ],
    "overall_sentiment_score": 0.250265,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AKRO",
        "relevance_score": "0.227538",
        "ticker_sentiment_score": "0.204661",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.171688",
        "ticker_sentiment_score": "0.170319",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMED",
        "relevance_score": "0.171688",
        "ticker_sentiment_score": "0.170319",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PHG",
        "relevance_score": "0.227538",
        "ticker_sentiment_score": "0.297915",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Hologic  ( HOLX )  Q3 Earnings Surpass Estimates, Margins Rise",
    "url": "https://www.zacks.com/stock/news/2311578/hologic-holx-q3-earnings-surpass-estimates-margins-rise",
    "time_published": "20240730T120800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Hologic (HOLX) delivers strong performances across all its franchises in the third quarter of fiscal 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/91/69871.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.110044,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "HOLX",
        "relevance_score": "0.295867",
        "ticker_sentiment_score": "0.243183",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.11324",
        "ticker_sentiment_score": "0.042984",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.11324",
        "ticker_sentiment_score": "0.049619",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.187608",
        "ticker_sentiment_score": "0.069124",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Waters  ( WAT )  Q2 Earnings & Sales Beat Estimates, Fall Y/Y",
    "url": "https://www.zacks.com/stock/news/2313398/waters-wat-q2-earnings-sales-beat-estimates-fall-yy",
    "time_published": "20240731T173300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Waters' (WAT) second-quarter results are hurt by weak end-market momentum and softness in Asia, Americas and Europe.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.998311"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.026135,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AKRO",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.188221",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.153797",
        "ticker_sentiment_score": "0.086416",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WAT",
        "relevance_score": "0.780721",
        "ticker_sentiment_score": "0.048059",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMED",
        "relevance_score": "0.153797",
        "ticker_sentiment_score": "0.158626",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Penumbra  ( PEN )  Tops on Q2 Earnings, Lowers Sales View",
    "url": "https://www.zacks.com/stock/news/2313226/penumbra-pen-tops-on-q2-earnings-lowers-sales-view",
    "time_published": "20240731T140300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Penumbra's (PEN) Thrombectomy product category shows encouraging growth trends, reflecting strong momentum in CAVT products.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/63046.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.120127,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "PEN",
        "relevance_score": "0.446742",
        "ticker_sentiment_score": "0.293596",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.141171",
        "ticker_sentiment_score": "0.084405",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.141171",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.233108",
        "ticker_sentiment_score": "0.11153",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Neogen  ( NEOG )  Q4 Earnings Miss Estimates, Margins Crash",
    "url": "https://www.zacks.com/stock/news/2312689/neogen-neog-q4-earnings-miss-estimates-margins-crash",
    "time_published": "20240731T120700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Neogen's (NEOG) Food Safety and Animal Safety businesses witness a year-over-year decrease in revenues in the fourth quarter of fiscal 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/85/66981.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.073871,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.047322",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NEOG",
        "relevance_score": "0.461132",
        "ticker_sentiment_score": "0.197987",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.054447",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.220008",
        "ticker_sentiment_score": "0.07983",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Labcorp  ( LH )  Q2 Earnings Surpass Estimates  ( revised ) ",
    "url": "https://www.zacks.com/stock/news/2314612/labcorp-lh-q2-earnings-surpass-estimates-revised",
    "time_published": "20240801T190200",
    "authors": [
      "Mark Vickery"
    ],
    "summary": "Labcorp (LH) beats on earnings and revenues in the second quarter, entering the second half of 2024 with robust momentum.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.114505,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.126561",
        "ticker_sentiment_score": "0.046181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.126561",
        "ticker_sentiment_score": "0.053134",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LH",
        "relevance_score": "0.168197",
        "ticker_sentiment_score": "0.159768",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.076763",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "0JDB",
        "relevance_score": "0.084572",
        "ticker_sentiment_score": "0.120656",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Exact Sciences Q2 Loss Narrower Than Expected, Sales Beat - Abbott Laboratories  ( NYSE:ABT ) , Exact Sciences  ( NASDAQ:EXAS ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40103157/exact-sciences-q2-loss-narrower-than-expected-sales-beat",
    "time_published": "20240801T171128",
    "authors": [
      "Zacks"
    ],
    "summary": "Exact Sciences Corporation EXAS reported a net loss of 9 cents per share in second-quarter 2024, narrower than the year-ago loss of 45 cents per share. The figure beat the Zacks Consensus Estimate of a loss of 37 cents per share.",
    "banner_image": "https://staticx-tuner.zacks.com/images/charts/70/1722514623.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999953"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.073563,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.159569",
        "ticker_sentiment_score": "0.117293",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXAS",
        "relevance_score": "0.454174",
        "ticker_sentiment_score": "0.033488",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HAE",
        "relevance_score": "0.211652",
        "ticker_sentiment_score": "0.083887",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.262805",
        "ticker_sentiment_score": "0.204739",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "BD  ( BDX )  Q3 Earnings Surpass Estimates, Margins Expand",
    "url": "https://www.zacks.com/stock/news/2314564/bd-bdx-q3-earnings-surpass-estimates-margins-expand",
    "time_published": "20240801T165700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "BD's (BDX) overall topline benefits from revenue growth in all segments in the fiscal third quarter.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/54381.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.134097,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "EW",
        "relevance_score": "0.031612",
        "ticker_sentiment_score": "0.165224",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.063174",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.125953",
        "ticker_sentiment_score": "0.021057",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.125953",
        "ticker_sentiment_score": "0.019883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.125953",
        "ticker_sentiment_score": "0.115689",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Avanos  ( AVNS )  Q2 Earnings Top Estimates, Gross Margin Contracts",
    "url": "https://www.zacks.com/stock/news/2314560/avanos-avns-q2-earnings-top-estimates-gross-margin-contracts",
    "time_published": "20240801T165500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Strength in Avanos' (AVNS) Digestive Health segment drives its second-quarter performance.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/dd/52606.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999606"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.126693,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.080188",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVNS",
        "relevance_score": "0.159569",
        "ticker_sentiment_score": "0.068369",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.159569",
        "ticker_sentiment_score": "0.024095",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.159569",
        "ticker_sentiment_score": "0.022751",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Labcorp  ( LH )  Q2 Earnings Surpass Estimates, Margins Increase",
    "url": "https://www.zacks.com/stock/news/2314219/labcorp-lh-q2-earnings-surpass-estimates-margins-increase",
    "time_published": "20240801T134700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Labcorp (LH) beats on earnings and revenues in the second quarter, entering the second half of 2024 with robust momentum.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/63046.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.118859,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.130453",
        "ticker_sentiment_score": "0.046852",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.130453",
        "ticker_sentiment_score": "0.053906",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LH",
        "relevance_score": "0.173333",
        "ticker_sentiment_score": "0.163058",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.215702",
        "ticker_sentiment_score": "0.078587",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "0JDB",
        "relevance_score": "0.087185",
        "ticker_sentiment_score": "0.121346",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Exact Sciences  ( EXAS )  Q2 Loss Narrower Than Expected, Sales Beat",
    "url": "https://www.zacks.com/stock/news/2314363/exact-sciences-exas-q2-loss-narrower-than-expected-sales-beat",
    "time_published": "20240801T130300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Exact Sciences' (EXAS) second-quarter 2024 top-line results reflect robust revenues from the Screening and Precision Oncology segments.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/63046.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999986"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.049769,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.161349",
        "ticker_sentiment_score": "0.092816",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXAS",
        "relevance_score": "0.458708",
        "ticker_sentiment_score": "0.036738",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HAE",
        "relevance_score": "0.213988",
        "ticker_sentiment_score": "0.073201",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.265666",
        "ticker_sentiment_score": "0.156757",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "QIAGEN  ( QGEN )  Q2 Earnings Surpass Estimates, Margins Crash",
    "url": "https://www.zacks.com/stock/news/2313918/qiagen-qgen-q2-earnings-surpass-estimates-margins-crash",
    "time_published": "20240801T124000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "QIAGEN's (QGEN) earnings and revenues beat estimates in the second quarter. The company remains bullish on solid growth trends in the core business.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/69315.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.102873,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "QGEN",
        "relevance_score": "0.370969",
        "ticker_sentiment_score": "0.237238",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.043268",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.049947",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.065552",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Teleflex Tops Q2 Earnings Estimates, Raises 2024 Outlook - Teleflex  ( NYSE:TFX ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40131223/teleflex-tops-q2-earnings-estimates-raises-2024-outlook",
    "time_published": "20240802T173630",
    "authors": [
      "Zacks"
    ],
    "summary": "Teleflex Incorporated TFX posted adjusted earnings per share from continuing operations of $3.42 in the second quarter of 2024, up 0.3% from the year-ago quarter's figure. The metric topped the Zacks Consensus Estimate by 2.7%.",
    "banner_image": "https://staticx-tuner.zacks.com/images/charts/40/1722586620.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.17651,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.069798",
        "ticker_sentiment_score": "0.053182",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.069798",
        "ticker_sentiment_score": "0.062223",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.069798",
        "ticker_sentiment_score": "0.093383",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TFX",
        "relevance_score": "0.338582",
        "ticker_sentiment_score": "0.21278",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "ResMed's Q4 Earnings Surpass Estimates, Margins Expand - Abbott Laboratories  ( NYSE:ABT ) , Quest Diagnostics  ( NYSE:DGX ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40131230/resmeds-q4-earnings-surpass-estimates-margins-expand",
    "time_published": "20240802T170825",
    "authors": [
      "Zacks"
    ],
    "summary": "ResMed Inc.'s RMD adjusted earnings per share in the fourth quarter of fiscal 2024 were $2.08, up 30% year over year. The metric beat the Zacks Consensus Estimate by 2.5%.",
    "banner_image": "https://staticx-tuner.zacks.com/images/charts/37/1722586174.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999996"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.241642,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RMD",
        "relevance_score": "0.335709",
        "ticker_sentiment_score": "0.497288",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.129284",
        "ticker_sentiment_score": "0.058357",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.129284",
        "ticker_sentiment_score": "0.068909",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.2138",
        "ticker_sentiment_score": "0.100853",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Seizing Opportunities in Medical Foods Market to Grow at 7.5% CAGR, Reaching USD 44 Billion by 2031- Report by Transparency Market Research Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40136611/seizing-opportunities-in-medical-foods-market-to-grow-at-7-5-cagr-reaching-usd-44-billion-by-2031-",
    "time_published": "20240802T163937",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Transparency Market Research, Inc., Aug. 02, 2024 ( GLOBE NEWSWIRE ) -- As per the report published by Transparency Market Research ( TMR ) , the global Medical Foods Market ( \uc758\ub8cc\uc2dd\ud488\uc2dc\uc7a5 ) is estimated to reach US$ 44.0 Bn by 2031 at a noticeable CAGR of 7.5% ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.217298,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.033846",
        "ticker_sentiment_score": "0.058398",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MGAAF",
        "relevance_score": "0.033846",
        "ticker_sentiment_score": "0.066986",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.067632",
        "ticker_sentiment_score": "0.120011",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FSNUF",
        "relevance_score": "0.033846",
        "ticker_sentiment_score": "0.066986",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRGM",
        "relevance_score": "0.033846",
        "ticker_sentiment_score": "0.066986",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.101296",
        "ticker_sentiment_score": "0.057761",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NSRGF",
        "relevance_score": "0.067632",
        "ticker_sentiment_score": "0.084872",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bio-Rad  ( BIO )  Q2 Earnings Surpass Estimates, Guidance Lowered",
    "url": "https://www.zacks.com/stock/news/2315332/bio-rad-bio-q2-earnings-surpass-estimates-guidance-lowered",
    "time_published": "20240802T141600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Bio-Rad (BIO) witnesses growth in the second quarter across the Clinical Diagnostics segment, primarily driven by an increased demand for quality control and blood typing products.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/54381.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999997"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.076476,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BIO",
        "relevance_score": "0.173333",
        "ticker_sentiment_score": "0.142112",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.130453",
        "ticker_sentiment_score": "0.081001",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.130453",
        "ticker_sentiment_score": "0.055082",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.215702",
        "ticker_sentiment_score": "0.10484",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Omnicell  ( OMCL )  Q2 Earnings Top Estimates, Margins Down",
    "url": "https://www.zacks.com/stock/news/2315347/omnicell-omcl-q2-earnings-top-estimates-margins-down",
    "time_published": "20240802T132300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Omnicell's (OMCL) Q2 results outpace expectations despite a challenging customer environment.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/63046.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.135229,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "OMCL",
        "relevance_score": "0.435177",
        "ticker_sentiment_score": "0.356106",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.152178",
        "ticker_sentiment_score": "0.088171",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.201944",
        "ticker_sentiment_score": "0.11831",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.250902",
        "ticker_sentiment_score": "0.120207",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Teleflex  ( TFX )  Tops Q2 Earnings Estimates, Raises 2024 Outlook",
    "url": "https://www.zacks.com/stock/news/2314994/teleflex-tfx-tops-q2-earnings-estimates-raises-2024-outlook",
    "time_published": "20240802T121400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Teleflex's (TFX) diversified portfolio and global footprint have driven durable growth in the second quarter of 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/58862.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.1626,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.104835",
        "ticker_sentiment_score": "0.042952",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.104835",
        "ticker_sentiment_score": "0.049414",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.104835",
        "ticker_sentiment_score": "0.064511",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TFX",
        "relevance_score": "0.339511",
        "ticker_sentiment_score": "0.208513",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "ResMed's  ( RMD )  Q4 Earnings Surpass Estimates, Margins Expand",
    "url": "https://www.zacks.com/stock/news/2314987/resmeds-rmd-q4-earnings-surpass-estimates-margins-expand",
    "time_published": "20240802T121100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "ResMed (RMD) delivers solid performance across all regions and business segments in the fourth quarter of fiscal 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/95/59803.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.225684,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RMD",
        "relevance_score": "0.338582",
        "ticker_sentiment_score": "0.486464",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.130453",
        "ticker_sentiment_score": "0.046852",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.130453",
        "ticker_sentiment_score": "0.053906",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.215702",
        "ticker_sentiment_score": "0.078587",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Forget Johnson & Johnson: Another Healthcare Giant Is a Much Better Bet for Growth",
    "url": "https://www.fool.com/investing/2024/08/02/forget-johnson-johnson-this-could-be-a-much-better/",
    "time_published": "20240802T091700",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Abbott Laboratories' growth rate may look comparable to Johnson & Johnson's, but in the long run it could become much higher.",
    "banner_image": "https://g.foolcdn.com/editorial/images/784778/a-group-of-scientists-looking-at-a-report.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.272999,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.626755",
        "ticker_sentiment_score": "0.428021",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.462395",
        "ticker_sentiment_score": "0.301853",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Unstoppable Dividend Stocks to Buy if There's a Stock Market Sell-Off",
    "url": "https://www.fool.com/investing/2024/08/03/2-unstoppable-dividend-stocks-to-buy-if-a-sell-off/",
    "time_published": "20240803T104500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "Dividend stocks are great. cheap dividend stocks are better.",
    "banner_image": "https://g.foolcdn.com/editorial/images/785210/person-sitting-at-a-desk-looking-at-two-monitors.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.993856"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.307438,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.173645",
        "ticker_sentiment_score": "0.177066",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.298957",
        "ticker_sentiment_score": "0.125028",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Hims & Hers  ( HIMS )  Gains 45.8% in Three Months: What's Next?",
    "url": "https://www.zacks.com/stock/news/2316328/hims-hers-hims-gains-458-in-three-months-whats-next",
    "time_published": "20240805T163000",
    "authors": [
      "Debanjana Dey"
    ],
    "summary": "Hims & Hers (HIMS) is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/79/961.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.416961,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HIMS",
        "relevance_score": "0.321673",
        "ticker_sentiment_score": "0.361677",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.109956",
        "ticker_sentiment_score": "0.146481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TDOC",
        "relevance_score": "0.109956",
        "ticker_sentiment_score": "0.146481",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Immunoassay Market Surges to USD 39.66 Billion by 2031, Propelled by 4.67% CAGR - Verified Market Research\u00ae",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40161821/immunoassay-market-surges-to-usd-39-66-billion-by-2031-propelled-by-4-67-cagr-verified-market-rese",
    "time_published": "20240805T141500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Lewes, Delaware, Aug. 05, 2024 ( GLOBE NEWSWIRE ) -- The Global Immunoassay Market Size is projected to grow at a CAGR of 4.67% from 2024 to 2031, according to a new report published by Verified Market Research\u00ae.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/54097ce1-6e07-411d-8cc7-f86096bda0f1/immunoassay-market-size-and-forecast-1024x576.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.274905,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TRIB",
        "relevance_score": "0.027795",
        "ticker_sentiment_score": "0.095953",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.027795",
        "ticker_sentiment_score": "0.095953",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSMXF",
        "relevance_score": "0.027795",
        "ticker_sentiment_score": "0.095953",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.027795",
        "ticker_sentiment_score": "0.095953",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.027795",
        "ticker_sentiment_score": "0.095953",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RSSS",
        "relevance_score": "0.027795",
        "ticker_sentiment_score": "0.168128",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIO",
        "relevance_score": "0.027795",
        "ticker_sentiment_score": "0.095953",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SEMHF",
        "relevance_score": "0.027795",
        "ticker_sentiment_score": "0.095953",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DHR",
        "relevance_score": "0.027795",
        "ticker_sentiment_score": "0.095953",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Tandem Diabetes  ( TNDM )  Q2 Earnings Beat, '24 View Raised",
    "url": "https://www.zacks.com/stock/news/2316187/tandem-diabetes-tndm-q2-earnings-beat-24-view-raised",
    "time_published": "20240805T134700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Tandem Diabetes' (TNDM) top and bottom lines outpace estimates in the second quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/63046.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.047205,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "0.086685",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.191549",
        "ticker_sentiment_score": "0.070202",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TNDM",
        "relevance_score": "0.191549",
        "ticker_sentiment_score": "-0.119718",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.238133",
        "ticker_sentiment_score": "0.115235",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Polymerase Chain Reaction Market to Reach $16 Billion by 2034 at 10% CAGR - Fact.MR Analysis",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40156065/polymerase-chain-reaction-market-to-reach-16-billion-by-2034-at-10-cagr-fact-mr-analysis",
    "time_published": "20240805T103000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Rockville, MD, Aug. 05, 2024 ( GLOBE NEWSWIRE ) -- As per this updated industry report by Fact.MR, a market research and competitive intelligence provider, the global polymerase chain reaction market size is expected to attain a valuation of US$ 6.2 billion in 2024.",
    "banner_image": "https://ml.globenewswire.com/media/f482b854-04d1-4f4e-9237-f7c7c6823e10/small/factmr-logo-png.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.318234,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BMXMF",
        "relevance_score": "0.033236",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.033236",
        "ticker_sentiment_score": "0.091702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "A",
        "relevance_score": "0.033236",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.033236",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.033236",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.066414",
        "ticker_sentiment_score": "0.079129",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIO",
        "relevance_score": "0.033236",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QGEN",
        "relevance_score": "0.033236",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LAB",
        "relevance_score": "0.033236",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DHR",
        "relevance_score": "0.033236",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares U.S. Medical Devices ETF  ( IHI ) ?",
    "url": "https://www.zacks.com/stock/news/2315697/should-you-invest-in-the-ishares-us-medical-devices-etf-ihi",
    "time_published": "20240805T102005",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for IHI ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default331.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.24763,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.065327",
        "ticker_sentiment_score": "0.031022",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SEM",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.026877",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.070327",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.070327",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.070327",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Worried About a Market Correction? 2 High-Yield Dividend Stocks You Can Buy Now and Hold Forever.",
    "url": "https://www.fool.com/investing/2024/08/05/worried-about-a-market-correction-2-high-yield-div/",
    "time_published": "20240805T095600",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Recent market pressure could worsen, but that won't stop these successful businesses from raising their dividend payouts.",
    "banner_image": "https://g.foolcdn.com/editorial/images/785854/smart-investor-looking-at-stock-charts-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.918141"
      }
    ],
    "overall_sentiment_score": 0.050877,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.266828",
        "ticker_sentiment_score": "0.068603",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.054359",
        "ticker_sentiment_score": "0.054981",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.266828",
        "ticker_sentiment_score": "0.237324",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "IDEXX Q2 Earnings Miss Estimates, 2024 View Down - Abbott Laboratories  ( NYSE:ABT ) , Quest Diagnostics  ( NYSE:DGX ) ",
    "url": "https://www.benzinga.com/news/earnings/24/08/40193340/idexx-q2-earnings-miss-estimates-2024-view-down",
    "time_published": "20240806T181753",
    "authors": [
      "Zacks"
    ],
    "summary": "IDEXX Laboratories, Inc. IDXX posted second-quarter 2024 earnings per share of $2.44, down 8.6% year over year. The figure missed the Zacks Consensus Estimate by 14.9%. Comparable constant-currency EPS of $3.02 improved 14.8% year over year.",
    "banner_image": "https://staticx-tuner.zacks.com/images/charts/11/1722950838.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999997"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.184287,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IDXX",
        "relevance_score": "0.22574",
        "ticker_sentiment_score": "0.021924",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.136629",
        "ticker_sentiment_score": "0.107109",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.181477",
        "ticker_sentiment_score": "0.07899",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.22574",
        "ticker_sentiment_score": "0.142648",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Meal Replacement Market Surges to USD 16.62 Billion by 2031, Propelled by 4.40% CAGR - Verified Market Research\u00ae",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40191275/meal-replacement-market-surges-to-usd-16-62-billion-by-2031-propelled-by-4-40-cagr-verified-market",
    "time_published": "20240806T140000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Lewes, Delaware, Aug. 06, 2024 ( GLOBE NEWSWIRE ) -- The Global Meal Replacement Market Size is projected to grow at a CAGR of 4.40% from 2024 to 2031, according to a new report published by Verified Market Research\u00ae.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/4889a22f-7bfd-4a7d-8546-5329ff3df3a5/meal-replacement-market-is-estimated-to-grow-at-a-cagr-of-4-40-reach-us-16-62-bn-by-the-end-of-2031-768x432.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.320962,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.03178",
        "ticker_sentiment_score": "0.109351",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HLF",
        "relevance_score": "0.03178",
        "ticker_sentiment_score": "0.109351",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GLAPF",
        "relevance_score": "0.03178",
        "ticker_sentiment_score": "0.109351",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NSRGF",
        "relevance_score": "0.03178",
        "ticker_sentiment_score": "0.109351",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RSSS",
        "relevance_score": "0.03178",
        "ticker_sentiment_score": "0.170418",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "IDEXX  ( IDXX )  Q2 Earnings Miss Estimates, 2024 View Down",
    "url": "https://www.zacks.com/stock/news/2317144/idexx-idxx-q2-earnings-miss-estimates-2024-view-down",
    "time_published": "20240806T134700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "IDEXX's (IDXX) Q2 earnings miss estimates but revenues meet the same.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/63046.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.165677,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IDXX",
        "relevance_score": "0.227859",
        "ticker_sentiment_score": "0.021967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.137934",
        "ticker_sentiment_score": "0.084561",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.183198",
        "ticker_sentiment_score": "0.067927",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.227859",
        "ticker_sentiment_score": "0.111222",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Henry Schein  ( HSIC )  Q2 Earnings Surpass, 2024 Guidance Slashed",
    "url": "https://www.zacks.com/stock/news/2316783/henry-schein-hsic-q2-earnings-surpass-2024-guidance-slashed",
    "time_published": "20240806T125700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Henry Schein's (HSIC) second-quarter results reflect an improvement in sales trends in distribution businesses.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fb/64446.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      }
    ],
    "overall_sentiment_score": 0.142587,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CURN",
        "relevance_score": "0.042723",
        "ticker_sentiment_score": "0.126446",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.127682",
        "ticker_sentiment_score": "0.046372",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.127682",
        "ticker_sentiment_score": "0.053353",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HSIC",
        "relevance_score": "0.546745",
        "ticker_sentiment_score": "0.314544",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.211191",
        "ticker_sentiment_score": "0.077287",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Down 40% in 1 Day, Is DexCom Stock Still a Buy?",
    "url": "https://www.fool.com/investing/2024/08/06/down-40-in-1-day-is-dexcom-stock-still-a-buy/",
    "time_published": "20240806T110000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Competition and new growth headwinds could derail the stock even further.",
    "banner_image": "https://g.foolcdn.com/editorial/images/785365/two-investors-look-at-figures.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.996718"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.063306,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DXCM",
        "relevance_score": "0.477704",
        "ticker_sentiment_score": "0.031623",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.056674",
        "ticker_sentiment_score": "0.049",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.056674",
        "ticker_sentiment_score": "0.049",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "STERIS Q1 Earnings Beat Estimates, Operating Margin Falls - Steris  ( NYSE:STE ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40225735/steris-q1-earnings-beat-estimates-operating-margin-falls",
    "time_published": "20240807T185023",
    "authors": [
      "Zacks"
    ],
    "summary": "STERIS plc STE reported first-quarter fiscal 2025 adjusted earnings per share of $2.03, up 10.3% from the year-ago quarter's figure. The figure surpassed the Zacks Consensus Estimate by 2 cents.",
    "banner_image": "https://staticx-tuner.zacks.com/images/charts/1e/1723034957.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999996"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.1822,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.090304",
        "ticker_sentiment_score": "0.098517",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.135094",
        "ticker_sentiment_score": "0.068041",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.179454",
        "ticker_sentiment_score": "0.124141",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STE",
        "relevance_score": "0.390227",
        "ticker_sentiment_score": "0.272364",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Globus Medical Q2 Earnings Top Estimates, '24 View Up - Abbott Laboratories  ( NYSE:ABT ) , Quest Diagnostics  ( NYSE:DGX ) ",
    "url": "https://www.benzinga.com/news/earnings/24/08/40225737/globus-medical-q2-earnings-top-estimates-24-view-up",
    "time_published": "20240807T184856",
    "authors": [
      "Zacks"
    ],
    "summary": "Globus Medical, Inc. GMED reported second-quarter 2024 adjusted earnings per share of 75 cents, which beat the Zacks Consensus Estimate by 10.3%. The figure increased 19% year over year.",
    "banner_image": "https://staticx-tuner.zacks.com/images/charts/29/1723034409.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.256128,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.137409",
        "ticker_sentiment_score": "0.107432",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.182506",
        "ticker_sentiment_score": "0.079314",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GMED",
        "relevance_score": "0.313674",
        "ticker_sentiment_score": "0.351828",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.227007",
        "ticker_sentiment_score": "0.143283",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Charles River  ( CRL )  Q2 Earnings Beat Estimates, 2024 View Down",
    "url": "https://www.zacks.com/stock/news/2318347/charles-river-crl-q2-earnings-beat-estimates-2024-view-down",
    "time_published": "20240807T173000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Charles River's (CRL) Manufacturing business segments report organic revenue growth, partially offset by lower revenues in the DSA and RMS segments.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/85/66981.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.101913,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.135094",
        "ticker_sentiment_score": "0.08364",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRL",
        "relevance_score": "0.223248",
        "ticker_sentiment_score": "0.184974",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.179454",
        "ticker_sentiment_score": "0.066922",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.223248",
        "ticker_sentiment_score": "0.109422",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Zimmer Biomet  ( ZBH )  Beats on Q2 Earnings, Cuts Revenue View",
    "url": "https://www.zacks.com/stock/news/2318276/zimmer-biomet-zbh-beats-on-q2-earnings-cuts-revenue-view",
    "time_published": "20240807T161300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Zimmer Biomet's (ZBH) strategic expansion of international business contributes to the top line in the second quarter.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2f/61766.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.184883,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ZBH",
        "relevance_score": "0.411848",
        "ticker_sentiment_score": "0.377584",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.129052",
        "ticker_sentiment_score": "0.081752",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.171485",
        "ticker_sentiment_score": "0.066199",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CBRE",
        "relevance_score": "0.043186",
        "ticker_sentiment_score": "0.169205",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.213423",
        "ticker_sentiment_score": "0.105594",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Globus Medical  ( GMED )  Q2 Earnings Top Estimates, '24 View Up",
    "url": "https://www.zacks.com/stock/news/2318208/globus-medical-gmed-q2-earnings-top-estimates-24-view-up",
    "time_published": "20240807T142600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Globus Medical (GMED) delivers massive sales and earnings growth in the second quarter of 2024. However, margins contract.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/63046.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.240271,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.13873",
        "ticker_sentiment_score": "0.084822",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.184246",
        "ticker_sentiment_score": "0.068211",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GMED",
        "relevance_score": "0.316555",
        "ticker_sentiment_score": "0.337845",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.229149",
        "ticker_sentiment_score": "0.111726",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "STERIS  ( STE )  Q1 Earnings Beat Estimates, Operating Margin Falls",
    "url": "https://www.zacks.com/stock/news/2318207/steris-ste-q1-earnings-beat-estimates-operating-margin-falls",
    "time_published": "20240807T142600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "STERIS' (STE) first-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues. The contraction of the operating margin is concerning.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/63046.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.165856,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.135602",
        "ticker_sentiment_score": "0.083803",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.180124",
        "ticker_sentiment_score": "0.067101",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.224072",
        "ticker_sentiment_score": "0.109744",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STE",
        "relevance_score": "0.391583",
        "ticker_sentiment_score": "0.262974",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "CVS Health  ( CVS )  Beats Q2 Earnings, Narrows '24 EPS Outlook",
    "url": "https://www.zacks.com/stock/news/2317864/cvs-health-cvs-beats-q2-earnings-narrows-24-eps-outlook",
    "time_published": "20240807T130200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "CVS Health (CVS) delivers a year-over-year improvement in revenues, driven by growth in the Health Care Benefits and Pharmacy & Consumer Wellness segments.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/59/54380.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.217831,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CVS",
        "relevance_score": "0.47672",
        "ticker_sentiment_score": "0.431392",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.138198",
        "ticker_sentiment_score": "0.048257",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.138198",
        "ticker_sentiment_score": "0.055523",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.138198",
        "ticker_sentiment_score": "0.072502",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bruker  ( BRKR )  Q2 Earnings Meet Mark, '24 Revenue Outlook Raised",
    "url": "https://www.zacks.com/stock/news/2317698/bruker-brkr-q2-earnings-meet-mark-24-revenue-outlook-raised",
    "time_published": "20240807T113200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Bruker (BRKR) delivers robust revenue growth in the second quarter despite soft general market conditions.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/53200.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.189476,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BRKR",
        "relevance_score": "0.519739",
        "ticker_sentiment_score": "0.435127",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.12023",
        "ticker_sentiment_score": "0.045146",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.12023",
        "ticker_sentiment_score": "0.051942",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.199037",
        "ticker_sentiment_score": "0.073813",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:NANO",
        "relevance_score": "0.12023",
        "ticker_sentiment_score": "0.170459",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Dividend Growth Stocks to Buy Hand Over Fist in August",
    "url": "https://www.fool.com/investing/2024/08/07/dividend-growth-stocks-buy-hand-over-fist-august/",
    "time_published": "20240807T091000",
    "authors": [
      "Justin Pope"
    ],
    "summary": "There are blue-chip bargains paying large and growing dividends in the healthcare space.",
    "banner_image": "https://g.foolcdn.com/editorial/images/785724/money-trees-long-term-investing.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999701"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.9545"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.280693,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.046633",
        "ticker_sentiment_score": "0.067943",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.093108",
        "ticker_sentiment_score": "0.081485",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.317722",
        "ticker_sentiment_score": "0.354872",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.317722",
        "ticker_sentiment_score": "0.154637",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "OPKO Health  ( OPK )  Q2 Earnings Top Estimates, Gross Margin Down",
    "url": "https://www.zacks.com/stock/news/2319449/opko-health-opk-q2-earnings-top-estimates-gross-margin-down",
    "time_published": "20240808T161400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Despite OPKO Health's (OPK) strength in the Diagnostics segment, its overall second-quarter results reflect soft performances.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/47/62145.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.988915"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.004812,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CURN",
        "relevance_score": "0.042048",
        "ticker_sentiment_score": "-0.112386",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.08398",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OPK",
        "relevance_score": "0.506917",
        "ticker_sentiment_score": "0.016334",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.167032",
        "ticker_sentiment_score": "0.024842",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.167032",
        "ticker_sentiment_score": "0.023457",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.042048",
        "ticker_sentiment_score": "0.011773",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "National Vision Tops Q2 Earnings, Lowers '24 Outlook - National Vision Holdings  ( NASDAQ:EYE ) ",
    "url": "https://www.benzinga.com/news/earnings/24/08/40254280/national-vision-tops-q2-earnings-lowers-24-outlook",
    "time_published": "20240808T153522",
    "authors": [
      "Zacks"
    ],
    "summary": "National Vision Holdings, Inc. EYE delivered an adjusted EPS ( earnings per share ) of 15 cents in the second quarter of 2024 compared with 17 cents in the year-ago period. The figure surpassed the Zacks Consensus Estimate of 6 cents.",
    "banner_image": "https://staticx-tuner.zacks.com/images/charts/50/1723114757.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999997"
      }
    ],
    "overall_sentiment_score": 0.131671,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "EYE",
        "relevance_score": "0.471156",
        "ticker_sentiment_score": "0.183952",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.053919",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.063279",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.13637",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "-0.05905",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Myriad Genetics Q2 Earnings Surpass, '24 Outlook Raised - Abbott Laboratories  ( NYSE:ABT ) , Quest Diagnostics  ( NYSE:DGX ) ",
    "url": "https://www.benzinga.com/news/mid-cap/24/08/40254297/myriad-genetics-q2-earnings-surpass-24-outlook-raised",
    "time_published": "20240808T153009",
    "authors": [
      "Zacks"
    ],
    "summary": "Myriad Genetics, Inc. MYGN reported adjusted earnings of 5 cents per share in the second quarter of 2024 compared to the Zacks Consensus Estimate of a loss of 1 cent per share. The reported figure also compares to a loss of 8 cents per share in the year-ago quarter.",
    "banner_image": "https://staticx-tuner.zacks.com/images/charts/42/1723113961.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.141797,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "QGEN",
        "relevance_score": "0.047185",
        "ticker_sentiment_score": "0.109982",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.140896",
        "ticker_sentiment_score": "0.061009",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.140896",
        "ticker_sentiment_score": "0.072041",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.232661",
        "ticker_sentiment_score": "0.107877",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MYGN",
        "relevance_score": "0.364053",
        "ticker_sentiment_score": "0.271557",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Envista  ( NVST )  Q2 Earnings & Revenues Miss, Margins Fall",
    "url": "https://www.zacks.com/stock/news/2319365/envista-nvst-q2-earnings-revenues-miss-margins-fall",
    "time_published": "20240808T151300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Envista's (NVST) Spark division sales witness a slowdown in the second quarter due to the deferment of a larger portion of case revenues.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/54381.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999994"
      }
    ],
    "overall_sentiment_score": 0.0,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.153145",
        "ticker_sentiment_score": "0.089803",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.203215",
        "ticker_sentiment_score": "0.075002",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.252463",
        "ticker_sentiment_score": "0.120812",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVST",
        "relevance_score": "0.393462",
        "ticker_sentiment_score": "-0.177577",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Veracyte  ( VCYT )  Q2 Earnings Beat Estimates, '24 Sales View Up",
    "url": "https://www.zacks.com/stock/news/2319283/veracyte-vcyt-q2-earnings-beat-estimates-24-sales-view-up",
    "time_published": "20240808T130900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Veracyte's (VCYT) second-quarter 2024 performance reflects the strength of its testing business.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/63046.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999919"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.133744,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "VCYT",
        "relevance_score": "0.444595",
        "ticker_sentiment_score": "0.423453",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.175009",
        "ticker_sentiment_score": "0.098057",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.231884",
        "ticker_sentiment_score": "0.081532",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.287537",
        "ticker_sentiment_score": "0.13421",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "These Stocks Just Dropped by 40% and 15% -- Should You Buy the Dip?",
    "url": "https://www.fool.com/investing/2024/08/08/these-stocks-just-dropped-by-40-and-15-should-you/",
    "time_published": "20240808T124500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "It might be a great time to buy low.",
    "banner_image": "https://g.foolcdn.com/editorial/images/785566/dexcom-g6-full-family.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.972756"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.98396"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.206535,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DXCM",
        "relevance_score": "0.338251",
        "ticker_sentiment_score": "0.094051",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.027685",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PINS",
        "relevance_score": "0.338251",
        "ticker_sentiment_score": "0.351101",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "National Vision  ( EYE )  Tops Q2 Earnings, Lowers '24 Outlook",
    "url": "https://www.zacks.com/stock/news/2318931/national-vision-eye-tops-q2-earnings-lowers-24-outlook",
    "time_published": "20240808T122500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "National Vision (EYE) delivers an earnings beat in the second quarter of 2024 and announces new transformative actions for long-term growth.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/80/66138.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999997"
      }
    ],
    "overall_sentiment_score": 0.119821,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "EYE",
        "relevance_score": "0.474321",
        "ticker_sentiment_score": "0.181635",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.137409",
        "ticker_sentiment_score": "0.046903",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.137409",
        "ticker_sentiment_score": "0.054146",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.137409",
        "ticker_sentiment_score": "0.030029",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.09186",
        "ticker_sentiment_score": "-0.059161",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Myriad Genetics  ( MYGN )  Q2 Earnings Surpass, '24 Outlook Raised",
    "url": "https://www.zacks.com/stock/news/2318906/myriad-genetics-mygn-q2-earnings-surpass-24-outlook-raised",
    "time_published": "20240808T121600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Myriad Genetics (MYGN) delivers a strong performance across its portfolio in the second quarter of 2024 and increases its long-term revenue growth rate target.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/47/62145.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.118173,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "QGEN",
        "relevance_score": "0.047654",
        "ticker_sentiment_score": "0.109992",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.142284",
        "ticker_sentiment_score": "0.049033",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.142284",
        "ticker_sentiment_score": "0.056416",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.234911",
        "ticker_sentiment_score": "0.084146",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MYGN",
        "relevance_score": "0.367412",
        "ticker_sentiment_score": "0.265993",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here's why Abbott India stock price surged 5% on August 8; details here",
    "url": "https://www.business-standard.com/markets/news/here-s-why-abbott-india-stock-price-surged-5-on-august-8-details-here-124080800556_1.html",
    "time_published": "20240808T070424",
    "authors": [
      "SI Reporter"
    ],
    "summary": "The uptick in the pharma company's stock price came after it posted a healthy set of numbers in the June quarter of financial year 2025 (Q1FY25).",
    "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/misc/2023-03/21/full/market-stocks-stock-market-trading-stock-market-1679390560-47312620.jpg?im=FeatureCrop,size=(826,465)",
    "source": "Business Standard",
    "category_within_source": "Markets",
    "source_domain": "www.business-standard.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      }
    ],
    "overall_sentiment_score": 0.169937,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.096283",
        "ticker_sentiment_score": "0.045114",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Got the Market Sell-Off Blues? Do These 3 Things Right Now",
    "url": "https://www.fool.com/investing/2024/08/11/got-the-market-sell-off-blues-do-these-3-things-ri/",
    "time_published": "20240811T112800",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "You aren't powerless in the face of what the market throws at you.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F786309%2Finvestor-expresses-regret.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.089522,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.156123",
        "ticker_sentiment_score": "0.01216",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.104455",
        "ticker_sentiment_score": "0.124987",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Biodegradable Stents Market Size is on Track for Significant Expansion to USD 809.2 Million by 2034 with 7.8% CAGR | Analysis by Transparency Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40345867/biodegradable-stents-market-size-is-on-track-for-significant-expansion-to-usd-809-2-million-by-203",
    "time_published": "20240813T163415",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Transparency Market Research Inc., Aug. 13, 2024 ( GLOBE NEWSWIRE ) -- As per the report published by Transparency Market Research, the global biodegradable stents market ( Markt f\u00fcr biologisch abbaubare Stents was worth US$ 351.6 Mn in 2023 and is expected ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/99d436ec-207d-4cd9-92a9-27ea1f8a77fb/biodegradable-stents-market.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.334683,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.037155",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.037155",
        "ticker_sentiment_score": "0.056337",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.111144",
        "ticker_sentiment_score": "0.066252",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.037155",
        "ticker_sentiment_score": "0.056337",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRUMF",
        "relevance_score": "0.037155",
        "ticker_sentiment_score": "0.056337",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Abbott Laboratories Stock Could Soar to $143, According to a Wall Street Analyst. Is It a Buy Around $108?",
    "url": "https://www.fool.com/investing/2024/08/12/abbott-laboratories-stock-could-soar-to-143-accord/",
    "time_published": "20240813T002900",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "An unexpected diabetes partnership with Medtronic bodes well for Abbott's biggest growth driver.",
    "banner_image": "https://g.foolcdn.com/editorial/images/786808/investment-presentation2-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.247093,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CURN",
        "relevance_score": "0.050786",
        "ticker_sentiment_score": "-0.109967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.249873",
        "ticker_sentiment_score": "0.221881",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.050786",
        "ticker_sentiment_score": "0.217437",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.201105",
        "ticker_sentiment_score": "0.176356",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.050786",
        "ticker_sentiment_score": "0.040944",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Rheumatology Therapeutics Market Size is Anticipated to Surpass Revenue of USD 65.1 Billion by 2034 at a Grow CAGR of 2.6% | Transparency Market Research Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40382614/rheumatology-therapeutics-market-size-is-anticipated-to-surpass-revenue-of-usd-65-1-billion-by-203",
    "time_published": "20240814T213000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Transparency Market Research, Inc.-, Aug. 14, 2024 ( GLOBE NEWSWIRE ) -- As per the report published by Transparency Market Research, the global rheumatology therapeutics market ( \u30ea\u30a6\u30de\u30c1\u6cbb\u7642\u85ac\u5e02\u5834 ) was worth US$ 48.8 Billion in 2023 and is expected to reach US$ ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/a8fed192-c91a-4fb3-9f0b-9237251567b2/rheumatology-therapeutics-market.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.138353,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BMXMF",
        "relevance_score": "0.03798",
        "ticker_sentiment_score": "0.135565",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.03798",
        "ticker_sentiment_score": "0.051692",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.03798",
        "ticker_sentiment_score": "0.135565",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMAWF",
        "relevance_score": "0.03798",
        "ticker_sentiment_score": "0.135565",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.03798",
        "ticker_sentiment_score": "0.135565",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.03798",
        "ticker_sentiment_score": "0.135565",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSRLF",
        "relevance_score": "0.03798",
        "ticker_sentiment_score": "0.135565",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIO",
        "relevance_score": "0.03798",
        "ticker_sentiment_score": "0.135565",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.03798",
        "ticker_sentiment_score": "0.135565",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "0.06894",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DHR",
        "relevance_score": "0.03798",
        "ticker_sentiment_score": "0.135565",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Chlamydia Infection Diagnostics and Therapeutics Market Size is Estimated to Reach 2.3 Billion, Expanding at a CAGR of 6.9 % by 2034 | TMR Research",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40372339/chlamydia-infection-diagnostics-and-therapeutics-market-size-is-estimated-to-reach-2-3-billion-exp",
    "time_published": "20240814T155201",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Transparency Market Research Inc., Aug. 14, 2024 ( GLOBE NEWSWIRE ) -- As per the report published by Transparency Market Research, the global chlamydia infection diagnostics and therapeutics market ( \ud074\ub77c\ubbf8\ub514\uc544 \uac10\uc5fc \uc9c4\ub2e8 \ubc0f \uce58\ub8cc\uc81c \uc2dc\uc7a5 ) was worth US$ 1.1 Billion in 2023 ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/6c7fcd4a-22c9-442c-94f6-e613cdddc87f/chlamydia-infection-diagnostics-and-therapeutics-market.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.147152,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BMXMF",
        "relevance_score": "0.036587",
        "ticker_sentiment_score": "-0.028254",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.036587",
        "ticker_sentiment_score": "0.051403",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMAWF",
        "relevance_score": "0.036587",
        "ticker_sentiment_score": "-0.028254",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIO",
        "relevance_score": "0.036587",
        "ticker_sentiment_score": "-0.028254",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.036587",
        "ticker_sentiment_score": "-0.028254",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.109455",
        "ticker_sentiment_score": "0.045263",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DHR",
        "relevance_score": "0.036587",
        "ticker_sentiment_score": "-0.028254",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.036587",
        "ticker_sentiment_score": "-0.028254",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.036587",
        "ticker_sentiment_score": "-0.028254",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.036587",
        "ticker_sentiment_score": "-0.028254",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSRLF",
        "relevance_score": "0.036587",
        "ticker_sentiment_score": "-0.028254",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSOI",
        "relevance_score": "0.036587",
        "ticker_sentiment_score": "0.189473",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BNXYF",
        "relevance_score": "0.036587",
        "ticker_sentiment_score": "0.189473",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Nutraceutical Market Surges to USD 453.78 Billion by 2031, Propelled by 2.10% CAGR - Verified Market Research\u00ae",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40368964/nutraceutical-market-surges-to-usd-453-78-billion-by-2031-propelled-by-2-10-cagr-verified-market-r",
    "time_published": "20240814T141500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Lewes, Delaware, Aug. 14, 2024 ( GLOBE NEWSWIRE ) -- The Global Nutraceutical Market Size is projected to grow at a CAGR of 2.10% from 2024 to 2031, according to a new report published by Verified Market Research\u00ae.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/0b99d04e-f3e3-4dda-ba7b-2871bab340ea/nutraceutical-market-size-and-forecast-768x432.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.303121,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.033098",
        "ticker_sentiment_score": "0.109966",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HLF",
        "relevance_score": "0.033098",
        "ticker_sentiment_score": "0.109966",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NSRGF",
        "relevance_score": "0.033098",
        "ticker_sentiment_score": "0.109966",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.033098",
        "ticker_sentiment_score": "0.109966",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HAIN",
        "relevance_score": "0.033098",
        "ticker_sentiment_score": "0.109966",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RSSS",
        "relevance_score": "0.033098",
        "ticker_sentiment_score": "0.17109",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 High-Yielding Dividend Growth Stocks That Retirees Can Rely On for Recurring Income",
    "url": "https://www.fool.com/investing/2024/08/17/3-high-yielding-dividend-growth-stocks-that-retire/",
    "time_published": "20240817T140000",
    "authors": [
      "David Jagielski"
    ],
    "summary": "These stocks all pay more than 3%, and they have been regularly increasing their payouts in recent years.",
    "banner_image": "https://g.foolcdn.com/editorial/images/786770/a-person-counting-money-in-their-living-room.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999967"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.356372,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PLD",
        "relevance_score": "0.320279",
        "ticker_sentiment_score": "0.520726",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.054857",
        "ticker_sentiment_score": "0.119432",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.417995",
        "ticker_sentiment_score": "0.444782",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.054857",
        "ticker_sentiment_score": "0.033885",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.369946",
        "ticker_sentiment_score": "0.222933",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Looking for Safe Dividend Income? These 3 Stocks Have Rock-Solid Payouts.",
    "url": "https://www.fool.com/investing/2024/08/17/looking-for-safe-dividend-income-these-3-stocks-ha/",
    "time_published": "20240817T131000",
    "authors": [
      "David Jagielski"
    ],
    "summary": "These stocks pay above-average yields, and their dividend income could rise higher in the future.",
    "banner_image": "https://g.foolcdn.com/editorial/images/786768/a-couple-reviewing-a-statement.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99977"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.196584,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.15347",
        "ticker_sentiment_score": "0.193316",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.051441",
        "ticker_sentiment_score": "-0.033003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "T",
        "relevance_score": "0.301315",
        "ticker_sentiment_score": "0.16261",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.15347",
        "ticker_sentiment_score": "0.21912",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Unstoppable Healthcare Stocks to Buy Right Now With Less Than $200",
    "url": "https://www.fool.com/investing/2024/08/18/2-unstoppable-healthcare-stocks-to-buy-right-now/",
    "time_published": "20240818T144500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "These companies' growth paths should only be briefly interrupted by headwinds.",
    "banner_image": "https://media.ycharts.com/charts/a2321f70eae9ea118150d0a6bc3e2c59.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.94762"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.95493"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.264664,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DXCM",
        "relevance_score": "0.49219",
        "ticker_sentiment_score": "0.368067",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GRWC",
        "relevance_score": "0.052801",
        "ticker_sentiment_score": "0.270837",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.052801",
        "ticker_sentiment_score": "0.075066",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Companion Diagnostics Market Size to Hit USD 9.3 Billion Revenue by 2028 with 9% CAGR: Report by Transparency Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40465060/companion-diagnostics-market-size-to-hit-usd-9-3-billion-revenue-by-2028-with-9-cagr-report-by-tra",
    "time_published": "20240820T143821",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Transparency Market Research Inc., Aug. 20, 2024 ( GLOBE NEWSWIRE ) -- The global companion diagnostics market ( \ub3d9\ubc18\uc9c4\ub2e8 \uc2dc\uc7a5 ) was worth US$ 5.2 Bn in 2020 and is expected to reach US$ 9.3 Billion by the year 2028 at a sizzling CAGR of 9.0% between 2020 and 2028.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/02b80288-636d-4be6-9b2a-a6cd6b677392/companion-diagnostics-market.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.038428,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BMXMF",
        "relevance_score": "0.03478",
        "ticker_sentiment_score": "0.035786",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "A",
        "relevance_score": "0.03478",
        "ticker_sentiment_score": "0.035786",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.03478",
        "ticker_sentiment_score": "0.051003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.03478",
        "ticker_sentiment_score": "0.035786",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXAS",
        "relevance_score": "0.03478",
        "ticker_sentiment_score": "0.035786",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ILMN",
        "relevance_score": "0.03478",
        "ticker_sentiment_score": "0.035786",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QGEN",
        "relevance_score": "0.104078",
        "ticker_sentiment_score": "0.051455",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.104078",
        "ticker_sentiment_score": "0.070137",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Continuous Blood Glucose Monitoring Can Materially Improve The Quality Of Life For People With Diabetes - Glucotrack Wants To Make It Easier - Abbott Laboratories  ( NYSE:ABT ) , DexCom  ( NASDAQ:DXCM ) ",
    "url": "https://www.benzinga.com/partner/health-care/24/08/40459450/continuous-blood-glucose-monitoring-can-materially-improve-the-quality-of-life-for-people-wit",
    "time_published": "20240820T120658",
    "authors": [
      "Meg Flippin"
    ],
    "summary": "You can't wing it when it comes to diabetes. Everything you eat and drink, the amount of physical activity you engage in and the medicines you take must be monitored closely. Keeping your blood glucose level within its target range is vital in preventing other medical issues.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.073867,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DXCM",
        "relevance_score": "0.058615",
        "ticker_sentiment_score": "-0.038007",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GCTK",
        "relevance_score": "0.203094",
        "ticker_sentiment_score": "0.048642",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.058615",
        "ticker_sentiment_score": "-0.007",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Laboratory Consumables Market Size Poised for Growth with Surpassing USD 301.2 Billion by 2031 at a 5.1% CAGR: Transparency Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40510671/laboratory-consumables-market-size-poised-for-growth-with-surpassing-usd-301-2-billion-by-2031-at-",
    "time_published": "20240822T152005",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Transparency Market Research, Inc., Aug. 22, 2024 ( GLOBE NEWSWIRE ) -- As per the report published by Transparency Market Research, the global laboratory consumables market ( \uc2e4\ud5d8\uc2e4 \uc18c\ubaa8\ud488 \uc2dc\uc7a5 ) was worth US$ 191.2 Billion in 2022 and is expected to reach US$ 301.2 ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/7eec8c9b-40ba-43bd-b830-1186c07a2820/laboratory-consumables-market-.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.225286,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "A",
        "relevance_score": "0.035661",
        "ticker_sentiment_score": "-0.035718",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.035661",
        "ticker_sentiment_score": "0.048332",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.035661",
        "ticker_sentiment_score": "-0.035718",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EKDHF",
        "relevance_score": "0.035661",
        "ticker_sentiment_score": "-0.035718",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GLW",
        "relevance_score": "0.035661",
        "ticker_sentiment_score": "-0.035718",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTOIF",
        "relevance_score": "0.035661",
        "ticker_sentiment_score": "0.103297",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.035661",
        "ticker_sentiment_score": "-0.035718",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.106699",
        "ticker_sentiment_score": "0.065222",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DHR",
        "relevance_score": "0.035661",
        "ticker_sentiment_score": "-0.035718",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Jim Cramer's top 10 things to watch in the stock market Thursday",
    "url": "https://www.cnbc.com/2024/08/22/jim-cramers-top-10-things-to-watch-in-the-stock-market-thursday.html",
    "time_published": "20240822T130623",
    "authors": [],
    "summary": "Citi backs Nvidia ahead of earnings, while James Gorman is in charge of Disney's succession planning.",
    "banner_image": null,
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998682"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      }
    ],
    "overall_sentiment_score": 0.17351,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.162073",
        "ticker_sentiment_score": "0.128639",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.054359",
        "ticker_sentiment_score": "0.049002",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.054359",
        "ticker_sentiment_score": "0.070025",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.214937",
        "ticker_sentiment_score": "0.075724",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TJX",
        "relevance_score": "0.054359",
        "ticker_sentiment_score": "0.070025",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.054359",
        "ticker_sentiment_score": "0.020059",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBUX",
        "relevance_score": "0.108466",
        "ticker_sentiment_score": "0.005555",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.108466",
        "ticker_sentiment_score": "0.16055",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.054359",
        "ticker_sentiment_score": "0.117781",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DELL",
        "relevance_score": "0.054359",
        "ticker_sentiment_score": "0.020059",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "URBN",
        "relevance_score": "0.108466",
        "ticker_sentiment_score": "0.110261",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Abbott Laboratories, Nu Holdings And More On CNBC's 'Final Trades' - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/08/40506059/abbott-laboratories-nu-holdings-and-more-on-cnbcs-final-trades",
    "time_published": "20240822T124821",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Halftime Report Final Trades,\" Karen Firestone of Aureus Asset Management said Abbott Laboratories ABT has a strong pipeline and the stock is starting to move. On July 18, Abbott reported second-quarter sales of $10.38 billion, up 4%, almost in line with the consensus of $10.37 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/22/untitled_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.265802,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.392948",
        "ticker_sentiment_score": "0.552851",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NU",
        "relevance_score": "0.696319",
        "ticker_sentiment_score": "0.060157",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTS",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Abbott  ( ABT )  Gets FDA Approval for Aspirin-Free HeartMate 3 Regimen",
    "url": "https://www.zacks.com/stock/news/2326206/abbott-abt-gets-fda-approval-for-aspirin-free-heartmate-3-regimen",
    "time_published": "20240823T131200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Abbott's (ABT) labeling update, exclusively for patients with a HeartMate 3 heart pump, secures the FDA's approval.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e0/1871.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.9545"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.223099,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MASI",
        "relevance_score": "0.179121",
        "ticker_sentiment_score": "0.09968",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.090134",
        "ticker_sentiment_score": "0.250226",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.179121",
        "ticker_sentiment_score": "0.106826",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.134841",
        "ticker_sentiment_score": "0.135251",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.134841",
        "ticker_sentiment_score": "0.052418",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Unstoppable Dividend Stocks to Buy Right Now",
    "url": "https://www.fool.com/investing/2024/08/25/3-unstoppable-dividend-stocks-to-buy-right-now/",
    "time_published": "20240825T223000",
    "authors": [
      "and Prosper Junior Bakiny",
      "Keith Speights",
      "David Jagielski"
    ],
    "summary": "These stocks are the A-team for income investors.",
    "banner_image": "https://g.foolcdn.com/editorial/images/788183/two-people-looking-at-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.382955,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.282777",
        "ticker_sentiment_score": "0.365654",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.282777",
        "ticker_sentiment_score": "0.335334",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.237204",
        "ticker_sentiment_score": "0.186795",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Diagnostic Giants Labcorp, Roche To Ramp Up Testing Capacity Amid Global Concerns Over New Mpox Strain - Labcorp Holdings  ( NYSE:LH ) ",
    "url": "https://www.benzinga.com/news/large-cap/24/08/40559658/diagnostic-giants-labcorp-roche-to-ramp-up-testing-capacity-amid-global-concerns-over-new-mpox-str",
    "time_published": "20240826T173631",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Labcorp Holdings Inc LH is reportedly collaborating with U.S. health regulators to determine whether it should scale up its mpox testing capabilities, following global concerns over a newly detected virus strain outside Africa.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/26/Congo-Worst-Affected.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": -0.016672,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DGX",
        "relevance_score": "0.197413",
        "ticker_sentiment_score": "-0.157634",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.197413",
        "ticker_sentiment_score": "-0.157634",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "BVNKF",
        "relevance_score": "0.197413",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Dexcom's Stelo Device Brings Affordable Continuous Glucose Monitoring To Type 2 Diabetes Patients - DexCom  ( NASDAQ:DXCM ) ",
    "url": "https://www.benzinga.com/news/large-cap/24/08/40556465/dexcoms-stelo-device-brings-affordable-continuous-glucose-monitoring-to-type-2-diabetes-patients",
    "time_published": "20240826T153906",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "In March, the FDA approved DexCom Inc's DXCM Stelo Glucose Biosensor System as the first over-the-counter ( OTC ) continuous glucose monitor ( CGM ) . The Dexcom Stelo Glucose Biosensor System is an integrated CGM ( iCGM ) intended for people 18 and older who do not use insulin.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/26/biotech-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.187903,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DXCM",
        "relevance_score": "0.705377",
        "ticker_sentiment_score": "0.4255",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.206685",
        "ticker_sentiment_score": "0.163215",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "This Is Great News for Medtronic, but Is It Time to Buy the Stock?",
    "url": "https://www.fool.com/investing/2024/08/26/great-news-for-medtronic-investors-time-to-buy/",
    "time_published": "20240826T130000",
    "authors": [
      "Dan Victor"
    ],
    "summary": "This MedTech leader is back on track with profitable growth.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F788089%2Fgettyimages-2150701511-1200x800-5b2df79.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.993856"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.400165,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GEHC",
        "relevance_score": "0.058188",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EW",
        "relevance_score": "0.058188",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.058188",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.657331",
        "ticker_sentiment_score": "0.541866",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.058188",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.058188",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Abbott's Core Businesses Thrive Despite Macroeconomic Issues",
    "url": "https://www.zacks.com/stock/news/2327754/abbotts-core-businesses-thrive-despite-macroeconomic-issues",
    "time_published": "20240827T150200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "ABT is particularly gaining from the strong adoption of its market leading systems and demand for testing that takes place in a variety of settings.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.9545"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.168472,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EXAS",
        "relevance_score": "0.210274",
        "ticker_sentiment_score": "0.113441",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "0.052841",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.210274",
        "ticker_sentiment_score": "0.232255",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Eli Lilly, Chevron, Abbott and Bridger Aerospace",
    "url": "https://www.zacks.com/stock/news/2327368/the-zacks-analyst-blog-eli-lilly-chevron-abbott-and-bridger-aerospace",
    "time_published": "20240827T063000",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Eli Lilly, Chevron, Abbott and Bridger Aerospace are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/73/488.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.292416,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.305058",
        "ticker_sentiment_score": "0.131484",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAER",
        "relevance_score": "0.206245",
        "ticker_sentiment_score": "-0.028124",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.104002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.206245",
        "ticker_sentiment_score": "0.200844",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HES",
        "relevance_score": "0.052112",
        "ticker_sentiment_score": "0.273767",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "ABT Expands Pure Bliss Line of Products for Advanced Infant Nutrition",
    "url": "https://www.zacks.com/stock/news/2328328/abt-expands-pure-bliss-line-of-products-for-advanced-infant-nutrition",
    "time_published": "20240828T134100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Abbott announces the expansion of its Pure Bliss by Similac line of products for infant nutrition with Organic and Organic A2 Milk infant formulas.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.980509"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.448968,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TMDX",
        "relevance_score": "0.219312",
        "ticker_sentiment_score": "0.152684",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.219312",
        "ticker_sentiment_score": "0.225107",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.055492",
        "ticker_sentiment_score": "0.120871",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.165409",
        "ticker_sentiment_score": "0.060544",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.272181",
        "ticker_sentiment_score": "0.208561",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.055492",
        "ticker_sentiment_score": "0.485272",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Looking Into Abbott Laboratories's Recent Short Interest - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/08/40628656/looking-into-abbott-laboratoriess-recent-short-interest",
    "time_published": "20240829T153019",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Abbott Laboratories's ABT short percent of float has fallen 7.59% since its last report. The company recently reported that it has 12.68 million shares sold short, which is 0.73% of all regular shares that are available for trading.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1724945416_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.262256,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.079385",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Monster Stocks You Can Buy Right Now Before They Surge Even Higher",
    "url": "https://www.fool.com/investing/2024/08/30/2-monster-stocks-you-can-buy-right-now-before-they/",
    "time_published": "20240830T134500",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "These businesses can stand the test of time in a diversified portfolio.",
    "banner_image": "https://g.foolcdn.com/editorial/images/788639/getty-happy-victory-profits-winning-success-gains-pleased.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.244036,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CAVA",
        "relevance_score": "0.142005",
        "ticker_sentiment_score": "0.135819",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.366736",
        "ticker_sentiment_score": "0.145436",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.047559",
        "ticker_sentiment_score": "0.073038",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Rock-Solid Pharma Stocks to Buy Now and Hold Forever",
    "url": "https://www.fool.com/investing/2024/08/30/3-rock-solid-pharma-stocks-to-buy-now-and-hold-for/",
    "time_published": "20240830T104500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "These three have secure core businesses, plus multiple paths to grow.",
    "banner_image": "https://g.foolcdn.com/editorial/images/788607/doctor-and-nurse-talk-with-investor.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.94762"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.238076,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.089797",
        "ticker_sentiment_score": "-0.003168",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.134339",
        "ticker_sentiment_score": "0.043756",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.089797",
        "ticker_sentiment_score": "-0.004225",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Medtronic Stock a Buy?",
    "url": "https://www.fool.com/investing/2024/09/01/is-medtronic-stock-a-buy/",
    "time_published": "20240901T124500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "It might not be the most exciting business, but it has other things going its way.",
    "banner_image": "https://g.foolcdn.com/editorial/images/788711/diabetes-patient-adjusting-device.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.988915"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.255659,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MDT",
        "relevance_score": "0.523784",
        "ticker_sentiment_score": "0.29039",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.063091",
        "ticker_sentiment_score": "0.136098",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 High-Yield Dividend Stocks to Buy in September and Hold for a Decade or Longer",
    "url": "https://www.fool.com/investing/2024/09/01/2-high-yield-dividend-stocks-to-buy-in-september-a/",
    "time_published": "20240901T095300",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "A drugmaker and a telecom business have what it takes to safely boost your passive income stream.",
    "banner_image": "https://g.foolcdn.com/editorial/images/789010/investors-evaluating-a-stock-purchase-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.206401,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "T",
        "relevance_score": "0.222838",
        "ticker_sentiment_score": "0.160048",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.328819",
        "ticker_sentiment_score": "0.231537",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.056407",
        "ticker_sentiment_score": "0.058914",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Dividend Stocks You Can Safely Hold Through a Recession",
    "url": "https://www.fool.com/investing/2024/09/02/2-dividend-stocks-you-can-safely-hold-through-a/",
    "time_published": "20240902T124500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "These stocks can help you sleep peacefully at night, even in bad times.",
    "banner_image": "https://g.foolcdn.com/editorial/images/788898/doctor-with-patient-talking.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      }
    ],
    "overall_sentiment_score": 0.210419,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.264515",
        "ticker_sentiment_score": "0.155202",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.05387",
        "ticker_sentiment_score": "0.072757",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is DexCom a Millionaire-Maker Stock?",
    "url": "https://www.fool.com/investing/2024/09/02/is-dexcom-a-millionaire-maker-stock/",
    "time_published": "20240902T111200",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The stock has delivered superior returns in the past 19 years.",
    "banner_image": "https://g.foolcdn.com/editorial/images/788047/dexcom-g6-full-family.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      }
    ],
    "overall_sentiment_score": 0.273415,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.052455",
        "ticker_sentiment_score": "0.035922",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PODD",
        "relevance_score": "0.052455",
        "ticker_sentiment_score": "0.141586",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.104683",
        "ticker_sentiment_score": "0.121976",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TNDM",
        "relevance_score": "0.052455",
        "ticker_sentiment_score": "0.141586",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.642977",
        "ticker_sentiment_score": "0.493744",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Healthy Returns: Eli Lilly could soon become the first $1 trillion health-care stock",
    "url": "https://www.cnbc.com/2024/09/05/healthy-returns-eli-lilly-could-become-the-first-1-trillion-healthcare-stock.html",
    "time_published": "20240905T184706",
    "authors": [],
    "summary": "Eli Lilly could be on its way to topping $1 trillion in market value. Meanwhile, Abbott launches its first over-the-counter continuous glucose monitor in U.S.",
    "banner_image": null,
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.22981,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.043579",
        "ticker_sentiment_score": "0.124722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.043579",
        "ticker_sentiment_score": "0.124722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.087027",
        "ticker_sentiment_score": "-0.038955",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.043579",
        "ticker_sentiment_score": "0.119764",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Abbott Laboratories Recalls Some Sensors For Its Popular FreeStyle Libre 3 Glucose Monitoring System - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/news/large-cap/24/09/40738686/abbott-laboratories-recalls-some-sensors-for-its-popular-freestyle-libre-3-glucose-monitoring-syst",
    "time_published": "20240905T184524",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Thursday, Abbott Laboratories ABT said it is recalling some FreeStyle Libre 3 sensors after finding that a small number of FreeStyle Libre 3 sensors may provide incorrect high glucose readings.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/05/abbott-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.046575,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.324495",
        "ticker_sentiment_score": "0.087574",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Hims & Hers Stock Plunges 32.1% in Three Months: What's Next?",
    "url": "https://www.zacks.com/stock/news/2332325/hims-hers-stock-plunges-321-in-three-months-whats-next",
    "time_published": "20240905T160300",
    "authors": [
      "Debanjana Dey"
    ],
    "summary": "HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.331018,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HIMS",
        "relevance_score": "0.320453",
        "ticker_sentiment_score": "0.210001",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.082251",
        "ticker_sentiment_score": "0.028275",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TDOC",
        "relevance_score": "0.082251",
        "ticker_sentiment_score": "0.028275",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Abbott launches its first over-the-counter continuous glucose monitor in the U.S.",
    "url": "https://www.cnbc.com/2024/09/05/-abbott-launches-its-first-over-the-counter-continuous-glucose-monitor-in-the-us.html",
    "time_published": "20240905T130001",
    "authors": [],
    "summary": "Abbott Laboratories announced Lingo, its first over-the-counter continuous glucose monitor, is available in the U.S.",
    "banner_image": null,
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.167094,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NKE",
        "relevance_score": "0.037563",
        "ticker_sentiment_score": "-0.194728",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.037563",
        "ticker_sentiment_score": "0.17488",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.037563",
        "ticker_sentiment_score": "0.106946",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ULTA",
        "relevance_score": "0.037563",
        "ticker_sentiment_score": "0.357201",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.037563",
        "ticker_sentiment_score": "0.03335",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Got $1,000? 3 Healthcare Stocks to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/09/05/got-1000-healthcare-stocks-buy-and-hold-forever/",
    "time_published": "20240905T085000",
    "authors": [
      "Justin Pope"
    ],
    "summary": "There is something for everybody in America's $4.5 trillion healthcare market.",
    "banner_image": "https://g.foolcdn.com/editorial/images/787539/healthcare-nurse.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.988915"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.379156,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.345674",
        "ticker_sentiment_score": "0.374821",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.051003",
        "ticker_sentiment_score": "0.214468",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.152178",
        "ticker_sentiment_score": "0.199721",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.345674",
        "ticker_sentiment_score": "0.381327",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Abbott's Lingo CGM System Gains U.S. Availability: Stock to Gain?",
    "url": "https://www.zacks.com/stock/news/2332712/abbotts-lingo-cgm-system-gains-us-availability-stock-to-gain",
    "time_published": "20240906T133700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "ABT made its CGM system Lingo available in the United States. The system can be used by consumers aged 18 years and older who are not on insulin.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b8/1573.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.980509"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.293906,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TMDX",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.144392",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.253514",
        "ticker_sentiment_score": "0.293932",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.051551",
        "ticker_sentiment_score": "0.12946",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.153797",
        "ticker_sentiment_score": "0.057773",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.253514",
        "ticker_sentiment_score": "0.197138",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Things You Need to Know if You Buy AbbVie Stock Today",
    "url": "https://www.fool.com/investing/2024/09/09/3-things-you-need-to-know-if-you-buy-abbvie-stock/",
    "time_published": "20240909T160500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "This dynamic big pharma is undergoing a few key changes.",
    "banner_image": "https://g.foolcdn.com/editorial/images/789927/doctor-and-businessman-working-on-digital-tablet-in-the-office.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.246889,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.193207",
        "ticker_sentiment_score": "0.149755",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.064973",
        "ticker_sentiment_score": "0.042028",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.064973",
        "ticker_sentiment_score": "0.059427",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Stocks That Are Passive Income Machines to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/09/11/2-stocks-that-are-passive-income-machines-to-buy-a/",
    "time_published": "20240911T105900",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "You can take these dividends straight to the bank.",
    "banner_image": "https://g.foolcdn.com/editorial/images/789836/doctor-holding-elderly-patients-hand.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      }
    ],
    "overall_sentiment_score": 0.213804,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.515636",
        "ticker_sentiment_score": "0.377301",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.37552",
        "ticker_sentiment_score": "0.323864",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Does Workday Have a Major Revenue Problem?",
    "url": "https://www.fool.com/investing/2024/09/12/does-workday-have-a-major-revenue-problem/",
    "time_published": "20240912T140800",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "Its top-line growth is slowing. However, there are some positive factors that could mitigate that.",
    "banner_image": "https://g.foolcdn.com/editorial/images/789376/a-group-of-people-gathered-around-a-table-in-an-office.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.995973"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.300135,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SHAK",
        "relevance_score": "0.061949",
        "ticker_sentiment_score": "0.212189",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.061949",
        "ticker_sentiment_score": "0.212189",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CCZ",
        "relevance_score": "0.061949",
        "ticker_sentiment_score": "0.212189",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Pacemaker Devices Market Size to Reach USD 6.9 Billion by 2034, Driven by Minimally Invasive Techniques and Personalized Medicine | Transparency Market Research Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40856519/pacemaker-devices-market-size-to-reach-usd-6-9-billion-by-2034-driven-by-minimally-invasive-techni",
    "time_published": "20240913T151357",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Transparency Market Research, Inc., Sept. 13, 2024 ( GLOBE NEWSWIRE ) -- The global pacemaker devices market ( \uc2ec\uc7a5\ubc15\ub3d9\uae30 \uc7a5\uce58 \uc2dc\uc7a5 ) is estimated to surge at a CAGR of 3.8% from 2024 to 2034.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/fb2838b8-05ab-488b-80d2-737a1c2b815c/pacemaker-devices-market.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.431268,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.032961",
        "ticker_sentiment_score": "0.050574",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.065866",
        "ticker_sentiment_score": "0.197897",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.065866",
        "ticker_sentiment_score": "0.197897",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.098659",
        "ticker_sentiment_score": "0.053052",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.098659",
        "ticker_sentiment_score": "0.110089",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Ultra-Safe Dividend Stocks for Retirees to Buy and Hold",
    "url": "https://www.fool.com/investing/2024/09/13/3-ultra-safe-dividend-stocks-for-retirees-to-buy/",
    "time_published": "20240913T130000",
    "authors": [
      "David Jagielski"
    ],
    "summary": "These stocks have increased their payouts for decades.",
    "banner_image": "https://g.foolcdn.com/editorial/images/789982/two-people-shaking-hands-at-a-meeting.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.752319"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.349319,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ENB",
        "relevance_score": "0.239541",
        "ticker_sentiment_score": "0.224229",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.145145",
        "ticker_sentiment_score": "0.338722",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ICNB",
        "relevance_score": "0.048621",
        "ticker_sentiment_score": "0.143933",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.239541",
        "ticker_sentiment_score": "0.319766",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Stocks to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/09/14/3-stocks-to-buy-and-hold-forever/",
    "time_published": "20240914T113000",
    "authors": [
      "Keith Speights",
      "David Jagielski",
      "and Prosper Junior Bakiny"
    ],
    "summary": "These stocks are built for the long run.",
    "banner_image": "https://g.foolcdn.com/editorial/images/790595/hands-behind-head-young-man.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.302576,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.420783",
        "ticker_sentiment_score": "0.432652",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.218423",
        "ticker_sentiment_score": "0.259411",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.260652",
        "ticker_sentiment_score": "0.074855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.044222",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Unstoppable Healthcare Stocks to Buy Right Now for Less Than $200",
    "url": "https://www.fool.com/investing/2024/09/14/2-unstoppable-healthcare-stocks-to-buy-right-now-f/",
    "time_published": "20240914T093000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "No need to break the bank to get in on these excellent companies.",
    "banner_image": "https://media.ycharts.com/charts/afbb325916a5bf3ec0bf2c08d120daf7.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.918141"
      }
    ],
    "overall_sentiment_score": 0.276063,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.05257",
        "ticker_sentiment_score": "0.079634",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTRCF",
        "relevance_score": "0.104911",
        "ticker_sentiment_score": "0.231754",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.402135",
        "ticker_sentiment_score": "0.23158",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.258351",
        "ticker_sentiment_score": "0.356008",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Can AbbVie Regain Its Status As a Top Dividend Growth Stock?",
    "url": "https://www.fool.com/investing/2024/09/16/can-abbvie-regain-its-status-as-a-top-dividend-gro/",
    "time_published": "20240916T110000",
    "authors": [
      "George Budwell"
    ],
    "summary": "The dividend growth powerhouse is turning the corner.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F790803%2Fu-turn.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.312508,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.409171",
        "ticker_sentiment_score": "0.390142",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.085629",
        "ticker_sentiment_score": "0.129735",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Abata Therapeutics Appoints Joanne Beck, Ph.D., as Chief Technical Officer",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40874218/abata-therapeutics-appoints-joanne-beck-ph-d-as-chief-technical-officer",
    "time_published": "20240916T110000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "WATERTOWN, Mass., Sept. 16, 2024 ( GLOBE NEWSWIRE ) -- Abata Therapeutics, a clinical-stage biotech company focused on transforming lives with Treg therapies for severe autoimmune and inflammatory diseases, today announced the appointment of Joanne Beck, Ph.D., as chief technical officer.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.273548,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ATXS",
        "relevance_score": "0.052226",
        "ticker_sentiment_score": "-0.022833",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.052226",
        "ticker_sentiment_score": "-0.022833",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.052226",
        "ticker_sentiment_score": "0.115902",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.052226",
        "ticker_sentiment_score": "0.115902",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Abbott Laboratories' Best Segment Just Got Even Better: Is the Stock a Buy?",
    "url": "https://www.fool.com/investing/2024/09/16/abbott-laboratories-best-segment-just-got-even-bet/",
    "time_published": "20240916T091200",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The company continues to flex its innovative muscles.",
    "banner_image": "https://g.foolcdn.com/editorial/images/790441/diabetes-patient-adjusting-device.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.744043"
      }
    ],
    "overall_sentiment_score": 0.283356,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.48268",
        "ticker_sentiment_score": "0.351664",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Abbott Laboratories' Attractive Valuation Ranks It Among Top Large-Cap MedTech Companies, Says Analyst - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40946305/abbott-laboratories-attractive-valuation-ranks-it-among-top-large-cap-medtech-compa",
    "time_published": "20240919T190319",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Piper Sandler initiated coverage on Abbott Laboratories ABT, noting the company as a versatile large-cap with an attractive valuation. Abbott has a diversified business model with solid distribution across segments ( medtech, diagnostics, nutrition, pharmaceuticals ) and geography.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/19/untitled_4.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.20466,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RBGLY",
        "relevance_score": "0.184598",
        "ticker_sentiment_score": "-0.195087",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.440549",
        "ticker_sentiment_score": "0.261473",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RBGPF",
        "relevance_score": "0.092927",
        "ticker_sentiment_score": "-0.136368",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Europe Molecular Diagnostics Market Size & Share to Surpass USD 17.3 billion by 2034 | Analysis by Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40944113/europe-molecular-diagnostics-market-size-share-to-surpass-usd-17-3-billion-by-2034-analysis-by-tra",
    "time_published": "20240919T164934",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Transparency Market Research, Inc. , Sept. 19, 2024 ( GLOBE NEWSWIRE ) -- The Europe molecular diagnostics market is estimated to flourish at a CAGR of 10.2% from 2024 to 2034.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/1275d4a5-ef98-478c-97ff-9d57c607aed4/molecular-diagnostics-market.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.381384,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BMXMF",
        "relevance_score": "0.063933",
        "ticker_sentiment_score": "0.231762",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "A",
        "relevance_score": "0.031992",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.031992",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.063933",
        "ticker_sentiment_score": "0.166617",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.031992",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSRLF",
        "relevance_score": "0.031992",
        "ticker_sentiment_score": "0.318053",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIO",
        "relevance_score": "0.031992",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRFS",
        "relevance_score": "0.031992",
        "ticker_sentiment_score": "0.158971",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "QGEN",
        "relevance_score": "0.063933",
        "ticker_sentiment_score": "0.212384",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ORYZF",
        "relevance_score": "0.031992",
        "ticker_sentiment_score": "0.158971",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.095771",
        "ticker_sentiment_score": "0.082276",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Abbott Stock Hurt by Macroeconomic Issues & FX Headwind",
    "url": "https://www.zacks.com/stock/news/2338593/abbott-stock-hurt-by-macroeconomic-issues-fx-headwind",
    "time_published": "20240919T144900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Foreign exchange fluctuation is a major headwind for ABT, as a considerable percentage of its revenues comes from outside the United States.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976671"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.839681"
      }
    ],
    "overall_sentiment_score": 0.11017,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AXGN",
        "relevance_score": "0.148121",
        "ticker_sentiment_score": "0.053956",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMDX",
        "relevance_score": "0.19661",
        "ticker_sentiment_score": "0.154104",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.148121",
        "ticker_sentiment_score": "-0.054784",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KIDS",
        "relevance_score": "0.291182",
        "ticker_sentiment_score": "0.099287",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:EUR",
        "relevance_score": "0.049629",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/news/24/09/40937700/this-abbott-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-thursday",
    "time_published": "20240919T124213",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Piper Sandler analyst Adam Maeder initiated coverage on Abbott Laboratories ABT with an Overweight rating ...",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19083945/image-154-1024x512.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.282128,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.348919",
        "ticker_sentiment_score": "-0.063093",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CHTR",
        "relevance_score": "0.348919",
        "ticker_sentiment_score": "0.272987",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HLX",
        "relevance_score": "0.236972",
        "ticker_sentiment_score": "0.175155",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NOG",
        "relevance_score": "0.236972",
        "ticker_sentiment_score": "0.211272",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TPB",
        "relevance_score": "0.348919",
        "ticker_sentiment_score": "0.419196",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Heart Failure Monitoring Systems Market Growth to Reach US$ 24,612.2 Million at a CAGR of 5.7% by 2034 | Fact.MR",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40934283/heart-failure-monitoring-systems-market-growth-to-reach-us-24-612-2-million-at-a-cagr-of-5-7-by-20",
    "time_published": "20240919T100000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Rockville, MD, Sept. 19, 2024 ( GLOBE NEWSWIRE ) -- According to Fact.MR, a market research and competitive intelligence provider, the global heart failure monitoring systems market is estimated to reach a valuation of US$ 14,079.6 million in 2024 and is expected to grow at a CAGR of 5.7% during ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/c968a57a-0435-4f6e-bade-03aac87495ef/heart-failure-monitoring-systems-market.jpg",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.362841,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.059711",
        "ticker_sentiment_score": "0.016026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.089462",
        "ticker_sentiment_score": "0.031098",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.089462",
        "ticker_sentiment_score": "0.08166",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GE",
        "relevance_score": "0.119088",
        "ticker_sentiment_score": "0.018556",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.029876",
        "ticker_sentiment_score": "0.105544",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PHG",
        "relevance_score": "0.059711",
        "ticker_sentiment_score": "0.016026",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "DexCom Is Great. Here's Why You Shouldn't Buy It.",
    "url": "https://www.fool.com/investing/2024/09/25/dexcom-is-great-heres-why-you-shouldnt-buy-it/",
    "time_published": "20240925T134500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Two key uncertainties make the prospect of buying it today riskier than is desirable.",
    "banner_image": "https://media.ycharts.com/charts/a45f74f7ab0caee33f8f304d48e56e8f.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.988915"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.197055,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DXCM",
        "relevance_score": "0.307603",
        "ticker_sentiment_score": "0.175968",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.05257",
        "ticker_sentiment_score": "0.077999",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.05257",
        "ticker_sentiment_score": "-0.013009",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is DexCom a Millionaire Maker?",
    "url": "https://www.fool.com/investing/2024/09/25/is-dexcom-a-millionaire-maker/",
    "time_published": "20240925T120700",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "It isn't the most likely candidate to make someone a millionaire, but it's theoretically possible.",
    "banner_image": "https://g.foolcdn.com/editorial/images/790548/doctors-with-investors.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.972756"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.247732,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DXCM",
        "relevance_score": "0.277118",
        "ticker_sentiment_score": "0.128403",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.05654",
        "ticker_sentiment_score": "0.14695",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off",
    "url": "https://www.fool.com/investing/2024/09/25/2-unstoppable-dividend-stocks-to-buy-if-a-selloff/",
    "time_published": "20240925T103500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "These dividend players could lift your portfolio no matter what the market is doing.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F791677%2Fgettyimages-an-investor-reads-something-on-his-phone.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99393"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.928769"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.359918,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.113062",
        "ticker_sentiment_score": "0.372902",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.113062",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Forget Novo Nordisk, Buy This Magnificent Dividend Stock Instead",
    "url": "https://www.fool.com/investing/2024/09/26/forget-novo-nordisk-buy-this-magnificent-dividend/",
    "time_published": "20240926T123000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "Even the mighty Novo Nordisk can't hold a candle to its peer in this area.",
    "banner_image": "https://media.ycharts.com/charts/274fc80dee3744f630d06f23387c1cae.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.318167,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.550151",
        "ticker_sentiment_score": "0.412957",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.12013",
        "ticker_sentiment_score": "0.159675",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MPW",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "-0.014039",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.294446",
        "ticker_sentiment_score": "0.406178",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "WBA",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "-0.014039",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Excellent Dividend Stocks to Buy With Less Than $200",
    "url": "https://www.fool.com/investing/2024/09/28/2-excellent-dividend-stocks-to-buy-with-less-than/",
    "time_published": "20240928T090000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "Abbott Laboratories and Johnson & Johnson both have raised their dividends annually for more than 50 years.",
    "banner_image": "https://media.ycharts.com/charts/f09d2b0e2d98551346d9b46063a4402f.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.244485,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.25726",
        "ticker_sentiment_score": "0.311586",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.306325",
        "ticker_sentiment_score": "0.184425",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Down More Than 50%, Is DexCom Stock a Bargain Now?",
    "url": "https://www.fool.com/investing/2024/10/02/down-more-than-50-is-dexcom-stock-a-bargain-now/",
    "time_published": "20241002T081100",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Demand for blood glucose monitors is strong, but DexCom isn't the only competitor in this lucrative market.",
    "banner_image": "https://g.foolcdn.com/editorial/images/792566/investor-calculator-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.162949,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MDT",
        "relevance_score": "0.104228",
        "ticker_sentiment_score": "0.162878",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.605524",
        "ticker_sentiment_score": "0.209756",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.104228",
        "ticker_sentiment_score": "0.03257",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Expanding Continuous Glucose Monitoring Options: How Glucotrack Is Helping Usher In The Next Generation Of Diabetes Care Technology - Abbott Laboratories  ( NYSE:ABT ) , DexCom  ( NASDAQ:DXCM ) ",
    "url": "https://www.benzinga.com/partner/health-care/24/10/41162090/expanding-continuous-glucose-monitoring-options-how-glucotrack-is-helping-usher-in-the-next-g",
    "time_published": "20241003T120306",
    "authors": [
      "Joshenomoto@benzinga.com"
    ],
    "summary": "Introduced in the late 1990s, continuous glucose monitoring ( CGM ) revolutionized diabetes care. Prior to CGM, home blood glucose monitoring ( BGM ) methodologies - which involve patients using a lancet to prick their fingers and apply a drop of blood to a test strip - represented the norm.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/03/Screenshot-2024-10-03-at-5-30-47PM.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.1396,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GCTK",
        "relevance_score": "0.307603",
        "ticker_sentiment_score": "0.116885",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.05257",
        "ticker_sentiment_score": "0.130596",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.078783",
        "ticker_sentiment_score": "0.107187",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.078783",
        "ticker_sentiment_score": "-0.003077",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Beaten-Down Growth Stocks You Might Regret Not Buying",
    "url": "https://www.fool.com/investing/2024/10/05/2-beaten-down-growth-stocks-you-might-regret-not/",
    "time_published": "20241005T104500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "Their headwinds won't last forever.",
    "banner_image": "https://media.ycharts.com/charts/b9217d04221e3a9bb6fa601f58f6a4ca.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.972756"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.980716"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.275476,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ROKU",
        "relevance_score": "0.420705",
        "ticker_sentiment_score": "0.371902",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.241924",
        "ticker_sentiment_score": "0.340688",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.04912",
        "ticker_sentiment_score": "0.113088",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Top Dividend Stocks Yielding 3% or More to Buy Without Hesitation Right Now",
    "url": "https://www.fool.com/investing/2024/10/05/2-top-dividend-stocks-yielding-3-or-more-to-buy/",
    "time_published": "20241005T101500",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "These companies can lend growth and dividend returns to a long-term investor's portfolio.",
    "banner_image": "https://g.foolcdn.com/editorial/images/792527/investing-woman-wall-street-suit-stocks-finance-1.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999186"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.94762"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.181548,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.143415",
        "ticker_sentiment_score": "0.089662",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.036037",
        "ticker_sentiment_score": "0.030721",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ICNB",
        "relevance_score": "0.036037",
        "ticker_sentiment_score": "-0.024285",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.036037",
        "ticker_sentiment_score": "0.084206",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KHC",
        "relevance_score": "0.380802",
        "ticker_sentiment_score": "0.195899",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Magnificent Dividend Stocks to Buy in October",
    "url": "https://www.fool.com/investing/2024/10/06/3-magnificent-dividend-stocks-to-buy-in-october/",
    "time_published": "20241006T095000",
    "authors": [
      "David Jagielski",
      "Keith Speights",
      "and Prosper Junior Bakiny"
    ],
    "summary": "These dividend stocks are great picks as the fall season gets underway.",
    "banner_image": "https://g.foolcdn.com/editorial/images/792876/retired-woman-investing-laptop-401k-ira.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999922"
      }
    ],
    "overall_sentiment_score": 0.334621,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.364053",
        "ticker_sentiment_score": "0.389014",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.094204",
        "ticker_sentiment_score": "0.067748",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LDNXF",
        "relevance_score": "0.047185",
        "ticker_sentiment_score": "0.147599",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.277433",
        "ticker_sentiment_score": "0.354037",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.232661",
        "ticker_sentiment_score": "0.213443",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Billionaires Are Loading Up on This High-Yield Dividend Stock. Should You?",
    "url": "https://www.fool.com/investing/2024/10/06/billionaires-are-loading-up-on-this-high-yield-div/",
    "time_published": "20241006T083100",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Declining earnings haven't scared billionaire investors away from this stock.",
    "banner_image": "https://g.foolcdn.com/editorial/images/792959/investor-looks-worried-at-computer-in-a-living-room-setting-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.247688,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.585687",
        "ticker_sentiment_score": "0.37233",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.054236",
        "ticker_sentiment_score": "0.200856",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BGNE",
        "relevance_score": "0.054236",
        "ticker_sentiment_score": "-0.055095",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "How Is The Market Feeling About Abbott Laboratories? - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/10/41215818/how-is-the-market-feeling-about-abbott-laboratories",
    "time_published": "20241007T200018",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Abbott Laboratories's ABT short percent of float has risen 4.05% since its last report. The company recently reported that it has 13.36 million shares sold short, which is 0.77% of all regular shares that are available for trading.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1728331215_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.287757,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.148634",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Abbott Laboratories Analyst Is Bullish About MedTech, Non-MedTech Growth - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41233611/abbott-laboratories-analyst-is-bullish-about-medtech-non-medtech-growth",
    "time_published": "20241008T155952",
    "authors": [
      "Priya Nigam"
    ],
    "summary": "Abbott Laboratories's ABT MedTech portfolio is growing at a CAGR ( compounded annual growing rate ) of 11%-13%. The company's non-MedTech operations are expanding by low-to-mid single-digit percentages, according to Oppenheimer.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/08/Oct-15--2019-Sunnyvale-----Ca-----Usa---.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.349263,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.601928",
        "ticker_sentiment_score": "0.356448",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "A Look Into Abbott Laboratories Inc's Price Over Earnings - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/insights/news/24/10/41232001/a-look-into-abbott-laboratories-incs-price-over-earnings",
    "time_published": "20241008T150026",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In the current market session, Abbott Laboratories Inc. ABT share price is at $114.38, after a 0.90% increase. Moreover, over the past month, the stock decreased by 2.33%, but in the past year, spiked by 24.15%.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1728399623_0_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.222972,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.317527",
        "ticker_sentiment_score": "0.098827",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/news/24/10/41228094/this-abbott-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-tuesday",
    "time_published": "20241008T130330",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Oppenheimer analyst Suraj Kalia initiated coverage on Abbott Laboratories ABT with an Outperform rating and ...",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/08090124/image-51-1024x504.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.317175,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.367865",
        "ticker_sentiment_score": "0.457017",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.126784",
        "ticker_sentiment_score": "0.064667",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FXNC",
        "relevance_score": "0.367865",
        "ticker_sentiment_score": "0.463202",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.126784",
        "ticker_sentiment_score": "-0.094415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCAX",
        "relevance_score": "0.367865",
        "ticker_sentiment_score": "-0.202607",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "RCUS",
        "relevance_score": "0.367865",
        "ticker_sentiment_score": "0.139662",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HWM",
        "relevance_score": "0.367865",
        "ticker_sentiment_score": "0.467303",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Should You Bet on HOLX Stock This Breast Cancer Awareness Month?",
    "url": "https://www.zacks.com/stock/news/2348255/should-you-bet-on-holx-stock-this-breast-cancer-awareness-month",
    "time_published": "20241009T134600",
    "authors": [
      "Moumi Mondal"
    ],
    "summary": "Hologic has kicked off the annual breast cancer awareness month with a new campaign. But how well is the stock doing now?",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/12/31139.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.21192,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HOLX",
        "relevance_score": "0.368227",
        "ticker_sentiment_score": "0.30533",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "QGEN",
        "relevance_score": "0.076358",
        "ticker_sentiment_score": "-0.008164",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.076358",
        "ticker_sentiment_score": "-0.008164",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Blood Screening Market Growth at USD 6.33 Billion by 2031 | SkyQuest Technology",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41250900/blood-screening-market-growth-at-usd-6-33-billion-by-2031-skyquest-technology",
    "time_published": "20241009T133248",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Westford, USA, Oct. 09, 2024 ( GLOBE NEWSWIRE ) -- Global Blood Screening Market size was valued at USD 3.30 Billion in 2023 to USD 6.33 Billion by 2031, at a CAGR of 8.50% during the forecast period ( 2024-2031 ) . Blood screening is the process of screening donated blood.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.210588,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BMXMF",
        "relevance_score": "0.033799",
        "ticker_sentiment_score": "-0.001881",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTRA",
        "relevance_score": "0.033799",
        "ticker_sentiment_score": "-0.001881",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HOLX",
        "relevance_score": "0.033799",
        "ticker_sentiment_score": "-0.001881",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.033799",
        "ticker_sentiment_score": "-0.001881",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSMXF",
        "relevance_score": "0.033799",
        "ticker_sentiment_score": "-0.001881",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.033799",
        "ticker_sentiment_score": "-0.001881",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.033799",
        "ticker_sentiment_score": "-0.001881",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIO",
        "relevance_score": "0.033799",
        "ticker_sentiment_score": "-0.001881",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRFS",
        "relevance_score": "0.067536",
        "ticker_sentiment_score": "-0.002005",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SEMHF",
        "relevance_score": "0.033799",
        "ticker_sentiment_score": "-0.001881",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HAE",
        "relevance_score": "0.033799",
        "ticker_sentiment_score": "-0.001881",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DHR",
        "relevance_score": "0.033799",
        "ticker_sentiment_score": "-0.001881",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "At-home Testing Kits Market to be Worth USD 12.3 billion by 2034, Growing a CAGR 5.9% - Exclusive Report by Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41247090/at-home-testing-kits-market-to-be-worth-usd-12-3-billion-by-2034-growing-a-cagr-5-9-exclusive-repo",
    "time_published": "20241009T112000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Transparency Market Research Inc. -, Oct. 09, 2024 ( GLOBE NEWSWIRE ) -- The global at-home testing kits market ( \uc7ac\ud0dd \ud14c\uc2a4\ud2b8 \ud0a4\ud2b8 \uc2dc\uc7a5 ) is estimated to ascend at a CAGR of 5.9% from 2024 to 2034.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/b71c9b0d-45cb-40b4-aef3-f436b4c53e18/at-home-testing-kits-market.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.373238,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.032825",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.065595",
        "ticker_sentiment_score": "0.161566",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "OSUR",
        "relevance_score": "0.098255",
        "ticker_sentiment_score": "0.166496",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.098255",
        "ticker_sentiment_score": "0.055124",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares U.S. Medical Devices ETF  ( IHI ) ?",
    "url": "https://www.zacks.com/stock/news/2347943/should-you-invest-in-the-ishares-us-medical-devices-etf-ihi",
    "time_published": "20241009T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for IHI ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default201.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.177529,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SEM",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.026877",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.070327",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.070327",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.070327",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Down More Than 50% From Its High, Is DexCom Stock a Buy?",
    "url": "https://www.fool.com/investing/2024/10/09/down-more-than-50-from-high-dexcom-stock-buy/",
    "time_published": "20241009T101500",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Is DexCom's business in trouble, or could this be a great buying opportunity for investors?",
    "banner_image": "https://g.foolcdn.com/editorial/images/793107/person-checking-their-blood-sugar-levels-on-a-device.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.904684"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999365"
      }
    ],
    "overall_sentiment_score": 0.126712,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DXCM",
        "relevance_score": "0.541766",
        "ticker_sentiment_score": "0.154086",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.065685",
        "ticker_sentiment_score": "0.215297",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Sports Nutrition Market Size to Hit $46.41 Billion, Globally, by 2031 Growing at 8.6% CAGR | Exclusive Report by The Insight Partners",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41272645/sports-nutrition-market-size-to-hit-46-41-billion-globally-by-2031-growing-at-8-6-cagr-exclusive-r",
    "time_published": "20241010T134833",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "US & Canada, Oct. 10, 2024 ( GLOBE NEWSWIRE ) -- According to The Insight \"Sports Nutrition Market Global Analysis - by Product Type, Distribution Channel, and Geography\" offers a comprehensive overview of the sports nutrition industry.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.281504,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PEP",
        "relevance_score": "0.025008",
        "ticker_sentiment_score": "0.067232",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.025008",
        "ticker_sentiment_score": "0.067232",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HLF",
        "relevance_score": "0.025008",
        "ticker_sentiment_score": "0.067232",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GLAPF",
        "relevance_score": "0.025008",
        "ticker_sentiment_score": "0.067232",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cramer's week ahead: Major banks, Taiwan Semi and Netflix report as earnings season gets into full swing",
    "url": "https://www.cnbc.com/2024/10/11/cramers-week-ahead-taiwan-semi-netflix-goldman-sachs-citi-earnings.html",
    "time_published": "20241011T224251",
    "authors": [],
    "summary": "Charles Schwab, Bank of America, Johnson & Johnson, Walgreens, UnitedHealth Group Morgan Stanley, Procter & Gamble and Abbott Laboratories all report earnings.",
    "banner_image": null,
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.967645"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      }
    ],
    "overall_sentiment_score": 0.097428,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.064276",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.064276",
        "ticker_sentiment_score": "-0.089474",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "0.231841",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "0.131823",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "0.131823",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.184864",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "-0.154208",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "SLB",
        "relevance_score": "0.064276",
        "ticker_sentiment_score": "0.010048",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "0.131823",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.064276",
        "ticker_sentiment_score": "-0.132152",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.184864",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.064276",
        "ticker_sentiment_score": "0.010048",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.064276",
        "ticker_sentiment_score": "0.010048",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SCHW",
        "relevance_score": "0.064276",
        "ticker_sentiment_score": "0.110539",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock",
    "url": "https://www.fool.com/investing/2024/10/12/interested-in-weight-loss-stocks-besides-novo-nord/",
    "time_published": "20241012T183100",
    "authors": [
      "Adam Spatacco"
    ],
    "summary": "BioAge Labs is the latest pharmaceutical company looking to make waves in the weight loss realm.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F793569%2Fgettyimages-1166581794.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.110608,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALT",
        "relevance_score": "0.061159",
        "ticker_sentiment_score": "-0.030155",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.061159",
        "ticker_sentiment_score": "-0.053275",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIOA",
        "relevance_score": "0.68145",
        "ticker_sentiment_score": "0.176071",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.061159",
        "ticker_sentiment_score": "0.053065",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.061159",
        "ticker_sentiment_score": "-0.036",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Iridium Gearing Up to Report Q3 Earnings: Here's What to Expect - Iridium Comms  ( NASDAQ:IRDM ) , Equifax  ( NYSE:EFX ) ",
    "url": "https://www.benzinga.com/news/earnings/24/10/41315948/iridium-gearing-up-to-report-q3-earnings-heres-what-to-expect",
    "time_published": "20241014T174704",
    "authors": [
      "Zacks"
    ],
    "summary": "Iridium Communications IRDM is slated to release third-quarter 2024 earnings on Oct. 17, before market open. The Zacks Consensus estimate for revenues is pegged at $205.7 million, indicating an increase of 4.1% from the year-ago level.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/charts/ab/81094.jpg?v=885335854",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999756"
      }
    ],
    "overall_sentiment_score": 0.242738,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IRDM",
        "relevance_score": "0.223248",
        "ticker_sentiment_score": "0.193319",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.135094",
        "ticker_sentiment_score": "0.18121",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.090304",
        "ticker_sentiment_score": "0.159066",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EFX",
        "relevance_score": "0.135094",
        "ticker_sentiment_score": "0.172765",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Iridium Gearing Up to Report Q3 Earnings: Here's What to Expect",
    "url": "https://www.zacks.com/stock/news/2349984/iridium-gearing-up-to-report-q3-earnings-heres-what-to-expect",
    "time_published": "20241014T141500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Iridium's third-quarter performance is likely to have benefited from momentum in commercial service revenues and increasing subscriber base.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/75/2558.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999953"
      }
    ],
    "overall_sentiment_score": 0.21766,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IRDM",
        "relevance_score": "0.222838",
        "ticker_sentiment_score": "0.186377",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.134841",
        "ticker_sentiment_score": "0.170189",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.134841",
        "ticker_sentiment_score": "0.170189",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EFX",
        "relevance_score": "0.134841",
        "ticker_sentiment_score": "0.136455",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Abbott's Q3 Earnings Release Coming Up, EPD Business in Focus",
    "url": "https://www.zacks.com/stock/news/2349820/abbotts-q3-earnings-release-coming-up-epd-business-in-focus",
    "time_published": "20241014T132800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "ABT's Neuromodulation growth is expected to have been driven by strong demand in international markets for the Eterna rechargeable spinal cord stimulation device.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999998"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.282462,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MASI",
        "relevance_score": "0.061394",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.122425",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ACAD",
        "relevance_score": "0.061394",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RDNT",
        "relevance_score": "0.061394",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What to Expect From Badger Meter Stock Ahead of its Q3 Earnings",
    "url": "https://www.zacks.com/stock/news/2349679/what-to-expect-from-badger-meter-stock-ahead-of-its-q3-earnings",
    "time_published": "20241014T113900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "BMI's third-quarter performance is likely to have benefited from increased demand for its digital smart water solutions.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/75/2558.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.99989"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.329038,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.17715",
        "ticker_sentiment_score": "0.200877",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.17715",
        "ticker_sentiment_score": "0.200877",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EFX",
        "relevance_score": "0.17715",
        "ticker_sentiment_score": "0.161286",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMI",
        "relevance_score": "0.3986",
        "ticker_sentiment_score": "0.402596",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Columbus Day: Is Stock Market Open Today? - Abbott Laboratories  ( NYSE:ABT ) , Bank of America  ( NYSE:BAC ) ",
    "url": "https://www.benzinga.com/news/24/10/41309748/columbus-day-is-stock-market-open-today",
    "time_published": "20241014T104616",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "As Columbus Day approaches, investors and market participants are preparing for a unique trading environment. This U.S. holiday, observed on Monday, October 14, 2024, will see a mix of open and closed financial markets, impacting trading activities.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/14/Market-Update.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999696"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.173887,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.245339",
        "ticker_sentiment_score": "-0.10352",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.245339",
        "ticker_sentiment_score": "-0.10352",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.124164",
        "ticker_sentiment_score": "0.22275",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.245339",
        "ticker_sentiment_score": "-0.10352",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.245339",
        "ticker_sentiment_score": "-0.10352",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSM",
        "relevance_score": "0.245339",
        "ticker_sentiment_score": "-0.10352",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Top-Rated Stocks to Watch as Earnings Approach: ABT, EFX, SLG",
    "url": "https://www.zacks.com/commentary/2350839/3-top-rated-stocks-to-watch-as-earnings-approach-abt-efx-slg",
    "time_published": "20241015T200000",
    "authors": [
      "Shaun Pruitt"
    ],
    "summary": "Sporting a Zacks Rank #2 (Buy), here are three top-rated stocks that investors will want to consider as their Q3 results approach on Wednesday, October 16.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2b/65212.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999986"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.36588,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EFX",
        "relevance_score": "0.361802",
        "ticker_sentiment_score": "0.452204",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.222157",
        "ticker_sentiment_score": "0.382708",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "UnitedHealth Q3 Earnings Beat on Domestic Commercial Business",
    "url": "https://www.zacks.com/stock/news/2350974/unitedhealth-q3-earnings-beat-on-domestic-commercial-business",
    "time_published": "20241015T164200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "UNH's third-quarter earnings benefit on the back of client wins in the Optum Rx sub-unit, partly offset by an elevated operating expense level.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/16/2258.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999992"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.168296,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EHC",
        "relevance_score": "0.080865",
        "ticker_sentiment_score": "0.114092",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.121037",
        "ticker_sentiment_score": "0.111373",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CI",
        "relevance_score": "0.080865",
        "ticker_sentiment_score": "0.075284",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.352223",
        "ticker_sentiment_score": "0.221534",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Neogen Q1 Earnings Miss Estimates, Margins Crash",
    "url": "https://www.zacks.com/stock/news/2350702/neogen-q1-earnings-miss-estimates-margins-crash",
    "time_published": "20241015T125500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "NEOG's Food Safety and Animal Safety businesses witness a year-over-year decrease in revenues in the first quarter of fiscal 2025.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d6/3739.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.99992"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": -0.002405,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.101367",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NEOG",
        "relevance_score": "0.389636",
        "ticker_sentiment_score": "0.030024",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AHCO",
        "relevance_score": "0.151539",
        "ticker_sentiment_score": "-0.001287",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADUS",
        "relevance_score": "0.201105",
        "ticker_sentiment_score": "0.121042",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is a Surprise Coming for Abbott  ( ABT )  This Earnings Season?",
    "url": "https://www.zacks.com/stock/news/2350467/is-a-surprise-coming-for-abbott-abt-this-earnings-season",
    "time_published": "20241015T124600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Abbott (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.99237"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.4558,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.76191",
        "ticker_sentiment_score": "0.553804",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Why Abbott Laboratories Stock Was a Winner on Wednesday",
    "url": "https://www.fool.com/investing/2024/10/16/why-abbott-laboratories-stock-was-a-winner-on-wedn/",
    "time_published": "20241016T224153",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "Investors bumped its shares higher following a decent, if unspectacular, earnings report.",
    "banner_image": "https://g.foolcdn.com/editorial/images/794367/child-receiving-a-vaccination-shot-from-a-healthcare-professional.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.367497,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.2872",
        "ticker_sentiment_score": "0.528368",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Abbott Stock Gains on Q3 Earnings Beat, Margins Expand",
    "url": "https://www.zacks.com/stock/news/2351773/abbott-stock-gains-on-q3-earnings-beat-margins-expand",
    "time_published": "20241016T175700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "ABT delivers a strong underlying base business performance in the third quarter of 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/50/73256.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999992"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.261953,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AVIR",
        "relevance_score": "0.113956",
        "ticker_sentiment_score": "0.029633",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.188781",
        "ticker_sentiment_score": "0.13471",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.038101",
        "ticker_sentiment_score": "0.044002",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AHCO",
        "relevance_score": "0.113956",
        "ticker_sentiment_score": "-0.001115",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADUS",
        "relevance_score": "0.151539",
        "ticker_sentiment_score": "0.100758",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Tech Stocks Stall, Small Caps Surge As Regional Banks Rally, Airlines Rocket: What's Driving Markets Wednesday? - Alcoa  ( NYSE:AA ) ",
    "url": "https://www.benzinga.com/news/earnings/24/10/41364779/tech-stocks-stall-small-caps-surge-as-regional-banks-rally-airlines-rocket-whats-driving-markets-we",
    "time_published": "20241016T174441",
    "authors": [
      "Piero Cingari"
    ],
    "summary": "Small-cap stocks outperformed large caps in Wednesday's session, with the Russell 2000 Index surging to test July 2024 highs on the back of expectations for interest rate cuts and a strong rally in regional banks. Financial stocks continued their upward momentum, buoyed by strong earnings reports.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/16/Wall-Street_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.875462"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.072849,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AA",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UAL",
        "relevance_score": "0.272029",
        "ticker_sentiment_score": "0.039477",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IBKR",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "-0.510392",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "CFG",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMI",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.272029",
        "ticker_sentiment_score": "0.102717",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSX",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.020963",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ASML",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "-0.367202",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "DFS",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EFX",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STLD",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.233239",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Alibaba, Linde, Abbott Laboratories and Value Line",
    "url": "https://www.zacks.com/stock/news/2351703/the-zacks-analyst-blog-highlights-alibaba-linde-abbott-laboratories-and-value-line",
    "time_published": "20241016T150800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Alibaba, Linde, Abbott Laboratories and Value Line are part of the Zacks top Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/db/2802.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.347358,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BABA",
        "relevance_score": "0.104911",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LIN",
        "relevance_score": "0.208017",
        "ticker_sentiment_score": "0.205822",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.104911",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VALU",
        "relevance_score": "0.1568",
        "ticker_sentiment_score": "0.134333",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Price Over Earnings Overview: Abbott Laboratories - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/insights/news/24/10/41358117/price-over-earnings-overview-abbott-laboratories",
    "time_published": "20241016T141543",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In the current session, the stock is trading at $118.67, after a 2.26% increase. Over the past month, Abbott Laboratories Inc. ABT stock increased by 3.30%, and in the past year, by 24.34%.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1729088141_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.040606,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.390904",
        "ticker_sentiment_score": "0.104761",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "US Stocks Mixed; Abbott Reports Better-Than-Expected Q3 Results - Abbott Laboratories  ( NYSE:ABT ) , 180 Life Sciences  ( NASDAQ:ATNF ) ",
    "url": "https://www.benzinga.com/markets/equities/24/10/41357767/us-stocks-mixed-abbott-reports-better-than-expected-q3-results",
    "time_published": "20241016T140317",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "U.S. stocks traded mixed this morning, with the Dow Jones index gaining around 20 points on Wednesday. The Dow traded up 0.05% to 42,762.18 while the NASDAQ fell 0.06% to 18,305.30. The S&P 500 also fell, dropping, 0.07% to 5,811.21. Financials shares jumped by 0.7% on Wednesday.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/16/Wall-Street.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.070997,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DRUG",
        "relevance_score": "0.270773",
        "ticker_sentiment_score": "0.515132",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SVCO",
        "relevance_score": "0.182506",
        "ticker_sentiment_score": "-0.136284",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STEC",
        "relevance_score": "0.182506",
        "ticker_sentiment_score": "0.296266",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.182506",
        "ticker_sentiment_score": "0.508569",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ATNF",
        "relevance_score": "0.270773",
        "ticker_sentiment_score": "0.139623",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VS",
        "relevance_score": "0.182506",
        "ticker_sentiment_score": "0.413506",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Zacks Investment Ideas feature highlights: Abbott Laboratories, Equifax and SL Green Realty",
    "url": "https://www.zacks.com/stock/news/2351607/zacks-investment-ideas-feature-highlights-abbott-laboratories-equifax-and-sl-green-realty",
    "time_published": "20241016T140300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Abbott Laboratories, Equifax and SL Green Realty are part of the Zacks Investment Ideas article.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999986"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.36574,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EFX",
        "relevance_score": "0.391923",
        "ticker_sentiment_score": "0.420868",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.267559",
        "ticker_sentiment_score": "0.341842",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SLG",
        "relevance_score": "0.330876",
        "ticker_sentiment_score": "0.357156",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Abbott Laboratories' Q3 Earnings: Revenue And EPS Beat, Company Says Well-Positioned To Achieve Upper End Of Annual Forecast - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/news/earnings/24/10/41356487/abbott-laboratories-q3-earnings-revenue-and-eps-beat-company-says-well-positioned-to-achieve-upper-",
    "time_published": "20241016T130823",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Wednesday, Abbott Laboratories ABT reported third-quarter sales of $10.64 billion, up 4.9% year over year, beating the consensus of $10.55 billion. Organic sales growth for the underlying base business was 8.2%, led by double-digit growth in Medical Devices.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/16/Oct-15--2019-Sunnyvale-----Ca-----Usa---.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.390542,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SSTK",
        "relevance_score": "0.116348",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.339356",
        "ticker_sentiment_score": "-0.171509",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Achieve Life Sciences Promotes Jaime Xinos to Chief Commercial Officer to Advance Commercial Readiness of Cytisinicline",
    "url": "https://www.globenewswire.com/news-release/2024/10/16/2963976/0/en/Achieve-Life-Sciences-Promotes-Jaime-Xinos-to-Chief-Commercial-Officer-to-Advance-Commercial-Readiness-of-Cytisinicline.html",
    "time_published": "20241016T120000",
    "authors": [
      "Achieve Life Sciences"
    ],
    "summary": "SEATTLE and VANCOUVER, British Columbia, Oct. 16, 2024 ( GLOBE NEWSWIRE ) -- Achieve Life Sciences, Inc. ( Nasdaq: ACHV ) , a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for the treatment of nicotine dependence, is pleased to ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/121ccb0d-c3bc-44d5-a431-ee2834c93a79",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.171519,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ACHV",
        "relevance_score": "0.158519",
        "ticker_sentiment_score": "0.22166",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.031907",
        "ticker_sentiment_score": "0.055974",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.031907",
        "ticker_sentiment_score": "0.055974",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Achieve Life Sciences Promotes Jaime Xinos to Chief Commercial Officer to Advance Commercial Readiness of Cytisinicline - Achieve Life Sciences  ( NASDAQ:ACHV ) ",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41354690/achieve-life-sciences-promotes-jaime-xinos-to-chief-commercial-officer-to-advance-commercial-readi",
    "time_published": "20241016T120000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "SEATTLE and VANCOUVER, British Columbia, Oct. 16, 2024 ( GLOBE NEWSWIRE ) -- Achieve Life Sciences, Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.744043"
      }
    ],
    "overall_sentiment_score": 0.180707,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ACHV",
        "relevance_score": "0.151349",
        "ticker_sentiment_score": "0.214115",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.030446",
        "ticker_sentiment_score": "0.052747",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.030446",
        "ticker_sentiment_score": "0.052747",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nasdaq, S&P 500 Futures Edge Up After Tuesday's Chip Sell-off - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/10/41353878/us-stocks-could-open-narrowly-mixed-after-tuesdays-chip-sell-off-bitcoin-heads-to-68k-oil-slips",
    "time_published": "20241016T112917",
    "authors": [
      "Shanthi Rexaline"
    ],
    "summary": "U.S. stock futures point to a flattish start on Wednesday after the S&P 500 Index and the Dow Jones Industrial Average retreated from record highs in the previous session.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/16/NYSE.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.94762"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.021984,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AA",
        "relevance_score": "0.105836",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DFS",
        "relevance_score": "0.105836",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.105836",
        "ticker_sentiment_score": "0.181143",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CSCO",
        "relevance_score": "0.105836",
        "ticker_sentiment_score": "0.311366",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVCR",
        "relevance_score": "0.105836",
        "ticker_sentiment_score": "-0.192479",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "QCOM",
        "relevance_score": "0.105836",
        "ticker_sentiment_score": "-0.197541",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.105836",
        "ticker_sentiment_score": "-0.197541",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "KMI",
        "relevance_score": "0.105836",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.105836",
        "ticker_sentiment_score": "0.181143",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.053035",
        "ticker_sentiment_score": "0.145661",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STLD",
        "relevance_score": "0.105836",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.105836",
        "ticker_sentiment_score": "-0.110592",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Abbott Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/news/earnings/24/10/41351053/abbott-gears-up-for-q3-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-a",
    "time_published": "20241016T075353",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Abbott Laboratories ABT will release earnings results for its third quarter, before the opening bell on Wednesday, Oct. 16. Analysts expect the North Chicago, Illinois-based company to report quarterly earnings at $1.2 per share, up from $1.14 per share in the year-ago period.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/16/Stock-market-analysts.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.185746,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.236972",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.11983",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nasdaq Dips 1% Amid Plunge In Chipmaker Stocks: Fear & Greed Index Moves To 'Greed' Zone - NVIDIA  ( NASDAQ:NVDA ) ",
    "url": "https://www.benzinga.com/news/earnings/24/10/41350830/nasdaq-dips-1-amid-plunge-in-chipmaker-stocks-fear-greed-index-moves-to-greed-zone",
    "time_published": "20241016T071326",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "The CNN Money Fear and Greed index showed a decline in the overall market sentiment, while the index moved to the \"Greed\" zone on Tuesday. U.S. stocks settled lower on Tuesday, with the Dow Jones index falling more than 300 points during the session. ASML Holding N.V.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/16/Market-Sentiment--Fear-And-Greed-Index--.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": -0.168187,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.19661",
        "ticker_sentiment_score": "-0.129737",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.19661",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.19661",
        "ticker_sentiment_score": "0.194351",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.19661",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.19661",
        "ticker_sentiment_score": "-0.129737",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBD",
        "relevance_score": "0.099066",
        "ticker_sentiment_score": "-0.362329",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.19661",
        "ticker_sentiment_score": "0.194351",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ASML",
        "relevance_score": "0.19661",
        "ticker_sentiment_score": "-0.129737",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Morgan Stanley, Abbott Laboratories And 3 Stocks To Watch Heading Into Wednesday - HomeStreet  ( NASDAQ:HMST ) ",
    "url": "https://www.benzinga.com/news/earnings/24/10/41350412/morgan-stanley-abbott-laboratories-and-3-stocks-to-watch-heading-into-wednesday",
    "time_published": "20241016T063406",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "With U.S. stock futures trading mixed this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Morgan Stanley MS to report quarterly earnings at $1.58 per share on revenue of $14.41 billion before the opening bell, according to data from ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/16/morgan-stanley-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999336"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.34662,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IBKR",
        "relevance_score": "0.38489",
        "ticker_sentiment_score": "-0.086984",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.38489",
        "ticker_sentiment_score": "0.513186",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.262522",
        "ticker_sentiment_score": "0.322708",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Abbott Labs Path to Double-Digit Earnings Growth In 2025? This Analyst Is Optimistic - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41389304/abbott-labs-path-to-double-digit-earnings-growth-in-2025-this-analyst-is-optimistic",
    "time_published": "20241017T184219",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Wednesday, Abbott Laboratories ABT reported third-quarter sales of $10.64 billion, up 4.9% year over year, beating the consensus of $10.55 billion. Organic sales growth for the underlying base business was 8.2%, led by double-digit growth in Medical Devices.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.99246"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.260445,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.369319",
        "ticker_sentiment_score": "0.167217",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Abbott's Growth and Dividends Make It a Smart Portfolio Pick - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/news/earnings/24/10/41382172/abbotts-growth-and-dividends-make-it-a-smart-portfolio-pick",
    "time_published": "20241017T165711",
    "authors": [
      "MarketBeat"
    ],
    "summary": "There are many reasons to own Abbott Laboratories ABT, but they all boil down to one thing: consistent market-beating returns. A study published by Hendrik Bessembinder, a professor of finance at Arizona State University, found that Abbott is the 11th top-returning stock since 1937 and #1 among ...",
    "banner_image": "https://www.marketbeat.com/logos/articles/med_20241016081501_chart-abt-10162024.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.287987,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.275246",
        "ticker_sentiment_score": "0.200371",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Pharmerging Market Size Projected to Surpass USD 7.1 Billion by 2034 at an 11.6% CAGR| Report by Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41385094/pharmerging-market-size-projected-to-surpass-usd-7-1-billion-by-2034-at-an-11-6-cagr-report-by-tra",
    "time_published": "20241017T153646",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Transparency Market Research, Inc., Oct. 17, 2024 ( GLOBE NEWSWIRE ) -- The pharmerging market accounted for US$ 2.1 billion in 2023. It is expected to advance at a CAGR of 11.6% from 2024 to 2034 and reach US$ 7.1 billion by the end of 2034.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/189205ba-f1ce-492f-a96b-5f9f034f881e/pharmerging-market.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.263889,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.035821",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.035821",
        "ticker_sentiment_score": "0.106278",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.035821",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.107175",
        "ticker_sentiment_score": "0.018849",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PHG",
        "relevance_score": "0.035821",
        "ticker_sentiment_score": "0.079128",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Company News for Oct 17, 2024",
    "url": "https://www.zacks.com/stock/news/2352496/company-news-for-oct-17-2024",
    "time_published": "20241017T151100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Companies In The News Are: ABT, CFG, FHN, IBKR.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/db/2802.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.9545"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.094083,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "IBKR",
        "relevance_score": "0.582526",
        "ticker_sentiment_score": "-0.075374",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.582526",
        "ticker_sentiment_score": "0.446592",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CFG",
        "relevance_score": "0.582526",
        "ticker_sentiment_score": "-0.306309",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "FHN",
        "relevance_score": "0.582526",
        "ticker_sentiment_score": "0.43542",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Analyst Predicts Bitcoin High In Weeks, $90K By Year-End; TSMC Nears $1 Trillion Valuation After 8% Premarket Surge - Top Headlines Today While US Slept",
    "url": "https://www.benzinga.com/markets/cryptocurrency/24/10/41382444/analyst-predicts-bitcoin-high-in-weeks-90k-by-year-end-tsmc-nears-1-trillion-valuation-aft",
    "time_published": "20241017T140916",
    "authors": [
      "Akanksha Bakshi"
    ],
    "summary": "ESMA Pushes For Stronger Crypto Regulations Under MiCA Framework Crypto Advocate Reacts To Elizabeth Warren's 'Return On Investment' Allegations Against John Deaton, Outlines ROI He Expects From GOP Candidate Bitcoin Defies Election Jitters, Analyst Sees King Crypto Scaling $70K Milestone Again ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/17/Soccer--Bitcoin.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.95493"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.124857,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "WIT",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.029991",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXPE",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.215881",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "OPTGF",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.17618",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TCTZF",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.232828",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "-0.236822",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "SSNLF",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.130509",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.439347",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "0.136545",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BX",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.320095",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TDG",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.168272",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ADIL",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.22969",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WKSP",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "-0.01087",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SAVE",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "-0.496092",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.072435",
        "ticker_sentiment_score": "0.049572",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AA",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BABA",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.249701",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DEA",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.168272",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "-0.187983",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.099709",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAH",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.168272",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.439347",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NOK",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "-0.365491",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "TME",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.232828",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PSX",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.286902",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.108466",
        "ticker_sentiment_score": "0.11775",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:ETH",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.146588",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:NANO",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.187071",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRYPTO:SHIB",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.113275",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:DOGE",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "0.171497",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "These Analysts Increase Their Forecasts On Abbott Laboratories After Better-Than-Expected Q3 Earnings - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/news/earnings/24/10/41380804/these-analysts-increase-their-forecasts-on-abbott-laboratories-after-better-than-expected-q3-earnin",
    "time_published": "20241017T131442",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Abbott Laboratories ABT reported better-than-expected third-quarter results on Wednesday. The company posted sales of $10.64 billion, up 4.9% year over year, beating the consensus of $10.55 billion. Abbott's adjusted diluted earnings per share was $1.21, beating the analyst estimates of $1.20.",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17091351/image-151-1024x512.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.307297,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MS",
        "relevance_score": "0.163909",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.320974",
        "ticker_sentiment_score": "0.696511",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "AbbVie Does 'Very Well,' Cramer's Favorite? Abbott Laboratories - Abbott Laboratories  ( NYSE:ABT ) , AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/10/41379749/abbvie-is-doing-very-well-but-jim-cramers-favorite-abbott-laboratories",
    "time_published": "20241017T124934",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Mad Money Lightning Round,\" Jim Cramer said AbbVie Inc. ABBV is doing \"very, very well.\" However, he added that Abbott Laboratories ABT remains his favorite in the group right now. AbbVie was founded in 2013 when it became a separate company from Abbott.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/17/abbvie-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.262289,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.086907",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SG",
        "relevance_score": "0.404563",
        "ticker_sentiment_score": "0.141787",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CORZQ",
        "relevance_score": "0.309539",
        "ticker_sentiment_score": "0.340065",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ORCL",
        "relevance_score": "0.493128",
        "ticker_sentiment_score": "0.534909",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.493128",
        "ticker_sentiment_score": "0.041475",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLOV",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.155277",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GXO",
        "relevance_score": "0.404563",
        "ticker_sentiment_score": "0.345606",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Meta To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Thursday - Meta Platforms  ( NASDAQ:META ) ",
    "url": "https://www.benzinga.com/news/24/10/41379312/meta-to-rally-around-13-here-are-10-top-analyst-forecasts-for-thursday",
    "time_published": "20241017T123657",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Needham raised Clear Secure, Inc. YOU price target from $40 to $45. Needham analyst Joshua Reilly ...",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17075912/image-146-1024x524.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999967"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.312302,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JKHY",
        "relevance_score": "0.222838",
        "ticker_sentiment_score": "0.203024",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.222838",
        "ticker_sentiment_score": "0.148941",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYF",
        "relevance_score": "0.222838",
        "ticker_sentiment_score": "0.294915",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.149656",
        "ticker_sentiment_score": "0.138204",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PHUN",
        "relevance_score": "0.222838",
        "ticker_sentiment_score": "0.173021",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.149656",
        "ticker_sentiment_score": "0.138204",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OI",
        "relevance_score": "0.222838",
        "ticker_sentiment_score": "0.037284",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DASH",
        "relevance_score": "0.222838",
        "ticker_sentiment_score": "0.203024",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LII",
        "relevance_score": "0.222838",
        "ticker_sentiment_score": "0.325416",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SR",
        "relevance_score": "0.222838",
        "ticker_sentiment_score": "0.005213",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Abbott Laboratories Stock a Buy?",
    "url": "https://www.fool.com/investing/2024/10/17/is-abbott-laboratories-stock-a-buy/",
    "time_published": "20241017T113000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The healthcare stock is lagging the market this year.",
    "banner_image": "https://media.ycharts.com/charts/cf84002912a2a573df271a6031049b41.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      }
    ],
    "overall_sentiment_score": 0.162632,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TRMNF",
        "relevance_score": "0.057907",
        "ticker_sentiment_score": "-0.062322",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.115509",
        "ticker_sentiment_score": "0.091057",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.337044",
        "ticker_sentiment_score": "0.349383",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Rapid Medical Diagnostic Kits Market to Surpass $26 Billion with 4% CAGR by 2034 | Fact.MR Analysis",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41376663/rapid-medical-diagnostic-kits-market-to-surpass-26-billion-with-4-cagr-by-2034-fact-mr-analysis",
    "time_published": "20241017T110000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Rockville, MD, Oct. 17, 2024 ( GLOBE NEWSWIRE ) -- Fact.MR, a market research and competitive intelligence provider, reveals in its updated research report that the global rapid medical diagnostic kit market is approximated at a size of US$ 17.6 billion in 2024 and is forecasted to increase to ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/71926703-cfde-4fde-85d1-dc027551f7e3/rapid-medical-diagnostic-kit-market.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.358256,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BMXMF",
        "relevance_score": "0.03448",
        "ticker_sentiment_score": "0.091218",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRIB",
        "relevance_score": "0.03448",
        "ticker_sentiment_score": "0.091218",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.03448",
        "ticker_sentiment_score": "0.091218",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.03448",
        "ticker_sentiment_score": "0.091218",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZTS",
        "relevance_score": "0.03448",
        "ticker_sentiment_score": "0.091218",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIO",
        "relevance_score": "0.03448",
        "ticker_sentiment_score": "0.091218",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.03448",
        "ticker_sentiment_score": "0.091218",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DHR",
        "relevance_score": "0.03448",
        "ticker_sentiment_score": "0.091218",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Key Trends in Infant Clinical Nutrition Industry Propel Toward a US$ 49.47 billion Valuation: Fact.MR Study",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41374199/key-trends-in-infant-clinical-nutrition-industry-propel-toward-a-us-49-47-billion-valuation-fact-m",
    "time_published": "20241017T074500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Rockville Pike, Oct. 17, 2024 ( GLOBE NEWSWIRE ) -- A newly published study by Fact.MR, a market research and competitive intelligence provider, mentions that revenue from the demand for infant clinical nutrition is approximated to reach a valuation of US$ 27.55 billion in 2024.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/6ef6d48e-62ba-41fb-ad37-98968f5bc7b6/infant-clinical-nutrition-market-outlook-1.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.303498,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "INGR",
        "relevance_score": "0.036869",
        "ticker_sentiment_score": "0.089157",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.073659",
        "ticker_sentiment_score": "0.144303",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FSNUF",
        "relevance_score": "0.036869",
        "ticker_sentiment_score": "0.089157",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAX",
        "relevance_score": "0.036869",
        "ticker_sentiment_score": "0.089157",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NSRGF",
        "relevance_score": "0.073659",
        "ticker_sentiment_score": "0.079734",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PRGO",
        "relevance_score": "0.036869",
        "ticker_sentiment_score": "0.089157",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RBGPF",
        "relevance_score": "0.036869",
        "ticker_sentiment_score": "0.089157",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Where Will DexCom Be in 5 Years?",
    "url": "https://www.fool.com/investing/2024/10/18/where-will-dexcom-be-in-5-years/",
    "time_published": "20241018T120000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "Recent developments might have scared away some investors, but patience could pay off.",
    "banner_image": "https://media.ycharts.com/charts/b59f065b39b7f3526c9cc44312ecdb4c.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.243012,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DXCM",
        "relevance_score": "0.658507",
        "ticker_sentiment_score": "0.41184",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.05833",
        "ticker_sentiment_score": "0.099072",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 No-Brainer Pharmaceutical Stocks to Buy With $500 Right Now",
    "url": "https://www.fool.com/investing/2024/10/18/3-no-brainer-pharmaceutical-stocks-to-buy-with-500/",
    "time_published": "20241018T091000",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "These stocks could deliver big over the long term.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F794412%2Fgettyimages-scientists-in-lab01.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.998311"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.372282,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.052455",
        "ticker_sentiment_score": "0.184634",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.104683",
        "ticker_sentiment_score": "0.078",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.207571",
        "ticker_sentiment_score": "0.110364",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.104683",
        "ticker_sentiment_score": "0.200124",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever",
    "url": "https://www.fool.com/investing/2024/10/19/want-decades-of-passive-income-2-stocks-to-buy-now/",
    "time_published": "20241019T135700",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "These companies' longtime shareholders have generally been rewarded.",
    "banner_image": "https://g.foolcdn.com/editorial/images/794279/physicians-in-an-operating-room.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.300861,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.21258",
        "ticker_sentiment_score": "0.328311",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.263942",
        "ticker_sentiment_score": "0.256908",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "P/E Ratio Insights for Abbott Laboratories - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/insights/news/24/10/41462513/pe-ratio-insights-for-abbott-laboratories",
    "time_published": "20241022T173046",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In the current market session, Abbott Laboratories Inc. ABT stock price is at $116.19, after a 0.68% decrease. However, over the past month, the company's stock increased by 2.51%, and in the past year, by 24.17%.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1729618243_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.130125,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.334762",
        "ticker_sentiment_score": "0.123989",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Growing Biosimilars Business Supports ABT Stock, Macro Issues Hurt",
    "url": "https://www.zacks.com/stock/news/2356127/growing-biosimilars-business-supports-abt-stock-macro-issues-hurt",
    "time_published": "20241023T162000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.983783"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      }
    ],
    "overall_sentiment_score": 0.224871,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BAX",
        "relevance_score": "0.102449",
        "ticker_sentiment_score": "0.054426",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MASI",
        "relevance_score": "0.102449",
        "ticker_sentiment_score": "0.054426",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.203215",
        "ticker_sentiment_score": "0.325366",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.05133",
        "ticker_sentiment_score": "0.157435",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.102449",
        "ticker_sentiment_score": "0.054426",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:EUR",
        "relevance_score": "0.05133",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Beat the Nasdaq With This Cash-Gushing Dividend Stock",
    "url": "https://www.fool.com/investing/2024/10/23/beat-the-nasdaq-with-this-cash-gushing-dividend-st/",
    "time_published": "20241023T105000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The company is performing well despite recently losing its biggest growth driver.",
    "banner_image": "https://media.ycharts.com/charts/1e4214ac7ed64e44b91332f6a4fbd401.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.209965,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.055751",
        "ticker_sentiment_score": "0.091987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.055751",
        "ticker_sentiment_score": "0.091987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.558244",
        "ticker_sentiment_score": "0.251438",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.055751",
        "ticker_sentiment_score": "0.116997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.11123",
        "ticker_sentiment_score": "0.064919",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "FeganScott Launches Investigation into Abbott Laboratories Employees Credit Union Data Breach",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41530304/feganscott-launches-investigation-into-abbott-laboratories-employees-credit-union-data-breach",
    "time_published": "20241024T201542",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "CHICAGO, Oct. 24, 2024 ( GLOBE NEWSWIRE ) -- Attorneys at the law firm FeganScott have launched an investigation into the Abbott Laboratories Employees Credit Union ( ALEC ) data breach, which, according to company reports, occurred during an August cyberattack against the Illinois-based credit ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.130969,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.109455",
        "ticker_sentiment_score": "0.128512",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.109455",
        "ticker_sentiment_score": "0.082027",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Molina Healthcare Q3 Earnings Beat Estimates on Growing Premiums",
    "url": "https://www.zacks.com/stock/news/2357177/molina-healthcare-q3-earnings-beat-estimates-on-growing-premiums",
    "time_published": "20241024T173700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "MOH's third-quarter results benefit from growing membership and rising premiums, partially offset by rising expenses.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/80448.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999974"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.214636,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EHC",
        "relevance_score": "0.093653",
        "ticker_sentiment_score": "0.109797",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.140076",
        "ticker_sentiment_score": "0.060813",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.140076",
        "ticker_sentiment_score": "0.080372",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MOH",
        "relevance_score": "0.319488",
        "ticker_sentiment_score": "0.24323",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Community Health Q3 Earnings Miss on Lower Adjusted Admissions",
    "url": "https://www.zacks.com/stock/news/2357173/community-health-q3-earnings-miss-on-lower-adjusted-admissions",
    "time_published": "20241024T172900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "CYH's third-quarter earnings suffer a setback due to lower admissions and patient days. Improved occupancy levels and reimbursement rates partially offset the negatives.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/80448.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999919"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.113941,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.138997",
        "ticker_sentiment_score": "0.08491",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CYH",
        "relevance_score": "0.273807",
        "ticker_sentiment_score": "-0.029018",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.138997",
        "ticker_sentiment_score": "0.087349",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MOH",
        "relevance_score": "0.138997",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Immunoassay Market to Surpass Market Valuation of USD 54.27 Billion by 2031 | SkyQuest Technology",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41514552/immunoassay-market-to-surpass-market-valuation-of-usd-54-27-billion-by-2031-skyquest-technology",
    "time_published": "20241024T120000",
    "authors": [],
    "summary": "Westford, USA, Oct. 24, 2024 ( GLOBE NEWSWIRE ) -- SkyQuest projects that the Global Immunoassay Market will reach a value of USD 54.27 Billion by 2031, with a CAGR of 5.59% during the forecast period ( 2024-2031 ) .",
    "banner_image": null,
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.194543,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BMXMF",
        "relevance_score": "0.036926",
        "ticker_sentiment_score": "0.017056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "A",
        "relevance_score": "0.036926",
        "ticker_sentiment_score": "0.017056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSMXF",
        "relevance_score": "0.036926",
        "ticker_sentiment_score": "0.017056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIO",
        "relevance_score": "0.036926",
        "ticker_sentiment_score": "0.017056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SEMHF",
        "relevance_score": "0.036926",
        "ticker_sentiment_score": "0.017056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DHR",
        "relevance_score": "0.036926",
        "ticker_sentiment_score": "0.017056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ENZ",
        "relevance_score": "0.036926",
        "ticker_sentiment_score": "0.017056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TECH",
        "relevance_score": "0.036926",
        "ticker_sentiment_score": "0.017056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.036926",
        "ticker_sentiment_score": "0.017056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.036926",
        "ticker_sentiment_score": "0.017056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.036926",
        "ticker_sentiment_score": "0.017056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSRLF",
        "relevance_score": "0.036926",
        "ticker_sentiment_score": "0.017056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QGEN",
        "relevance_score": "0.036926",
        "ticker_sentiment_score": "0.017056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SZIHF",
        "relevance_score": "0.036926",
        "ticker_sentiment_score": "0.017056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QDEL",
        "relevance_score": "0.036926",
        "ticker_sentiment_score": "0.017056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TOSCF",
        "relevance_score": "0.073773",
        "ticker_sentiment_score": "0.018113",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "HCA Healthcare Beats on Q3 Earnings, Reaffirms 2024 EPS View",
    "url": "https://www.zacks.com/stock/news/2358015/hca-healthcare-beats-on-q3-earnings-reaffirms-2024-eps-view",
    "time_published": "20241025T162500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "HCA's quarterly results benefit from improved admissions and inpatient surgeries, partially offset by the impact of hurricanes and rising salaries and benefits expenses.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/80448.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.998947"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.186393,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.053876",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.055078",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCA",
        "relevance_score": "0.47037",
        "ticker_sentiment_score": "0.366842",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MOH",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Dividend Growth Stocks You Can Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/10/26/3-dividend-growth-stocks-you-can-buy-and-hold-fore/",
    "time_published": "20241026T113000",
    "authors": [
      "Keith Speights",
      "and Prosper Junior Bakiny",
      "David Jagielski"
    ],
    "summary": "These healthcare stocks have fantastic dividend track records.",
    "banner_image": "https://g.foolcdn.com/editorial/images/795225/couple-looking-at-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.320127,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.328455",
        "ticker_sentiment_score": "0.280552",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.167904",
        "ticker_sentiment_score": "0.151135",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.289381",
        "ticker_sentiment_score": "0.406408",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Peripheral Stent Implant Market is Projected to Climb to US$ 7.76 Billion by 2034 | Fact.MR Report",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41570484/peripheral-stent-implant-market-is-projected-to-climb-to-us-7-76-billion-by-2034-fact-mr-report",
    "time_published": "20241028T113000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Rockville, MD, Oct. 28, 2024 ( GLOBE NEWSWIRE ) -- The global peripheral stent implant market is set to be valued at US$ 4.11 billion in 2024 and is projected to expand at 6.6% CAGR from 2024 to 2034.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/c296590b-a5fe-4c76-8e3a-7c3910061684/peripheral-stent-implant-market.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.261751,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.036532",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.036532",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRUMF",
        "relevance_score": "0.072987",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.036532",
        "ticker_sentiment_score": "0.206091",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.036532",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.036532",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MCRPF",
        "relevance_score": "0.036532",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company's Next Stage of Growth",
    "url": "https://www.globenewswire.com/news-release/2024/10/28/2969910/0/en/Fennec-Pharmaceuticals-Strengthens-Executive-Leadership-Team-with-Three-Key-Appointments-to-Accelerate-the-Company-s-Next-Stage-of-Growth.html",
    "time_published": "20241028T102300",
    "authors": [
      "Fennec Pharmaceuticals Inc."
    ],
    "summary": "~ Pierre S. Sayad, PhD, M.S., Appointed Chief Medical Officer ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/a7bddf94-9a70-4437-b5fa-d701f0b9426d",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.12886,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "FENC",
        "relevance_score": "0.137222",
        "ticker_sentiment_score": "0.132138",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KPTI",
        "relevance_score": "0.039386",
        "ticker_sentiment_score": "0.134458",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.019699",
        "ticker_sentiment_score": "0.143836",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company's Next Stage of Growth - Fennec Pharmaceuticals  ( NASDAQ:FENC ) ",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41569189/fennec-pharmaceuticals-strengthens-executive-leadership-team-with-three-key-appointments-to-accele",
    "time_published": "20241028T102300",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "~ Pierre S. Sayad, PhD, M.S., Appointed Chief Medical Officer ~ ~ Terry Evans Appointed Chief Commercial Officer ~ ~ Christiana Cioffi, MBA, Appointed Chief Strategy Officer ~ RESEARCH TRIANGLE PARK, N.C., Oct. 28, 2024 ( GLOBE NEWSWIRE ) -- Fennec Pharmaceuticals Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.128711,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "FENC",
        "relevance_score": "0.148159",
        "ticker_sentiment_score": "0.134094",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KPTI",
        "relevance_score": "0.037242",
        "ticker_sentiment_score": "0.131719",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.018626",
        "ticker_sentiment_score": "0.14013",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AngioDynamics Stock Plunges 13.8% in Three Months: What's Next?",
    "url": "https://www.zacks.com/stock/news/2359699/angiodynamics-stock-plunges-138-in-three-months-whats-next",
    "time_published": "20241029T144300",
    "authors": [
      "Debanjana Dey"
    ],
    "summary": "ANGO enhances its offerings and expands the breadth of its products and services. However, macro challenges are likely to continue to hurt its performance.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/34/973.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.185902,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BSX",
        "relevance_score": "0.123951",
        "ticker_sentiment_score": "0.119904",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.123951",
        "ticker_sentiment_score": "0.119904",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "ABT's New Trial on Advanced Heart Failure Outcomes Set to Boost Stock",
    "url": "https://www.zacks.com/stock/news/2359250/abts-new-trial-on-advanced-heart-failure-outcomes-set-to-boost-stock",
    "time_published": "20241029T120700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Abbott initiates the TEAM-HF trial to improve outcomes for advanced heart failure.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.994953"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.193481,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RMD",
        "relevance_score": "0.103331",
        "ticker_sentiment_score": "0.054563",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.103331",
        "ticker_sentiment_score": "0.055519",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GMED",
        "relevance_score": "0.103331",
        "ticker_sentiment_score": "0.054563",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.154455",
        "ticker_sentiment_score": "0.095459",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Invesco Pharmaceuticals ETF  ( PJP )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2361385/is-invesco-pharmaceuticals-etf-pjp-a-strong-etf-right-now",
    "time_published": "20241031T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default41.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999997"
      }
    ],
    "overall_sentiment_score": 0.28471,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.06109",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.06109",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.268594",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.06109",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "5 Dividend Stocks to Double Up on Right Now -- Plus Some Dividend ETFs",
    "url": "https://www.fool.com/investing/2024/10/31/5-dividend-stocks-to-double-up-on-right-now/",
    "time_published": "20241031T093000",
    "authors": [
      "Selena Maranjian"
    ],
    "summary": "It's hard to beat the power of dividend-paying stocks. They have outperformed non-payers significantly.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F795426%2Fgetty-hiking-outdoors-beard.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999975"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.247253,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MO",
        "relevance_score": "0.055751",
        "ticker_sentiment_score": "0.033122",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.055751",
        "ticker_sentiment_score": "-0.02202",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.055751",
        "ticker_sentiment_score": "-0.02202",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.11123",
        "ticker_sentiment_score": "0.209389",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.055751",
        "ticker_sentiment_score": "0.064112",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "O",
        "relevance_score": "0.11123",
        "ticker_sentiment_score": "0.060634",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Tryptamine API Market is Set to Reach $2.25 Billion with 11.5% CAGR by 2034 | Fact.MR Report",
    "url": "https://www.benzinga.com/pressreleases/24/11/g41771015/tryptamine-api-market-is-set-to-reach-2-25-billion-with-11-5-cagr-by-2034-fact-mr-report",
    "time_published": "20241106T123000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Rockville, MD, Nov. 06, 2024 ( GLOBE NEWSWIRE ) -- According to a new industry report by Fact.MR, the global tryptamine API market is projected to be worth US$ 757.2 million in 2024 and thereafter advance at 11.5% CAGR from 2024 to 2034.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/18fb0e6e-db43-4c11-b7bd-6fd62b559f8c/tryptamine-api-market.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.155293,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "APG",
        "relevance_score": "0.164188",
        "ticker_sentiment_score": "-0.009626",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.041323",
        "ticker_sentiment_score": "-0.069904",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.041323",
        "ticker_sentiment_score": "-0.069904",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Sarcopenia Treatment Market to Experience 4.2% CAGR, Reaching US$ 4.63 Billion by 2034 | Fact.MR Report",
    "url": "https://www.benzinga.com/pressreleases/24/11/g41803914/sarcopenia-treatment-market-to-experience-4-2-cagr-reaching-us-4-63-billion-by-2034-fact-mr-report",
    "time_published": "20241107T123000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Rockville, MD, Nov. 07, 2024 ( GLOBE NEWSWIRE ) -- The world population has crossed 8 billion, with a significant number of elderly people suffering from sarcopenia. As per a new study by Fact.MR, the global sarcopenia treatment market is estimated at US$ 3.07 billion in 2024 and is projected to ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/dffe8a91-4256-447a-9e0b-0df6773f886f/sarcopenia-treatment-market.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.330212,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVS",
        "relevance_score": "0.043579",
        "ticker_sentiment_score": "-0.051706",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.043579",
        "ticker_sentiment_score": "-0.051706",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HLN",
        "relevance_score": "0.043579",
        "ticker_sentiment_score": "-0.051706",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.043579",
        "ticker_sentiment_score": "-0.051706",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.043579",
        "ticker_sentiment_score": "-0.051706",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "1 Stock to Buy Near Its 52-Week Low and Hold for 10 Years",
    "url": "https://www.fool.com/investing/2024/11/08/1-stock-to-buy-near-its-52-week-low-and-hold-for/",
    "time_published": "20241108T151500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "This medical device company is down but not out.",
    "banner_image": "https://media.ycharts.com/charts/fbbb3077b2f24261ca34385e48193feb.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.156355,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DXCM",
        "relevance_score": "0.56296",
        "ticker_sentiment_score": "0.29265",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.061949",
        "ticker_sentiment_score": "0.022071",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights like Amazon.com, Procter & Gamble, Abbott and NVE",
    "url": "https://www.zacks.com/stock/news/2367214/the-zacks-analyst-blog-highlights-like-amazoncom-procter-gamble-abbott-and-nve",
    "time_published": "20241108T131300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Amazon.com, Procter & Gamble, Abbott and NVE are part of the Zacks top Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/92/486.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.355336,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVEC",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.12615",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.157827",
        "ticker_sentiment_score": "0.056099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.404563",
        "ticker_sentiment_score": "0.170267",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Dividend Kings That Would Have Doubled Your Money in 5 Years",
    "url": "https://www.fool.com/investing/2024/11/08/2-dividend-kings-that-would-have-doubled-your-mone/",
    "time_published": "20241108T100000",
    "authors": [
      "David Jagielski"
    ],
    "summary": "You can be a little greedy sometimes and find great stocks that possess solid growth prospects and also pay dividends.",
    "banner_image": "https://g.foolcdn.com/editorial/images/796253/investor-calculating-stock-returns-on-a-calculator.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.989041"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.348232,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VZIO",
        "relevance_score": "0.069495",
        "ticker_sentiment_score": "0.16787",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.514619",
        "ticker_sentiment_score": "0.373076",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "0.141165",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.514619",
        "ticker_sentiment_score": "0.396988",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever",
    "url": "https://www.fool.com/investing/2024/11/08/want-decades-of-passive-income-2-stocks-to-buy-now/",
    "time_published": "20241108T091500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "You'll also like these stocks for their track record of earnings growth.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F796743%2Fgettyimages-smiling-investor.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.980509"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.391827,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.116348",
        "ticker_sentiment_score": "0.187391",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.116348",
        "ticker_sentiment_score": "0.282322",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "My Favorite Dividend King to Buy in November",
    "url": "https://www.fool.com/investing/2024/11/09/abbvie/",
    "time_published": "20241109T104800",
    "authors": [
      "Keith Speights"
    ],
    "summary": "This Dividend King truly wears the crown.",
    "banner_image": "https://g.foolcdn.com/editorial/images/796634/king-chess-piece-held-by-woman.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.335795,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.564693",
        "ticker_sentiment_score": "0.458944",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.05654",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Spectacular High-Yield Dividend Stocks to Buy in November",
    "url": "https://www.fool.com/investing/2024/11/10/spectacular-high-yield-dividend-stocks-to-buy-in/",
    "time_published": "20241110T143000",
    "authors": [
      "David Jagielski",
      "and Prosper Junior Bakiny",
      "Keith Speights"
    ],
    "summary": "High yields aren't a warning indicator with these three stocks.",
    "banner_image": "https://g.foolcdn.com/editorial/images/797003/scientists-in-a-lab-monitor-microscope.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999922"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.293865,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.361407",
        "ticker_sentiment_score": "0.434985",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.046816",
        "ticker_sentiment_score": "0.178476",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.402761",
        "ticker_sentiment_score": "0.326656",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.230892",
        "ticker_sentiment_score": "0.281124",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Hims & Hers Stock Gains 31.1% Since Q3 Earnings: What's Next?",
    "url": "https://www.zacks.com/stock/news/2369800/hims-hers-stock-gains-311-since-q3-earnings-whats-next",
    "time_published": "20241113T152800",
    "authors": [
      "Debanjana Dey"
    ],
    "summary": "HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.455547,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HIMS",
        "relevance_score": "0.380591",
        "ticker_sentiment_score": "0.396013",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.07913",
        "ticker_sentiment_score": "0.263239",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TDOC",
        "relevance_score": "0.07913",
        "ticker_sentiment_score": "0.263239",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Ultra-Safe Dividend Stocks That Have Been Paying Dividends for More Than 100 Years",
    "url": "https://www.fool.com/investing/2024/11/14/3-ultra-safe-dividend-stocks-that-have-been-paying/",
    "time_published": "20241114T111900",
    "authors": [
      "David Jagielski"
    ],
    "summary": "These are income stocks you can buy and hold forever.",
    "banner_image": "https://g.foolcdn.com/editorial/images/797238/a-couple-looking-at-a-statement.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      }
    ],
    "overall_sentiment_score": 0.286386,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KO",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "0.287248",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.243864",
        "ticker_sentiment_score": "0.150183",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.147818",
        "ticker_sentiment_score": "0.196658",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Dividend Kings to Buy for a Lifetime of Passive Income",
    "url": "https://www.fool.com/investing/2024/11/22/2-dividend-kings-to-buy-for-passive-income/",
    "time_published": "20241122T172100",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "Dividend Kings are among the best income stocks on the market. Any corporation capable of raising its payouts for 50 consecutive years -- the requirement to become a Dividend King -- has an incredibly strong business capable of navigating company-specific challenges and economic peaks and ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/798548/person-drinking-bottled-drink-with-a-straw.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.839681"
      }
    ],
    "overall_sentiment_score": 0.199478,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KO",
        "relevance_score": "0.270373",
        "ticker_sentiment_score": "0.08229",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.217834",
        "ticker_sentiment_score": "0.109531",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cell Counting Market is expected to generate a revenue of USD 16.5 Billion by 2031, Globally, at 6.20% CAGR: Verified Market Research\u00ae",
    "url": "https://www.benzinga.com/pressreleases/24/11/g42166496/cell-counting-market-is-expected-to-generate-a-revenue-of-usd-16-5-billion-by-2031-globally-at-6-2",
    "time_published": "20241125T151500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Lewes, Delaware, Nov. 25, 2024 ( GLOBE NEWSWIRE ) -- The Global Cell Counting Market Size is projected to grow at a CAGR of 6.20% from 2024 to 2031, according to a new report published by Verified Market Research\u00ae.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/4d4e92b6-a3bd-49ef-a14b-8c6a97bc1a35/global-cell-counting-market-size-and-forecast-1024x576.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.290559,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "A",
        "relevance_score": "0.022368",
        "ticker_sentiment_score": "0.040417",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.022368",
        "ticker_sentiment_score": "0.040417",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSMXF",
        "relevance_score": "0.022368",
        "ticker_sentiment_score": "0.040417",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SUVPF",
        "relevance_score": "0.022368",
        "ticker_sentiment_score": "0.040417",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.022368",
        "ticker_sentiment_score": "0.040417",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RSSS",
        "relevance_score": "0.022368",
        "ticker_sentiment_score": "0.164405",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.022368",
        "ticker_sentiment_score": "0.040417",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIO",
        "relevance_score": "0.022368",
        "ticker_sentiment_score": "0.040417",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OCPNF",
        "relevance_score": "0.022368",
        "ticker_sentiment_score": "0.040417",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DHR",
        "relevance_score": "0.022368",
        "ticker_sentiment_score": "0.040417",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Wearable Patch Market to Expand at a High 7.9% CAGR through 2031 | SkyQuest Technology",
    "url": "https://www.benzinga.com/pressreleases/24/11/g42158479/wearable-patch-market-to-expand-at-a-high-7-9-cagr-through-2031-skyquest-technology",
    "time_published": "20241125T101001",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Westford, USA, Nov. 25, 2024 ( GLOBE NEWSWIRE ) -- SkyQuest projects that the wearable patch market size will attain a value of USD 17.09 billion by 2031, with a CAGR of 7.9% over the forecast period ( 2024-2031 ) .",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.333709,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.048523",
        "ticker_sentiment_score": "0.057301",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MASI",
        "relevance_score": "0.048523",
        "ticker_sentiment_score": "0.057301",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IRTC",
        "relevance_score": "0.048523",
        "ticker_sentiment_score": "0.057301",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PODD",
        "relevance_score": "0.048523",
        "ticker_sentiment_score": "0.057301",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.048523",
        "ticker_sentiment_score": "0.057301",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.048523",
        "ticker_sentiment_score": "0.057301",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PHG",
        "relevance_score": "0.048523",
        "ticker_sentiment_score": "0.057301",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income",
    "url": "https://www.fool.com/investing/2024/11/26/2-high-yield-dividend-stocks-to-buy-now-for-a-life/",
    "time_published": "20241126T100300",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Investors looking for a way to pump up their passive income streams want to turn their attention toward the pharmaceutical industry. From the end of 2022 through Nov. 22, the benchmark S&P 500 index rose by a stunning 55.5%, but many of its drug-selling components haven't participated in the ...",
    "banner_image": "https://media.ycharts.com/charts/34d49543d4741856f5330321da34b958.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.220953,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BHVN",
        "relevance_score": "0.055751",
        "ticker_sentiment_score": "0.098877",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.273399",
        "ticker_sentiment_score": "0.08876",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.055751",
        "ticker_sentiment_score": "0.102879",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.37552",
        "ticker_sentiment_score": "0.427768",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Top Research Reports for Abbott, BlackRock & ConocoPhillips",
    "url": "https://www.zacks.com/research-daily/2375844/top-research-reports-for-abbott-blackrock-conocophillips",
    "time_published": "20241127T182400",
    "authors": [
      "Sheraz Mian"
    ],
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories (ABT), BlackRock, Inc. (BLK) and ConocoPhillips (COP), as well as two micro-cap stocks, NetSol Technologies, Inc. (NTWK) and Optex Systems Holdings, Inc (OPXS).",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default278.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.225532,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "OPXS",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.109151",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.109151",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COP",
        "relevance_score": "0.267559",
        "ticker_sentiment_score": "0.164947",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NTWK",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.109151",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "ABT Stock Benefits From First Patient Procedures With TAVI System",
    "url": "https://www.zacks.com/stock/news/2375880/abt-stock-benefits-from-first-patient-procedures-with-tavi-system",
    "time_published": "20241127T140100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Abbott announces its investigational TAVI balloon-expandable system???s first patient procedures. This investigational TAVI system aims to offer best-in-class heart blood flow.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.95493"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.28372,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PEN",
        "relevance_score": "0.149038",
        "ticker_sentiment_score": "0.055418",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RMD",
        "relevance_score": "0.149038",
        "ticker_sentiment_score": "0.055418",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.099683",
        "ticker_sentiment_score": "0.071386",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HAE",
        "relevance_score": "0.197816",
        "ticker_sentiment_score": "0.111857",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Technetium-99m Market Poised for Growth, Projected to Reach Over US$ 8.6 Billion by 2034 | Transparency Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/11/g42233486/technetium-99m-market-poised-for-growth-projected-to-reach-over-us-8-6-billion-by-2034-transparenc",
    "time_published": "20241128T143000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, Transparency Market Research, Inc., Nov. 28, 2024 ( GLOBE NEWSWIRE ) -- The Technetium-99m market ( March\u00e9 du techn\u00e9tium-99m ) is experiencing significant growth due to its essential role in medical diagnostics, particularly in imaging for chronic and non-communicable ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/253373be-47e5-45be-ba61-484216b48bce/technetium-99m-market-outlook.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.32904,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.032338",
        "ticker_sentiment_score": "0.05231",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.032338",
        "ticker_sentiment_score": "0.19629",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SBGSF",
        "relevance_score": "0.032338",
        "ticker_sentiment_score": "0.19629",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HTHIF",
        "relevance_score": "0.032338",
        "ticker_sentiment_score": "0.19629",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.096801",
        "ticker_sentiment_score": "0.074238",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GE",
        "relevance_score": "0.032338",
        "ticker_sentiment_score": "0.19629",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Growing EPD Business Supports ABT Stock Amid Macroeconomic Issues",
    "url": "https://www.zacks.com/stock/news/2377105/growing-epd-business-supports-abt-stock-amid-macroeconomic-issues",
    "time_published": "20241129T151500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Abbott has a unique opportunity to scale a capital-efficient licensing model that can help the emerging market population access life-changing medicines.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.983605"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      }
    ],
    "overall_sentiment_score": 0.252174,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PEN",
        "relevance_score": "0.100518",
        "ticker_sentiment_score": "0.054133",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.199447",
        "ticker_sentiment_score": "0.338788",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GMED",
        "relevance_score": "0.100518",
        "ticker_sentiment_score": "0.054133",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.050359",
        "ticker_sentiment_score": "0.157271",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HAE",
        "relevance_score": "0.150278",
        "ticker_sentiment_score": "0.115502",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:EUR",
        "relevance_score": "0.050359",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Abbott, BlackRock, ConocoPhillips, NetSol and Optex Systems",
    "url": "https://www.zacks.com/stock/news/2376789/the-zacks-analyst-blog-abbott-blackrock-conocophillips-netsol-and-optex-systems",
    "time_published": "20241129T070000",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Abbott, BlackRock, ConocoPhillips, NetSol and Optex Systems are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f8/614.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.218022,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "OPXS",
        "relevance_score": "0.130571",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.130571",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COP",
        "relevance_score": "0.257668",
        "ticker_sentiment_score": "0.086903",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTWK",
        "relevance_score": "0.130571",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Reasons to Buy DexCom Stock Like There's No Tomorrow",
    "url": "https://www.fool.com/investing/2024/12/02/3-reasons-to-buy-dexcom-stock-like-no-tomorrow/",
    "time_published": "20241202T141200",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "Medical device specialist DexCom ( NASDAQ: DXCM ) is going through a rough patch. The company's shares are down sharply year to date due to unimpressive financial results -- and some of the headwinds it has encountered are, no doubt, concerning.",
    "banner_image": "https://media.ycharts.com/charts/7f8ec8a1e485b38a87a4fe77ecb4f29e.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.253942,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DXCM",
        "relevance_score": "0.719473",
        "ticker_sentiment_score": "0.40289",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.114409",
        "ticker_sentiment_score": "0.076562",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Driving Innovation In Diabetes Management: Glucotrack Begins Enrollment For Human Clinical Trials For Its Implantable Continuous Blood Glucose Monitor - Abbott Laboratories  ( NYSE:ABT ) , DexCom  ( NASDAQ:DXCM ) ",
    "url": "https://www.benzinga.com/partner/biotech/24/12/42290788/driving-innovation-in-diabetes-management-glucotrack-begins-enrollment-for-human-clinical-trials-",
    "time_published": "20241203T140046",
    "authors": [
      "Joshenomoto@benzinga.com"
    ],
    "summary": "In the rapidly evolving medical technology sector, diabetes management specialist Glucotrack Inc. GCTK aims to disrupt the present care framework for the benefit of patients. Thanks to its Continuous Blood Glucose Monitor ( CBGM ) , millions of people affected by the disease may be able to access ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/03/Screenshot-2024-12-03-at-7-43-04PM.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.232893,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DXCM",
        "relevance_score": "0.076847",
        "ticker_sentiment_score": "-0.001022",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GCTK",
        "relevance_score": "0.335772",
        "ticker_sentiment_score": "0.330682",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.076847",
        "ticker_sentiment_score": "-0.001022",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 High-Yield Dividend Growth Stocks to Buy in December and Hold for a Decade or Longer",
    "url": "https://www.fool.com/investing/2024/12/03/3-high-yield-dividend-growth-stocks-to-buy-in-dece/",
    "time_published": "20241203T092400",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "It's been a great couple of years for the stock market. From the end of 2022 through Nov. 29, the benchmark S&P 500 ( SNPINDEX: ^GSPC ) index rose a whopping 57.1% higher.During this bull run, stock prices have bounded forward much further than earnings from their underlying businesses.",
    "banner_image": "https://g.foolcdn.com/editorial/images/799277/board-room-chart-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999701"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.275012,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.049526",
        "ticker_sentiment_score": "0.156113",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RPRX",
        "relevance_score": "0.196212",
        "ticker_sentiment_score": "0.173649",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.196212",
        "ticker_sentiment_score": "0.163973",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.049526",
        "ticker_sentiment_score": "0.149845",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIPC",
        "relevance_score": "0.380736",
        "ticker_sentiment_score": "0.427828",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Peering Into Abbott Laboratories's Recent Short Interest - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/12/42364441/peering-into-abbott-laboratoriess-recent-short-interest",
    "time_published": "20241206T143027",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Abbott Laboratories's ABT short percent of float has fallen 14.63% since its last report. The company recently reported that it has 12.05 million shares sold short, which is 0.7% of all regular shares that are available for trading.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1733495423_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.262256,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.079385",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Invesco Large Cap Value ETF  ( PWV )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2380644/is-invesco-large-cap-value-etf-pwv-a-strong-etf-right-now",
    "time_published": "20241209T112007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default270.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999998"
      }
    ],
    "overall_sentiment_score": 0.331182,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.114137",
        "ticker_sentiment_score": "0.060868",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.114137",
        "ticker_sentiment_score": "0.060868",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.22595",
        "ticker_sentiment_score": "0.276708",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.114137",
        "ticker_sentiment_score": "0.060868",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the Invesco Pharmaceuticals ETF  ( PJP ) ?",
    "url": "https://www.zacks.com/stock/news/2381261/should-you-invest-in-the-invesco-pharmaceuticals-etf-pjp",
    "time_published": "20241210T112008",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default292.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.220947,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.132004",
        "ticker_sentiment_score": "0.070801",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.132004",
        "ticker_sentiment_score": "0.070801",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.196877",
        "ticker_sentiment_score": "0.141519",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.132004",
        "ticker_sentiment_score": "0.070801",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Jim Cramer: Abbott Laboratories 'Legal Stuff' Is Behind Them - Archer Aviation  ( NYSE:ACHR ) , Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/12/42437595/jim-cramer-says-keep-owning-this-energy-stock-abbott-laboratories-legal-stuff-is-behind-",
    "time_published": "20241211T140622",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Mad Money Lightning Round,\" Jim Cramer said Occidental Petroleum OXY is one of his \"least favorite oils.\"",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/11/jim-cramer-shutterstock.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.133721,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "OXY",
        "relevance_score": "0.488007",
        "ticker_sentiment_score": "-0.391283",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "ACHR",
        "relevance_score": "0.377142",
        "ticker_sentiment_score": "0.412809",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "COO",
        "relevance_score": "0.377142",
        "ticker_sentiment_score": "0.225036",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.256989",
        "ticker_sentiment_score": "0.090066",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "-0.102167",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMI",
        "relevance_score": "0.377142",
        "ticker_sentiment_score": "0.21559",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMS",
        "relevance_score": "0.377142",
        "ticker_sentiment_score": "-0.16448",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ET",
        "relevance_score": "0.377142",
        "ticker_sentiment_score": "0.580752",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "In-vitro Colorectal Cancer Screening Tests Market to Reach Over US$ 2.5 Bn by 2034, Driven by a 7.1% CAGR | Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/12/g42436794/in-vitro-colorectal-cancer-screening-tests-market-to-reach-over-us-2-5-bn-by-2034-driven-by-a-7-1-",
    "time_published": "20241211T135057",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, Transparency Market Research Inc. - , Dec. 11, 2024 ( GLOBE NEWSWIRE ) -- The global in-vitro colorectal cancer screening tests market ( march\u00e9 des tests de d\u00e9pistage du cancer colorectal in vitro ) was valued at US$ 1.2 billion in 2023 and is projected to expand at a CAGR ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/0702a22b-1756-445a-b042-05d16db393ee/in-vitro-colorectal-cancer-screening-tests-market.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.08347,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.033515",
        "ticker_sentiment_score": "0.052606",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QGEN",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.095203",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.033515",
        "ticker_sentiment_score": "-0.016956",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.033515",
        "ticker_sentiment_score": "-0.104935",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.100308",
        "ticker_sentiment_score": "-0.030611",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.033515",
        "ticker_sentiment_score": "-0.155165",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Should You Invest in the iShares U.S. Medical Devices ETF  ( IHI ) ?",
    "url": "https://www.zacks.com/stock/news/2381887/should-you-invest-in-the-ishares-us-medical-devices-etf-ihi",
    "time_published": "20241211T112008",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for IHI ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default118.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.198159,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SEM",
        "relevance_score": "0.131284",
        "ticker_sentiment_score": "0.026984",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.131284",
        "ticker_sentiment_score": "0.070609",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.131284",
        "ticker_sentiment_score": "0.070609",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.131284",
        "ticker_sentiment_score": "0.070609",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Adobe Q4 Earnings Beat Estimates, Shares Fall on Weak Outlook",
    "url": "https://www.zacks.com/stock/news/2382693/adobe-q4-earnings-beat-estimates-shares-fall-on-weak-outlook",
    "time_published": "20241212T141900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "ADBE's fourth-quarter fiscal 2024 results reflect strong adoption of Digital Media and Digital Experience.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/931.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.99992"
      }
    ],
    "overall_sentiment_score": 0.154824,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.093897",
        "ticker_sentiment_score": "0.010626",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.031364",
        "ticker_sentiment_score": "0.168536",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.031364",
        "ticker_sentiment_score": "-0.016947",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.031364",
        "ticker_sentiment_score": "-0.015163",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.031364",
        "ticker_sentiment_score": "0.082312",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.031364",
        "ticker_sentiment_score": "-0.015163",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.031364",
        "ticker_sentiment_score": "0.082312",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.031364",
        "ticker_sentiment_score": "0.082312",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADBE",
        "relevance_score": "0.654648",
        "ticker_sentiment_score": "0.326761",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.031364",
        "ticker_sentiment_score": "0.082312",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HUBS",
        "relevance_score": "0.031364",
        "ticker_sentiment_score": "0.168536",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.093897",
        "ticker_sentiment_score": "-0.018977",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "1 Magnificent S&P 500 Dividend Stock Down 14% to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/12/12/1-magnificent-sp-500-dividend-stock-down-14-to-buy/",
    "time_published": "20241212T110000",
    "authors": [
      "Bradley Guichard"
    ],
    "summary": "This will go down in history as an incredible year for stocks. The S&P 500 hit a new all-time high 50 times. For perspective, there are about 250 trading days in the year. So, on average, the market made history every five days this year.",
    "banner_image": "https://media.ycharts.com/charts/04690dae5cdf0318f153ec25dd40dcfc.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.214907,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.70826",
        "ticker_sentiment_score": "0.380907",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.076358",
        "ticker_sentiment_score": "0.22722",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Adobe  ( ADBE )  Q4 2024 Earnings Call Transcript",
    "url": "https://www.fool.com/earnings/call-transcripts/2024/12/11/adobe-adbe-q4-2024-earnings-call-transcript/",
    "time_published": "20241212T023016",
    "authors": [
      "Motley Fool Transcribing"
    ],
    "summary": "ADBE earnings call for the period ending September 30, 2024.",
    "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.972756"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.308555,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EVR",
        "relevance_score": "0.004519",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PYPL",
        "relevance_score": "0.004519",
        "ticker_sentiment_score": "0.033786",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSCDF",
        "relevance_score": "0.004519",
        "ticker_sentiment_score": "0.033786",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.004519",
        "ticker_sentiment_score": "0.103242",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.009038",
        "ticker_sentiment_score": "0.03332",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.004519",
        "ticker_sentiment_score": "0.188754",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.004519",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.004519",
        "ticker_sentiment_score": "0.169675",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.004519",
        "ticker_sentiment_score": "0.188754",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.004519",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.009038",
        "ticker_sentiment_score": "0.140591",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSNLF",
        "relevance_score": "0.004519",
        "ticker_sentiment_score": "0.033786",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.004519",
        "ticker_sentiment_score": "0.169675",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.009038",
        "ticker_sentiment_score": "0.028916",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.004519",
        "ticker_sentiment_score": "0.188754",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ADBE",
        "relevance_score": "0.20117",
        "ticker_sentiment_score": "0.234009",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.009038",
        "ticker_sentiment_score": "0.118566",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CNC",
        "relevance_score": "0.004519",
        "ticker_sentiment_score": "0.033786",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HUBS",
        "relevance_score": "0.009038",
        "ticker_sentiment_score": "0.062295",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALIZF",
        "relevance_score": "0.004519",
        "ticker_sentiment_score": "0.033786",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NSRGF",
        "relevance_score": "0.004519",
        "ticker_sentiment_score": "0.188754",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "TransMedics Stock Plunges 57.5% in Three Months: What's Next?",
    "url": "https://www.zacks.com/stock/news/2383547/transmedics-stock-plunges-575-in-three-months-whats-next",
    "time_published": "20241213T171700",
    "authors": [
      "Debanjana Dey"
    ],
    "summary": "TMDX is enhancing its current focus on making meaningful progress across each of its growth initiatives. However, macro challenges are likely to hurt its performance.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.254218,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GEHC",
        "relevance_score": "0.114137",
        "ticker_sentiment_score": "-0.017215",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMDX",
        "relevance_score": "0.58401",
        "ticker_sentiment_score": "0.407278",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.076236",
        "ticker_sentiment_score": "-0.01538",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.114137",
        "ticker_sentiment_score": "-0.017215",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever",
    "url": "https://www.fool.com/investing/2024/12/15/want-decades-passive-income-stocks-buy-and-hold/",
    "time_published": "20241215T103500",
    "authors": [
      "Justin Pope"
    ],
    "summary": "These companies have ingrained competitive advantages in an evergreen industry backed by decades of dividend growth.",
    "banner_image": "https://g.foolcdn.com/editorial/images/800052/forever-investing.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      }
    ],
    "overall_sentiment_score": 0.243192,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.391158",
        "ticker_sentiment_score": "0.122827",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.051003",
        "ticker_sentiment_score": "-0.028898",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.250902",
        "ticker_sentiment_score": "0.311697",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.29887",
        "ticker_sentiment_score": "0.34943",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors - Assertio Holdings  ( NASDAQ:ASRT ) ",
    "url": "https://www.benzinga.com/pressreleases/24/12/g42529180/assertio-holdings-inc-appoints-mark-reisenauer-to-its-board-of-directors",
    "time_published": "20241217T133000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LAKE FOREST, Ill., Dec. 17, 2024 ( GLOBE NEWSWIRE ) -- Assertio Holdings, Inc. ( \"Assertio\" or the \"Company\" ) ASRT, a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced today that Mark Reisenauer has been appointed as an ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.199934,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ASRT",
        "relevance_score": "0.454714",
        "ticker_sentiment_score": "0.170333",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.04823",
        "ticker_sentiment_score": "0.031833",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.04823",
        "ticker_sentiment_score": "0.031833",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Leadership in Dialysis Services and Products Drives FMS Stock",
    "url": "https://www.zacks.com/stock/news/2384399/leadership-in-dialysis-services-and-products-drives-fms-stock",
    "time_published": "20241217T125700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Fresenius Medical Care leads global dialysis services, driving growth through innovation, restructuring and a strong global footprint in 120+ countries.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/09/2677.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.319194,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.090989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FSNUF",
        "relevance_score": "0.392948",
        "ticker_sentiment_score": "0.385552",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ARAY",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "-0.019859",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAX",
        "relevance_score": "0.045569",
        "ticker_sentiment_score": "0.141954",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MASI",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.100859",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FMS",
        "relevance_score": "0.352432",
        "ticker_sentiment_score": "0.270133",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DVA",
        "relevance_score": "0.045569",
        "ticker_sentiment_score": "0.141954",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's Why You Should Retain Stryker Stock in Your Portfolio for Now",
    "url": "https://www.zacks.com/stock/news/2384385/heres-why-you-should-retain-stryker-stock-in-your-portfolio-for-now",
    "time_published": "20241217T124200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "SYK continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/40/1670.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999759"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.316915,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MASI",
        "relevance_score": "0.117678",
        "ticker_sentiment_score": "0.095394",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.570165",
        "ticker_sentiment_score": "0.450663",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ARAY",
        "relevance_score": "0.117678",
        "ticker_sentiment_score": "-0.017303",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "ABT Stock Up on First Successful LBBAP Procedures With AVEIR Pacemaker",
    "url": "https://www.zacks.com/stock/news/2385071/abt-stock-up-on-first-successful-lbbap-procedures-with-aveir-pacemaker",
    "time_published": "20241218T124800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Abbott completes the world's first leadless pacing procedures in the left bundle branch of the heart.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.99489"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.2947,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PEN",
        "relevance_score": "0.152178",
        "ticker_sentiment_score": "0.119091",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PAHC",
        "relevance_score": "0.101797",
        "ticker_sentiment_score": "0.056463",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.152178",
        "ticker_sentiment_score": "0.15022",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HAE",
        "relevance_score": "0.152178",
        "ticker_sentiment_score": "0.117733",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Reasons to Retain GE HealthCare Stock in Your Portfolio Now",
    "url": "https://www.zacks.com/stock/news/2385060/reasons-to-retain-ge-healthcare-stock-in-your-portfolio-now",
    "time_published": "20241218T123600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "GEHC's continued focus on innovations, acquisitions and partnerships raises optimism about the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e0/1871.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.997335"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.323033,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GEHC",
        "relevance_score": "0.417419",
        "ticker_sentiment_score": "0.43559",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MASI",
        "relevance_score": "0.109289",
        "ticker_sentiment_score": "0.092787",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.072987",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LNTH",
        "relevance_score": "0.036532",
        "ticker_sentiment_score": "0.074513",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RDNT",
        "relevance_score": "0.036532",
        "ticker_sentiment_score": "0.032088",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARAY",
        "relevance_score": "0.109289",
        "ticker_sentiment_score": "-0.016786",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Reasons to Add McKesson Stock to Your Portfolio Right Now",
    "url": "https://www.zacks.com/stock/news/2385061/reasons-to-add-mckesson-stock-to-your-portfolio-right-now",
    "time_published": "20241218T123500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "MCK's strategic collaborations and strength in Biologics raise optimism about the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/58/608.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999336"
      }
    ],
    "overall_sentiment_score": 0.277697,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MASI",
        "relevance_score": "0.116725",
        "ticker_sentiment_score": "0.093959",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSGR",
        "relevance_score": "0.039033",
        "ticker_sentiment_score": "-0.020473",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.077972",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MCK",
        "relevance_score": "0.537109",
        "ticker_sentiment_score": "0.387374",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.039033",
        "ticker_sentiment_score": "0.113695",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARAY",
        "relevance_score": "0.116725",
        "ticker_sentiment_score": "-0.018408",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Smartest Dividend Stocks to Buy With $500 Right Now",
    "url": "https://www.fool.com/investing/2024/12/18/the-smartest-dividend-stocks-to-buy-with-500/",
    "time_published": "20241218T101500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "As an investor, your goal is to select quality stocks that will advance over a period of years -- but this doesn't mean you have to wait a long time for all of the rewards. If you add a few dividend stocks to your portfolio, you'll start collecting returns on a regular basis -- without lifting a ...",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F801154%2Fgettyimages-135538318.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.955357"
      }
    ],
    "overall_sentiment_score": 0.342913,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TRMNF",
        "relevance_score": "0.047654",
        "ticker_sentiment_score": "0.35124",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.095138",
        "ticker_sentiment_score": "0.108093",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.28008",
        "ticker_sentiment_score": "0.258465",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.095138",
        "ticker_sentiment_score": "0.140836",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Protein Hydrolysate Ingredient Market Projects to reach US$ 6.15 billion Valuation by 2034",
    "url": "https://www.benzinga.com/pressreleases/24/12/g42547858/protein-hydrolysate-ingredient-market-projects-to-reach-us-6-15-billion-valuation-by-2034",
    "time_published": "20241218T092118",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Rockville Pike, Dec. 18, 2024 ( GLOBE NEWSWIRE ) -- The global protein hydrolysate ingredient market is projected to reach US$ 6.15 billion by the end of 2034, up from US$ 3.53 billion in 2024, according to a new industry analysis compiled by Fact.MR.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/7810d6b8-06ef-4a0b-aa5c-b548b18434a4/protein-hydrolysate-ingredient-market.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.369245,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BNTGF",
        "relevance_score": "0.033562",
        "ticker_sentiment_score": "-0.056419",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INGR",
        "relevance_score": "0.033562",
        "ticker_sentiment_score": "-0.056419",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.033562",
        "ticker_sentiment_score": "-0.056419",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EVKIF",
        "relevance_score": "0.033562",
        "ticker_sentiment_score": "-0.056419",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADM",
        "relevance_score": "0.067064",
        "ticker_sentiment_score": "-0.060106",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KRYAY",
        "relevance_score": "0.033562",
        "ticker_sentiment_score": "-0.056419",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GLAPF",
        "relevance_score": "0.033562",
        "ticker_sentiment_score": "-0.056419",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Adobe Stock Slips 20% in a Week: Should You Brace for a Tough 2025?",
    "url": "https://www.zacks.com/stock/news/2385862/adobe-stock-slips-20-in-a-week-should-you-brace-for-a-tough-2025",
    "time_published": "20241219T162300",
    "authors": [
      "Aniruddha Ganguly"
    ],
    "summary": "ADBE shares are benefiting from strong demand for its creative products and expanding clientele amid increasing competition and stretched valuation.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/931.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      }
    ],
    "overall_sentiment_score": 0.284965,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.197816",
        "ticker_sentiment_score": "0.121928",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.194833",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.055468",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "-0.016966",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.081987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "-0.016966",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.081987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.081987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADBE",
        "relevance_score": "0.765945",
        "ticker_sentiment_score": "0.399433",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.081987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HUBS",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.194833",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.149038",
        "ticker_sentiment_score": "0.0706",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "4 Healthcare Technology Innovators to Invest in Before the New Year",
    "url": "https://www.zacks.com/stock/news/2385834/4-healthcare-technology-innovators-to-invest-in-before-the-new-year",
    "time_published": "20241219T155600",
    "authors": [
      "Urmimala Biswas"
    ],
    "summary": "Here, we have presented four healthcare technology stocks for stable portfolio gains in 2025: VCYT, OMCL, MASI and ABT.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/31/74133.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.348246,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VCYT",
        "relevance_score": "0.231963",
        "ticker_sentiment_score": "0.310525",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MASI",
        "relevance_score": "0.199584",
        "ticker_sentiment_score": "0.310856",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "OMCL",
        "relevance_score": "0.199584",
        "ticker_sentiment_score": "0.360889",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.240358",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.033609",
        "ticker_sentiment_score": "0.111803",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Reasons to Retain ABT Stock in Your Portfolio Now",
    "url": "https://www.zacks.com/stock/news/2385655/reasons-to-retain-abt-stock-in-your-portfolio-now",
    "time_published": "20241219T131500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Investors feel optimistic about Abbott's robust strength in the EPD and Nutrition businesses. Yet, unfavorable forex impacts are concerning.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986413"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.360348,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PEN",
        "relevance_score": "0.203215",
        "ticker_sentiment_score": "0.124026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.153145",
        "ticker_sentiment_score": "0.356386",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GMED",
        "relevance_score": "0.153145",
        "ticker_sentiment_score": "0.15305",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HAE",
        "relevance_score": "0.203215",
        "ticker_sentiment_score": "0.143928",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:EUR",
        "relevance_score": "0.05133",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Top Dividend Stocks to Buy and Hold Through 2025 and Beyond",
    "url": "https://www.fool.com/investing/2024/12/19/2-top-dividend-stocks-to-buy-and-hold-through-2025/",
    "time_published": "20241219T110000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "What will be the hottest investing trend on Wall Street next year? Maybe artificial intelligence will keep up its momentum, or perhaps interest in weight loss-focused pharmaceutical companies will increase. Whatever the answer is, it probably won't be dividend investing.",
    "banner_image": "https://g.foolcdn.com/editorial/images/800762/nurse-holding-patients-hands.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.839681"
      }
    ],
    "overall_sentiment_score": 0.334899,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.448842",
        "ticker_sentiment_score": "0.366317",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.40375",
        "ticker_sentiment_score": "0.40553",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now",
    "url": "https://www.zacks.com/stock/news/2386174/reasons-to-hold-west-pharmaceutical-stock-in-your-portfolio-now",
    "time_published": "20241220T130200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "WST continues to gain momentum due to its strength in the Pharma market unit. However, the decline across its Generics and Biologics business units is concerning.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/41/899.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.96136"
      }
    ],
    "overall_sentiment_score": 0.248356,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CURN",
        "relevance_score": "0.049322",
        "ticker_sentiment_score": "-0.178616",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "MASI",
        "relevance_score": "0.147216",
        "ticker_sentiment_score": "0.106599",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WST",
        "relevance_score": "0.422268",
        "ticker_sentiment_score": "0.247263",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.098456",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARAY",
        "relevance_score": "0.147216",
        "ticker_sentiment_score": "-0.019464",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Veracyte, Omnicell, Masimo and Abbott Laboratories",
    "url": "https://www.zacks.com/stock/news/2386077/the-zacks-analyst-blog-highlights-veracyte-omnicell-masimo-and-abbott-laboratories",
    "time_published": "20241220T100800",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Veracyte, Omnicell, Masimo and Abbott Laboratories are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.339274,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VCYT",
        "relevance_score": "0.246895",
        "ticker_sentiment_score": "0.274978",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MASI",
        "relevance_score": "0.21686",
        "ticker_sentiment_score": "0.258668",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "OMCL",
        "relevance_score": "0.21686",
        "ticker_sentiment_score": "0.311144",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.155853",
        "ticker_sentiment_score": "0.186016",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.031364",
        "ticker_sentiment_score": "0.1108",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "My Top 10 Stocks to Buy for 2025",
    "url": "https://www.fool.com/investing/2024/12/21/my-top-10-stocks-to-buy-for-2025/",
    "time_published": "20241221T090500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "It's that time of year again. I'm not referring to buying gifts and preparing holiday meals -- although that may be part of your agenda too. It's time to look back on your portfolio's performance and plan for the year ahead.It's been a solid year for many, with all three indexes heading for ...",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F801386%2Fgettyimages-1070239362.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.294166,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.057698",
        "ticker_sentiment_score": "0.101011",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRMNF",
        "relevance_score": "0.028868",
        "ticker_sentiment_score": "0.271297",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VKTX",
        "relevance_score": "0.057698",
        "ticker_sentiment_score": "0.189079",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.057698",
        "ticker_sentiment_score": "0.125112",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRWD",
        "relevance_score": "0.115094",
        "ticker_sentiment_score": "0.172189",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ETSY",
        "relevance_score": "0.199977",
        "ticker_sentiment_score": "0.029445",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.057698",
        "ticker_sentiment_score": "0.239009",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.115094",
        "ticker_sentiment_score": "0.231631",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.171892",
        "ticker_sentiment_score": "0.119767",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.115094",
        "ticker_sentiment_score": "0.101426",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLTR",
        "relevance_score": "0.057698",
        "ticker_sentiment_score": "0.025011",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Ensign Expands Footprint With Buyout of Eight Healthcare Facilities",
    "url": "https://www.zacks.com/stock/news/2387090/ensign-expands-footprint-with-buyout-of-eight-healthcare-facilities",
    "time_published": "20241223T174300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "ENSG agrees to buy eight healthcare facilities from Providence Home and Community Care, expanding its footprint.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.360586,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.362858",
        "ticker_sentiment_score": "0.145033",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CDNA",
        "relevance_score": "0.294093",
        "ticker_sentiment_score": "0.147108",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DOCS",
        "relevance_score": "0.294093",
        "ticker_sentiment_score": "0.097908",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ENSG",
        "relevance_score": "0.490988",
        "ticker_sentiment_score": "0.662178",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Merit Medical Stock Rises Following FDA Nod for WRAPSODY Device",
    "url": "https://www.zacks.com/stock/news/2387027/merit-medical-stock-rises-following-fda-nod-for-wrapsody-device",
    "time_published": "20241223T163000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "MMSI announces FDA approval for the WRAPSODY Cell-Impermeable Endoprosthesis.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d7/2961.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.322268,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MASI",
        "relevance_score": "0.151539",
        "ticker_sentiment_score": "0.104603",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MMSI",
        "relevance_score": "0.249873",
        "ticker_sentiment_score": "0.259752",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.101367",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARAY",
        "relevance_score": "0.151539",
        "ticker_sentiment_score": "-0.021172",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Excellent Dividend Stocks to Buy on the Dip",
    "url": "https://www.fool.com/investing/2024/12/23/2-excellent-dividend-stocks-to-buy-on-the-dip/",
    "time_published": "20241223T093200",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "AbbVie ( NYSE: ABBV ) and Amgen ( NASDAQ: AMGN ) have a lot in common. They are both leading drugmakers and have strong dividend track records. Both also recently saw their shares fall significantly in one day, following unimpressive clinical data for otherwise promising candidates.Despite their ...",
    "banner_image": "https://media.ycharts.com/charts/4bcb02efb3ae79099f939b6b71ea724e.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.26662,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.512596",
        "ticker_sentiment_score": "0.31906",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.055364",
        "ticker_sentiment_score": "0.085",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.373112",
        "ticker_sentiment_score": "0.395561",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.055364",
        "ticker_sentiment_score": "0.077088",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.055364",
        "ticker_sentiment_score": "0.21904",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here's Why You Should Retain Inogen Stock in Your Portfolio Now",
    "url": "https://www.zacks.com/stock/news/2387688/heres-why-you-should-retain-inogen-stock-in-your-portfolio-now",
    "time_published": "20241224T183000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Expanding product portfolio and high prospects for POC raise optimism for INGN stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.994953"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.30492,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MASI",
        "relevance_score": "0.139804",
        "ticker_sentiment_score": "0.103535",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.09347",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INGN",
        "relevance_score": "0.402761",
        "ticker_sentiment_score": "0.38187",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ARAY",
        "relevance_score": "0.139804",
        "ticker_sentiment_score": "-0.01888",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:EUR",
        "relevance_score": "0.046816",
        "ticker_sentiment_score": "-0.08188",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.046816",
        "ticker_sentiment_score": "-0.08188",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Glaukos Stock Down Despite NDA Submission of Epioxa to the FDA",
    "url": "https://www.zacks.com/stock/news/2387681/glaukos-stock-down-despite-nda-submission-of-epioxa-to-the-fda",
    "time_published": "20241224T173800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "GKOS announces New Drug Application submission for its Epioxa to the FDA.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/25271.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.857896"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.319861,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GKOS",
        "relevance_score": "0.477704",
        "ticker_sentiment_score": "0.359534",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MASI",
        "relevance_score": "0.168884",
        "ticker_sentiment_score": "0.114895",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.113062",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARAY",
        "relevance_score": "0.168884",
        "ticker_sentiment_score": "-0.022732",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Integer Holdings Gains 34.4% in One Year: What's Driving the Stock?",
    "url": "https://www.zacks.com/stock/news/2387680/integer-holdings-gains-344-in-one-year-whats-driving-the-stock",
    "time_published": "20241224T172600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "ITGR shares gain on the back of growth in the Medical segment. However, dependence on third-party suppliers is concerning.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d6/3739.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      }
    ],
    "overall_sentiment_score": 0.350593,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MASI",
        "relevance_score": "0.173333",
        "ticker_sentiment_score": "0.056936",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ULBI",
        "relevance_score": "0.058188",
        "ticker_sentiment_score": "-0.026014",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.116067",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ITGR",
        "relevance_score": "0.618922",
        "ticker_sentiment_score": "0.548739",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ARAY",
        "relevance_score": "0.173333",
        "ticker_sentiment_score": "-0.023164",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "OSUR Stock Rises Following the Acquisition of Sherlock Biosciences",
    "url": "https://www.zacks.com/stock/news/2388394/osur-stock-rises-following-the-acquisition-of-sherlock-biosciences",
    "time_published": "20241226T160700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "OraSure announces acquisition of Sherlock Biosciences to strengthen its molecular diagnostics portfolio.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.857896"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.314096,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MASI",
        "relevance_score": "0.155118",
        "ticker_sentiment_score": "0.106113",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.103778",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OSUR",
        "relevance_score": "0.255641",
        "ticker_sentiment_score": "0.286061",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ARAY",
        "relevance_score": "0.155118",
        "ticker_sentiment_score": "-0.021488",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Abbott Stock Worth Buying at a Discounted P/S Valuation?",
    "url": "https://www.zacks.com/stock/news/2388392/is-abbott-stock-worth-buying-at-a-discounted-ps-valuation",
    "time_published": "20241226T160000",
    "authors": [
      "Urmimala Biswas"
    ],
    "summary": "Abbott's strong market position, promising growth prospects and consistent share gains make it a compelling pick for investors.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.298173,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MDT",
        "relevance_score": "0.072765",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.072765",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.108958",
        "ticker_sentiment_score": "0.120185",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "HealthEquity Gains 46.8% in a Year: What's Driving the Stock?",
    "url": "https://www.zacks.com/stock/news/2388864/healthequity-gains-468-in-a-year-whats-driving-the-stock",
    "time_published": "20241227T145800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "HQY's sustained strength in HSAs raises optimism about the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d6/3739.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.995921"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.390533,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HQY",
        "relevance_score": "0.421485",
        "ticker_sentiment_score": "0.61197",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MASI",
        "relevance_score": "0.165031",
        "ticker_sentiment_score": "0.110427",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.110462",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARAY",
        "relevance_score": "0.165031",
        "ticker_sentiment_score": "-0.022388",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's Why You Should Retain Ecolab Stock in Your Portfolio Now",
    "url": "https://www.zacks.com/stock/news/2388858/heres-why-you-should-retain-ecolab-stock-in-your-portfolio-now",
    "time_published": "20241227T145600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "ECL continues to gain from its strong segmental performance and improved operating margin.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/34/973.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.96136"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.320604,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CURN",
        "relevance_score": "0.044885",
        "ticker_sentiment_score": "-0.052467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MASI",
        "relevance_score": "0.13409",
        "ticker_sentiment_score": "0.097684",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.089629",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARAY",
        "relevance_score": "0.13409",
        "ticker_sentiment_score": "-0.019708",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ECL",
        "relevance_score": "0.347492",
        "ticker_sentiment_score": "0.544106",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.044885",
        "ticker_sentiment_score": "-0.126314",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Growing Biosimilars Business, New Partnerships Support ABT Stock",
    "url": "https://www.zacks.com/stock/news/2388694/growing-biosimilars-business-new-partnerships-support-abt-stock",
    "time_published": "20241227T134600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/db/2802.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.983783"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      }
    ],
    "overall_sentiment_score": 0.221679,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PEN",
        "relevance_score": "0.102449",
        "ticker_sentiment_score": "0.056567",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RMD",
        "relevance_score": "0.102449",
        "ticker_sentiment_score": "0.056567",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.203215",
        "ticker_sentiment_score": "0.264128",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.05133",
        "ticker_sentiment_score": "0.161439",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HAE",
        "relevance_score": "0.153145",
        "ticker_sentiment_score": "0.076075",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:EUR",
        "relevance_score": "0.05133",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now",
    "url": "https://www.fool.com/investing/2024/12/28/2-no-brainer-healthcare-stocks-to-buy-with-1000-ri/",
    "time_published": "20241228T091500",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "A few different elements can make a stock a no-brainer buy. The company could be the leader in its market, or well diversified across various markets. In any case, it should have a solid track record of earnings growth and promising long-term prospects.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F801546%2Fgettyimages-happy-people-gather-around-a-computer.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999696"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.346621,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ISRG",
        "relevance_score": "0.117774",
        "ticker_sentiment_score": "0.157668",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.117774",
        "ticker_sentiment_score": "0.13753",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "How Is The Market Feeling About Abbott Laboratories? - Abbott Laboratories  ( NYSE:ABT ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/12/42730500/how-is-the-market-feeling-about-abbott-laboratories",
    "time_published": "20241230T193018",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Abbott Laboratories's ABT short percent of float has fallen 11.39% since its last report. The company recently reported that it has 12.10 million shares sold short, which is 0.7% of all regular shares that are available for trading.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1735587015_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.262256,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.079385",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's Why You Should Retain Integer Holdings Stock in Your Portfolio",
    "url": "https://www.zacks.com/stock/news/2389501/heres-why-you-should-retain-integer-holdings-stock-in-your-portfolio",
    "time_published": "20241230T144600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "ITGR's research and product development activities raise optimism about the stock. Rising demand for its products bodes well for the company.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e0/1871.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.890401"
      }
    ],
    "overall_sentiment_score": 0.297813,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MASI",
        "relevance_score": "0.155786",
        "ticker_sentiment_score": "0.106398",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ULBI",
        "relevance_score": "0.104228",
        "ticker_sentiment_score": "0.186193",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.104228",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ITGR",
        "relevance_score": "0.568148",
        "ticker_sentiment_score": "0.468185",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ARAY",
        "relevance_score": "0.155786",
        "ticker_sentiment_score": "-0.021548",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "5 MedTech Stocks That Are Poised to Beat the Market in 2025",
    "url": "https://www.zacks.com/stock/news/2389368/5-medtech-stocks-that-are-poised-to-beat-the-market-in-2025",
    "time_published": "20241230T140000",
    "authors": [
      "Harshit Gupta"
    ],
    "summary": "Here, we discuss five stocks that are likely to generate better than the market, driven by strong demand for existing products and the addition of innovative new devices.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/45/26891.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976671"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.385053,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SEM",
        "relevance_score": "0.026184",
        "ticker_sentiment_score": "0.106426",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.156123",
        "ticker_sentiment_score": "0.102626",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALGN",
        "relevance_score": "0.25726",
        "ticker_sentiment_score": "0.324922",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.232315",
        "ticker_sentiment_score": "0.289554",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.181721",
        "ticker_sentiment_score": "0.195863",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.207127",
        "ticker_sentiment_score": "0.223503",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Inogen Stock Rises as FDA Clears SIMEOX 200 Airway Clearance Device",
    "url": "https://www.zacks.com/stock/news/2389992/inogen-stock-rises-as-fda-clears-simeox-200-airway-clearance-device",
    "time_published": "20241231T142900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "INGN announces FDA clearance for the SIMEOX 200 Airway Clearance Device.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e6/2070.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.857896"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.334514,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MASI",
        "relevance_score": "0.139534",
        "ticker_sentiment_score": "0.102203",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.093289",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INGN",
        "relevance_score": "0.587962",
        "ticker_sentiment_score": "0.528643",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ARAY",
        "relevance_score": "0.139534",
        "ticker_sentiment_score": "-0.020137",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's Why You Should Retain Revvity Stock in Your Portfolio for Now",
    "url": "https://www.zacks.com/stock/news/2389895/heres-why-you-should-retain-revvity-stock-in-your-portfolio-for-now",
    "time_published": "20241231T132700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "RVTY's strong product portfolio raises optimism about the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.990786"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.307864,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CURN",
        "relevance_score": "0.045655",
        "ticker_sentiment_score": "-0.076",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MASI",
        "relevance_score": "0.13637",
        "ticker_sentiment_score": "0.098542",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.091162",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARAY",
        "relevance_score": "0.13637",
        "ticker_sentiment_score": "-0.019891",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RVTY",
        "relevance_score": "0.507932",
        "ticker_sentiment_score": "0.405853",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  }
]